22-Jan-18 | Bioverativ Inc | $11,600 | Sanofi will acquire all of the outstanding shares of Bioverativ and also expand Expands Sanofi’s presence in specialty care and strengthens leadership in rare diseases Adds leader in the growing hemophilia market and provides platform for expansion in other rare blood disorders Drives meaningful shareholder value with ROIC expected to exceed cost of capital within three years Enhances Sanofi’s sustainable revenue and earnings growth. Provides immediate Business EPS accretion. | Sanofi | Acquisition | United States |
22-Jan-18 | Juno Therapeutics Inc | $9,000 | Juno is a pioneer in the development of CAR (chimeric antigen receptor) T and TCR (T cell receptor) therapeutics with a broad, novel portfolio evaluating multiple targets and cancer indications. Adding to Celgene's lymphoma program, JCAR017 (lisocabtagene maraleucel; liso-cel) represents a potentially best-in-class CD19-directed CAR T currently in a pivotal program for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). | Celgene Corporation | Acquisition | United States |
07-Jan-18 | Impact Biomedicines | $7,000 | Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Based on the reported benefit risk profile of fedratinib from the JAKARTA-1 and JAKARTA-2 clinical trials, regulatory applications in myelofibrosis are planned beginning in the middle of 2018. | Celgene Corporation | Acquisition | United States |
29-Jan-18 | Ablynx | $4,800 | To advance the strategic transformation of Research and Development, expanding our late-stage pipeline and strengthening platform for growth in rare blood disorders. This acquisition builds on a successful existing partnership, pleased to reaffirm our commitment to Belgium, where the company invested significantly over the years in our state-of-the-art biologics manufacturing facility in Geel. | Sanofi | Acquisition | Belgium |
08-Jan-18 | Regeneron | $1,640 | To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs | Sanofi | Expansion | United States |
30-Jan-18 | Sirtex Medical Limited | $1,283 | This acquisition of a global leader in radioembolization extends Varian's leadership in radiation medicine, expands Varian's addressable market into interventional oncology, and is consistent with Varian's long-term growth and value creation strategy. Varian expects to leverage its capabilities in treatment planning and delivery, image guidance and processing, oncology practice management software, and radiation safety in combination with Sirtex's interventional oncology platform to provide | Varian Medical Systems | Acquisition | Australia |
04-Jan-18 | Arvinas | $830 | For the discovery and development of drug candidates using Arvinas’ proprietary PROTAC (PROteolysis TArgeting Chimeras) Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. | Pfizer Inc. | Licensing Agreement | United States |
31-Jan-18 | Cascadian Therapeutics | $614 | Enhances Seattle Genetics’ Portfolio of Solid Tumor Programs with Potential Rapid Registrational Pathways | Seattle Genetics | Acquisition | United States |
04-Jan-18 | MacroGenics | $380 | MacroGenics had entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to jointly discover and develop novel bispecific molecules to undisclosed targets. During the research term, both companies will leverage their respective platforms, including MacroGenics' DART® platform and Roche's CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate. | Roche | Research Agreement | United States |
03-Jan-18 | Addex Pharma | $330 | The collaboration includes an exclusive global license to lead candidate ADX71441, which is a novel, first-in-class, oral, small molecule and is expected to enter Phase 1 trials in 2018. The collaboration also includes exclusive global license to backup GABAB PAM compounds, as well as a research collaboration focused on discovering additional GABAB PAMs. | Indivior PLC | Collaboration | Switzerland |
03-Jan-18 | Boehringer Ingelheim Venture Fund (BIVF) | $300 | To invest in promising early stage start-up companies, focusing on regenerative medicine, infectious diseases and immune oncology among others, as well as growing the portfolio in the U.S. and opening doors for the BIVF in digital health | Boehringer Ingelheim | Series A Financing | Germany |
08-Jan-18 | CardioSert Ltd | $300 | To Acquire Novel Technology to Enhance Existing Technology Platforms and Strengthen Patent Portfolio | Microbot Medical Inc | Acquisition | United States |
04-Jan-18 | BioNTech AG | $270 | To advance its clinical pipeline of individualized immunotherapies covering a number of new approaches including mRNA and CAR-T / T-Cell receptors for the treatment of cancer and other diseases with high medical need | Redmile Group | Series A Financing | Germany |
08-Jan-18 | RegenXBio | $260 | The Development and Commercialization of Treatments for Spinal Muscular Atrophy | AveXis | Licensing Agreement | United States |
24-Jan-18 | Mitobridge Inc | $225 | The transaction accelerates Astellas’ research and development in diseases associated with mitochondrial dysfunctions and will enable the delivery of innovative new treatment options to patients | Astellas Pharma | Acquisition | United States |
05-Jan-18 | Jiangsu Hengrui Medicine | $223 | Development and Commercialization Partnership for Novel Immune-Mediated Dermatology Therapy Using SHR0302, for the treatment of dermatology disorder | Arcutis Inc | Licensing Agreement | China |
25-Jan-18 | Karyopharm Therapeutics Inc | $217 | To acquire Karyopharm’s investigational oral SINE compound KPT-350 and other assets for the treatment of certain neurological and neurodegenerative conditions. | Biogen | Acquisition | United States |
30-Jan-18 | Neomed Institute | $202 | To advance NEOMED's NEO1940 novel, peripherally restricted, CB1/CB2 agonist, clinic-ready drug candidate for the treatment of patients suffering from cancer and anorexia/weight loss associated with cancer | Artelo Biosciences | Licensing Agreement | Canada |
08-Jan-18 | Teva Pharmaceuticals | $200 | To develop, manufacture and commercialize eptinezumab in the U.S. and worldwide, excluding Japan and Korea | Alder BioPharmaceuticals | Licensing Agreement | Germany |
24-Jan-18 | Spark Therapeutics | $170 | To develop and commercialize investigational voretigene neparvovec outside the U.S. | Novartis | Licensing Agreement | United States |
09-Jan-18 | Adapsyn Bioscience | $162 | To Advance its Small Molecule Natural Product Platform and Pipeline; Announces Research Collaboration with Pfizer | Pfizer Inc. | Collaboration | Canada |
09-Jan-18 | Mallinckrodt plc | $153 | To Broaden Portfolio of Innovative Surgical Products | Baxter | Acquisition | United Kingdom |
05-Jan-18 | Denali Therapeutics | $240 | To Develop and Commercialize Therapies for Neurodegenerative Diseases | Takeda Pharmaceutical Company | Collaboration | United States |
31-Jan-18 | STAT-Dx | $147 | To launch a next-generation, fully integrated multiplex platform for syndromic disease testing | QIAGEN N.V. | Acquisition | United States |
23-Jan-18 | Gilead Sciences, Santa Monica | $135 | Under contract to buy the 160,000-square-foot flex building at 1800 Stewart St. from Agensys, Inc., a biotechnology and cancer-research company owned by Tokyo’s Astellas Pharma, Inc. | Gilead Sciences | Investment | United States |
23-Jan-18 | Tmunity Therapeutics | $100 | To Advance Portfolio of Next-Generation T cell Immunotherapies to Transform the Treatment of Cancer | Gilead Sciences | Series A Financing | United States |
04-Jan-18 | Receptos Inc | $100 | Focused on Discovering and Developing a Pipeline of Novel and Differentiated Drug Candidates | Omega Funds Venture Partners and | Series A Financing | United States |
04-Jan-18 | KBP Biosciences | $76 | Established China Biotechnology Company with Deep R&D Pipeline,Proceeds will also advance clinical development of lead candidate, KBP-5074, through Phase 2b trials for cardiovascular disease | Advantech Capital and SDIC Venture Capital etc | Series A Financing | United States |
22-Jan-18 | Data Sciences International Inc | $70 | To acquire 100% of the outstanding stock | Harvard Bioscience Inc | Acquisition | United States |
02-Jan-18 | Centrexion Therapeutics | $67 | The proceeds will be used to fund the Phase 3 program for Centrexion’s lead therapy, CNTX-4975, a synthetic, ultra-pure injection of trans-capsaicin, for the treatment of chronic pain due to knee osteoarthritis (OA) | New Enterprise Associates | Series D Financing | United States |
02-Jan-18 | QED Therapeutics | $65 | To Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics | BridgeBio Pharma | Licensing Agreement | United States |
22-Jan-18 | Eureka Therapeutics | $60 | To Advance Proprietary ARTEMIS™ T Cell Receptor Platform For Safer T Cell Therapies | Acorn Pacific Ventures | Series D Financing | United States |
18-Jan-18 | Pandion Therapeutics | $58 | To Advance Tissue-Specific Immune Modulator Drugs for Autoimmune and Inflammatory Diseases | Versant Ventures and Roche Venture Fund SR One and BioInnovation Capital | Series A Financing | United States |
07-Jan-18 | Alnylam Pharmaceuticals Inc | $50 | Enables Streamlined Development and Optimization of Commercial Opportunities for ATTR Amyloidosis and Hemophilia Programs | Sanofi | Partnership | United States |
03-Jan-18 | Scholar Rock Holding | $47 | To Advance Innovative Pipeline for SMA, Immuno-Oncology, Fibrosis, and Iron-Restricted Anemias | Redmile Group | Series C Financing | United States |
04-Jan-18 | Neurogastrx Inc | $45 | To fill out the management team and reach proof of concept with its lead asset, NG-101, which is intended to treat gastroparesis, a debilitating functional GI disorder | 5AM Ventures | Series A Financing | United States |
04-Jan-18 | Stoke Therapeutics | $40 | To support the further advancement of multiple pre-clinical development programs | Apple Tree Partners | Series A Financing | United States |
03-Jan-18 | Elstar Therapeutics | $39 | To Support Development of its Universal Targeted Immunotherapy Platform (UniTITM) | Apple Tree Partners | Series A Financing | United States |
04-Jan-18 | Enterome | $39 | To treat microbiome-associated diseases with a focus on inflammatory bowel diseases (IBD) and immuno-oncology (IO) indications | Seventure, Health for Life Capital, Lundbeck Fonden Ventures, Omnes Capital & Nestle Health Science | Series D Financing | France |
23-Jan-18 | Bonti | $16 | To continue developing EB-001, a unique botulinum neurotoxin, for its targeted therapeutic and aesthetic indications with significant addressable unmet needs in patients | Unknown | Investment | United States |
05-Jan-18 | Alliqua Biomedical | $29 | Celularity will acquire all of the property, assets and rights relating to the Company’s advanced biologic wound care business - including Biovance® amniotic membrane allograft and Interfyl® Human Connective Tissue Matrix - and the Company’s UltraMist® | Celularity | Purchase Agreement | United States |
30-Jan-18 | Corbus Pharmaceuticals | $25 | To Support Phase 2b Clinical Study of Lenabasum | Cystic Fibrosis Foundation | Development Agreement | United States |
02-Jan-18 | Inovio Pharmaceuticals | $43 | This collaboration of VGX-3100 encompasses the treatment and/or prevention of precancerous HPV infections and HPV-driven dysplasias (including cervical, vulvar and anal precancers) and excludes HPV-driven cancers and all combinations of VGX-3100 with other immunostimulants. The agreement also provides for potential inclusion of the Republic of Korea during the next three years. | ApolloBio Corp. | Licensing Agreement | United States |
01-Jan-18 | NexImmune | $23 | To Advance Endogenous Cellular ImmunoTherapy into Clinical Development | ArrowMark Partners and Barer & Son Capital | Series A Financing | United States |
04-Jan-18 | Oculis | $20 | The funds will be used to advance the clinical development of the Company's lead program OC-118, a proprietary topical product currently in a Phase IIb clinical trial for the treatment of Diabetic Macular Edema (DME) | Novartis | Series B Financing | Switzerland |
11-Jan-18 | KWS BioTest | $20 | The addition of KWS BioTest’s world-leading immunology expertise makes additional tools available in the increasingly active and promising therapeutic research areas of immunology, oncology, and autoimmune and infectious disease. | Charles River | Acquisition | United Kingdom |
17-Jan-18 | Enochian Biopharma | $20 | Enochian's technology will enhance DanDrit's research and development efforts in cellular therapy and add to its pipeline, which also includes cellular immuneoncology products for the prevention of relapse of metastatic colon cancer after resection and chemotherap | DanDrit Biotech USA | Acquisition | United States |
10-Jan-18 | PharmaIN Corporation | $17 | PharmaIN which has innovative platform technologies for drug discovery of various molecules including peptides, proteins and small molecules | Shionogi & Co., Ltd. | Collaboration | United States |
09-Jan-18 | BIAL | $16 | For the importation, packaging and commercialization of Opicapone in China (excluding Hong Kong, Macao and Taiwan). | Shanghai Fosun Pharmaceutical Group | Licensing Agreement | Portugal |
09-Jan-18 | Carmot Therapeutics | $15 | The funds will support development of the company’s lead type 2 diabetes drug, a dual GLP-1R/GIPR agonist, through early clinical proof of concept | Horizons Ventures | Series B Financing | United States |
16-Jan-18 | OWKIN | $13 | Funding will expand OWKIN Socrates, the first data driven discovery platform for clinical research | Otium Venture | Series A Financing | United States |
30-Jan-18 | Dosecann Inc | $9 | Dosecann investment to leverage existing synergies within MMJ portfolio | MMJ PhytoTech Limited | Acquisition | Canada |
16-Jan-18 | Pherecydes Pharma | $10 | To produce phages for compassionate use (ATU or Temporary Authorization for Use) in accordance with GMP. Pherecydes will move two programs into the clinical phase in 2018 and 2019 | Omnes Capital etc | Series B Financing | France |
17-Jan-18 | Pisgah Labs Inc | $10 | Acquisition of 100% share capital of Pisgah Labs Inc North Carolina. USA by Company's subsidiaries | Ipca Pharmaceutical Inc, USA (subs Onyx Scientific Ltd) | Acquisition | United States |
23-Jan-18 | Skyhawk Therapeutics, Inc | $8 | To Advance Its Novel Platform and Portfolio of Small Molecules That Correct RNA Expression | Alexandria Venture Investments | Seed Financing | United States |
23-Jan-18 | GT Biopharma Inc | $7 | To advance its immuno-oncology programs, which are based on the company's proprietary Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs™ and TetraKEs) and bispecific antibody-drug conjugate (ADC) platforms, neurology (CNS) pipeline progress, and for general corporate purposes | Oppenheimer Holdings | Financing | United States |
02-Jan-18 | Piedmont Pharmaceuticals LLC | $7 | Acquires Global ex-U.S. Product Rights and existing Royalty Streams to Resultz® | Nuvo Pharmaceuticals Inc., Deerfield Management Company | Acquisition | United States |
29-Jan-18 | Cellect Biotechnology | $4 | Company will issue 484,848 registered American Depository Shares (ADSs) at a purchase price of $8.25 per ADS in a registered direct offering. | HC Wainwright & Co | IPO | Israel |
08-Jan-18 | Level Brands Inc | $2 | To develop consumer products for kathy ireland® Health & Wellness, a licensor to Level Brands, and for Level Brands subsidiary I’M1, the company’s lifestyle brand for men | Isodiol International Inc | Licensing Agreement | United States |
16-Jan-18 | Metrion Biosciences | $1 | Industry-leading ion channel | SyndicateRoom | Investment | United Kingdom |
18-Jan-18 | Serum Institute of India Pvt Ltd | $0 | To manufacture & sell fully liquid Whole cell Pertussis (wP) and Salk based Injectable Polio Vaccine (IPV) based Hexavalent vaccine (DTwP-HepB-Hib-IPV) | Panacea Biotec Ltd | Collaboration | India |
29-Jan-18 | FDA | $0 | Regarding the design of its next study of lenabasum (formerly known as anabasum),on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint | Corbus Pharmaceuticals | Research Agreement | United States |
18-Jan-18 | Biocon | $0 | To develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. | Novartis | Partnership | India |
17-Jan-18 | Aeterna Zentaris Inc | $128 | To carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. | Strongbridge Biopharma plc | Licensing Agreement | United States |
10-Jan-18 | Syndax Pharmaceuticals Inc | $0 | To Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer | Roche | Clinical Collaboration | United States |
26-Jan-18 | Unipharm | $0 | To acquire a range of over-the-counter (OTC) medicines, Reinforce Strong Patient Focused Business in Russia | Takeda Pharmaceutical Company | Acquisition | Uzbekistan |
04-Jan-18 | Generation Bio | $0 | Developing GeneWave™ - A Breakthrough Platform for Re-Dosable Gene Therapy | Atlas Venture | Launch & Partnerships | United States |
09-Jan-18 | Boehringer Ingelheim | $0 | Two companies have entered into a commercial supply agreement for tislelizumab, BeiGene’s investigational anti-PD-1 antibody | BeiGene | Commercialization Agreement | Germany |
31-Jan-18 | TransPerfect Life Sciences | $0 | To support clinical trials and product development for the biopharmaceutical industry, Trial Interactive e-clinical and eTMF technology | Advarra | Partnership | United States |
30-Jan-18 | CorePharma | $0 | It provides us with a strong and reputable manufacturing infrastructure and an ideal location with headquarters in Middlesex | Impax Laboratories Inc | Acquisition | United States |
30-Jan-18 | Boston University School of Medicine | $0 | To Study the Effects of Alzheimer's Disease-associated Genetic Variants on Brain | Eisai Co., Ltd. | Research Agreement | United States |
30-Jan-18 | Porton Pharma Solutions | $0 | To expands the reach of our offerings to provide fully integrated API and drug product development and manufacturing solutions to our clients for seamless advancement of their programs from discovery to clinical development | BioDuro LLC | Cooperation Agreement | China |
29-Jan-18 | Prime Therapeutics | $0 | Outcomes-Based Contract for Jardiance®(empagliflozin) | Boehringer Ingelheim | Contract Agreement | United States |
26-Jan-18 | Sandoz | $0 | ANDA Portfolio to build a robust pipeline and commercialize quality drug candidates in China, including entecavir, an antiviral medication used in the treatment of hepatitis B viral infection (“HBV”) | CASI Pharmaceuticals | Acquisition | United States |
23-Jan-18 | ChemDiv Inc | $0 | To extending it into finding potent anti-infective drug candidates & to deliver a pipeline of novel high-quality hit series in the area of infectious diseases | Johnson & Johnson | Collaboration | United States |
19-Jan-18 | Eisai Co | $0 | For potential anticancer agent E7046 prostaglandin E2 (PGE2)receptor type EP4 antagonist | Adlai Nortye Biopharma | Licensing Agreement | Japan |
19-Jan-18 | Tabuk Pharmaceuticals | $0 | To commercialize and distribute Ivy ODF in the Kingdom of Saudi Arabia, the Gulf and Levant area | Red OTC Development GmbH | Licensing Agreement | Saudi Arabia |
17-Jan-18 | Undisclosed | $0 | To Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System | Relmada Therapeutics | Acquisition | |
16-Jan-18 | Compass Therapeutics | $0 | For the semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling of a therapeutic targeting solid tumors. Semi-mechanistic PK/PD models will be developed for mouse, cynomolgus monkey, and human species | Applied BioMath | Collaboration | United States |
23-Jan-18 | Valeant Pharmaceutical | $0 | Begins Promotion of SPRIX®( ketorolac tromethamine) Nasal Spray | Egalet Corporation | Partnership | United States |
23-Jan-18 | ABL Bio | $0 | To Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies & to Manufacture Clinical Material for SillaJen's JX-970 | SillaJen Inc | Collaboration | France |
10-Jan-18 | Roche | $0 | To Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer | Syndax Pharmaceuticals | Clinical Collaboration | United States |
10-Jan-18 | Syapse | $0 | To Advance Precision Medicine in Oncology, Companies work jointly to develop software products and analytics solutions | Roche | Collaboration | United States |
31-Jan-18 | Syapse | $0 | Partnership will democratize access to clinical trials and help community health systems find and enroll eligible patients at unprecedented scale | Medidata | Partnership | United States |
08-Jan-18 | GE Healthcare | $0 | To jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualised treatment options for cancer and critical care patients | Roche | Partnership | United States |
08-Jan-18 | Livongo Health | $0 | To study real-world evidence and develop new insights to reduce the burden on people living with diabetes | Eli Lilly and Company | Collaboration | United States |
08-Jan-18 | Intec Pharma | $0 | To explore using the Accordion Pill platform for a proprietary Novartis compound | Novartis | Collaboration | Israel |
04-Jan-18 | Pfizer Inc. | $0 | Focused on optimizing BLI’s proprietary BeaconTM Optofluidic platform with the goal of helping to accelerate Pfizer’s monoclonal antibody (mAb) discovery and gene editing workflows | Berkeley Lights, Inc | Collaboration | United States |
03-Jan-18 | Corsair Pharma | $0 | To Advance Novel Treprostinil Prodrugs | United Therapeutics Corporation | Collaboration | United States |
02-Jan-18 | BASES Pharmaceutical | $0 | These new assets and expertise complement the rest of our forecasting offerings | ZS Associates | Acquisition | United States |
02-Jan-18 | PharmaMar | $0 | For the marine-derived anticancer drug Aplidin® (plitidepsin) in Israel and the territory known as the Palestinian Authority | Megapharm Ltd | Licensing Agreement | Spain |
29-Jan-18 | Japan Tobacco Inc | $0 | Acquires rights to small molecule potassium channel inhibitors | Metrion Biosciences | Acquisition | Japan |
26-Jan-18 | Concept Life Sciences Group | $0 | Acquisition increases Concept’s global reach and supports growth strategy | Spectris plc | Acquisition | United Kingdom |
15-Jan-18 | Tsing Hua Testing & Analysis | $0 | Tsing Hua provides a comprehensive suite of testing services for wastewater, drinking water, ground water, fuel gas, ambient air, noise, soil and waste to a broad range of customers in Taiwan | Eurofins Scientific | Acquisition | Taiwan |
25-Jan-18 | Eurofins Scientific | $0 | Selcia provides Eurofins with an entry into the custom radiolabelling and innovative pre-clinical, integrated drug discovery services markets, both exciting new business streams for Eurofins offering significant growth potential | Selcia Limited | Acquisition | Luxembourg |
25-Jan-18 | UCL Great Ormond Street Institute of Child Health | $0 | To Develop Novel Gene Therapies for Blood-based Disorders | Synpromics | Partnership | United Kingdom |
23-Jan-18 | Mydent International Enterprises Corp | $0 | The DEFEND brand has developed a reputation for high quality at great value that resonates well with clinicians and dental organizations around the world | Young Innovations | Acquisition | United States |
23-Jan-18 | Solid Form Solutions Ltd | $0 | Combination Strengthens CDMO’s Early Phase Drug Development Offering | Avista Pharma Solutions | Acquisition | Scotland |
23-Jan-18 | TP3 Global | $0 | To expand worldwide presence and strengthen product portfolio | Softbox | Acquisition | United Kingdom |
22-Jan-18 | BioCryst Pharmaceuticals | $0 | To form a new enterprise focused on the development and commercialization of medicines to serve more patients suffering from rare diseases | Idera Pharmaceuticals | Merger Agreement | United States |
22-Jan-18 | Elion Labs | $0 | To Further Expand Industry-Leading Biophysical and Analytical Characterization Capabilities | KBI Biopharma | Acquisition | United States |
16-Jan-18 | Arno Therapeutics | $0 | The Acquisition of Apristor™ (Onapristone XR), an Investigational Phase 2 Drug for Metastatic Breast Cancer | Context Therapeutics | Acquisition | United States |
12-Jan-18 | DrugScan Inc | $0 | To lead the way on the front lines of the opioid crisis here and across the nation | ACM Global Laboratories (Rochester Regional Health) | Acquisition | United States |
16-Jan-18 | Maine Biotechnology Services (MBS) | $0 | The addition of over 80 new antibodies to its growing product portfolio, as well as custom antibody development services | BBI Solutions | Acquisition | United States |
08-Jan-18 | Accurate Medical Therapeutics | $0 | Acceleration of the interventional radiology strategy | Guerbet | Acquisition | Israel |
08-Jan-18 | Cork (Luxcel Biosciences ) | $0 | This acquisition expands Agilent's cell analysis portfolio with the addition of easy-to-use assay kits that are compatible with industry standard plate-readers | Agilent Technologies | Acquisition | Ireland |
08-Jan-18 | Merus | $0 | To develop and commercialize in China three bispecific antibodies utilizing Merus’ proprietary Biclonics® technology platform in the area of immuno-oncology. | Simcere Pharmaceutical Group | Collaboration | The Netherlands |
08-Jan-18 | Radiant Genomics | $0 | The addition brings Radiant Genomics’ leading-edge metagenomic technologies and accompanying genetic libraries to Zymergen’s core platform, accelerating Zymergen’s ability to identify and commercialize novel molecules used in a range of industries | Zymergen | Acquisition | United States |
05-Jan-18 | Vita Liberata | $0 | Adds Leading, All-Natural Product Line in Sunless Tanning to Crown’s Dermatology Portfolio | Crown Laboratories Inc & Hildred Capital Partners LLC | Acquisition | Ireland |
03-Jan-18 | Angiochem Inc | $0 | To develop and commercialize ANG1005 in China for treatment of patients with leptomeningeal carcinomatosis from breast cancer | Xinogen | Licensing Agreement | Canada |
04-Jan-18 | Zyga Technology | $0 | Acquisition Expands Spine Franchise Portfolio and Accelerates Growth Potential; Zyga Technology Provides Innovative SImmetry® Sacroiliac Joint Fusion System | RTI Surgical Inc | Acquisition | United States |
04-Jan-18 | Rocket Pharmaceuticals | $0 | It focus on advancing a pipeline of gene therapy programs targeting rare and undertreated diseases. | Inotek Pharmaceuticals Corporation | Merger Agreement | United States |
03-Jan-18 | Array BioPharma | $0 | To develop, manufacture and commercialise varlitinib | ASLAN Pharmaceuticals | Acquisition | United States |
03-Jan-18 | Viamet Pharmaceuticals | $0 | To advance the clinical development of VT 1161 for the treatment of RVVC and Onychomycosis | NovaQuest Capital Management LLC | Acquisition | United States |
03-Jan-18 | Glen Research Corporation (“Glen Research”) | $0 | Glen Research will continue its focus on superior customer service as part of the Maravai portfolio | Maravai LifeSciences & GTCR | Acquisition | United States |
09-Jan-18 | Inovio Pharmaceuticals | $0 | Advances development of Inovio’s ASPIRE™ (Antigen SPecific Immune REsponses) immunotherapy platform as a foundation for novel combination regimen approaches | The Parker Institute | Clinical Collaboration | United States |
18-Jan-18 | Pfizer Inc. | $0 | To Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma | Gilead Sciences | Clinical Collaboration | United States |
09-Jan-18 | Dracen Pharmaceuticals | $0 | To develop its platform of anticancer therapies | The Johns Hopkins University (Baltimore) & The Institute of Organic Chemistry and Biochemistry (Prague) | Licensing Agreement | United States |
18-Jan-18 | Bio-Pharm Inc | $0 | To expand the BPI facilities including R&D capabilities and will increase the number of product filings from BPI | Torrent Pharmaceuticals Limited | Acquisition | United States |
03-Jan-18 | Metanomics Health GmbH | $0 | To Create a New Global Leader in Metabolomics and Early Disease Detection | BIOCRATES Life Sciences AG | Acquisition | Germany |
14-Feb-18 | Nektar Therapeutics | $3,600 | To evaluate the full-potential of NKTR-214 plus Opdivo (nivolumab) across numerous tumors, based on promising early data from ongoing Phase 1/2 PIVOT clinical study | Bristol-Myers Squibb | Collaboration | United States |
18-Jan-18 | Sangamo Therapeutics | $3,150 | To Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer | Gilead Sciences | Collaboration | United States |
15-Feb-18 | Flatiron Health | $1,900 | To accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer | Roche | Acquisition | United States |
20-Feb-18 | Voyager Therapeutics | $1,200 | To Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases | AbbVie | Collaboration | United States |
09-Feb-18 | Pieris Pharmaceuticals | $1,200 | Pieris Pharmaceuticals entered into the collaboration with Seattle Genetics with the goal of developing multiple targeted bispecific immuno-oncology treatments for solid tumors and blood cancers. | Seattle Genetics | Collaboration | United States |
21-Feb-18 | CJ HealthCare | $1,200 | Kolmar Korea, which is the largest OEM manufacturer in the local cosmetics industry, is expected to beef up its medical cosmetics business based on the acquisition | Korea Kolmar | Acquisition | South Korea |
07-Feb-18 | Theravance Biopharma | $1,000 | Both Jointly Develop and Commercialize TD-1473, a Novel, Potent, Orally Administered and Intestinally Restricted pan-Janus Kinase (JAK) Inhibitor | Johnson & Johnson | Collaboration | Ireland |
20-Feb-18 | Wave Life Sciences Ltd. | $1,000 | To receive option to co-develop and co-commercialize investigational therapies in HD, ALS, FTD and SCA3 under a global 50:50 profit-split & receive right to license additional preclinical CNS programs | Takeda Pharmaceutical Company | Collaboration | United States |
13-Feb-18 | MPI Research | $800 | To enhance Charles River’s position as a leading global early-stage CRO by strengthening its ability to partner with clients across the drug discovery and development continuum | Charles River | Acquisition | United States |
12-Feb-18 | POXEL SA | $600 | For Development and Commercialization of Imeglimin in the U.S., Europe, and Additional Countries Worldwide | Roivant Sciences | Partnership | France |
01-Feb-18 | Moderna Therapeutics | $500 | The funding will help drive the company’s continued execution of its rapidly growing pipeline of 19 development candidates – including 10 programs in clinical trials | Abu Dhabi Investment Authority (ADIA) | Financing | United States |
21-Feb-18 | Viralytics | $394 | Proposed Acquisition of Viralytics Would Add Investigational Oncolytic Immunotherapy, CAVATAK ® , Supporting Merck’s Strategy to Broaden Its Pipeline with the Best Scientific Assets | Merck & Co. | Acquisition | Australia |
20-Feb-18 | Ionis Pharmaceuticals | $330 | Ionis Licences New Antisense Drug for Kidney Disease to AstraZeneca | AstraZeneca | Collaboration | United States |
14-Feb-18 | GNC Holdings | $300 | Hayao will also form a JV with GNC to make and distribute GNC supplements in China | Harbin Pharma | Investment | United States |
14-Feb-18 | TandemLife | $300 | Company will add advanced cardiopulmonary temporary support solutions to its portfolio | LivaNova | Acquisition | United States |
13-Feb-18 | TetraGenetics | $300 | TetraGenetics expertise and ideally suited to the capabilities of the TetraExpress™ platform technology. These programs build on TetraGenetics’ prior successes using the platform for the discovery of drug candidates targeting membrane proteins | Undisclosed | Collaboration | United States |
28-Feb-18 | Viela Bio | $250 | To create stand-alone company for early-stage inflammation and autoimmunity biologics | AstraZeneca | Financing | United States |
15-Feb-18 | Celularity | $250 | Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration | Celgene Corporation | Financing | United States |
28-Feb-18 | Novo Nordisk | $165 | To invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance. | Novo Nordisk | Investment | Denmark |
06-Feb-18 | ImmunoQure | $164 | Partnership for the development of an Interferon alpha human autoantibody | Servier | Partnership | Germany |
08-Feb-18 | Rani Therapeutics | $142 | Rani raises investment for manufacturing of a pill that replaces injections | GeneScience Pharmaceuticals | Financing | United States |
15-Feb-18 | Polyphor | $129 | To Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis and Other Pulmonary Diseases for POL6014 | Santhera Pharmaceuticals | Licensing Agreement | Switzerland |
21-Feb-18 | PROCEPT BioRobotics | $118 | Treatment of Benign Prostatic Hyperplasia | Viking Global Investors | Financing | United States |
15-Feb-18 | Oxford BioMedica | $105 | To use OXB’s LentiVector Enabled technology and access to its industrial-scale manufacturing technology | Bioverativ | Collaboration | United Kingdom |
12-Feb-18 | Avid Bioservices, Inc | $103 | Asset Assignment and Purchase Agreement for Avid's PS-Targeting Program Including Bavituximab | Oncologie, Inc. | Purchase Agreement | United States |
13-Feb-18 | Universal Cells | $103 | To fully utilize proprietary technology to produce pluripotent stem cells that have the potential to lower immunological rejection in numerous therapeutic areas | Astellas Pharma | Acquisition | United States |
27-Feb-18 | Generation Bio | $100 | To Advance Genewavetm Platform For Re-Dosable Gene Therapy | Fidelity Management | Investment | United States |
15-Feb-18 | BD (Becton, Dickinson and Company) | $100 | For Purchase of Divestment Assets, The assets acquired are soft tissue core needle biopsy products sold under the trade names of Achieve™ Programmable Automatic Biopsy System, Temno™ Biopsy System, Tru-Cut™ Biopsy Needles as well as Aspira® Pleural Effusion Drainage Kits, and the Aspira® Peritoneal Drainage System | Merit Medical Systems Inc | Investment | United States |
07-Feb-18 | Elastagen Pty Ltd | $95 | To Access Next Generation Injectable Portfolio & Clinical stage tropoelastin platform with potential applications in aesthetics, scar remodeling and surgical wound repair | Allergan plc | Acquisition | Australia |
27-Feb-18 | Surmodics | $92 | Companies to collaborate on product development, clinical trials and regulatory activities to obtain approval in U.S. and E.U. | Abbott | Clinical Collaboration | United States |
01-Feb-18 | AVROBIO, Inc | $60 | To Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases | Atlas Venture ; Syndicate | Series B Financing | United States |
28-Feb-18 | Inscripta | $56 | To accelerate development and commercialization of gene-editing tools — including enzymes, reagents, instrumentation, and software | Merieux Developpement and Paladin Capital Group | Series C Financing | France |
27-Feb-18 | Senti Biosciences | $53 | To Build the Future of Gene and Cell-Based Therapies | New Enterprise Associates | Series A Financing | United States |
21-Feb-18 | ORIC Pharmaceuticals | $50 | Proceeds will support advancement of ORIC-101 against treatment-resistant solid tumors and continued progress on mechanisms of resistance in cancer | Fidelity Management | Series C Financing | United States |
27-Feb-18 | Quentis Therapeutics | $48 | Role of small-molecule inhibitor of IRE1 alpha, a key ER stress pathway in Cancer Treatment | AbbVie | Series A Financing | United States |
20-Feb-18 | Tetraphase Pharmaceuticals, Inc. | $43 | Tetraphase and Everest will establish a joint steering committee to review and oversee all of Everest’s development and commercialization plans | Everest Medicines Limited | Licensing Agreement | United States |
14-Feb-18 | Ferring Biotech Centre | $32 | Ferring expands its capabilities in biologics through a new biotech centre & In addition to new biologics in reproductive medicine and women’s health, fertility treatment Rekovelle® (follitropin delta) will also be manufactured at the new centre | Ferring Pharmaceuticals | Investment | Switzerland |
01-Mar-18 | IQGEN Holdings LLC | $25 | The Vantage fund aims to invest in technology-driven healthcare companies in India and other Asian nations, founder and managing partner | Venture Capital | Investment | India |
28-Feb-18 | Revance Therapeutics | $25 | To Bring a Biosimilar to the Market for the development and commercialization of a proposed biosimilar to BOTOX® (onabotulinumtoxinA) | Mylan N.V. | Collaboration | United States |
27-Feb-18 | Neurona Therapeutics | $24 | Transplantation of selected neurons to treat intractable neurological diseases | The Column Group | Series A Financing | United States |
08-Feb-18 | UCB (Syndesi Therapeutics) | $21 | To develop a series of molecules that modulate the protein SV2A, which is involved in synaptic transmission | Johnson & Johnson | Partnership | Belgium |
26-Feb-18 | Exelixis, Inc. | $20 | Submission of Regulatory Filing for Esaxerenone (CS-3150) in Japan | Daiichi Sankyo | Collaboration | United States |
15-Feb-18 | ABAC Therapeutics | $20 | To Develop Therapeutic Solutions to Fight Antibiotic-Resistant Bacteria | Pontifax | Series A Financing | Spain |
26-Feb-18 | Prokarium | $10 | For clinical development of revolutionary thermostable vaccines | Riyadh Valley Company (RVC) & Saudi, Swedish and Korean investors | Investment | United Kingdom |
15-Feb-18 | SMART Medical Systems Ltd | $8 | SMART's present financing will be used primarily to commercialize its G-EYE® product | Signet Healthcare Partners, a NY-based healthcare | Series B Financing | Israel |
12-Feb-18 | Avadel Pharmaceuticals | $8 | Under the terms of the licensing and development agreement, Avadel will develop and provide Cerecor with four stable product formulations utilizing its LiquiTime™ and Micropump® platforms. | Cerecor, Inc. (CERC) | Asset Acquisition | Ireland |
23-Feb-18 | Aakar Innovations, Saathi Eco Innovations etc (India) | $8 | Support of women’s empowerment, sexual and reproductive health and rights, water and sanitation, and global mental health in India | Govt.of Canada through Global Affairs Canada | Investment | India |
28-Feb-18 | Synergy Pharmaceuticals | $5 | Acquires Exclusive Canadian Rights to FDA-Approved TRULANCE® | Cipher Pharmaceuticals | Acquisition | United States |
28-Feb-18 | Randob Labs | $4 | To divest the brand Balmex | Moberg Pharma AB | Investment | United States |
15-Feb-18 | Solaris Nutraceuticals | $2 | Building the largest medical cannabis greenhouse southern hemisphere facility | Federal Department of Innovation, Industry & Science | Grants & Awards | Australia |
26-Feb-18 | Amarantus | $2 | Phase 2b Eltoprazine program for Parkinson's disease levodopa-induced dyskinesia (PD-LID) and Cutanogen Corporation's pending pivotal trial in Pediatric Severe Burns | Dominick & Dickerman LLC | Financing | United States |
05-Feb-18 | SCIEX | $0 | Devised an isotopic methodology in which all biological molecules are uniformly and randomly labeled to create informative isotopic patterns that are readily discriminated from artifacts | IROA Technologies LLC | Marketing Agreement | United States |
08-Feb-18 | Massachusetts General Hospital | $0 | Progression of neurofibrillary tangles (NFTs) and Parkinson's Disease tau protein | Cerveau Technologies, Inc | Research Agreement | United States |
22-Feb-18 | Preora Healthcare | $0 | To Bring Novel Intracellular Visualization Technology to Cancer Diagnostic Market | Planet Innovation | Collaboration | United States |
22-Feb-18 | Evinance Innovation, Inc | $0 | This acquisition expands the capabilities of Varian's 360 Oncology™ care management platform by tightly integrating clinical workflow, decision support, and adherence tracking based on leading cancer care guidelines | Varian | Acquisition | Canada |
22-Feb-18 | Bridgemedica, LLC | $0 | To further diversify portfolio and expand into markets that we believe have strong growth potential | NN, Inc. | Acquisition | United States |
21-Feb-18 | ATUM | $0 | To Accelerate Drug Discovery ATUM licenses Company’s Leap-In Transposase® Technology | Just Biotherapeutics | Licensing Agreement | United States |
20-Feb-18 | Melinta Therapeutics | $0 | Eurofarma Laboratórios is Melinta’s commercialization and distribution partner for all countries in South and Central America and the Caribbean, including Argentina. The proposed indication for delafloxacin in Argentina is for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI). | Eurofarma Laboratorios | Commercialization Agreement | Brazil |
20-Feb-18 | Orthotaxy | $0 | To Develop Next-Generation Robotic-Assisted Surgery Platform in Orthopaedics | Johnson & Johnson | Acquisition | France |
20-Feb-18 | Pure Applied Sciences | $0 | To acquire Pure Applied Sciences and its brand PureOrganix, a line of organic and pure cannabis oils and related accessories | Cannabis Strategic Ventures, In | Acquisition | United States |
15-Feb-18 | ABAC Therapeutics | $18 | ABAC develops new targeted antibiotics for patients with severe infections | Debiopharm Innovation Fund | Acquisition | Spain |
13-Feb-18 | Apex Resource Technologies | $0 | Medical Plastics Leader Enhances Specialty Products Portfolio & Design Engineering Through Acquisition | Spectrum Plastics Group | Acquisition | United States |
09-Feb-18 | Vaxart, Inc. | $0 | To develop oral recombinant vaccines as tablets | CAS Group | Merger Agreement | South Africa |
12-Feb-18 | Kerafast Inc. | $0 | Absolute Antibody specializes in the sequencing, engineering and recombinant production of antibodies. Their catalog offers more than 3,400 recombinant antibodies in new engineered versions, absolutely defined at the amino acid level to ensure batch-to-batch reproducibility. | Absolute Antibody Ltd. | Merger Agreement | United States |
08-Feb-18 | Corpus Medical | $0 | Combining Advanced Catheter Technology Design and Development with Confluent Medical Manufacturing Capabilities | Confluent Medical Technologies | Acquisition | United States |
07-Feb-18 | IncoCare Gunhild Vieler GmbH | $0 | To further strengthen its position in Germany. Together, Coloplast and IncoCare will bring innovative products and services to more users across Germany | Coloplast | Acquisition | Germany |
06-Feb-18 | Texas A&M University Health Science Center College of Medicine Institute for Regenerative Medicine | $0 | The Agreement for Alzheimer’s Research & Celltex acquires intellectual property license, signs multi-year research study with Texas A&M Health Science Center | Celltex Therapeutics Corporation | Licensing Agreement | United States |
01-Feb-18 | NCPC GeneTech Biotechnology | $0 | To export CJ-40001, a second-generation erythropoietin (EPO) biosimilar | CJ HealthCare | Contract Agreement | China |
01-Feb-18 | Sanofi | $0 | To develop, manufacture, and commercialize Leukine (sargramostim) | Partner Therapeutics | Acquisition | France |
01-Feb-18 | Amgen | $0 | Agreement for the cholesterol-lowering drug, Repatha® (evolocumab) | Abarca | Contract Agreement | United States |
22-Feb-18 | Biohaven Pharmaceutical Holding Company | $0 | To provide Catalent’s Zydis® ODT (orally disintegrating tablet) fast-dissolving formulation for the development of Biohaven’s lead calcitonin gene-related peptide (CGRP) receptor antagonist product candidate, rimegepant | Catalent U.K. Swindon Zydis Limited | Licensing Agreement | United States |
17-Feb-18 | Health Elite Club Limited ("HECL") | $0 | To Distribute ZanthoSyn® in China | Cardax, Inc | Purchase Agreement | Hong Kong |
13-Feb-18 | GC Pharma | $0 | To Develop and Commercialise GCC-4401C, an Investigational Anticoagulant | Lee's Pharmaceutical (HK) Limited | Licensing Agreement | South Korea |
13-Feb-18 | Shanghai Dahua Pharmaceutical Co.,Ltd. | $0 | To increase access to contraceptive implants | DKT International | Partnership | China |
13-Feb-18 | BC Platforms | $0 | It will be using its technology solutions and research platform, including BCRQUEST.COM, to study data in cardiovascular diseases | Pfizer Inc. | Partnership | Switzerland |
08-Feb-18 | MKO Global Partners | $0 | Company expands presence in the pharma consulting space with the addition of pricing and payer strategy services | Two Labs | Partnership | United States |
01-Feb-18 | AstraZeneca | $0 | Immuno Oncology Clinical Trial Collaboration & it will evaluate combination of SNDX-6352 with durvalumab (ImfinziTM) in solid tumors | Syndax Pharmaceuticals | Collaboration | United Kingdom |
14-Feb-18 | Roivant Sciences | $0 | A proposal to jointly develop Arbutus’ nucleic acid delivery platform based on its Lipid Nanoparticle (LNP) technology and GalNAc technology (collectively, Delivery Technologies) through a new company that would jointly own, manage, and develop the Delivery Technologies | Arbutus Biopharma Corporation | Exclusivity Agreement | Switzerland |
08-Feb-18 | Fujifilm Corporation | $0 | To develop regenerative medicine therapies using cardiomyocytes derived from iPSC for the treatment of heart failure | Takeda Pharmaceutical Company | Collaboration | Japan |
21-Feb-18 | Arix Bioscience plc | $0 | To develop and commercialise innovative therapies. | Ipsen | Partnership | United Kingdom |
22-Feb-18 | SCD Pharmaceuticals | $0 | To develop, manufacture and market a portfolio of ophthalmic products in the U.S. and Canada | Glenmark Pharmaceuticals | Collaboration | United States |
22-Feb-18 | Kallyope Inc. | $0 | To Advance Programs Targeting the Gut-Brain Axis | Euclidean Capital and Two Sigma Ventures | Series B Financing | United States |
21-Feb-18 | Johnson & Johnson | $0 | To establish a collaborative laboratory focused on 3D bioprinting | AMBER | Collaboration | United States |
22-Feb-18 | Regulus Therapeutics Inc. | $0 | Agreement follows the recent opening of WuXi STA’s oligonucleotide R&D labs in China and the USAn | WuXi AppTec | Collaboration | United States |
20-Feb-18 | Atomo Diagnostics | $0 | To create next generation FebriDx® tests that are anticipated to transform the diagnosis of febrile acute respiratory infections (ARI) at the point-of-care | RPS Diagnostics | Partnership | Australia |
22-Feb-18 | Babraham Research Campus in Cambridge (UK) | $0 | To accelerate its AI-enabled drug development | BenevolentAI | Acquisition | United Kingdom |
26-Feb-18 | AGC Biologics | $0 | To continue development and advancement of CB 2679d through the clinic | Catalyst Biosciences | Manufacturing Investment | United States |
26-Feb-18 | Selexis | $0 | To Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates | Xencor | Expanded Partnership | Switzerland |
26-Feb-18 | Biosensorix | $0 | To Develop Next-Generation Point-of-Care Diagnostics Based on Research at Ben Gurion University | BGNTechnologies | Collaboration | Singapore |
26-Feb-18 | Bioventus | $0 | To Co-Develop Next Generation Bone Allograft | LifeLink Tissue Bank | Partnership | United States |
28-Feb-18 | Likarda | $0 | To offer online access to its innovative 3D compound screening and assay development services to scientists around the globe. | Science Exchange | Partnership | United States |
27-Feb-18 | Cipla | $0 | For the promotion and sale of tocilizumab and the 2nd brand of bevacizumab (Avastin) | Roche | Partnership | India |
27-Feb-18 | Aldeyra Therapeutics | $0 | To Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases | Johnson & Johnson | Research Agreement | United States |
27-Feb-18 | Elekta | $0 | To continue development of clinical protocols for MR-linac technology | Memorial Sloan Kettering Cancer Center (MSK) | Collaboration | Sweden |
27-Feb-18 | Janssen Pharmaceuticals | $0 | For access to TESARO's ZEJULA® (niraparib), an orally administered poly (ADP-ribose) polymerase (PARP) inhibitor undergoing clinical development, PARP inhibitor niraparib for Sierra's Phase 1b/2 combination trial with Chk1 inhibitor SRA737 | Sierra Oncology, Inc. | Supply Agreement | United States |
26-Feb-18 | Edico Genome | $0 | To Streamline Clinical Next-Generation Sequencing Workflows | InterSystems | Partnership | United States |
27-Feb-18 | Kaken Pharmaceutical Co., Ltd | $0 | To Develop And Commercialize New Chemical Entity For Psoriasis | Valeant Pharmaceuticals | Licensing Agreement | Japan |
26-Feb-18 | Bavarian Nordic | $0 | To evaluate CV301 in combination with durvalumab in colorectal and pancreatic cancers | Georgetown University Dr. Michael Pishvaian | Collaboration | Denmark |
26-Feb-18 | Roche | $0 | To Evaluate Combination of ZEJULA® (Niraparib) and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder Cancer | TESARO, Inc. | Collaboration | United States |
27-Feb-18 | Naveos | $0 | Acquisition expands suite of revenue integrity solutions for healthcare providers and adds market-leading capabilities in government reimbursement | Revint Solutions | Acquisition | United States |
26-Feb-18 | MHM Services | $0 | To Expand National Footprint In Correctional Healthcare Sector | Centene Corporation | Acquisition | United States |
28-Feb-18 | Acorda Therapeutics, Inc | $0 | Developing therapies which improve the lives of people with neurological disorders- Parkinson’s disease and multiple sclerosis | Scopia Capital Management | Collaboration | United States |
27-Feb-18 | Median Technologies | $0 | Median and CMIC will leverage complementary expertise to help biopharmaceutical companies accelerate oncology drug development in Japan, China and East Asia. | CMIC HOLDINGS Co., Ltd. | Collaboration | United States |
26-Feb-18 | Tissue Regenix | $0 | Companies collaborate to educate surgeons and hospitals about the safety, comfort and performance advantages of DermaPure® biologic for pelvic floor surgery | ARMS Medical | Collaboration | United States |
26-Feb-18 | CellSystems GmbH | $0 | For AlphaSTEM™ Naïve Stem Cell Culture System | Minerva Biotechnologies | Distribution Agreement | Germany |
21-Feb-18 | Tolmar Australia Pty Limited | $0 | Exclusive distribution rights for the oncology medication Eligard® | Mundipharma | Acquisition | Australia |
08-Feb-18 | Q Biomed Inc | $0 | For a Novel Companion Biomarker for Monitoring Glaucoma , Under the agreement granting the exclusive right to license the technology, | Washington University in St. Louis | Option Agreement | United States |
27-Feb-18 | Mindstrong Health | $0 | Development of digital biomarkers for selected mental health conditions | Takeda Pharmaceutical Company | Partnership | United States |
26-Feb-18 | Elsevier | $0 | To Enable Deeper Research into Traditional Chinese Medicine | Beijing University of Chinese Medicine | Collaboration | United States |
08-Feb-18 | HOVON | $0 | To Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Chemotherapy | GlycoMimetics, Inc | Clinical Collaboration | The Netherlands |
13-Feb-18 | Medidata | $0 | To include Edge eTMF and Edge CTMS | Aperio or iNNO Clinical | Expansion | United States |
20-Feb-18 | MAB Discovery GmbH (MABD) | $0 | To develop novel antibody therapeutics based on MABD’s unique discovery platform | Cullinan Oncology, LLC | Collaboration | Germany |
19-Feb-18 | OncoLens | $0 | Enabling patients to enroll in trials faster, obtain treatment at local community cancer centers | Optimal Research | Collaboration | United States |
15-Feb-18 | BullFrog AI | $0 | To Improve Antipsychotic Drug Selection | Lieber Institute for Brain Development | Collaboration | United States |
06-Feb-18 | Charles River | $0 | To Accelerate Drug Discovery and Development | HemaCare | Partnership | United States |
08-Mar-18 | Express Scripts | $67,000 | To create an expanded portfolio of health services with greater choice, alignment and value across a proven services platform | Cigna Corporation | Acquisition | United States |
27-Mar-18 | Novartis | $13,000 | Agreement with Novartis to buyout Novartis’ 36.5% stake in the Consumer Healthcare Joint Venture for $13 billion (£9.2 billion) | GlaxoSmithKline | Joint Venture | Switzerland |
08-Mar-18 | Eisai Co | $5,760 | Companies to Jointly Develop and Commercialize LENVIMA, as Monotherapy and in Combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.’s KEYTRUDA® (pembrolizumab) for Multiple Cancer Types | Merck & Co. | Collaboration | Japan |
16-Mar-18 | Johnson & Johnson | $2,100 | Johnson & Johnson today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion, subject to customary adjustments. | Platinum Equity | Acquisition | United States |
15-Mar-18 | Ionis Pharmaceuticals | $1,700 | Collaboration advances commercial readiness for planned mid-2018 inotersen launch, positioning Akcea to successfully launch two drugs for significant rare diseases this year | Akcea Therapeutics | Licensing Agreement | United States |
16-Mar-18 | Prexton Therapeutics BV | $1,113 | Foliglurax is a first-in-class treatment, which entered clinical phase II testing in Parkinson’s disease in July 2017. | H. Lundbeck A/S | Acquisition | The Netherlands |
29-Mar-18 | Irvine Scientific Sales Company (ISUS) , IS Japan (ISJ) | $800 | The expected synergies are 1) the further expansion of the contact development and manufacturing business for biopharmaceuticals, 2) the acceleration of research and development in the area of regenerative medicine, and 3) the further expansion of reagent business. | FUJIFILM Corporation | Acquisition | United States |
12-Mar-18 | Nutranext | $700 | Nutranext’s products include multivitamins under the Rainbow Light® brand, the No. 2 vitamin brand in the natural channel1; specialty minerals under the Natural Vitality® brand, the No. 1 anti-stress and sleep brand in the natural channel2; and supplements for hair, skin and nails under the Neocell® brand. | The Clorox Company | Acquisition | United States |
16-Mar-18 | Pfizer Inc. | $590 | PF-04958242 is an AMPA receptor potentiator designed to facilitate neurotransmission for cognitive impairment associated with schizophrenia (CIAS). | Biogen | Asset Acquisition | United States |
28-Mar-18 | CureTech | $553 | InSight will make an immediate payment of $50 million which will be used to fund development of CureTech’s immunotherapy candidate, which is currently geared towards the treatment of diffuse intrinsic pontine glioma (DIPG), a rare variety of brain tumour. | InSight Biopharmaceuticals Ltd. | Acquisition | Israel |
26-Mar-18 | National Institute For Bioprocessing Research & Training | $462 | Shire, the Ireland-domiciled pharma group that specialises in rare diseases, has signed a training deal with the National Institute of Bioprocessing Research and Training (Nibrt) in Dublin. The €375 million investment will create the company’s European quality control hub for its biologics portfolio. | Shire PLC | Collaboration | Ireland |
21-Mar-18 | NxThera | $406 | Acquisition expands portfolio with minimally invasive treatment option for patients with benign prostatic hyperplasia. NxThera developed and commercialized, in the United States (U.S.) and Europe, the Rez?m® system which is a minimally invasive therapy in a growing category of treatment options for men with symptoms arising from BPH | Boston Scientific | Acquisition | United States |
26-Mar-18 | Arena Pharmaceuticals, Inc. | $406 | Arena anticipates using the net proceeds from the offering for the clinical and preclinical development of drug candidates, including its planned Phase 3 programs for etrasimod for the treatment of ulcerative colitis and ralinepag for the treatment of pulmonary arterial hypertension, for general corporate purposes, including working capital and costs associated with manufacturing services, and for capital expenditures. | Undisclosed | IPO | United States |
05-Mar-18 | Heidelberg Pharma AG | $334 | The collaboration will combine Magenta’s stem cell platform with proprietary antibodies across up to four exclusive targets with Heidelberg Pharma’s proprietary ATAC (Antibody Targeted Amanitin Conjugates) platform. | Magenta Therapeutics | Collaboration | Germany |
29-Mar-18 | C4X Discovery | $294 | C4X Discovery signs licensing agreement with Indivior for addiction programme worth up to $294 million. | Indivior PLC | Licensing Agreement | United Kingdom |
08-Mar-18 | Advanced Analytical Technologies, Inc. | $250 | This acquisition will enhance Agilent's existing expertise and technology, while giving customers a more comprehensive set of solutions. AATI solutions are comprised of instruments, software and consumables aimed at simplifying complex workflows. | Agilent Technologies | Acquisition | United States |
12-Mar-18 | Cogentix Medical Inc. | $214 | The addition of Cogentix’s suite of technology will significantly expand LABORIE’S therapeutic offering, thereby providing customers and their patients with comprehensive, clinically-relevant solutions along the disease treatment continuum. | LABORIE Medical Technologies | Acquisition | Canada |
01-Mar-18 | Helix OpCo LLC | $200 | Helix operates one of the world’s largest CLIA-and-CAP-accredited Next Generation Sequencing laboratories. Powered by Illumina technologies, Helix uses its proprietary Exome+ assay to sequence each customer’s 20,000 protein-coding genes as well as additional information-rich areas identified by Helix’s scientific team. | DFJ Growth | Series B Financing | United States |
20-Mar-18 | Prothena Corporation plc | $150 | Collaboration focuses on preclinical programs targeting proteins implicated in several neurodegenerative diseases, including tau, TDP-43 and an undisclosed third target | Celgene Corporation | Collaboration | Ireland |
27-Mar-18 | Homology Medicines | $150 | Homology Medicines is based on an important scientific discovery – a novel set of adeno-associated virus vectors derived from human hematopoietic stem cells (AAVHSCs) that are designed to precisely and efficiently deliver genetic medicines in vivo either through gene therapy or gene editing. | Undisclosed | IPO | Germany |
07-Mar-18 | STEMCELL Technologies | $142 | STEMCELL Technologies has signed an exclusive license with Indiana University Innovation and Commercialization Office for patented rights to groundbreaking inner ear organoid technologies. | Indiana University Innovation and Commercialization Office | Licensing Agreement | Canada |
20-Mar-18 | Oxford Nanopore | $140 | Funding will support new manufacturing facility, commercial expansion, and development of new innovative products. | GIC, CCB International, Hostplus | Financing | United Kingdom |
19-Mar-18 | Arcus Biosciences, Inc. | $138 | Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist and an anti-PD-1 antibody, both of which are in Phase 1 trials, as well as a small molecule inhibitor of CD73 and an anti-TIGIT antibody, which are in IND-enabling studies. | Undisclosed | IPO | United States |
07-Mar-18 | Aptose Biosciences | $125 | Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced an exclusive global license agreement that provides OHM Oncology with the rights for the development, manufacture and commercialization of APL-581, as well as related molecules from Aptose’s dual bromodomain and extra-terminal domain motif (BET) protein and kinase inhibitor program. Aptose will retain reacquisition rights to certain mole | OHM Oncology | Licensing Agreement | United States |
21-Mar-18 | TCR2 Therapeutics | $125 | Proceeds will support clinical development of lead program TC-210 and expansion of the multi-format TRuC™-T cell pipeline in solid tumors and blood cancers | MPM Capital; 6 Dimensions Capital, | Series B Financing | United States |
29-Mar-18 | Hua Medicine | $117 | The financing is expected to fully fund the Company through completion of its two Phase 3 trials and commercial launch in China for Dorzagliatin (HMS5552), a new first-in-class, 4th-generation glucokinase activator (GKA) that treats the impaired blood glucose sensor function, and thereby seeks to address the underlying cause of Type 2 diabetes. | Blue Pool Capital, Alibaba Group | Series D Financing | China |
05-Mar-18 | Vividion Therapeutics | $101 | Collaboration utilizes Vividion’s unique proteome-wide ligand and target discovery platform. | Celgene Corporation | Research Agreement | United States |
01-Mar-18 | Rubius Therapeutics | $100 | Proceeds from the financing will be used to accelerate the development of the Company’s portfolio of RCTs™ towards clinical proof-ofconcept, and to enhance its manufacturing capacity and capabilities. | Flagship Pioneering | Financing | United States |
02-Mar-18 | Tricida, Inc. | $100 | This financing provides Tricida with significant financial flexibility as it continues the development of TRC101 for the treatment of metabolic acidosis in chronic kidney disease patients | Hercules Capital, Inc. | Financing | United States |
27-Mar-18 | Nabriva Therapeutics | $95 | As part of the license agreement, Nabriva has granted a Roivant subsidiary an exclusive license to develop and commercialize lefamulin in the greater China region, specifically the People’s Republic of China, Hong Kong, Macau, and Taiwan. | Roivant Sciences | Financing | Ireland |
15-Mar-18 | Ideaya Biosciences | $94 | Proceeds to advance multiple synthetic lethality and immuno-oncology therapies into the clinic | Nextech Invest | Series B Financing | United States |
02-Mar-18 | JW Therapeutics | $90 | By combining Juno’s world-class technology and platform with WuXi AppTec Group’s local expertise, R&D and manufacturing platform, and broader partnerships, JW Therapeutics has successfully initiated the development of its first CD19-directed investigational therapy, JWCAR029 (a CAR-T therapy being studied for the treatment of B-cell malignancies initially focusing on relapsed and refractory DCBCL). | Temasek, Sequoia Capital China, YuanMing Capital etc. | Series A Financing | China |
20-Mar-18 | Tempus | $80 | The additional funds will be used to further grow and scale the company’s clinical and molecular analytic platform. | New Enterprise Associates | Series D Financing | United States |
08-Mar-18 | Prevail Therapeutics | $75 | Prevail’s lead program, PR001, will be developed for a genetic subset of Parkinson’s disease and other mechanistically-related disorders. | OrbiMed | Series A Financing | United States |
09-Mar-18 | Humacyte, Inc. | $75 | The funding is expected to support Humacyte’s ongoing HUMANITY study, the company’s pivotal Phase III study assessing the human acellular vessel (HAV), or HUMACYL®, as a conduit for hemodialysis in patients with end-stage renal disease who are not candidates for fistula placement. | PointState Capital | Series C Financing | United States |
08-Mar-18 | Evotec AG | $74 | Evotec-led platform expands current initiatives to accelerate research and development (“R&D”) of novel anti-infectives. Sanofi to licence more than 10 infectious disease R&D assets to evotec while retaining option rights for development and commercialisation. | Sanofi | Research Agreement | Germany |
28-Mar-18 | Tempest Therapeutics | $70 | Proceeds from the Series B financing will support the advancement of lead program TPST-8844 into the clinic in the next 12 months as well as advancement of at least two other programs into the clinic shortly thereafter. | Versant Ventures, F-Prime Capital, Quan Capital | Series B Financing | United States |
13-Mar-18 | Crinetics Pharmaceuticals | $64 | Crinetics Pharmaceuticals plans to use the proceeds to fund the continuing development of CRN00808, an oral nonpeptide somatostatin agonist for the potential treatment of acromegaly, to develop additional new targeted therapeutics for endocrine disorders and endocrine related cancers, and for general corporate purposes. | Perceptive Advisors | Series B Financing | United States |
22-Mar-18 | Rheos Medicines | $60 | Founded by luminaries in the field of immunometabolism, Rheos aims to identify mechanisms and discover medicines that tune metabolic pathways in immune cells. Company’s therapeutics will focus on well-defined patient subsets in heterogeneous diseases including autoimmunity, inflammation and in immuno-oncology applications. | Third Rock Ventures | Series A Financing | United States |
12-Mar-18 | BioXcel Therapeutics | $60 | The proceeds from the IPO will be used to fund the Phase II testing of the company's two most advanced drug candidates: BXCL501 and BXCL701. About $42 million of the total amount raised through the IPO will be used for Phase II research, with much of the remaining money slated to be used for working capital and for general corporate purposes, according to the company's SEC filing. | Undisclosed | IPO | United States |
27-Mar-18 | Singlera Genomics | $60 | The funds will help Singlera expand the development and commercialization of its non-invasive genetic tests for early-stage cancer detection and clinical validation studies. | Green Pine Capital Partners | Series A Financing | United States |
02-Mar-18 | CARsgen Therapeutics | $60 | The funds will be used in support of Investigational New Drug submissions of several CAR-T therapeutics and Next-generation CAR-T research. | Undisclosed | Financing | China |
09-Mar-18 | Xeris Pharmaceuticals | $55 | The proceeds from the two financings will help accelerate the development of additional product candidates applying Xeris’ ready-to-use glucagon to intermittent and chronic-use indications that require administration over a longer period. | Silicon Valley Bank | Series C Financing | United States |
13-Mar-18 | Bristol-Myers Squibb | $55 | As part of the restructuring, Biohaven will pay BMS an upfront payment of $50 million in return for a low single digit reduction in the royalties payable on net sales of rimegepant and a mid-single digit reduction in the royalties payable on net sales of BHV-3500. | Biohaven Pharmaceutical Holding Company Ltd. | Licensing Agreement | United States |
19-Mar-18 | Unity Biotechnology | $55 | Proceeds from this financing will be used to advance the company's lead senolytic drug candidates into human clinical trials. UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. | EcoR1 Capital Fund, 6 Dimensions Capital | Series C Financing | United States |
23-Mar-18 | Mabion S.A. | $51 | Mabion intends to use the net proceeds from the financing to cover the cost of the expansion of production capacity in Konstantynów ?ódzki, Poland and costs and expenses related to the development and commercialization of Mabion CD20. | European Bank For Reconstruction And Development (EBRD) And PFR Life Science Sp. Z O.O. | Private Placement | Poland |
20-Mar-18 | CASI Pharmaceuticals | $50 | The Company is working on its portfolio of 29 abbreviated new drug applications (ANDAs) (including 25 FDA-approved and 4 pending approval) that were recently acquired from Sandoz, and will continue to further expand the pipeline as part of their mission to bring innovative and high-quality medicines to the market. | ETP Global Fund LP, IDG-Accel China Growth Fund III | Private Placement | United States |
14-Mar-18 | Foghorn Therapeutics | $50 | Company’s Proprietary Gene Traffic ControlTM Product Platform Provides a New Way to Think About Treating Disease | Flagship Pioneering | Launch & Partnerships | United States |
26-Mar-18 | Adagene Inc. | $50 | The funds from this round of financing will be used to advance novel antibody therapeutics into human trials across the globe. The antibodies discovered from our Dynamic Precision Library [DPL] platform enable translational research of our therapeutic leads on the intact immune system of highly predictive preclinical models. | Sequoia China | Series C Financing | China |
22-Mar-18 | CBT Pharmaceuticals | $47 | The agreement gives CBT exclusive world-wide development and commercialization rights to a novel, recombinant, human monoclonal antibody which targets a differentiated epitope on the cytotoxic T-lymphocyte antigen-4 (CTLA-4) molecule. Binding of this antibody to CTLA-4 blocks the interaction of CTLA-4 with its ligands CD80/CD86 thus allowing the cytotoxic T cells to function actively. | Crown Bioscience | Licensing Agreement | United States |
12-Mar-18 | TAE Life Sciences | $40 | TAE Life Sciences is leveraging TAE Technologies’ unique accelerator-based neutron beam technology for Boron Neutron Capture Therapy (BNCT) to bring promising treatment potential for head and neck, glioblastoma multiforme (GBM) and other cancers that are difficult or impossible to treat with traditional methods. | Neuboron Medtech, Ltd., ARTIS Ventures | Series A Financing | United States |
22-Mar-18 | Dracen Pharmaceuticals | $40 | Dracen will develop its glutamine antagonists both in single agent settings as well as in combination with immune checkpoint inhibitors such as anti-PD-1 and anti-PD-L1. The goal of these therapies is to increase the number of responders to anti-cancer therapy and extend survival; and potentially, to provide anti-tumor responses in areas currently evading immuno-oncology approaches. | Deerfield Management | Series A Financing | United States |
06-Mar-18 | Themis Bioscience | $38 | First major investment by Coalition for Epidemic Preparedness Innovations (CEPI) to advance vaccine development and manufacturing on two of CEPI’s highest priority infectious diseases. | Coalition for Epidemic Preparedness Innovations (CEPI) | Financing | Norway |
01-Mar-18 | Finch Therapeutics | $36 | The combination of the two biotechs also came with new support from Crestovo supporter Chris Shumway of Shumway Capital, who helped bring the syndicate together. | Takeda Pharmaceutical Company | Series B Financing | United States |
09-Mar-18 | Adagene Inc. | $36 | The collaboration with WuXi Biologics will support supply of Adagene’s products for clinical trials under Investigational New Drug (IND) applications in both China and United States. | WuXi AppTec | Research Agreement | China |
16-Mar-18 | Bavarian Nordic | $36 | With funding from the DoD, Bavarian Nordic will utilize its proprietary MVA-BN® platform to develop a vaccine against various strains of the virus, for which there is currently no preventative vaccine treatment available. | United States Department of Defense (DoD) | Partnership | Denmark |
05-Mar-18 | ViewPoint Therapeutics | $35 | ViewPoint plans to use the proceeds of the financing to develop its lead product candidate, VP1-001, through clinical proof-of-concept studies in patients with cataracts and presbyopia. In addition, ViewPoint anticipates that the proceeds will also allow the Company to advance second-generation compounds from its ongoing medicinal chemistry efforts. | The Rise Fund | Series B Financing | United States |
08-Mar-18 | Gelesis | $30 | The proceeds from the financing will be used to support commercial-stage manufacturing, product launch preparations, company operations, and clinical advancement of the Company’s pipeline of additional product candidates for gastrointestinal disorders, including Type 2 diabetes and non-alcoholic steatohepatitis/non-alcoholic fatty liver disease (NASH/NAFLD). The Company also plans to submit Gelesis100 for regulatory approvals in the US and Europe in 2018. | PureTech Health | Financing | United States |
13-Mar-18 | AbCellera Biologics Inc. | $30 | Under DARPA’s Pandemic Prevention Platform (P3) program, AbCellera will apply its state-of-the art capabilities in human antibody discovery and immune profiling to establish rapid countermeasures for viral pandemics. | Defense Advanced Research Projects Agency (DARPA) | Collaboration | Canada |
06-Mar-18 | Science 37 | $29 | This three-year commitment will enable a more extensive portfolio of trials powered by the Network Oriented Research Assistant (NORA®), Science 37’s proprietary technology platform that enables patients to participate in clinical research regardless of their geographical location using mobile devices and telemedicine services. | Novartis | Partnership | United States |
08-Mar-18 | Cyteir Therapeutics | $29 | Financing proceeds will be used to advance RAD51 inhibitor toward the clinic and expand small-molecule synthetic lethality platform for oncology and autoimmune diseases. | DROIA Oncology Ventures | Series B Financing | United States |
13-Mar-18 | Kiadis Pharma N. V. | $29 | This €23.4 million private placement will fund the Company into H2 2019 and thus well beyond potential EU approval and into potential European launch of ATIR101™. | Undisclosed | Private Placement | The Netherlands |
06-Mar-18 | Medeon Biodesign, Inc. | $20 | Under the terms of the agreement, Terumo will pay US$20 million upfront and additional payments based on the achievement of future specific development milestones. It will be funded through cash on hand. | Terumo Corporation | Asset Acquisition | Taiwan |
20-Mar-18 | Cipher Pharmaceuticals | $20 | The Canadian business portfolio to be acquired by Cipher includes commercial and pipeline hospital products administered in the acute care setting, including Brinavess® (vernakalant IV), Aggrastat® (tirofiban hydrochloride), Xydalba™ (dalbavancin hydrochloride), andnTrevyent® a drug device combination that delivers treprostinil, the world's leading treatment for pulmonary arterial hypertension. | Cardiome Pharma Corporation | Partnership | Canada |
13-Mar-18 | Escalier Biosciences | $19 | Escalier is developing both topical and oral ROR?t drug candidates for psoriasis and expects to be in the clinic with its topical compound in mid 2018. | Forbion | Series B Financing | The Netherlands |
15-Mar-18 | Minakem SAS | $18 | The €14.5M ($18M) investment from parent company Minafin is the first of this magnitude. It will enable the company to set up a new production line, increasing production capacity by 28m3. | Minafin S.A. | Financing | France |
06-Mar-18 | 23Mofang (Chengdu 23 Magic Cube Biotechnology Co., Ltd.) | $16 | Maximum cost for the 23Mofang test is $158. Its biochip, which was co-developed with Thermo Fisher Scientific, tests for as many as 300 medical conditions. Proceeds from the newest round of financing will be used to enlarge its test centre, boost research and development of products, and expand further into the market. | Matrix Partners China | Series B Financing | China |
15-Mar-18 | Arbor Biotechnologies, Inc. | $16 | Arbor’s discovery platform employs a diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – to curate and mine the natural genetic diversity for impactful peptides, proteins, and enzymes. This approach enables systematic and high-throughput discovery of new molecules for improving human health and sustainability. | ARCH Venture Partners, Faridan Ventures | Series A Financing | United States |
01-Mar-18 | Cullgen | $15 | Cullgen's new drug discovery platform has the advantage of accelerating NCEs into clinical development in a cost and time efficient manner to benefit patients. Initial drug discovery programs will focus on oncology and expand into areas such as inflammatory and autoimmune diseases. | GNI Group Ltd. | Seed Financing | United States |
06-Mar-18 | Oxford Vacmedix | $13 | Spun out by Oxford University Innovation in 2012, OVM is commercialising research led by Dr Shisong Jiang, ndeveloped as a partnership between Oxford University’s Department of Oncology and the Medical Research nCouncil’s Weatherall Institute of Molecular Medicine, also based in Oxford. The technology uses the novel, proprietary platform of recombinant overlapping peptides to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy. | Cancer Rop Co | Series A Financing | United Kingdom |
29-Mar-18 | Swift Medical | $12 | Already the market frontrunner with more than 1,000 facilities signed up across North America, Swift forges further ahead with plans to expand to every wound patient’s bedside. | Data Collective | Series A Financing | Canada |
19-Mar-18 | twoXAR, Inc. | $10 | The proceeds will be used to build the company’s drug pipeline through partnerships and accelerate preclinical development of existing candidates. | SoftBank Ventures, Andreessen Horowitz Bio Fund, OS Fund | Series A Financing | United States |
05-Mar-18 | Veru Inc. | $10 | Under the terms of the deal, Veru received $10 million at closing and may receive an additional $2 million upon potential signing of tenders for FC2 Female Condom® product with two large international customers, subject to minimum units ordered. | SWK Holdings | Financing | United States |
02-Mar-18 | City of Hope National Medical Center | $6 | The City of Hope trial hopes to address this unmet medical need for adults with severe SCD. | California Institute for Regenerative Medicine | Grants & Awards | United States |
15-Mar-18 | Parachute Health | $6 | Health Tech Platform Revolutionizes $50 Billion Medical Equipment Industry by Reducing Hospital Costs & Improving Patient Care | Greater New York Hospital Association Ventures, Loeb Holding Corporation | Seed Financing | United States |
13-Mar-18 | Immutep S.A. | $5 | Immutep Limited has announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha (“efti” or “IMP321”) with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a new clinical trial that will evaluate the combination in several solid tumours. | Merck & Co. | Clinical Collaboration | Australia |
05-Mar-18 | MicuRx Pharmaceutical Inc | $5 | The new agent MRX-8 is designed to overcome the limiting nephrotoxicity of current polymyxins. Current preclinical data demonstrated its high efficacy, with the reduced nephrotoxicity as well as attenuated acute or neuromuscular toxicity, when compared to existing polymyxin drugs. | Combating Antibiotic Resistant Bacteria Accelerator (CARB-X) | Financing | United States |
13-Mar-18 | Immuron Limited | $4 | Immuron has received a number of recent offers for financial support following the release of the Company’s positive top-line results of its IMM-124E Phase II Non-Alcoholic Steatohepatitis (NASH) clinical study. | Joseph Gunnar & Co., LLC | Private Placement | Australia |
28-Mar-18 | BriaCell Therapeutics Corp. | $3 | The Company will use the proceeds from the Note Offering and the Non-Brokered Unit Offering, which includes investments from leading U.S. biotech funds such as Brio Capital Master Fund Ltd., Efrat Investments LLC and Mario Family Partners LP, to: (i) finance the Company’s Phase-2a clinical trial; (ii) to finance the Company’s pursuit of other research opportunities; and (iii) for working capital and general corporate purposes. | Brio Capital Master Fund Ltd., | Purchase Agreement | Canada |
14-Mar-18 | PixCell Medical | $3 | The two-year award was granted through Horizon 2020's SME instrument, which targets high potential SMEs with groundbreaking products that have the potential to profoundly impact the EU economy and global healthcare. | European Commission | Grants & Awards | Israel |
08-Mar-18 | Metactive Medical, Inc. | $3 | This new investment capital and grant funding will be used to continue the development of Metactive's novel platform of embolic products, which we believe will provide physicians with devices that are exceptionally deliverable, can be placed with a high level of precision, are resistant to migration, and provide immediate, complete, and lasting occlusion. | National Heart, Lung and Blood Institute (NHLBI-NIH) | Series A Financing | United States |
21-Mar-18 | Titan Pharmaceuticals | $2 | In addition to providing an opportunity to expand the commercialization of Probuphine beyond the United States, the additional financial resources and flexibility provided by this transaction enables Titan Pharma to evaluate options to further strengthen our balance sheet, position Probuphine for commercial success in the U.S., and work to advance our pipeline of other ProNeura™-based product candidates. | L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. | Asset Acquisition | United States |
05-Mar-18 | Wellthy Therapeutics | $2 | Wellthy Therapeutics enables treatment of type-II diabetes using a hybrid of AI and human paramedical coaches to improve health literacy | Manipal Education and Medical Group International India Pvt. Ltd. (MEMG) | Seed Financing | India |
14-Mar-18 | Laurent Pharmaceuticals Inc. | $2 | This new award is in addition to the US$ 3 million development award already committed by the CF Foundation to the Company. LAU-7b is a once-a-day oral pro-resolving therapy with potential to treat chronic pulmonary inflammation that leads to irreversible lung damage in patients with CF, regardless of their CFTR genotype. | Cystic Fibrosis Foundation | Grants & Awards | Canada |
21-Mar-18 | SemaThera Inc | $2 | SemaThera Inc announces today the closing of a $2MUS co-investment from Senju Pharmaceutical Co., Ltd. and AmorChem L.P. for the development of its lead candidate, ST-102, in preparation for a clinical trial application in diabetic macular edema (DME). | Senju Pharmaceutical, AmorChem | Licensing Agreement | Canada |
23-Mar-18 | Amplia Therapeutics | $2 | In acquiring Amplia, Innate will acquire that company's Focal Adhesion Kinase (FAK) cancer programme. FAK is emerging as a promising target in cancer therapy. | Innate Immunotherapeutics | Asset Acquisition | Australia |
08-Mar-18 | Cytox | $1 | The project, ‘The development and implementation of polygenic risk scoring algorithms for stratifying individuals for future cognitive decline due to Alzheimer’s Disease in non-symptomatic and early cognitive impaired subjects’, will evaluate and validate the clinical utility of a customised genetic variation (single nucleotide polymorphism, SNP) panel associated with the development of Alzheimer’s disease (AD). | Innovate UK | Financing | United Kingdom |
02-Mar-18 | RegeneRx Biopharmaceuticals, Inc. | $1 | RegeneRx, through its U.S joint venture, ReGenTree LLC, recently completed patient enrollment and treatment in its second Phase 3 clinical trial in approximately 600 patients with dry eye syndrome, reported positive clinical results, and has scheduled a meeting with the U.S. FDA in April 2018. | Sabby Healthcare Master Fund, Ltd., | Purchase Agreement | United States |
01-Mar-18 | Susan G. Komen | $0.25 | The partnership between the three organizations has raised nearly $1 million to date, thanks to two earlier matching gift campaigns in 2016 and 2017. | The Milburn Foundation, IBC Research Foundation | Partnership | United States |
20-Mar-18 | CNS Pharmaceuticals, Inc. | $1 | In a step toward democratizing the financing of a breakthrough cancer drug technology, CNS Pharmaceuticals, Inc., announced today the launch of its equity crowdfunding campaign on Republic, utilizing new equity crowdfunding securities laws called regulation CF or Reg CF for short, to support the development of Berubicin, its lead drug candidate for the treatment of Glioblastoma, the most aggressive type of brain cancer. | Undisclosed | Financing | Switzerland |
22-Mar-18 | Chiome Bioscience | $0 | Under this Agreement, Chiome grants SemaThera license to exclusively evaluate humanized anti-Semaphorin 3A antibody and an option right to obtain a worldwide exclusive license to use, develop and commercialize the Chiome's Antibody for both therapeutic and diagnostic uses. | SemaThera Inc | Development Agreement | Japan |
01-Mar-18 | Pear Therapeutics | $0 | Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis. Collaboration combines Novartis' leadership in biomedical research and clinical development with Pear's expertise in digital therapeutics. | Novartis | Partnership | United States |
02-Mar-18 | Perlara | $0 | Perlara, a drug discovery platform company partnering with highly motivated families and drug developers to treat diseases thought too rare to attract the interest of pharmaceutical companies, today announced a collaboration with Harvard Medical School and the Undiagnosed Diseases Network to launch PerlQuests for two rare monogenic neurodevelopmental disorders. | Undiagnosed Diseases Network | Research Agreement | United States |
02-Mar-18 | Hologic, Inc. | $0 | Partnership will allow hospitals easier access to integrated suites of diagnostic imaging modalities, advanced informatics and services for comprehensive breast screening and diagnosis | Royal Philips | Partnership | United States |
05-Mar-18 | MyBiotics Pharma Ltd. | $0 | This agreement follows the first agreement between the two parties signed in June 2017, for the validation of MyBiotics' technology in the treatment of a non-disclosed gastroenterology condition. | Ferring Pharmaceuticals | Licensing Agreement | Israel |
05-Mar-18 | EMcision International | $0 | EMcision’s flagship product, the HabibTM EndoHPB, was the world’s first endoscopic device for tumour ablation via ERCP using radiofrequency energy in patients with advanced and inoperable pancreatic cancer and cholangiocarcinoma. | Boston Scientific | Acquisition | United Kingdom |
06-Mar-18 | Ligand Pharmaceuticals | $0 | LGD-6972 to be a foundational program for Metavant, a new company formed by Roivant to pursue the development of innovative therapies for cardiometabolic diseases. | Roivant Sciences | Licensing Agreement | United States |
06-Mar-18 | Apexigen | $0 | Study to evaluate the safety and tolerability of APX005M, a CD40 agonistic antibody, in pediatric patients with recurrent or refractory brain tumors | Pediatric Brain Tumor Consortium | Clinical Collaboration | United States |
06-Mar-18 | Shire Plc | $0 | License Expands Pipeline in Cardiovascular Disease based on Compelling Data Showing Improvement in Chest Pain, Exercise Capacity and Mortality | Caladrius Biosciences, Inc. | Licensing Agreement | Ireland |
07-Mar-18 | Selexis | $0 | Selexis SUREtechnology Platform™ in use for the generation of high-performance research cell banks for Compugen | Compugen | Licensing Agreement | Switzerland |
08-Mar-18 | CDI Labs | $0 | Proteomics company leverages microarray capability to develop a high-throughput test that detects and discriminates between Zika and Dengue viruses | Johns Hopkins, UPenn, Florida State University | Research Agreement | United States |
08-Mar-18 | Surface Oncology | $0 | Under the terms of the agreement Surface Oncology will contract with ProBioGen to develop and manufacture another antibody for potential use in clinical trials. ProBioGen will develop several stable cell lines in parallel, gradually reduce the candidate number and conclude with process development and GMP manufacturing for a single antibody product candidate | ProBioGen AG | Manufacturing Investment | Germany |
09-Mar-18 | Integrated DNA Technologies | $0 | IDT's primary business is the manufacturing of high-quality, custom DNA and RNA oligonucleotides serving customers in the academic and biopharmaceutical research, biotechnology, agriculture, clinical diagnostics, and pharmaceutical development end markets. | Danaher Corporation | Acquisition | Singapore |
10-Mar-18 | Regeneron | $0 | To help ensure more affordable and timely access to patients most in need, Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi will offer payers that agree to reduce burdensome access barriers for high-risk patients a further reduced net price for Praluent® (alirocumab) Injection, in alignment with a new value assessment for high-risk patients from the Institute for Clinical and Economic Review (ICER) available here. | Sanofi | Licensing Agreement | United States |
12-Mar-18 | Lohmann Therapie-Systeme AG | $0 | Currently, Intec is producing the AP-CD/LD capsules for its Phase 3 clinical trial at its existing manufacturing facility in Jerusalem and will work together with LTS to establish commercial scale production capabilities for AP-CD/LD capsules. | Intec Pharma Ltd. | Manufacturing Investment | Germany |
12-Mar-18 | IO Biotech ApS | $0 | IO Biotech’s lead candidate, IO102, is an IDO-derived immune modulating therapy with dual mode of action killing both cancer and immune-suppressive cells. IO Biotech’s IDO-derived immune modulating therapies have previously shown a favorable safety profile and signs of promising anti-tumor activity in a first in man trial of heavily pre-treated patients with NSCLC. | Merck & Co. | Clinical Collaboration | Denmark |
12-Mar-18 | Lannett Company, Inc | $0 | Initially, the agreements cover one product from each partner, Diclofenac ER and Fluvastatin ER. Under the third agreement, Lannett will provide five of its currently marketed products to Pharmaceutical Associates, Inc. (PAI) for repackaging into unit dose cups and distribution into the managed care and hospital markets. | Pharmaceutical Associates, Inc. (PAI), Undisclosed Partner | Partnership | United States |
12-Mar-18 | Windtree Therapeutics, Inc | $0 | Eleison has an exclusive worldwide license to inhaled lipid cisplatin (ILC), a novel, sustained release formulation of cisplatin in a nanoscale lipid-based complex administered via inhalation or intraperitoneally. | Eleison Pharmaceuticals, Inc. | Research Agreement | United States |
12-Mar-18 | IQVIA | $0 | The new initiative will be called the MOVR (NeuroMuscular ObserVational Research) Data Hub. The enhancements will capitalize on improvements in health care information technology and systemically unify and aggregate both clinical and genetics data with patient-reported information. | Muscular Dystrophy Association (MDA) | Disease Registry Expansion | United States |
12-Mar-18 | Natera Inc | $0 | QIAGEN N.V., a world leader in providing Sample to Insight molecular solutions, and Natera, Inc., a leading developer of next-generation sequencing (NGS) assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor DNA, today announced a partnership to develop cutting-edge cell-free DNA assays for use on QIAGEN’s GeneReader NGS System. | QIAGEN N.V. | Partnership | United States |
13-Mar-18 | Crown BioScience | $0 | Phanes will gain access to CrownBio’s clinically relevant CDX models, exclusive PDX models and robust in vitro assays to propel their innovative drug discovery pipeline. | Phanes Therapeutics | Partnership | United States |
13-Mar-18 | Schott Kaisha Pvt Ltd | $0 | SCHOTT AG and Daikyo Seiko Ltd. are announcing that SCHOTT adaptiQ® vials and Daikyo PLASCAP® plastic press-fit closures are confirmed as a Product Set for use with Vanrx Pharmasystems’ Aseptic Filling Workcells. | Vanrx Pharmasystems Inc. | Partnership | India |
13-Mar-18 | SanBio Group | $0 | SanBio is developing and pursuing the rapid commercialization in Japan and the US of its proprietary regenerative medicine product, SB623, as a new drug candidate for central nervous system disorders. Both the Phase 2b clinical trial of SB623 for the treatment of chronic motor deficit from ischemic stroke, which is being conducted in the US, and the Phase 2 global clinical trial of SB623 for the treatment of chronic motor deficit from traumatic brain injury (TBI), which is being conducted in Jap | Hitachi Chemical Co., Ltd | Joint Venture | Japan |
13-Mar-18 | AmpliPhi Biosciences | $0 | The agreement covers individual patient expanded access for AmpliPhi’s investigational bacteriophage therapeutics AB-SA01, targeting Staphylococcus aureus, and AB-PA01, targeting Pseudomonas aeruginosa. | U.S. Department of Veterans Affairs | Research Agreement | United States |
13-Mar-18 | Ideaya Biosciences | $0 | IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies, today announced that it has entered into a partnership agreement with Cancer Research UK’s (CRUK) Commercial Partnerships Team and the Drug Discovery Unit at the Cancer Research UK Manchester Institute, part of the University of Manchester, UK, to develop small molecule inhibitors of Poly(ADP-ribose) glycohydrolase (PARG). | Cancer Research UK | Partnership | United States |
13-Mar-18 | RxAdvance | $0 | Centene has had a long-standing commitment to providing comprehensive and integrated specialty services, including pharmacy management expertise provided through its Envolve division. Under this partnership, Centene and external customers will leverage Envolve's clinical competencies and RxAdvance's Collaborative PBM Cloud™ platform to deliver integrated, real-time, and data-driven pharmacy management services. | Centene Corporation | Partnership | United States |
13-Mar-18 | Avillion LLP | $0 | Avillion has signed a co-development agreement with Pearl Therapeutics Inc., a wholly owned subsidiary of the AstraZeneca Plc group, to advance PT027 through a global clinical development programme for the treatment of asthma. | AstraZeneca | Development Agreement | United Kingdom |
13-Mar-18 | Sosei Group Corporation | $0 | Sosei Group, the world leader in GPCR medicine design and development, announced that it has regained worldwide rights from Teva Pharmaceutical Industries Ltd. to develop and commercialize lead candidate HTL0022562 and other novel small molecule CGRP antagonists for the treatment of migraine and other severe headaches. | Teva Pharmaceutical Industries Ltd. | Commercialization Agreement | Japan |
13-Mar-18 | AveXis, Inc. | $0 | Includes exclusive worldwide rights to AAV9-SMN product and route of administration | Genethon | Licensing Agreement | United States |
14-Mar-18 | TARIS Biomedical LLC | $0 | This collaboration will focus on better understanding the natural history and disease outcomes for patients diagnosed with Muscle Invasive Bladder Cancer (MIBC), through analysis of Sweden’s National Registry of Urinary Bladder Cancer (SNRUBC) and BladderBaSe disease registries. | Uppsala Clinical Research Center (UCR) | Research Agreement | United States |
14-Mar-18 | ImmunoRestoration, Inc. | $0 | The agreement provides for ImmunoRestoration to commercialize certain intellectual property and technology related to the potential treatment of breast and other cancers. | University of Pennsylvania | Licensing Agreement | United States |
14-Mar-18 | Cancer Genetics Inc. | $0 | The partnership combines CGI’s Focus::NGS® offering, a suite of next generation sequencing (NGS) tests providing a comprehensive view of the patient genomic profile for both solid tumors and hematologic malignancies, with PierianDx’s integrated NGS workflow and analysis solution, Clinical Genomics WorkSpace™ (CGW), allowing for streamlined and accurate analysis, interpretation, and reporting. | PierianDx | Partnership | United States |
14-Mar-18 | Noramco, Inc. | $0 | Noramco, Inc., a global leading producer of controlled substances for the pharmaceutical industry, and AMPAC Fine Chemicals (AFC), a major manufacturer of Active Pharmaceutical Ingredients (APIs) with cGMP facilities in the United States, today announced a strategic partnership to produce certain US DEA controlled substances for use in the treatment of addiction, abuse prevention, cannabinoids for clinical indications, and for the treatment of attention deficit hyperactivity disorder (ADHD). | AMPAC Fine Chemicals (AFC) | Partnership | United States |
15-Mar-18 | Continuum Clinical, LLC, | $0 | Company Expands Worldwide Evidence™ Observational Research Services, Adds Health Economics Outcomes Research (HEOR) and Patient Registry Capabilities | Worldwide Clinical Trials | Acquisition | United States |
15-Mar-18 | LenioBio GmbH | $0 | LenioBio will market the innovation to bio-pharmaceutical developers under the brand name ALiCE™. | Dow AgroSciences LLC | Licensing Agreement | Germany |
15-Mar-18 | Martin Pharmaceuticals | $0 | Two accomplished healthcare executives, David Martin Geliebter and Sven Martin Jacobson, founders of Remedy Pharmaceuticals, announced the launch of Martin Pharmaceuticals, with the mission of repurposing already-approved drugs in order to offer life-changing advances to patients afflicted with rare (orphan) diseases or challenging medical conditions. Martin is the sixth healthcare company the pair has started since 2001. | Undisclosed | Seed Financing | United States |
16-Mar-18 | IntegenX, Inc. | $0 | IntegenX solutions include the RapidHIT platforms, software analysis tools and related consumables that are highly compatible with Thermo Fisher's short tandem repeat (STR) chemistries for human identification. | Thermo Fisher Scientific | Acquisition | United States |
19-Mar-18 | Intezyne Technologies, Inc. | $0 | Intezyne, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it has partnered with Exosome Diagnostics, a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics, to design and validate an assay for use in Intezyne's upcoming Phase 1/2 clinical trials of IT-139, a novel Cancer Resistance Pathway (CRP) inhibitor for the treatment of pancreatic, gastric and other cancers in combination with existing a | Exosome Diagnostics, Inc | Partnership | United States |
20-Mar-18 | Nexcelom Bioscience LLC | $0 | The funding will be primarily used to support Nexcelom’s worldwide growth initiatives. Founded in 2003, Nexcelom is a fast-growing supplier of innovative cellular analysis instruments, software and related consumables used in a broad range of research fields including immuno-oncology, cell therapy, drug discovery, vaccine development and manufacturing, and therapeutic cell line generation. | Ampersand Capital Partners | Partnership | United States |
20-Mar-18 | Celltrion Healthcare | $0 | Third biosimilar deal with Celltrion Healthcare cements Mundipharma’s leadership position in the biosimilar market and is testament to Mundipharma’s commercializationnexpertise. | Mundipharma | Partnership | South Korea |
20-Mar-18 | Hirokodo Pharmaceutical Co., Ltd. | $0 | Based on scientific evidence, Shin Kowato Pharmaceutical aims seriously for the worldwide realization of productive aging. | Shinkowa Pharmaceutical Co., Ltd | Acquisition | Japan |
21-Mar-18 | Alnylam Pharmaceuticals Inc | $0 | Collaboration based on new findings from the Regeneron Genetics Center® showing variant in HSD17B13 gene is associated with reduced risk of chronic liver diseases | Regeneron Pharmaceuticals, Inc. | Research Agreement | United States |
21-Mar-18 | International Myeloma Foundation (IMF) | $0 | Study is among the largest and most comprehensive in multiple myeloma (MM), and will assess outcomes from 1,500 patients with MM and the t(11;14) translocation at participating International Myeloma Foundation sites globally. | AbbVie | Partnership | United States |
23-Mar-18 | EnDev Laboratories | $0 | Tergus Has Added Early Development & Skin Biology Capabilities with EnDev Laboratories | Tergus Pharma | Acquisition | United States |
23-Mar-18 | Innate Biologics, LLC | $0 | The therapeutic platform is being developed to treat inflammation associated with auto-immune conditions such as asthma, rheumatoid arthritis, psoriasis, obesity, idiopathic pulmonary fibrosis, ulcerative colitis and Crohn’s disease, and other conditions and syndromes characterized by activation of inflammatory pathways. | The Wistar Institute | Research Agreement | United States |
26-Mar-18 | Syngene International | $0 | Syngene scientists to work with GSK to advance drug discovery in multiple therapeutic areas | GlaxoSmithKline | Research Agreement | India |
26-Mar-18 | Aslan Pharma | $0 | ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its American Depository Shares (ADSs) in the United States. | Undisclosed | IPO | Singapore |
26-Mar-18 | Arpeggio Biosciences | $0 | Data generated in this collaboration could enable FORMA to better understand the translational utility of its small molecule pipeline of therapeutics targeting cancer and other serious diseases. | FORMA Therapeutics | Research Agreement | Canada |
26-Mar-18 | NanoMedSyn | $0 | Research agreement focuses on evaluating a potential treatment for a lysosomal storage disorder using NanoMedSyn’s proprietary AMFA technology | Shire PLC | Clinical Collaboration | France |
27-Mar-18 | OncoDNA | $0 | OncoDNA, the Cancer Theranostic Company, said today that it has inked a distribution agreement with PromTest LLC (Armenia), a company offering a wide range of high-quality clinical, molecular testing services to meet diagnostic and treatment planning requirements. | PromTest LLC | Distribution Agreement | Belgium |
27-Mar-18 | ACI Clinical | $0 | ACI Clinical will continue to operate as an independent service organization within the Clinical Services Division. WCG will support ACI Clinical as it continues to expand, with access to capital, complementary clinical and regulatory expertise, and corporate support. | WCG (WIRB-Copernicus Group) Clinical Services Division | Acquisition | United States |
27-Mar-18 | Ascendance Biotechnology, Inc. (Hepregen & ESI BIO, Inc.) | $0 | BioIVT is adding Hepregen’s HepatoPac®, HepatoMune™ and HepatoStem™ liver cell and stem cell product lines to its drug safety testing and toxicology portfolios. | BioIVT | Acquisition | United States |
28-Mar-18 | Biocept | $0 | Collaboration plans to establish Biocept as Thermo Fisher Center of Excellence for liquid biopsy and to pursue commercial opportunities in both pharmaceutical and clinical markets | Thermo Fisher Scientific | Commercialization Agreement | United States |
28-Mar-18 | Nichi-Iko Pharmaceutical | $0 | Under the agreement, Eisai will transfer all shares of Eisai’s wholly-owned subsidiary Elmed Eisai Co., Ltd. (Headquarters: Tokyo, “Elmed Eisai”) to Nichi-Iko incrementally in accordance with progress of the strategic alliance agreement, and both companies will promote cooperation in building Eisai’s Total Inclusive Ecosystem as well as collaboration on the active pharmaceutical ingredient (API) business promoted primarily at Eisai’s Vizag Plant in India. | Eisai Co., Ltd. | Partnership | Japan |
28-Mar-18 | bluebird bio., Inc | $0 | bluebird bio, Inc. and Celgene Corporation today announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for the potential treatment of patients with relapsed/refractory multiple myeloma in the United States. | Celgene Corporation | Development Agreement | United States |
28-Mar-18 | Abide Therapeutics | $0 | Abide Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting the serine hydrolase family of enzymes, announced today it has granted Celgene an exclusive worldwide license for ABX-1772, a preclinical drug candidate discovered by Abide. | Celgene Corporation | Licensing Agreement | United States |
28-Mar-18 | Unum Pharma | $0 | Unum Therapeutics is actively building a pipeline of ACTR programs in combination with a wide range of proprietary, tumor-targeting antibodies for use in both hematologic and solid tumor cancers. | Undisclosed | IPO | United States |
29-Mar-18 | Actinium Pharmaceuticals | $0 | Collaborative research agreement will utilize Actinium’s AWE Technology Platform to generate Actinium Radio-Conjugates on selected Astellas targeting agents | Astellas Pharma | Research Agreement | United States |
30-Mar-18 | Ligand Pharmaceuticals | $0 | OmniAb is a three-species transgenic-animal platform consisting of four different technologies used for producing mono- and bispecific human therapeutic antibodies. | venBio Partners | Licensing Agreement | United States |
26-Mar-18 | CutisPharma, Inc. | $0 | CutisPharma, Inc., a specialty pharmaceutical company that for two decades has been the industry leader in providing innovative solutions to pharmacists, with its recently approved 505(b)(2) NDA for FIRVANQ™ vancomycin oral solution kit by the FDA, today announced that it has been acquired by NovaQuest Capital Management, L.L.C. | NovaQuest Capital Management LLC | Acquisition | United States |
05-Mar-18 | Molecular Response LLC | $0 | BioDuro LLC, a leading global life sciences contract research and development organization, announced today the acquisition of Molecular Response LLC and its world-class translational oncology research platform, including its biobank of >100,000 viable tumor specimens. | BioDuro LLC | Acquisition | United States |
27-Mar-18 | Daiichi Sankyo | $0 | New campaign "Get Iron Informed" aims to educate people about Iron Deficiency Anemia, a condition that affects 36 to 76 percent of people with inflammatory bowel diseases. | Crohn's & Colitis Foundation | Collaboration | Japan |
15-Mar-18 | ChemConnection B.V. | $0 | This announcement follows a series of acquisitions by Belgium-headquartered Ardena and is part of its strategy to form a leading integrated drug development company and reach the €30m sales mark this year. | Ardena | Acquisition | The Netherlands |
09-Apr-18 | AveXis, Inc. | $8,700 | AveXis’ lead product candidate, AVXS-101, expected to enhance Novartis’s position as a gene therapy and neuroscience leader. | Novartis | Acquisition | United States |
19-Apr-18 | Merck Group | $4,200 | This acquisition enables P&G to expand its successful consumer health care business by adding a fast-growing portfolio of differentiated, physician-supported brands ( Vicks, Metamucil, Pepto-Bismol, Crest and Oral-B) across a broad geographic footprint. | Procter & Gamble (P&G) | Acquisition | Germany |
03-Apr-18 | Cellectis | $2,800 | Allogene will assume the strategic collaboration and license agreement with Cellectis, with exclusive rights to develop and commercialize previously defined allogeneic UCART programs directed at select targets. | Allogene Therapeutics | Collaboration | France |
16-Apr-18 | Shire PLC | $2,400 | The transaction covers the transfer of Shire’s Oncology business including in-market products ONCASPAR® (pegaspargase), a component of multi-agent treatment for acute lymphoblastic leukemia (ALL) and ex-U.S. rights to ONIVYDE® (irinotecan pegylated liposomal formulation), a component of multi-agent treatment for metastatic pancreatic cancer post gemcitabine based therapy. | Servier | Business Unit Acquisition | Ireland |
21-Apr-18 | Sound Inpatient Physicians Holdings | $2,150 | Fresenius Medical Care, the world’s largest provider of dialysis products and services, today has signed a definitive agreement to divest its controlling interest in Sound Inpatient Physicians Holdings, LLC (“Sound”) to an investment consortium led by Summit Partners, L.P. for total transaction proceeds of $2.15 billion (EUR 1.76 billion). The divestment is expected to generate a pre-tax book gain of approximately EUR 800 million. | Fresenius Medical Care | Divestment | United States |
06-Apr-18 | Mylan | $2,098 | The Notes will be issued by Mylan Inc. and guaranteed by Mylan N.V., and Mylan intends to use the net proceeds from the offering to redeem $1.5 billion aggregate principal amount of outstanding notes due in 2018 and 2019. | Mylan N.V. | IPO | United States |
23-Apr-18 | Curo Health Services | $1,400 | Curo is a hospice operator with 245 outlets in 22 states. Humana will hold a 40% minority interest in the company when the deal is completed, expected by summer of 2018. | Humana | Acquisition | United States |
04-Apr-18 | OSE Immunotherapeutics SA | $1,196 | Assuming all milestones are met, OSE stands to receive more than €1.1 billion. OSE-172, an anti-SIRP-alpha monoclonal antibody, is currently in late stage preclinical development with potential in various cancers. | Boehringer Ingelheim | Licensing Agreement | France |
10-Apr-18 | Analogic Corporation | $1,100 | This 10-month, comprehensive process resulted in today’s transaction with Altaris that provides stockholders with immediate, substantial, and certain cash value. The Board strongly believes that a transaction with a buyer with strategic assets like Altaris provides maximum value for and is in the best interest of Analogic stockholders. | Altaris Capital Partners, LLC, | Merger Agreement | United States |
02-Apr-18 | GE Healthcare | $1,050 | To acquire the Enterprise Financial Management (Revenue-Cycle, Centricity Business), Ambulatory Care Management (Centricity Practice Solution) and Workforce Management (formerly API Healthcare) | Veritas Capital | Acquisition | United States |
20-Apr-18 | Ionis Pharmaceuticals | $1,000 | Transaction builds upon the productive collaboration that produced SPINRAZA® as well as two antisense drug candidates currently in the clinic, with the potential to advance up to seven more drug candidates to the clinic within the next two years. | Biogen | Collaboration | United States |
11-Apr-18 | Wilson Therapeutics AB | $855 | WTX101 is in Phase 3 Development as a Novel Treatment for Wilson Disease, a Rare, Genetic, and Chronic Copper-Mediated Liver Disorder | Alexion Pharmaceuticals | Acquisition | Sweden |
24-Apr-18 | Covance Food Solutions (LabCorp®) | $670 | Covance Food Solutions, which became part of LabCorp through its 2015 acquisition of Covance, offers an extensive set of routine and specialized laboratory testing and consulting services focused on ensuring product safety, quality and adherence to targeted internal and external standards for existing and in-development food, beverage and supplement products. | Eurofins Scientific | Acquisition | United States |
04-Apr-18 | Sigilon Therapeutics | $473 | Sigilon will create proprietary products comprised of induced pluripotent stem cells, a type of stem cell derived from adult cells, engineered into differentiated insulin-producing pancreatic beta cells and encapsulated using Sigilon's Afibromer drug delivery system. | Eli Lilly and Company | Collaboration | United States |
05-Apr-18 | EpiDestiny Inc. | $400 | EpiDestiny recently completed a phase 1 trial with EPI01 in SCD patients demonstrating the potential for EPI01 to serve as a safe and highly meaningful disease-modifying therapy for SCD.n | Novo Nordisk | Licensing Agreement | United States |
02-Apr-18 | NextGen Healthcare (Quality Systems, Inc.) | $400 | This amended facility matures on March 29, 2023 and replaces NextGen Healthcare's prior $250 million facility. In addition to the increase from $250 million to $300 million in potential revolving credit commitments and/or term loans, the facility includes a $100 million accordion feature, which could accommodate additional borrowing up to $400 million in the aggregate. | JPMorgan Chase Bank | Credit agreement | United States |
30-Apr-18 | Industrial Development Authority (IDA), Ireland | $388 | A total of 48,000 L fed-batch and 6,000 L perfusion bioreactor capacity will be installed, representing the world's largest facility using single-use bioreactors. | WuXi AppTec | Manufacturing Investment | Ireland |
03-Apr-18 | Paragon Medical | $375 | Paragon strengthens NN's technical abilities, expands their product and finished device offerings, and adds key talent across the organization that will help continue to drive growth in their end markets. | NN, Inc. | Acquisition | United States |
20-Apr-18 | Proximagen | $370 | USL2612 is a novel investigational midazolam formulation, which has been specifically designed for intranasal delivery without active inhalation. It has been granted orphan drug designation and fast track designation by the United States Food and Drug Administration (FDA). | UCB | Asset Acquisition | United Kingdom |
06-Apr-18 | Healthium Medtech (HMPL) | $350 | Backed by the Apax Funds, Healthium plans to further deepen its presence in the Indian market and broaden its portfolio of specialty medtech products. | Apax Partners | Acquisition | India |
09-Apr-18 | Ionis Pharmaceuticals | $330 | AstraZeneca will be responsible for further development and commercialization of IONIS-AZ6-2.5-LRx. | AstraZeneca | Licensing Agreement | United States |
03-Apr-18 | Allogene Therapeutics | $300 | Pfizer Inc. and Allogene Therapeutics, Inc. today announced that the two companies have entered into an asset contribution agreement for Pfizer’s portfolio of assets related to allogeneic chimeric antigen receptor T cell (CAR T) therapy, an investigational immune cell therapy approach to treating cancer. | Pfizer Inc. | Series A Financing | United States |
16-Apr-18 | Clovis Oncology, Inc. | $300 | Clovis Oncology intends to use the combined net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca® (rucaparib) in the United States and, if approved by the European Commission, in Europe, funding of its development programs, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. | J.P. Morgan Securities LLC | IPO | Canada |
16-Apr-18 | Mallinckrodt plc | $300 | The debt was issued by Mallinckrodt International Finance SA in 2013 in preparation for the company's spin-off from its former parent | Mallinckrodt | Partnership | United Kingdom |
18-Apr-18 | nVision Medical Corporation | $275 | Boston Scientific plans to conduct additional clinical research with the nVision device to further establish how the cells it collects from the fallopian tubes can be used to render a diagnosis prior to surgery and help in the decision-making process for women at increased risk for ovarian cancer. | Boston Scientific | Acquisition | United States |
18-Apr-18 | MorphoSys AG | $239 | In total, MorphoSys expects the gross proceeds of the transaction to amount to USD 239,006,800, comprising the base offering of 8,300,000 ADSs (USD 207,832,000) and, upon closing, the exercised option to purchase 1,245,000 additional ADSs (USD 31,174,800). | J.P. Morgan Securities LLC | IPO | Germany |
30-Apr-18 | SteadyMed Therapeutics | $216 | SteadyMed's product portfolio includes Trevyent, a development-stage drug-device combination product that combines SteadyMed's two day, single use, disposable PatchPump® technology with treprostinil, a vasodilatory prostacyclin analogue, for the subcutaneous treatment of pulmonary arterial hypertension (PAH). | United Therapeutics Corporation | Acquisition | Israel |
02-Apr-18 | Compugen Inc. | $210 | Compugen will provide an exclusive license to MedImmune for the development of bi-specific and multi-specific antibody products derived from a Compugen pipeline program. MedImmune has the right to create multiple products under this license and will be solely responsible for all research, development and commercial activities under the agreement. | AstraZeneca | Licensing Agreement | Israel |
26-Apr-18 | Somerset Therapeutics, LLC, Wintac Limited | $190 | Endo is paying approximately $190 million in total for Somerset Therapeutics and Wintac's business. Together, the acquisitions will secure for Endo's Par Sterile injectable business Somerset Therapeutics' commercial and pipeline products as well as Wintac's manufacturing capabilities for those products. | Endo International plc | Acquisition | United States |
30-Apr-18 | LivaNova PLC | $190 | LivaNova’s portfolio is now concentrated on our areas of strength and leadership: cardiac surgery and neuromodulation. This transaction enables us to concentrate our efforts on developing market-leading businesses in these areas, and will assist us in enhancing LivaNova’s position as an innovative medical device company that improves the lives of patients around the world and creates value for our shareholders. | MicroPort Scientific Corporation | Divestment | United Kingdom |
11-Apr-18 | Cellectis | $164 | The net proceeds to Cellectis from the offering are approximately $163.7 million, after deducting the estimated expenses related to the offering and the underwriting discounts and commissions payable by Cellectis. In connection with the offering, Cellectis granted the underwriters a 30-day option to purchase up to an additional 846,900 ADSs. | Goldman Sachs | IPO | France |
27-Apr-18 | Innovent Biologics | $150 | Capital Group Private Markets, a unit of U.S. investment firm Capital Group Companies, has led a US$150 million round in Chinese biotech firm Innovent Biologics, Inc. | Capital Group Private Markets | Series E Financing | China |
19-Apr-18 | Tocagen Inc. | $147 | Toca 511 & Toca FC is a cancer-selective immunotherapy currently under evaluation in an international Phase 3 trial, called Toca 5, for patients with recurrent high grade glioma (HGG), a type of brain tumor. The product candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA). | Beijing Apollo Venus Biomedical Technology Limited (ApolloBio Corp.) | Licensing Agreement | United States |
26-Apr-18 | 10x Genomics | $125 | The proceeds from these financings will fuel the Company’s innovation engine and will allow investment in new strategic opportunities. The funding will also help 10x to continue to expand its global commercial organization, including new offices in Leiden, The Netherlands and Shanghai, PRC, as well as to expand its internal manufacturing capabilities. | Wells Fargo Strategic Capital | Series D Financing | United States |
23-Apr-18 | Surface Oncology | $120 | In addition to the shares sold in the public offering, Surface announced the completion of the concurrent sale of an additional 766,666 shares at the initial offering price of $15.00 per share, for gross proceeds of $11.5 million, in a private placement to Novartis Institutes for Biomedical Research, Inc. | Novartis | Financing | United States |
19-Apr-18 | BenevolentAI | $115 | BenevolentAI’s current drug development portfolio demonstrates that it can cut early stage drug discovery by four years and potentially deliver efficiencies in the entire drug development process of 60% against pharmaceutical industry averages – significantly disrupting an industry that spends $180bn a year on R&D. | Woodford Investment Management | Financing | United Kingdom |
30-Apr-18 | Spark Therapeutics | $110 | Under the PRV program, a sponsor who receives FDA approval for a rare pediatric disease drug or biologic may qualify for a voucher to be redeemed at a future time for priority review of a subsequent marketing application for a different product. The PRV was received when LUXTURNATM (voretigene neparvovec-rzyl) was approved by the U.S. Food and Drug Administration (FDA). | Jazz Pharmaceuticals | Sales Agreement | United States |
02-Apr-18 | MacroGenics | $110 | The exercise of the underwriters’ option to purchase additional shares brought the total number of shares of common stock sold by MacroGenics in the offering to 5,175,000 and increased the gross proceeds from the offering (before deducting underwriting discounts and commissions and estimated offering expenses) to approximately $110.0 million. | Leerink Partners | IPO | United States |
03-Apr-18 | Lasergen, Inc. | $105 | Acquisition affirms Agilent’s strategic intent to grow in the diagnostics space and build a complete routine clinical NGS workflow | Agilent Technologies | Acquisition | United States |
11-Apr-18 | Livongo Health | $105 | Proceeds from the offering will support rapid market growth, continued investment in data science, deeper integration with clients and partners, and the development of Livongo’s comprehensive consumer platform based on the company’s ‘whole person’ approach. | General Catalyst | Financing | United States |
25-Apr-18 | Entasis Therapeutics | $104 | Collaboration will facilitate enrollment of pivotal global Phase 3 trial of ETX2514 in combination with sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii infections. | Zai Lab | Licensing Agreement | United States |
09-Apr-18 | Constellation Pharmaceuticals | $100 | Proceeds Will Help to Advance the Company’s Cancer Epigenetics Platform and Accelerate Development of Ongoing Therapeutic Programsn | Cormorant Asset Management | Financing | United States |
18-Apr-18 | Institute of Human Virology | $100 | The work is funded by the U.S. Centers for Disease Control and Prevention (CDC) through the President’s Emergency Plan for AIDS Relief (PEPFAR), in collaboration with the Government of Nigeria and the Global Fund to Fight AIDS, Tuberculosis and Malaria, to conduct the Nigeria AIDS Indicator and Impact Survey (NAIIS). | U.S. Centers for Disease Control and Prevention (CDC) | Collaboration | United States |
17-Apr-18 | Multilateral Initiative on Malaria Conference, Malaria Summit of the Commonwealth | $100 | Novartis announces a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth Heads of Government meeting on progress and remaining challenges toward the 2030 malaria elimination targets, together with Elimination 8 and the KEMRI-Wellcome Trust program. | Novartis | Research Agreement | United Kingdom |
17-Apr-18 | Metrics Contract Services | $80 | With this facility, Mayne Pharma triples its fluid-bed processing capacity globally. Metrics Contract Services is now able to offer clients a comprehensive ‘concept to commercialization’ solution under one FDA site registration. | Mayne Pharma | Manufacturing Investment | Australia |
11-Apr-18 | Lyon Porte-des-Alpes site | $78 | The German group has laid the first stone of a 5,700 sq m building at its Lyon Porte-des-Alpes (LPA) site. Known as F2IVE (Formulation and Filling of Inactivated Vaccines Extension), this major project will comprise a three-storey building - including 1,000 sq m of clean room space – mainly for formulating and distributing avian vaccines. | Boehringer Ingelheim | Investment | France |
23-Apr-18 | Orexigen Therapeutics, Inc. | $75 | Under the terms of the agreement, Orexigen will sell the world-wide rights to Contrave® (naltrexone HCl / bupropion HCl extended release) /Mysimba™ (naltrexone HCl and bupropion HCl prolonged release) and certain other Orexigen assets for $75 million in cash. The deal is subject to higher and better offers. | Nalpropion Pharmaceuticals, Inc. | Asset Acquisition | United States |
25-Apr-18 | Doctor On Demand | $74 | Doctor On Demand offers immediate access to board-certified physicians, psychiatrists, and licensed psychologists via smartphones, tablets, or desktop computers. | Princeville Global | Series C Financing | United States |
03-Apr-18 | Humco | $70 | This mutually beneficial merger will allow Humco to strengthen and add value to customers through Fagron’s extensive line of Active Pharmaceutical Ingredients, product portfolio and strong research and development. | Fagron Group BV | Merger Agreement | United States |
30-Apr-18 | Crescendo Biologics | $70 | Crescendo Biologics Ltd (Crescendo) the developer of multi-functional biologics with a focus on novel targeted T-cell engagers, announced today that it has completed a $70 million (€57 million) Series B financing. | Andera Partners | Series B Financing | United Kingdom |
10-Apr-18 | Beijing Biocytogen Co., Ltd. | $65 | This financing round was led by CMB International Capital and followed by SDIC Venture Capital (Round B leading investor), 3E Bioventures, Cowin Capital and Oriza Seed. Biocytogen will dedicate the funds raised on this round toward market development, technology and product development, construction of new base facilities as well as expanding its talent pool. | CMB International Capital Corporation Ltd | Series C Financing | China |
10-Apr-18 | Visionsense | $65 | Visionsense develops a minimally invasive stereoscope camera that enables 3D visualization of difficult areas, such as the brain, during surgery. | Medtronic PLC | Acquisition | Israel |
05-Apr-18 | Eidos Therapeutics | $64 | Funding supports Phase 2 clinical trials of AG10, a potential best-in-class therapy for transthyretin amyloidosis, and ongoing preparation for Phase 3 clinical trials | RA Capital | Series B Financing | United States |
30-Apr-18 | Synthorx | $63 | The financing proceeds will be used to advance Synthorin IL-2 into clinical trials in immune-oncology and further progress the company’s cytokine pipeline.n | OrbiMed | Series C Financing | United States |
06-Apr-18 | C3i Solutions | $60 | C3i’s expertise in the clinical, pharmacovigilance, and pharma sales support domains and the strong partnership will enable HCL’s life sciences customers to become more patient-centric and offer services to IT and business stakeholders | HCL Technologies | Acquisition | United States |
25-Apr-18 | Corvidia Therapeutics | $60 | Corvidia Therapeutics is nearing completion of a Phase 2 clinical trial for a genetically-defined patient population living with advanced chronic kidney disease. The Series B funding will be used to progress the lead clinical programs in chronic kidney disease and beyond as well as advance pre-clinical programs. | Venrock Healthcare Partners | Series B Financing | United States |
16-Apr-18 | Novavax, Inc. | $58 | Net proceeds from the offering are to be used for general corporate purposes, including but not limited to working capital, capital expenditures, research and development expenditures related to clinical and preclinical vaccine candidates, clinical trial expenditures, as well as acquisitions and other strategic purposes. | Ladenburg Thalmann | IPO | United States |
24-Apr-18 | Cedilla Therapeutics | $56 | Cedilla’s integrated product engine includes target-centric and unbiased approaches and is designed to produce small molecule therapeutics that degrade protein targets. Although degradation by small molecules has been observed serendipitously, degradation as a mechanism of action has not been pursued systematically in small molecule drug discovery. | Third Rock Ventures | Series A Financing | United States |
11-Apr-18 | Inovio Pharmaceuticals | $56 | CEPI will fund up to $56,000,000 to support Inovio’s pre-clinical and clinical advancement through Phase 2 of INO-4500, its Lassa fever vaccine, and INO-4700, its MERS vaccine. | Coalition for Epidemic Preparedness Innovations (CEPI) | Partnership | United States |
24-Apr-18 | REVOLUTION Medicines, Inc. | $56 | The financing was supported by a syndicate of premier life sciences investors led by Nextech Invest, an oncology-focused investment firm, and included participation from Casdin Capital, Schroder Adveq, The Column Group, Third Rock Ventures and additional undisclosed institutional investors. | Nextech Invest | Series B Financing | United States |
04-Apr-18 | Arvinas | $55 | Proceeds from the financing will support the advancement of the Company's two lead programs toward clinical investigation. The two programs, which target the androgen receptor for castration resistant prostate cancer and the estrogen receptor for ER+ positive breast cancer, both nominated orally available clinical candidates in the fourth quarter of 2017. | Nextech Invest | Series C Financing | United States |
09-Apr-18 | Magenta Therapeutics | $52 | Proceeds from the financing will be used to advance Magenta’s integrated portfolio of novel therapeutics, which includes Magenta’s targeted bone marrow transplant conditioning programs, stem cell mobilization and stem cell expansion programs. | Casdin Capital | Series C Financing | United States |
02-Apr-18 | Twist Bioscience | $50 | To use a portion of these funds to invest in the emerging vertical market opportunity presented by storing digital data in DNA as well as forward integration toward drug discovery | Undisclosed | Private Placement | United States |
03-Apr-18 | Securus Medical Group, Inc. | $50 | Acquisition strengthens electrophysiology cardiac ablation portfolio with thermal monitor | Boston Scientific | Acquisition | United States |
11-Apr-18 | Tessa Therapeutics | $50 | Tessa's Virus-Specific T cell (VST) technology is showing compelling results and an excellent safety profile in the treatment of cancer. | Novo Nordisk | Series A Financing | Singapore |
18-Apr-18 | Tetherex Pharmaceuticals, Inc. | $50 | Proceeds from the financing will be used to conduct a Phase 2 clinical trial evaluating the company's potential, first-in-class P-Selectin Glycoprotein Ligand-1 (PSGL-1) inhibitor candidate, SelK2, in the treatment of venous thromboembolism (VTE) in patients undergoing total knee replacement surgery. | MPM Capital | Series B Financing | United States |
25-Apr-18 | STEMCELL Technologies | $45 | The five-year, $138 million project will build a new advanced manufacturing facility for biologics in Burnaby, British Columbia. | Governments of Canada and British Columbia | Grants & Awards | Canada |
04-Apr-18 | Virta Health | $45 | The clinically-proven Virta Treatment reverses type 2 diabetes and significantly improves several chronic comorbidities, taking direct aim at these skyrocketing healthcare costs and nearly one-third of the more than $3 trillion in annual U.S. healthcare spend. | Venrock | Series B Financing | United States |
13-Apr-18 | Inventiva S.A. | $44 | Lanifibranor is the Inventiva’s lead drug candidate currently in Phase IIb development for both systemic sclerosis (SSc) and non-alcoholic steatohepatitis (NASH). | Namsen Capital | Investment | France |
25-Apr-18 | Juniper Pharmaceuticals, Inc. | $44 | The Juniper intravaginal ring technology allows for sustained drug delivery over time periods ranging from weeks to months. In addition to its newly acquired platform, Daré has two products currently in clinical development, including its lead candidate OvapreneTM, the non-hormonal contraceptive intravaginal ring. | Daré Bioscience | Licensing Agreement | United States |
12-Apr-18 | Enterprise Therapeutics | $41 | Enterprise Therapeutics is developing muco-regulatory therapies to treat patients with respiratory diseases of high unmet medical need, where mucus obstruction reduces lung function, leading to difficulty in breathing and recurrent lung infections. | Versant Ventures | Series B Financing | United Kingdom |
03-Apr-18 | Axonics Modulation Technologies, Inc. | $40 | Equity Round of $20 million led by Longitude Capital with Silicon Valley Bank Providing a $20 million Credit Facility | Longitude Capital | Financing | United States |
11-Apr-18 | Arbutus Biopharma (Genevant Sciences) | $38 | Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platforms | Roivant Sciences | Seed Financing | United States |
25-Apr-18 | Rallybio, LLC | $37 | Rallybio was co-founded in January 2018 by Martin Mackay, PhD, Stephen Uden MD, and Jeffrey Fryer, CPA, recognized leaders from the biopharma industry. The Company will develop innovative drug candidates against mechanisms that have strong biological rationales. Rallybio’s focus is on antibodies, small molecules and engineered proteins. | 5AM Ventures | Series A Financing | United States |
13-Apr-18 | Intec Pharma | $35 | Intec Pharma intends to use the net proceeds from this offering to fund its Phase III clinical trial for Accordion Pill Carbidopa/Levodopa, the company's leading product candidate for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, to advance its pre-commercial activities and for working capital and other general corporate purposes. | Pandion Therapeutics | IPO | Israel |
19-Apr-18 | Attenua, Inc. | $35 | Attenua, Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, today announced the completion of a $35 million Series A financing. | Omega Funds | Series A Financing | United States |
30-Apr-18 | Tmunity Therapeutics | $35 | The proceeds from the Series A will be used to advance and expand the business and operational structure of Tmunity to support the rapid translation, development and manufacture of its portfolio of novel T cell based immunotherapies, first for the treatment of cancer. | Kleiner Perkins | Series A Financing | United States |
02-Apr-18 | CMAB Biopharma Inc. | $34 | Upgrading CMAB's 2,000L Good Manufacturing Practices (GMP) facilities and will also enable the company to provide 50L/200L/500L/1,000L/2,000L bioreactor scale GMP manufacturing services. | CD Capital, C-Bridge Capital, Cormorant, Qianhai FoF Fund and Tigermed | Series B Financing | China |
21-Apr-18 | Elekta | $34 | Elekta MR-linac is the only radiation therapy delivery system that integrates an advanced linear accelerator with cutting-edge, high-field (1.5 Tesla) magnetic resonance imaging without compromising either system. Elekta MR-linac has extraordinary potential for ushering in a new paradigm of cancer care. | Proton Partners International Ltd | Asset Acquisition | Sweden |
16-Apr-18 | LimFlow SA | $34 | Proceeds from the Series C financing will fund the company’s major strategic initiatives through the second half of 2020, including completion of a U.S. pivotal trial for the LimFlow Percutaneous Deep Vein Arterialization System (pDVA). | Sofinnova Partners | Series C Financing | France |
24-Apr-18 | EryDel SpA | $32 | Funds will be used to accelerate the company’s international development and complete the registrational Phase III clinical trial of its lead product EryDex. | Sofinnova Partners | Financing | Italy |
05-Apr-18 | Element Genomics, Inc. | $30 | At the core of the Element Genomics platform is a suite of technologies to improve understanding of genome structure and function such as CRISPR editing technologies used for genomic and epigenomic regulatory region analysis and modulation, underpinned and enabled with advanced informatics capabilities, and driven by a strong scientific team. | UCB | Acquisition | United States |
24-Apr-18 | BRF Hospitals | $30 | University Health System provides advanced healthcare for patients in Shreveport, Monroe and surrounding areas. Operating the region’s only Level 1 Trauma Center, UHS is one of just six hospitals in the nation affiliated with St. Jude Children’s Research Hospital and home to state-designated Centers of Excellence, including the Feist-Weiller Cancer Center. | White Oak Healthcare Finance, LLC | Financing | United States |
18-Apr-18 | Medical Microinstruments | $25 | Medical Microinstruments is pioneering a disruptive advance in this surgical space by coupling the dexterity of robotically controlled wrist articulation with 5x to 40x motion scaling to match optical magnification. | Andera Partners | Series A Financing | Italy |
23-Apr-18 | Peptron Inc. | $24 | Peptron also raised USD$24 million for Phase 2 clinical trial of SR-exenatide in Parkinson's disease and operations of new manufacturing facility, which opens April 26 | National Institutes of Health (NIH) | Expansion | South Korea |
13-Apr-18 | BerGenBio ASA | $24 | BerGenBio intends to use the net proceeds of the Private Placement to fund the ongoing clinical development of pipeline candidates, strengthen working capital and general corporate purposes. | Undisclosed | Private Placement | Norway |
02-Apr-18 | Macrolide Pharmaceuticals | $20 | The new funding from both the financing and previously announced CARB-X award will accelerate development of the company’s novel, IV and orally-available macrolide antibiotics to address serious infections, including work to support filing an Investigational New Drug (IND) application for its lead program. | SR One | Financing | United States |
16-Apr-18 | Intact Vascular, Inc. | $20 | The Tack Endovascular System is a new solution for precision dissection repair following balloon angioplasty with a first-of-its-kind implant that is designed to help maintain vessel integrity and enhance blood flow to promote healing, improve outcomes and preserve limbs. | New Enterprise Associates | Series C Financing | United States |
11-Apr-18 | Pharnext SA | $19 | The proceeds will provide the Company with additional resources to fund its strategy and continue its growth in the perspective of the forthcoming results of the Phase 3 trial of its most advanced PLEODRUG™, PXT3003 in the treatment of Charcot-Marie-Tooth disease type 1A. | Tasly Pharmaceutical Holding Group | Private Placement | France |
03-Apr-18 | TFF Pharmaceuticals, Inc., | $14 | In early testing the Company's Thin Film Freezing (TFF) proprietary platform significantly improved the solubility of drugs that have poor water solubility. It does not require a proprietary device, excipient or delivery molecule to obtain deep lung delivery of small molecules, biologics, or uniform combo drugs of small molecules and/or biologics. | Liquid Venture Partners, National Securities Corporation | Series A Financing | United States |
26-Apr-18 | Achaogen, Inc. | $12 | The collaboration will focus on the development of a next-generation broad-spectrum aminoglycoside antibiotic capable of overcoming clinically-relevant resistance mechanisms and potentially treating highly-resistant gram-negative pathogens. | Combating Antibiotic Resistant Bacteria Accelerator (CARB-X) | Collaboration | United States |
24-Apr-18 | Undisclosed | $12 | MRA’s 2018 grants are made possible through the significant contributions of individuals, families, institutions and corporate allies. Donors and partners providing financial support for 75% or more of an award are listed below within the award naming. | Melanoma Research Alliance (MRA) | Partnership | |
10-Apr-18 | Promethera Biosciences SA | $12 | The proceeds will be used to accelerate the progression of Promethera’s clinical pipeline and to continue expanding the company’s research and development activities in addressing liver disease indications with significant unmet medical need such as acute-on-chronic liver failure (ACLF), nonalcoholic steatohepatits (NASH) and fibrosis. | Shibuya Corporation, Shinsei Corporate Investment | IPO | Belgium |
06-Apr-18 | Grifols | $11 | Under the agreement, Grifols will finance current and future research lines to advance the search for new treatments for HIV/AIDS and associated diseases, such as infectious, oncological, neurodegenerative and age-related conditions. | IrsiCaixa | Collaboration | Spain |
23-Apr-18 | Syna Therapeutics | $11 | The pharmaceutical company Reig Jofre strengthens its commitment to open innovation with the creation of the joint venture Syna Therapeutics, for the development of biopharmaceutical products in the field of biosimilar products and innovative molecules for a world market of around 1,000 million euros. | Laboratoris Reig I Jofre, LeanBio S.L. | Joint Venture | Spain |
25-Apr-18 | Groninger & Co. GmBH | $11 | Sharp – part of UDG Healthcare plc, a global leader in contract packaging and clinical supply services, has announced an investment of $11 million to increase its global cold storage and syringe assembly capacity in response to market demand. | Sharp (UDG Healthcare plc) | Investment | Germany |
23-Apr-18 | NuProbe Global | $11 | In pre-clinical trials, NuProbe’s technology improved qPCR and NGS mutation detection sensitivity by 10-100 fold with limit of detection down to 0.01 percent, and showed a multiplexing capability of 10-100 reactions for detecting hundreds of mutations in the same test tube. | Sequoia China | Series A Financing | United States |
09-Apr-18 | RubrYc Therapeutics | $10 | RubrYc is focused on improving drug discovery through proprietary insights into critical interactions at the drug/target interface. Using diverse chemical libraries developed and supplied by HealthTell, Inc., RubrYc is training algorithms that inform improved decision-making throughout drug discovery. | Paladin Capital Group | Financing | United States |
03-Apr-18 | Brainomix | $10 | Boehringer Ingelheim Venture Fund (BIVF), the corporate venture fund of the global pharmaceutical company Boehringer Ingelheim, a driving force in the field of stroke, joined the round, which was led by university investment veterans Parkwalk Advisors. | Boehringer Ingelheim | Investment | United Kingdom |
09-Apr-18 | Minnesota Cancer Clinical Trials Network,MnDRIVE | $8 | Led by the Masonic Cancer Center, University of Minnesota, the goal of the MNCCTN is to improve prevention, treatment and survivorship for all Minnesotans through greater access to cancer clinical trials. | Masonic Cancer Center, University of Minnesota | Partnership | United States |
25-Apr-18 | ExxonMobil Foundation | $7 | ExxonMobil’s malaria initiative helps to advance progress against the disease by working with nonprofit partners to build health system capacity, further malaria education, advance research and development, improve access to tools for prevention and treatment and support rising global health leaders. | ExxonMobil | Grants & Awards | Angola |
24-Apr-18 | X-Biotix Therapeutics, Inc. | $7 | Proceeds of the financing will enable X-Biotix to advance its pipeline of novel antibiotic candidates targeting a wide range of biological targets in essential pathways of Gram-negative bacterial cells. | Harvard Medical School | Series A Financing | United States |
02-Apr-18 | Nursing Home Facility | $6 | The parties will negotiate in good faith toward definitive agreements regarding the project. WHL would lease the land and be the developer of the project and would own the buildings on the site. | Union Bridge Holdings | Cooperation Agreement | Thailand |
02-Apr-18 | ReShape Lifesciences | $6 | ReShape Lifesciences intends to use the net proceeds from the registered direct offering to continue its commercialization efforts, for clinical and product development activities, and for other working capital and general corporate purposes. | Ladenburg Thalmann & Co. Inc | Purchase Agreement | United States |
30-Apr-18 | NovellusDx | $6 | "The additional funds will allow us to accelerate the execution of our strategy, move into commercialization and enable us to meet the need for functional oncology worldwide. This funding will also support continuing development and enhancement of NovellusDx’s technology using our excellent R&D team in Jerusalem”, said Haim Gil-Ad, CEO of NovellusDx. | Helsinn Investment Fund | Financing | Israel |
05-Apr-18 | Takeda Pharmaceutical Company Limited | $6 | The project has been selected for funding by the Global Health Innovative Technology Fund ("GHIT"). The Takeda-DNDi partnership will receive a sum of approximately 600 million yen from GHIT in support of its studies. | Global Health Innovative Technology Fund (GHIT) | Clinical Collaboration | Japan |
04-Apr-18 | DNA Script | $6 | New grants will accelerate DNA Script’s commercialization of its novel high speed, high efficiency, free-of-harsh-chemicals DNA synthesis technology | Horizon 2020 European Innovation Council Program, Aide au développement de l’innovation and Concours Mondial d’innovation programs of Bpifrance | Financing | France |
02-Apr-18 | Takeda Pharmaceutical Company Limited | $5 | To develop and commercialize T-3525770 (now RM-853). RM-853 is a potent, orally available ghrelin o-acyltransferase (GOAT) inhibitor currently in preclinical development for Prader-Willi Syndrome (PWS) | Rhythm Pharmaceuticals | Licensing Agreement | Japan |
06-Apr-18 | Cincinnati Children's Center for Stem Cell and Organoid Medicine (CuSTOM) | $5 | Transformational investment boosts human organ generation research | Farmer Family Foundation | Research Agreement | United States |
05-Apr-18 | Diaceutics | $5 | Financing will enable Diaceutics to accelerate product development, provide more support to pharmaceutical clients and improve patient testingn | Whiterock Capital Partners LLP | Financing | United States |
11-Apr-18 | RXi Pharmaceuticals | $5 | RXi plans to use the net proceeds to fund the preclinical and clinical development of its immuno-oncology program, for other research and development activities and for general working capital needs. | H.C. Wainwright & Co. | IPO | United States |
30-Apr-18 | Shenyang Shenhe Yixi Home Care Service Center | $5 | Shenyang Yixi operates 12 community elderly day-care centers (elderly day-care centers or activity centers) and a district home-care service center (a home-based elderly care center to provide service to the elderly at home) in, which are owned by the government. | Phoenix Creation Global Limited, (Union Bridge Holdings) | Letter of Intent | Hong Kong |
27-Apr-18 | Moberg Pharma | $4 | Balmex contains zinc oxide, the #1 doctor recommended ingredient for fighting diaper rash, plus a natural ingredient shown to help neutralize digestive enzymes that are known to irritate the skin. Balmex’s protective barrier also reduces friction on the skin caused by contact with the diaper as well as chafing from skin-on-skin contact. | Randob Labs | Divestment | Sweden |
16-Apr-18 | Technology Touching Life | $4 | Five research networks, awarded £3 million through a joint technology initiative, will harness new and emerging developments from the engineering and physical sciences to advance life sciences discovery research. | Medical Research Council (MRC) | Grants & Awards | United Kingdom |
09-Apr-18 | Zucara Therapeutics | $4 | As part of the agreement, Helmsley will provide the funding to support preclinical advancement of Zucara’s lead drug candidate. The partnership is structured as a program-related investment (PRI) in the form of a loan to Zucara. | Helmsley Charitable Trust | Financing | Canada |
03-Apr-18 | Abbott | $4 | Corona Remedies, the Ahmedabad-headquartered mid-sized pharmaceutical firm, has acquired two diabetes and hyperthyroidism brands, Obimet and Thyrocab, comprising 14 product line extensions, from multinational drug major Abbott India for an undisclosed sum. | Corona Remedies | Asset Acquisition | India |
04-Apr-18 | Apricus Biosciences | $4 | Total gross proceeds from the offering were approximately $3.55 million, before deducting the placement agent’s fees and other estimated offering expenses payable by Apricus. Apricus intends to use the net proceeds from the offering for working capital and general corporate purposes. | H.C. Wainwright & Co. | IPO | United States |
03-Apr-18 | CorWave | $4 | With this new financing, CorWave will be able to step up the pace of development of NovaPulse, a new mini-invasive cardiac support pump, and thereby improve the care of older patients suffering from chronic heart failure, one of the leading causes of death worldwide. | France’s Concours Mondial d'Innovation | Financing | France |
27-Apr-18 | Trevena, Inc. | $3 | Pharmbio Korea granted a license to develop, manufacture, and commercialize oliceridine in South Korea. Trevena to receive upfront and milestone payments and royalties, Oliceridine is currently under review by the USFDA for potential approval of a moderate-to-severe acute pain treatment. | Pharmbio Korea | Licensing Agreement | United States |
04-Apr-18 | IDT Australia, Ltd. | $3 | Today’s acquisition gives ANI full control of the re-commercialization program and the vast majority of the economics for these products. | ANI Pharmaceuticals, Inc. | Commercialization Agreement | Australia |
10-Apr-18 | FIMECS, Inc. | $2 | The company received compound assets including first-in-class E3 ligase binders and novel pseudokinase targeting binders, which enable the acceleration of protein degradation therapeutics to ‘undruggable’ targets — a critical area of cancer research requiring new innovation. | Takeda Pharmaceutical Company | Licensing Agreement | Japan |
30-Apr-18 | 4P Therapeutics Inc. | $2 | 4P Therapeutics will now become the Pharmaceutical and Development arm of Nutriband Inc. with a specific focus on Transdermal and Topical Technologies, prescription drugs and clinical development. | Nutriband Inc. | Acquisition | Canada |
30-Apr-18 | Daré Bioscience | $2 | The award will be applied to important clinical development efforts supporting Daré’s lead product candidate Ovaprene™, a non-hormonal, non-daily intravaginal ring being studied for pregnancy prevention. | National Institute of Child Health and Human Development (NICHD) | Grants & Awards | United States |
30-Apr-18 | Alavida Health | $2 | Alavida Health is a science-based treatment program that combines non-addictive medication, behavioural therapy and technology to help people decrease or stop their consumption of alcohol. Upon completion of the program, 91% of clients have reduced their drinking, with 75% reducing their alcohol consumption by more than 50%. | Nimbus Synergies Inc. | Financing | Canada |
15-Apr-18 | Annabis Medical | $2 | By combining Canopy Growth's extensive global experience and network with the strong national position of Annabis Medical, Canopy is proud to bring its renowned Spectrum Cannabis brand to another European market. | Canopy Growth Corporation | Acquisition | Czech Republic |
27-Apr-18 | BioServe Biotechnologies (Cancer Genetics, Inc.) | $2 | Under the terms of the definitive agreement, Cancer Genetics received an upfront payment of $1.6 million in cash from REPROCELL. The remaining balance will be payable approximately 6 months from closing and is subject to BioServe’s revenues for a four month period post-closing being equivalent to the same four month period in 2017. | Reprocell | Divestment | United States |
30-Apr-18 | Dr Borko Amulic (University of Bristol) | $2 | University of Bristol researcher Dr Borko Amulic has been awarded the Career Development Award by the Medical Research Council (MRC), worth £1.2 million. The money will be put towards his research into the ability of neutrophil immune cells to fight infections in the post-antibiotic age. | Medical Research Council (MRC) | Grants & Awards | United Kingdom |
26-Apr-18 | ADC Biotechnology | $2 | ADC Bio 's bioconjugation approach leverages the company’s patented Lock-Release technology, and can save several months of manufacturing time and up to 25% of overall manufacturing costs. | Downing LLP (Downing FOUR VCT Healthcare) | Investment | United Kingdom |
02-Apr-18 | Guided Therapeutics, Inc. | $1 | In addition, according to the contract, ITEM will pay GTHP a royalty for each Cervical Guide made and sold exclusively in Turkey and ITEM will be obligated to purchase 540 LuViva Advanced Cervical Scans and produce 3,450,000 Cervical Guides for the Turkish market over the next twelve years. | ITEM Medical Technologies Group | Licensing Agreement | United States |
06-Apr-18 | Aclaris Therapeutics | $1 | A-101 40% is a proprietary, high-concentration hydrogen peroxide-based topical solution designed for in-office application by a healthcare provider. It is a targeted treatment applied directly to the raised SK using a pen-like applicator. | Cipher Pharmaceuticals | Licensing Agreement | United States |
25-Apr-18 | Susan G. Komen | $1 | The funding will continue Komen’s targeted community outreach initiatives through the Conversations with Komen program and enable the organization to open a new satellite office in Milwaukee’s Amani neighborhood. | Kohl’s | Financing | United States |
27-Apr-18 | ORLink | $1 | ORLink saves hospitals time and money while improving communication and workflows for surgical teams | SAYJ Global Partners | Partnership | United States |
05-Apr-18 | Sotera Medical Corp. | $1 | Catheter ablation is a minimally invasive treatment option for patients with AF that can relieve symptoms and improve quality of life. One such risk is damage to the esophagus, which, while rare, can become a life-threatening complication. | JumpStart Inc. | Seed Financing | United States |
16-Apr-18 | Indee Labs | $1 | The project will see Indee Labs make a new generation of medicine, known as gene therapy, accessible to the masses. The impact of gene therapies will be similar to that of antibiotics seen during the last century - it will offer cures for most cancer sufferers with minimal side effects. | BioMedTech Horizons Program (Australian Govt.) | Grants & Awards | Australia |
06-Apr-18 | ModiQuest Research BV | $1 | Anticipated accretive annualized revenues of between C$3.5M to C$4.5M for fiscal 2019. Anticipated accretive annualized EBITDA of between C$750,000 to C$850,000 for fiscal 2019. European operations now account for approximately 66% of corporate revenues. | Immunoprecise Antibodies Ltd. | Acquisition | The Netherlands |
23-Apr-18 | Synpromics Ltd., Lonza Pharma & Biotech | $0.323 | Synpromics has employed its proprietary technology to develop new synthetic inducible/repressible cell-systems that are driven by non-toxic physiological or chemical stimulus, making them ideal for improving productivity and minimising costs during bioproduction. | Innovate UK | Grants & Awards | United Kingdom |
24-Apr-18 | ViaDerma, Inc. | $0.25 | According to the terms of the agreement, Vage will pay a 50% deposit to ViaDerma upon completion of the registration of Vitastem with the National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria’s equivalent to the FDA. The balance of the order will be paid to ViaDerma upon delivery of the product in about 8-10 weeks. | Vage Nigeria Ltd. | Sales Agreement | United States |
16-Apr-18 | University of Cincinnati, Emory University & University of Chicago | $0.15 | Relypsa will fund the grant awards of up to $50,000 each for one academic year. Relypsa’s grants will fund research in areas vital to improving the care of patients with kidney and heart diseases following patients prospectively at a single site who require treatment with either a renin angiotensin system blocker and/or a mineralocorticoid receptor antagonist to improve blood pressure and/or cardiac function. | Relypsa, Inc. (Vifor Pharma Group) | Grants & Awards | United States |
30-Apr-18 | Verily Life Sciences | $0 | Verily to Deploy Its Immunoscape™ Platform to Generate Insights from Gilead Clinical Trials. Through the collaboration, Gilead will provide clinical data and thousands of immune cell samples from participants before, during and after administration of novel drugs in the company’s ongoing Phase 2 and Phase 3 clinical studies. | Gilead Sciences | Clinical Collaboration | United States |
02-Apr-18 | GlaxoSmithKline | $0 | Acquistion of consumer healthcare manufacturing unit at Aiken, South Carolina (USA). | Avara Pharmaceutical Service | Acquisition | United States |
02-Apr-18 | CT Atlantic AG | $0 | XBiotech will use its proprietary manufacturing technology to advance the development of the True HumanTM anti-NY-ESO-1 monoclonal antibody, 12D7 | XBiotech USA, Inc. | Licensing Agreement | Switzerland |
03-Apr-18 | Scandicure AB | $0 | Servier will continue research started by Scandicure and advance Scandicure’s novel compounds through preclinical development using Servier’s drug discovery capabilities and knowledge of the disease areas. | Laboratoires Servier | Research Agreement | Sweden |
03-Apr-18 | Veredus Laboratories | $0 | Veredus' Lab-on-Chip technology platform and products have been established as market leaders in the global bio-surveillance market. | Sekisui Chemical Co., Ltd. | Acquisition | Singapore |
04-Apr-18 | Terns Pharmaceuticals | $0 | The agreement includes a clinical stage farnesoid X receptor (FXR) agonist, TERN-101, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, TERN-201, which is nearing IND submission, and a preclinical candidate that inhibits an undisclosed, well-validated NASH target. | Eli Lilly and Company | Licensing Agreement | United States |
04-Apr-18 | Iontas Limited | $0 | The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study. | IGEM Therapeutics | Research Agreement | United Kingdom |
04-Apr-18 | DarwinHealth | $0 | DarwinHealth’s proprietary database and technology were created to identify critical mechanisms linked to tumor dependencies and maintenance beyond genetic mutations, and include information on Master Regulators of specific tumor subtypes, as well as direct upstream modulators (both necessary for cancer cell maintenance) across more than 35 tumor and 90 tumor subtypes. | Daiichi Sankyo | Research Agreement | United States |
04-Apr-18 | Inception Neuroscience Program (Pipeline Therapeutics) | $0 | The acquisition is the culmination of a June 2014 alliance between Inception and Roche to discover and develop novel small molecules that promote remyelination of nerve fibers damaged during the progression of multiple sclerosis. | Roche | Acquisition | United States |
04-Apr-18 | Dunn Industries, Inc. | $0 | Dunn has expertise in a wide range of thermoplastic materials and offers both standard and custom-engineered tubing solutions. Its product line is also a complementary addition to the microextrusion tubing manufactured by Tekni-Plex’s Natvar business unit. | Tekni-Plex, Inc. | Acquisition | United States |
05-Apr-18 | Rebiotix Inc. | $0 | The most advanced investigational microbiome treatment from Rebiotix is RBX2660, a non-antibiotic treatment currently in Phase 3 development for the prevention of recurrent CDI. | Ferring Pharmaceuticals | Acquisition | United States |
05-Apr-18 | The University of Bath | $0 | Sapience will have exclusive rights to the development and commercialization of any novel compounds arising from this research. The agreement also provides Sapience with the right to build, own, operate and partner the discovery platform. | Sapience Therapeutics, Inc. | Research Agreement | United Kingdom |
05-Apr-18 | Samsung Bioepis | $0 | SB5 has been granted marketing authorization by the European Commission (EC) as IMRALDI®, and will be commercialized in Europe by Biogen. In the US, SB5 has not yet received regulatory approval. | AbbVie | Licensing Agreement | South Korea |
09-Apr-18 | Ranomics | $0 | VariantFind™ technology is a key component of Ranomics's functional genomics platform, and offers unprecedented scalability and flexibility in building DNA variant libraries. | Science Exchange | Collaboration | Canada |
10-Apr-18 | OptiGen, LLC | $0 | Through this evolution, Optigen's clients are believed to benefit from access to an expanded array of multiple tests—both for inherited diseases of particular interest to their breed. | Mars Petcare | Acquisition | United States |
10-Apr-18 | Mapi Pharma Ltd. | $0 | The two companies will partner on the development and commercialization of GA Depot, a long-acting Glatiramer Acetate product. Mylan is acquiring global marketing rights to the product - GA Depot. | Mylan N.V. | Partnership | Israel |
10-Apr-18 | Sleep.ai | $0 | Sleep.ai created an app and wearable for detecting if a user is snoring and/or grinding their teeth, known as bruxism, and helps dentists monitor patients after they've begun dental treatment for either condition. | SleepScore Labs | Acquisition | United States |
11-Apr-18 | Zealand Pharma | $0 | Zealand has entered a collaboration agreement with Roche Diabetes Care to use its Accu-Chek® Combo pump system in the Phase 3 trials with dasiglucagon for treatment of congenital hyperinsulinism (CHI). Dasiglucagon is a potential first-in-class glucagon analog, currently in plase 3 testing for delivery through infusion via the Accu-Chek® Combo pump system. | Roche | Clinical Collaboration | Denmark |
11-Apr-18 | Molecular Partners | $0 | MP0250 offers the possibility of targeting two main tumor escape pathways by blocking both hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) simultaneously while continued treatment with osimertinib suppresses EGFR-mutated NSCLC tumor cells. | AstraZeneca | Collaboration | Switzerland |
11-Apr-18 | Veracyte, Inc. | $0 | Through the new agreement, Veracyte will use its Afirma Xpression Atlas platform to provide Loxo Oncology with information regarding thyroid cancers with TRK fusions and RET alterations, for use in developing its targeted cancer therapies. | Loxo Oncology | Collaboration | United States |
11-Apr-18 | Livongo Health | $0 | Cambia and Livongo will collaborate to personalize health care for people who have ongoing health needs in simple, meaningful and tangible ways. Initially, the companies will work together to make Livongo’s category-leading Livongo for Diabetes solution available to Regence Blue Cross and Blue Shield in Idaho, Oregon, Utah, and Washington. The companies will then expand their partnership to co-develop solutions that personalize care for conditions such as hypertension and integrated behavioral h | Echo Health Ventures LLC, Cambia Health Solutions | Partnership | United States |
12-Apr-18 | Analytica Laser | $0 | Acquisition adds real-world effectiveness prediction and value assessment to Certara’s model-informed drug development and regulatory science decision-making portfolio | Certara | Acquisition | United Kingdom |
18-Apr-18 | NxGen Brands | $0 | Nutra Pharma is partnering with NxGen Brands, LLC to market and distribute their Over-the-Counter (OTC) pain reliever, Nyloxin® through all of their distribution channels | Nutra Pharma Corporation | Acquisition | United States |
23-Apr-18 | Australasian Medical & Scientific Ltd (AMSL), New Zealand Medical & Scientific Ltd (NZMS) | $0 | Under the terms of the arrangements, the diabetes divisions of AMSL and NZMS will perform all sales, marketing, and customer training and support for Tandem’s products in the regions. Timing for availability of Tandem products in Australia and New Zealand has not yet been announced. | Tandem Diabetes Care, Inc. | Distribution Agreement | Australia |
17-Apr-18 | RetroFit | $0 | With the acquisition Livongo adds to its client base innovative health plans and Fortune 1000 employers across a variety of industries. The company also gains a proven, evidence-based, Diabetes Prevention Program, enhances its data science capabilities, and boosts expertise in holistic weight management, including nutrition, exercise and mindset. | Livongo Health | Acquisition | United States |
11-Apr-18 | GlaxoSmithKline | $0 | GSK takes 19.9% equity stake in Orchard and seat on board | Orchard Therapeutics | Financing | United Kingdom |
04-Apr-18 | Head and Neck Cancer Alliance | $0 | As part of this joint effort, HNCA will be able to share valuable content through CURE® magazine, where audience will have access to unprecedented content including latest research, interviews and articles that can help oncologists better serve their patients. The SAP Program is designed to facilitate an open exchange of information among trusted peers, the goal of which is to improve patient care. | CURE Media Group | Partnership | United States |
04-Apr-18 | Kymera Therapeutics | $0 | Collaboration to Accelerate the Discovery of Protein Degrading Therapeutics. Using a small molecule-mediated knockdown strategy, Kymera rationally designs and develops heterobifunctional molecules that recruit disease-causing proteins to E3 ubiquitin ligases, resulting in the target protein’s ubiquitination and degradation, and the ultimate resolution of cellular dysregulation. | GlaxoSmithKline | Collaboration | United States |
04-Apr-18 | Miltenyi Biotec GmbH | $0 | Utilising the state-of-the-art, automated cell processing platform CliniMACS Prodigy®, Autolus has established a GMP production process for its programmed T cell therapies designed to address the challenges of commercial-scale manufacturing. | Autolus Limited | Supply Agreement | Germany |
26-Apr-18 | InSysBio LLC | $0 | The companies together have constructed a complex asthma model which facilitated the investigation of novel medicines and combination therapy scenarios. GSK has chosen InSysBio as a partner to implement a further expansion of the existing model. This will include new targets and clinical trial data to be able simulate more asthma treatment scenarios. | GlaxoSmithKline | Collaboration | Russia |
06-Apr-18 | PierianDx | $0 | PierianDx will partner with TriCore to bring to market new Next Generation Sequencing (NGS) assays, streamline the genomic data management process, customize reporting, and optimize the variant review and sign-out process. | TriCore Reference Laboratories | Partnership | United States |
17-Apr-18 | PierianDx | $0 | PierianDx’s software platform, the Clinical Genomics WorkSpace (CGW), streamlines accurate analysis, interpretation, and reporting for clinical labs seeking to expand NGS testing and personalized medicine. | RTI International | Partnership | United States |
02-Apr-18 | Brazos Biomedical, LLC | $0 | BRAZOS has a proprietary device (AURACIS™) in pre-clinical development to treat headache pain using transcutaneous electrical nerve stimulation (TENS) technology. | American Diversified Holdings Corporation | Acquisition | United States |
17-Apr-18 | Integrated Wellness Solutions (IWS) | $0 | The IWS acquisition comes as part of DHS Group’s expansion of their wellbeing program; a program that falls under the HealthSpective Engage platform which includes: fitness tracking and wearables, mental, financial and personal health modules. | Dynamic Health Strategies, LLC (DHS Group) | Acquisition | United States |
10-Apr-18 | Wave Life Sciences Ltd. | $0 | Under the collaboration, the companies will analyze and test oligonucleotides against potential therapeutic targets within multiple genes implicated in neuromuscular disorders. | Deep Genomics Inc. | Collaboration | Singapore |
05-Apr-18 | Ortho Clinical Diagnostics | $0 | The agreement is part of Ortho's ongoing MicroTip Partnership Assays program, through which Ortho collaborates with other diagnostics companies to validate and deliver a broad range of assays to the hospitals, hospital networks and labs who use Ortho's VITROS® 4600 Chemistry System and VITROS® 5600 Integrated System. | Thermo Fisher Scientific | Development Agreement | United Kingdom |
24-Apr-18 | Nektar Therapeutics | $0 | Nektar and Takeda will split the costs related to the clinical trial and each company will contribute their respective compounds to the clinical collaboration. | Takeda Pharmaceutical Company | Clinical Collaboration | United States |
06-Apr-18 | Avant Diagnostics, Inc., Elto Pharma, Inc. | $0 | Amarantus intends to assign diagnostic assets (LymPro Test, MSPrecise and NuroPro) to a new subsidiary that aligns with Amarantus' holding company business model. | Amarantus Bioscience Holdings, Inc. | Asset Acquisition | United States |
05-Apr-18 | Pharmacogenomics (PGx) Center of Excellence, University of Pittsburgh | $0 | The new center will feature Thermo Fisher's portfolio of PGx testing solutions, including its PharmacoScan platform, to study preemptive panel-based PGx testing and return results in at least 150,000 patients in western and central Pennsylvania. | Thermo Fisher Scientific | Licensing Agreement | United States |
18-Apr-18 | Pear Therapeutics | $0 | Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O™, potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with buprenorphine. | Novartis | Collaboration | United States |
24-Apr-18 | Topas Therapeutics GmbH | $0 | Companies join forces in immune tolerance to tackle ADA (anti-drug antibodies) | Boehringer Ingelheim | Collaboration | Germany |
23-Apr-18 | PSC Biotech | $0 | LSNE-Madison is a 37,000 square foot multi-product facility that will be used for the manufacturing of final drug products for pre-clinical to Phase III/commercial use. This new facility will also increase LSNE's capabilities to include the terminal sterilization of final product and additional quality control services. | Lyophilization Services of New England (LSNE) | Acquisition | United States |
24-Apr-18 | Medical University of Vienna | $0 | The company today also announced its partnership with the Medical University of Vienna for a 3-day pollen forecast on the Air Matters app, which retrieves its data from global pollen measurement sites, including the new measurement station at Philips’ Drachten site in the Netherlands. | Royal Philips | Partnership | Austria |
10-Apr-18 | Baliopharm AG | $0 | The transaction complements Promethera’s pipeline with an innovative antibody-based drug candidate that specifically binds to the tumor necrosis factor receptor 1 (TNF-R1). | Promethera Biosciences SA | Acquisition | Germany |
01-Apr-18 | New Jersey Urology, LLC | $0 | The newly-formed organization will create the largest group of urologists in the United States, with 96 providers in 46 locations across the state of New Jersey, including 4 Cancer Treatment Centers. | Delaware Valley Urology, LLC, Bloom Organization | Merger Agreement | United States |
24-Apr-18 | Cardiologic Ltd. | $0 | The autoRIC® device automatically delivers remote ischemic conditioning (“RIC”) to provide a non-invasive, cardio-protective therapy shown to reduce heart damage during heart attacks and certain cardiovascular procedures. | CellAegis Devices Inc. | Distribution Agreement | United Kingdom |
20-Apr-18 | Ciel Medical, Inc. | $0 | Vyaire management sees the acquisition of Ciel Medical as a step toward the company’s stated goal of becoming the global leader in the respiratory care market. | Vyaire Medical | Acquisition | United States |
26-Apr-18 | Acutronic Medical Systems, IMTmedical | $0 | Acquires Acutronic Medical Systems and agrees to acquire IMTmedical | Vyaire Medical | Acquisition | Switzerland |
05-Apr-18 | Broad Institute of MIT and Harvard | $0 | CRISPR-Cas9 commercial research tool technology acquired from Broad Institute will be used to build preclinical model animals and target treatment function analysis to further gene treatment research and development. | Macrogen, Inc. | Licensing Agreement | United States |
26-Apr-18 | Roche | $0 | Roche maintains commercial exclusivity for Foundation Medicine’s molecular information products in China, and in cooperation with DIAN continues its current in-county activities to support the broad integration of CGP into clinical care. | Foundation Medicine, Inc., | Collaboration | China |
09-Apr-18 | California Department of Public Health | $0 | The cGMP facility has a dedicated mRNA production area for the manufacture of cGMP-compliant mRNAs. In addition to supporting iPSC reprogramming efforts, cGMP mRNA will support ongoing internal development programs to generate iPSC derived cells. | Allele Biotechnology & Pharmaceuticals Inc. | Licensing Agreement | United States |
23-Apr-18 | Codexis, Inc. | $0 | The partnership will accelerate the creation and commercialization of new, low-cost, sustainable manufacturing processes, exploiting the benefits of biocatalysts to a growing number of the world’s small molecule pharmaceuticals. | Porton Pharma Solutions, Ltd. | Collaboration | United States |
04-Apr-18 | ReForm Biologics | $0 | As part of the collaboration, KBI will provide services to ReForm to further develop and validate its biologic formulation platform while also gaining access to ReForm’s proprietary technology. | KBI Biopharma | Collaboration | United States |
03-Apr-18 | Medidata | $0 | The agreement will result in the NHMRC Clinical Trial Centre consolidating multiple electronic data capture (EDC) solutions to the Medidata eClinical platform. | National Health and Medical Research Council Clinical Trial Centre (NHMRC CTC) | Partnership | United States |
13-Apr-18 | Polyphor | $0 | Polyphor today announced that it has successfully completed its Wellcome Trust collaboration which supported the development of novel Outer Membrane Protein Targeting Antibiotics (OMPTA) addressing the most resistant Gram-negative bacterial pathogens. | Wellcome Trust | Grants & Awards | Switzerland |
13-Apr-18 | QurAlis Corporation | $0 | QurAlis is developing three precision therapies targeting three distinct subtypes of ALS: a drug to restore a dysfunctional cellular waste clearance system that progressively poisons neurons; a drug to treat overactive neurons and prevent cell death via excitotoxicity; and a transformative device to remove toxic proteins. | MP Healthcare Venture Management (MPH) | Seed Financing | United States |
05-Apr-18 | Ubiquigent Limited | $0 | The collaboration builds on an existing long term relationship between the parties whereby FORMA has accessed Ubiquigent’s DUBprofiler™ platform for the screening of test compounds, leverages Ubiquigent’s chemistry and biology platforms to design novel DUB inhibitors. | FORMA Therapeutics | Partnership | United Kingdom |
09-Apr-18 | Morphotek®, Inc. (Eisai Inc.) | $0 | BlissBio has an exclusivity option to expand the territory beyond China to the global market and to develop therapeutic ADCs to two additional undisclosed oncology targets. | Bliss Biopharmaceutical Co., Ltd. (BlissBio) | Licensing Agreement | United States |
06-Apr-18 | Change Healthcare | $0 | Netsmart innovates electronic health records (EHRs), solutions and services that are powerful, intuitive and easy-to-use and provides accurate, up-to-date information which is easily accessible to care team members in behavioral health, care at home, senior living and social services. | Netsmart | Acquisition | United States |
09-Apr-18 | Change Healthcare | $0 | In a first for the telemedicine market, Doctor On Demand, a leading video medicine provider serving health plans, enterprise customers, and the DTC market, is now using the Change Healthcare Intelligent Healthcare Network. | Doctor On Demand | Collaboration | United States |
10-Apr-18 | Syntekabio | $0 | Yuhan Corporation said on Monday that it has signed a memorandum of understanding with Syntekabio to promote joint research on discovering biological markers or indicators of certain biological conditions by analyzing patients’ genomes and searching for new drug candidates using an AI-based platform. | Yuhan Corporation | Memorandum of Understanding | South Korea |
16-Apr-18 | STA Pharmaceutical Co., Ltd (WuXi AppTec) | $0 | PMD-026 is the first RSK inhibitor to demonstrate potential disease-modifying properties in triple-negative breast cancer (TNBC) | Phoenix Molecular Designs (PhoenixMD) | Manufacturing Investment | China |
30-Apr-18 | Avizia | $0 | This acquisition will bring to American Well a comprehensive acute care capability, including the best in class hospital-based cart lineup and custom software workflows for more than forty clinical specialties, including telestroke and tele-behavioral health. | American Well® | Acquisition | United States |
18-Apr-18 | Astellas Pharma | $0 | Antibody-Drug Conjugate (ADC) research was the core focus of work conducted at Agensys. Astellas will continue certain clinical trials and collaborationsnon some ADC programs that have been in progress at Agensys, including its collaboration with Seattle Genetics, Inc. | Gilead Sciences | Clinical Collaboration | Japan |
23-Apr-18 | NuProbe Global | $0 | New molecular strategy enriches multiple disease-related rare genetic DNA variants with high accuracy in a single assay to enable personalized diagnosis and treatments | Wyss Institute at Harvard University | Licensing Agreement | United States |
19-Apr-18 | Flowsion A/S | $0 | The grant was awarded to assist in the development of an innovative automatic blood glucose control system, Glucostat, developed by Flowsion. Glucostat is expected to reduce mortality, morbidity, length of stay and treatment costs dramatically for intensive care patients compared to existing technologies. | European Commission Horizon 2020 SME Instrument | Grants & Awards | Denmark |
18-Apr-18 | Grid Therapeutics, LLC | $0 | Grid’s Series B financing was led by Milestone Holdings, a California-based venture company boasting a strong history of identifying and funding companies developing disruptive technologies. | Milestone Holdings | Series B Financing | United States |
05-Apr-18 | Enterprise Therapeutics | $0 | The funding will be used to support pioneering research, leveraging Enterprise Therapeutics’ bronchosphere technology platform. Bronchospheres are a miniaturised model of the human airway to facilitate development of therapeutic products for the treatment of cystic fibrosis. | Cystic Fibrosis Trust | Financing | United Kingdom |
17-Apr-18 | Nordion Medical Isotopes (Sotera Health) | $0 | Through the agreement, BWXT will acquire essentially all of Nordion’s medical isotope assets, including the radiochemical operation and contract manufacturing services in Kanata, and the medical isotope operation in Vancouver, British Columbia. | BWX Technologies | Asset Acquisition | United States |
16-Apr-18 | University of Oxford | $0 | EMPA-KIDNEY will include approximately 5,000 people with established chronic kidney disease, with and without diabetes. The study will be part of the empagliflozin clinical development programme, the largest clinical development programme of an SGLT2 inhibitor. | Eli Lilly and Company | Clinical Collaboration | United Kingdom |
11-Apr-18 | Fujifilm Kyowa Kirin Biologics | $0 | Fujifilm Kyowa Kirin Biologics grants Mylan an exclusive license to commercialize the adalimumab biosimilar in Europe and will receive an up-front fee. In addition, Fujifilm Kyowa Kirin Biologics is eligible to receive a subsequent commercialization milestone payment and sales royalties. | Mylan N.V. | Licensing Agreement | Japan |
02-Apr-18 | Rubicon Pharmacies Canada Inc. | $0 | TorQuest Partners, one of Canada's leading mid-market private equity firms, is the majority shareholder of Amenity. | Amenity Holdings Inc. | Merger Agreement | Canada |
30-Apr-18 | Pure Sunfarms (Village Farms International Inc.) | $0 | Pure Sunfarms’ objective is to be a vertically integrated supplier and in addition to production ramp-up is focused on senior management hires, downstream product development, and development of distribution and marketing strategies. | Emerald Health Therapeutics | Supply Agreement | Canada |
09-Apr-18 | Magenta Therapeutics | $0 | The collaboration between Be The Match BioTherapies and Magenta leverages a wide range of Be The Match BioTherapies’ assets and services, including an extensive network of transplant centers and cord blood banks, as well as expertise in research protocols, payer policy and patient education development. | Be The Match BioTherapies | Series C Financing | United States |
10-Apr-18 | Synthace Limited | $0 | PIPETMAX® is a collaboration between Gilson and Synthace launching this summer. The software connects Gilson’s automated liquid handling platform, PIPETMAX, to the cloud and will make it easier to design and reproduce experiments. | PIPETMAX (Gilson, Inc.) | Collaboration | United Kingdom |
18-Apr-18 | Caris Life Sciences | $0 | Caris Molecular Intelligence® is a patented and proprietary service that uses a combination of technologies, including Next-Generation Sequencing (NGS), to examine each tumour at the various biological stages of cancer, which provides individualised data about a patient's cancer. | Mundipharma | Partnership | United States |
16-Apr-18 | Pennsylvania State University | $0 | This long-term relationship will support the education and preparation of the next generation of biotechnology leaders. Part of Sartorius’ investment will be to enhance the Fermentation Facility that will play a significant role in Penn State’s Center of Excellence in Industrial Biotechnology (CoEIB). | Sartorius Stedim Biotech | Partnership | United States |
30-Apr-18 | 4D Molecular Therapeutics (4DMT) | $0 | 4DMT will be responsible for vector discovery and optimization, product design and engineering, pre-clinical and early-stage clinical development, including manufacturing activities, while Roche will conduct pivotal clinical trials and commercialize the new therapeutics globally. | Roche | Expansion | United States |
17-Apr-18 | ProBioGen AG | $0 | Under the terms of the agreement, ProBioGen is developing a stable cell line, followed by process development and GMP clinical manufacturing for Tizona’s lead antibody drug candidate. | Tizona Therapeutics | Contract Agreement | Germany |
15-Apr-18 | American Association for Cancer Research | $0 | The alliance will build trans-Atlantic collaborations by establishing training and exchange programs, catalyzing scientific innovation by convening international meetings and workshops, and uniting the community to influence global research policy, among other important topics. | Cancer Research UK | Partnership | United States |
30-Apr-18 | Rosetta Genomics | $0 | Genoptix, Inc., a leading oncology diagnostic laboratory today announced that Rosetta Genomics’ stockholders have approved the acquisition of Rosetta Genomics by Genoptix. | Genoptix, Inc. | Acquisition | United States |
26-Apr-18 | Lombard Medical Operations | $0 | Concurrent with the UK administration process, parent company Lombard Medical, Inc. will be formally liquidated through a liquidator appointed by the Grand Court of the Cayman Islands and subsequently dissolved. | MicroPort Scientific Corporation | Acquisition | United Kingdom |
30-Apr-18 | Catheter Research Inc. (CRI) Medical | $0 | CRI is a manufacturer of interventional catheters, tube sets, and other assemblies for medical devices with expertise in final FDA product packaging for sterilization. CRI services OEM customers as well as sell their own catheter line under the brand Thomas Medical. | Biomerics ATL, LLC | Acquisition | United States |
24-Apr-18 | Freenome | $0 | By decoding cell-free (cf) biomarker patterns of once unthinkable complexity, ?Freenome?'s artificial intelligence (AI) genomics platform is poised to detect cancer at its earliest stages and help clinicians optimize the next generation of precision therapies. | Biognosys | Partnership | United States |
23-Apr-18 | SPI Pharma | $0 | The agreement will focus on finished dosage products for licensing to customers through dossiers developed by SPI Pharma for implementation by generic and branded pharmaceutical companies. Neither Noramco nor SPI has any intention to produce or market finished dosage forms. | Noramco | Licensing Agreement | United States |
30-Apr-18 | NX Development Corp (NXDC) | $0 | GleolanTM is an FDA-approved optical imaging agent indicated in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery. | photonamic GmbH & Co. KG | Acquisition | United States |
30-Apr-18 | Lexi Pharma Inc | $0 | Altum Pharma completed the acquisition of Lexi Pharma, a Canadian pharmaceutical company focused on the development of AP-002, a new chemical entity (NCE) small molecule with an active US FDA IND (Investigational New Drug application). | Altum Pharmaceuticals Inc. | Acquisition | Canada |
25-Apr-18 | National Center for Cardiovascular Diseases | $0 | As a response to this national epidemic, the collaboration will evaluate the health economic consequences of diabetes in China and develop a simple cardiovascular disease (CVD) risk calculator to improve screening and diabetes management at the primary care level. | Eli Lilly and Company | Research Agreement | China |
16-Apr-18 | Bristol-Myers Squibb | $0 | Under the agreement, Janssen Pharmaceuticals, Inc. and Bristol-Myers Squibb Company will advance BMS-986177 into Phase 2 clinical trials and establish a broad development program across multiple therapeutic indications. | Johnson & Johnson | Collaboration | United States |
26-Apr-18 | UCSD School of Medicine’s Center for Medicinal Cannabis Research (CMCR) | $0 | INSYS has agreed to provide its pharmaceutical-grade CBD oral solution—already under clinical evaluation in company-sponsored trials for treatment of refractory pediatric epilepsies—for this CMCR study, which is scheduled to start in 2019. | INSYS Therapeutics | Research Agreement | United States |
11-Apr-18 | Prayog Labs LLC | $0 | This novel delivery has the potential to provide a non-addictive treatment option for acute pain that patients may experience, for example, during dentistry procedures, post-surgery and with orthopedic defects. Meloxicam also is proposed to treat chronic pain. | Mylan N.V. | Licensing Agreement | United States |
12-Apr-18 | Jenner Institute of Oxford University | $0 | Through collaboration with the Jenner Institute, partners will improve the process of developing adenovirus vaccines, vaccines based on adenoviruses - a type of DNA virus. | Merck Group | Research Agreement | United Kingdom |
17-Apr-18 | ViaCyte | $0 | In addition to having the only islet cell replacement therapies in clinical-phase testing, ViaCyte continues to advance the field of differentiating pluripotent stem cells, including induced pluripotent stem cells, to optimize these therapies for type 1 diabetes and insulin-requiring type 2 diabetes. | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH) | Grants & Awards | United States |
26-Apr-18 | BioSig Technologies, Inc. | $0 | HLG counts some of the world’s top healthcare and technology companies among its clients, and it has spearheaded the creation and success of several global coalitions, including the Global CEO Initiative on Alzheimer’s Disease and Global Coalition on Aging. The HLG team for BioSig Technologies will be led by Mario Ottiglio, HLG managing director based in Geneva, who has deep experience in the healthcare and pharmaceutical arena. | High Lantern Group (HLG) | Partnership | United States |
16-Apr-18 | Applied BioMath, LLC | $0 | Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. | Pandion Therapeutics | Collaboration | United States |
25-Apr-18 | Applied BioMath, LLC | $0 | Applied BioMath announced a collaboration with Sanofi for the analysis of systems pharmacology pharmacokinetic (PK)/target engagement (TE) models for bispecific antibody combinations. | Sanofi | Collaboration | United States |
23-Apr-18 | Applied BioMath, LLC | $0 | In this collaboration, Applied BioMath will leverage MADI to predict optimal dosing regimens for Checkpoint Therapeutics' product candidates based on in vitro functional, in vivo efficacy, and preclinical toxicology data, as well as Phase 1 PK data. | Checkpoint Therapeutics | Collaboration | United States |
17-Apr-18 | Applied BioMath, LLC | $0 | The collaboration will focus on developing a mathematical model relating XmAb®24306 modulated potency and extended half-life to observed pharmacokinetics and in vivo T-cell stimulation. Such models can guide preclinical and clinical development of new biologic agents such as XmAb24306. | Xencor | Collaboration | United States |
27-Apr-18 | Amneal Pharmaceuticals, LLC, Impax Laboratories, Inc. | $0 | Upon closing the transaction, ANI will acquire a product portfolio consisting of five approved generic ANDAs and one pipeline product, Erythromycin IR tablets; ANI will also acquire a license, supply and distribution agreement for a second pipeline product, Diclofenac-Misoprostol DR tablets, with a pending ANDA. | ANI Pharmaceuticals, Inc. | Asset Acquisition | United States |
04-Apr-18 | Q-State Biosciences | $0 | In the collaboration, Q-State will use its proprietary drug discovery platform to develop novel cell-based assays that the companies will use to identify compound candidates. | Vertex Pharmaceuticals | Collaboration | United States |
27-Apr-18 | Stellar Biotechnologies, Inc. | $0 | At the effective time of the reverse share split, every seven shares of Stellar Biotechnologies common shares will be combined into one common share of Stellar Biotechnologies. | Undisclosed | Share Split | United States |
18-Apr-18 | Sempre Health | $0 | The two companies are seeking to engage 10,000 patients with diabetes on the Sempre Health platform in 2018. | Novo Nordisk | Collaboration | United States |
17-Apr-18 | SAMDI Tech, Inc. | $0 | Using its label-free and high-throughput SAMDI assay, the team at SAMDI Tech can screen a client’s target against any number of compounds. As hits are found, Enamine provides support with the follow-up chemistry needed to validate and optimize the compound’s activity. | Enamine | Partnership | United States |
23-Apr-18 | MAGiQ Therapeutics, Inc. (ReproCell) | $0 | MAGiQ is a 50:50 joint venture, in which Q Therapeutics will contribute its patented technology to derive and manufacture glial-restricted progenitor (GRP) cells from any tissue source, including induced pluripotent stem cells. | Q Therapeutics, Inc., | Joint Venture | United States |
30-Apr-18 | Total Scientific Ltd | $0 | RxCelerate provides bespoke drug development services to clients ranging from virtual biotech companies to global pharmaceutical giants. Its unique model is built around out-sourcing drug development expertise rather than practical experimental work, allowing RxCelerate to guide projects from discovery through to the clinic as efficiently as possible. | RxCelerate Ltd | Acquisition | United Kingdom |
26-Apr-18 | AllianceRx Walgreens Prime | $0 | The new drugs treat rare conditions such as Huntington's disease, severe asthma and cystic fibrosis (CF), or offer improved treatment protocols for hemophilia in adults and children. | Prime Therapeutics LLC | Access Agreement | United States |
10-Apr-18 | Oliver™ Suzhou Manufacturing Facility | $0 | In this facility, all manufacturing will occur within an ISO-7 certified clean room environment, and product capabilities include pouch making, roll stock converting (including slitting and printing), die-cut lid manufacturing, and mounting card production. | Oliver Healthcare | Manufacturing Investment | China |
04-Apr-18 | Q-State Biosciences | $0 | The collaboration calls for Q-State to build disease models using stem cell-derived neurons from epilepsy patients that can be employed with Q-State’s proprietary Optopatch technology, which permits the fine interrogation of neuronal networks by optical stimulation and recording the deficits in neuronal activity caused by genetic mutations. | UCB | Research Agreement | Belgium |
11-Apr-18 | Evotec AG | $0 | Evotec will leverage its highly skilled experts across all disciplines, primarily oncology, to implement a tailored drug development strategy for Petra-01 and will receive undisclosed research funding and success-based milestones. | Petra Pharma Corporation | Collaboration | Germany |
23-Apr-18 | Technical University of Denmark’s Department of Chemistry (DTU Chemistry) | $0 | The partnership includes workshops, special training sessions and project assignments, and as part of the program the students will get the opportunity to work directly with innovation and research in DTU Skylab’s laboratories, and they will get a unique opportunity to work on an ongoing research project with LEO Pharma. | Leo Pharma | Partnership | Denmark |
08-May-18 | Shire PLC | $62,000 | The new entity would be a global pharmaceutical giant with its roots in Japan, as Weber envisions it along with becoming a leader in gastroenterology, neuroscience, oncology, rare diseases and blood-derived therapies, used for serious conditions such as hemophilia. | Takeda Pharmaceutical Company | Acquisition | Ireland |
16-May-18 | Sivantos Pte. | $8,200 | Combined businesses to become a global R&D powerhouse as well as an innovation leader with approximately 800 specialists and abundant resources to further accelerate innovation of hearing instruments and tailored solutions including by leveraging its leading digital platform | Widex A/S | Merger Agreement | Denmark |
29-May-18 | Meridian Health Inc. | $2,500 | Meridian is one of the largest privately held, for-profit managed care organizations in the U.S. and serves approximately 1.1 million Medicaid, Medicare Advantage (MA), integrated dual-eligible and Health Insurance Marketplace members as of May 1, 2018 in Michigan, Illinois, Indiana and Ohio. | WellCare Health Plans | Acquisition | United States |
14-May-18 | MedReleaf Corp. | $2,470 | The proposed Transaction brings together two of Canada's premier cannabis companies with fully-aligned strategic visions and production philosophies, as well as complementary assets, distribution networks, products, and capabilities. | Aurora Cannabis Inc | Acquisition | Canada |
10-May-18 | ARMO BioSciences, Inc. | $1,600 | The acquisition will bolster Lilly's immuno-oncology program through the addition of ARMO's lead product candidate, pegilodecakin, a PEGylated IL-10 which has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types. | Eli Lilly and Company | Acquisition | United States |
02-May-18 | BeneVir Biopharm | $1,040 | BeneVir engineers oncolytic viruses through the T-Stealth™ platform to overcome the barrier of the body’s immune system. Janssen intends to advance pre-clinical candidates as standalone therapies and in combination with other immunotherapies for the treatment of solid tumor cancers | Johnson & Johnson | Acquisition | United States |
24-May-18 | Bicycle Therapeutics | $1,000 | The original collaboration was signed in late 2016 and with the expansion has a potential value in excess of $1 billion. Under the terms of the collaboration Bicycle is responsible for identifying Bicycles® for an undisclosed number of respiratory, cardiovascular and metabolic disease targets specified by AstraZeneca, while AstraZeneca is responsible for further development and product commercialization. The expansion provides additional disease targets and triggers an undisclosed milestone paym | AstraZeneca | Partnership Expansion | United Kingdom |
09-May-18 | Lodo Therapeutics Corp. | $969 | Compounds derived from natural products comprise a significant proportion of the small molecule drugs used to treat cancer, infections and chronic illnesses such as Type 2 diabetes. Rather than relying on culturing known strains of bacteria, Lodo Therapeutics’ genome-based approach leverages the power of microbial evolution to identify novel, naturally occurring compounds that have therapeutic potential in the treatment of cancer and drug-resistant bacterial infections. This approach is expected | Roche | Collaboration | United States |
18-May-18 | Ligand Pharmaceuticals | $650 | Ligand expects to use the remainder of the net proceeds from the offering of the notes to acquire or invest in complementary businesses, companies, products and technologies and for working capital and other general corporate purposes, including, without limitation, research and development activities to maintain Ligand’s platform technologies and for development of Ligand’s product candidates being developed internally. | Undisclosed | Private Placement | United States |
02-May-18 | Darling Ingredients Inc. | $616 | DG Finance will use the net proceeds from the offering of the Notes, together with borrowings under Darling's revolving credit facility, to repurchase the 2022 Notes validly tendered and accepted for purchase pursuant to the Tender Offer, including the payment of any Accrued Interest and costs and expenses incurred in connection therewith. | Darling Global Finance B.V. | Private Placement | United States |
14-May-18 | AurKa Pharma, Inc. | $575 | Under the terms of the agreement, Lilly will acquire all shares of AurKa Pharma. In return, AurKa Pharma shareholders will receive an upfront payment of $110 million. AurKa Pharma shareholders are also eligible to receive up to $465 million in regulatory and sales milestones should AK-01 gain approval in the U.S. and other markets, and achieve certain sales levels. | Eli Lilly and Company | Acquisition | Canada |
07-May-18 | AstraZeneca | $538 | Luye Pharma will pay $538m in consideration including $260m immediately following closure of the transaction. In addition, a milestone is payable on the successful transition of certain activities to Luye. AstraZeneca will continue to manufacture and supply Seroquel and Seroquel XR to Luye Pharma during a transition period. The upfront and future payments will be reported as Other Operating Income in the Company’s financial statements. | Luye Pharma Group | Licensing Agreement | United Kingdom |
23-May-18 | Cara Therapeutics | $520 | Cara Therapeutics, Inc. today announced that it has licensed worldwide rights, except in the U.S., Japan and South Korea, to commercialize KORSUVA (CR845/difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in dialysis patients to Vifor Fresenius Medical Care Renal Pharma Ltd, a joint company of Vifor Pharma Group and Fresenius Medical Care (NYSE:FMS) that specializes in treatments for CKD. | Vifor Fresenius Medical Care Renal Pharma (VFMCRP) | Licensing Agreement | United States |
14-May-18 | Zymeworks | $485 | Under the terms of the second agreement, Daiichi Sankyo will acquire licenses to Zymeworks’ Azymetric™ and EFECT™ technology platforms to develop two additional bispecific antibody therapeutics. In exchange, Zymeworks will receive an upfront technology access fee of US$18 million and may receive up to US$466.7 million in potential clinical, regulatory and commercial milestone payments. In addition, Zymeworks will receive up to double-digit tiered royalties on global product sales. | Daiichi Sankyo | Licensing Agreement | Canada |
30-May-18 | F-star Biotechnology Ltd. | $471 | In the ongoing collaboration between F-star and Denali announced in August 2016, the partners are developing Fcabs™ (Fc-domains with antigen-binding) against up to three different transporters in the blood-brain barrier (BBB). | Denali Therapeutics | Collaboration | Austria |
10-May-18 | InRetail Pharma | $400 | The Company is a leading pharmaceutical platform in the Andean region, with the largest retail pharmacy operation in Peru and one of the largest distribution networks in the Andean region. It operates throughout the pharmaceutical value chain, focusing on retail pharmacies and pharmaceutical distribution and marketing businesses. It also manufactures certain pharmaceutical products. | Citigroup | IPO | Peru |
30-May-18 | Industrial Development Authority (IDA), Ireland | $381 | An Taoiseach Leo Varadkar, Prime Minister of Ireland today announced that WuXi Biologics, a Hong Kong-listed (2269.HK) global open-access biologics technology platform company, is to invest €325 million and create 400 new jobs over five years in a new biologics drug substance manufacturing facility on the Industrial Development Authority's (IDA) greenfield site in Mullagharlin, Dundalk, Co. Louth. | WuXi AppTec | Manufacturing Investment | Ireland |
09-May-18 | DURECT Corporation | $323 | DURECT received an upfront payment from Sandoz of $20 million at the time the agreement between the two companies became effective in June 2017 and was initially eligible for up to an additional $43 million in payments based on successful development and regulatory milestones (of which $30 million is feasible following the results of the PERSIST Phase 3 clinical trial), and up to an additional $230 million in sales-based milestones. | Novartis | Licensing Agreement | United States |
07-May-18 | Procella Therapeutics, Smartwise (SWIB Holding) | $320 | The aim of the collaboration with the global biopharmaceutical company AstraZeneca is to develop new ways of regenerating parts of the heart muscle that have been damaged by a heart attack, using Procella Therapeutics' stem cell technology, as well as novel catheter injection methods, using Smartwise's Extroducer catheter. | AstraZeneca | Collaboration | Sweden |
21-May-18 | GRAIL, Inc. | $300 | The Series C funding will add to the company’s balance sheet and support ongoing development and validation of products for the early detection of cancer in GRAIL’s clinical research program. | Ally Bridge Group | Series C Financing | United States |
03-May-18 | Advanced Regenerative Manufacturing Institute | $300 | ARMI will work to integrate and organize the fragmented collection of industry practices and domestic capabilities in tissue Biofabrication technology to better position the US relative to global competition. ARMI will also focus on accelerating regenerative tissue research and creating state-of-the-art manufacturing innovations in biomaterial and cell processing | Organovo Holdings, Inc., Samsara Sciences | Partnership | United States |
21-May-18 | Takeda Pharmaceutical Company Limited | $280 | The shareholding is to be acquired in an all-cash, combined Stock Purchase Agreement by Takeda’s joint venture partner in Techpool: Shanghai Pharmaceutical Holding Co. Ltd. and a fund managed by SFund International Investment Fund Management Limited, a wholly-owned subsidiary of Guangzhou Industrial Investment Fund Management Co., Ltd. | Shanghai Pharmaceutical, Sunrise Bright Investment Ltd. | Purchase Agreement | China |
09-May-18 | CStone Pharmaceuticals | $260 | CStone has built a portfolio of more than ten assets, including four in various clinical stages. In particular, CS1001, China’s first full-length and fully human anti-PD-L1 monoclonal antibody, is completing Phase I dose escalation study and will soon enter registrational trials. | GIC Private Limited | Series B Financing | China |
24-May-18 | Brii Biosciences | $260 | Exclusive agreement with Vir Biotechnology, Inc. grants greater China rights for up to four infectious disease assets, Partnership with Alibaba Group's AliHealth to better identify and educate patients, and better connect them to clinics, healthcare resources, and medicines. | ARCH Venture Partners | Launch & Partnerships | China |
14-May-18 | Medigene AG | $259 | Under the revised terms of the agreement, the number of target antigen/MHC restriction combinations for the discovery of specific TCR lead candidates by Medigene will be increased from four to six. As part of this contractual expansion, Medigene will receive an additional one-time payment of USD 8 million. | bluebird bio, Inc. | Partnership | Germany |
23-May-18 | Epigen Biosciences | $200 | EPGN696 is an orally available, selective LPA1 receptor antagonist under development in diabetic and chronic kidney disease and other chronic diseases associated with metabolic syndrome. | Novo Nordisk | Licensing Agreement | United States |
24-May-18 | Karyopharm Therapeutics Inc | $162 | The agreement includes the development and commercialization of selinexor and eltanexor for the diagnosis, treatment and/or prevention of all human oncology indications in China and Macau. The agreement also includes the development and commercialization of KPT-9274 in all human oncology indications and verdinexor in human non-oncology indications in mainland China, Macau, Taiwan, Hong Kong, South Korea, and the ASEAN countries. | Antengene Corporation | Licensing Agreement | United States |
09-May-18 | Aquinox Pharmaceuticals, Inc. | $155 | Astellas to Obtain Development and Commercialization Rights to Rosiptor, Aquinox’s Lead Drug Candidate, in Japan and Certain Other Countries in the Asia-Pacific Region | Astellas Pharma | Licensing Agreement | Canada |
29-May-18 | Kiniksa Pharmaceuticals, Ltd. | $153 | Kiniksa, a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic medicines for debilitating diseases, has a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. | Goldman Sachs | IPO | Bermuda |
01-May-18 | Janssen Pharmaceuticals | $135 | PANCREAZE is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes, including porcine-derived lipases, proteases and amylases. The pancreatic enzymes in PANCREAZE act like digestive enzymes physiologically secreted by the pancreas. PANCREAZE is specifically indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. Upon closing, VIVUS will acquire PANCREAZ | VIVUS, Inc. | Asset Acquisition | United States |
03-May-18 | Moderna Therapeutics | $125 | Expansion Includes the Joint Development of Moderna’s KRAS Oncogene Program and Other Potential mRNA Cancer Vaccines; Merck to Make Equity Investment in Moderna | Merck & Co. | Expansion | United States |
10-May-18 | La Jolla Pharmaceuticals | $125 | La Jolla will receive $125 million in exchange for tiered royalty payments on worldwide net sales of GIAPREZA. The agreement was entered into by La Jolla’s wholly owned subsidiary, La Jolla Pharma, LLC, and HCR has no recourse under the agreement against La Jolla or any assets other than GIAPREZA. “This transaction provides us with a strong financial position to support the commercial launch of GIAPREZA, while at the same time furthering the development of LJPC-401 and our other programs,” said | HealthCare Royalty Partners | Financing | United States |
07-May-18 | Gemini Laboratories, LLC | $117 | Amneal Acquires Gemini Laboratories, LLC and Enters Into Biosimilar Partnership with mAbxience S.L. | Amneal Pharmaceuticals | Acquisition | United States |
03-May-18 | Myonexus Therapeutics | $105 | The most advanced of Myonexus’ programs, MYO-101, aims to treat LGMD2E, also known as beta-sarcoglycanopathy, a severe and debilitating form of LGMD characterized by progressive muscle fiber loss, inflammation and muscle fiber replacement with fat and fibrotic tissue. MYO-101 is designed to transfect a gene that codes for and restores beta-sarcoglycan protein with the goal of restoring the dystroglycan complex. | Sarepta Therapeutics | Partnership | United States |
24-May-18 | Portola Pharmaceuticals | $100 | Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company has received a $100 million milestone payment from HealthCare Royalty Partners (HCR) following the U.S. Food and Drug Administration (FDA) approval of Andexxa [coagulation Factor Xa (recombinant), inactivated-zhzo] on May 3, 2018. | HealthCare Royalty Partners | Milestone Payment | United States |
22-May-18 | Best Choice Inc. | $90 | Nutriband Inc. is pleased to announce that it has signed an exclusive 20-year, $90 million distribution agreement for its transdermal consumer product lines with Best Choice Inc., a Korean consumer products distributor with a 20-year history of working with major chain retailers, including Costco and Lotte Department Stores. | Nutriband Inc. | Distribution Agreement | South Korea |
15-May-18 | Beam Therapeutics | $87 | Beam aims to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. | F-Prime Capital Partners | Series A Financing | United States |
07-May-18 | Unity Biotechnology | $85 | Aggregate gross proceeds to the Company were approximately $85.0 million, before underwriting discounts, commissions and estimated offering expenses. All of the shares in the offering were offered by UNITY. UNITY’s common stock is listed on The Nasdaq Global Select Market under the ticker symbol “UBX.” | Goldman Sachs | IPO | United States |
14-May-18 | Ansun BioPharma, Inc. | $85 | Ansun plans to use the proceeds from the Series A to fund a Phase 3 clinical trial of its experimental anti-viral medication, DAS181. The FDA has granted both Fast Track status and Breakthrough therapy designation to DAS181, and Ansun is currently in the planning stage of a Phase 3 trial to treat hospitalized, immunocompromised subjects infected with parainfluenza virus. | Sinopharm Healthcare Fund | Series A Financing | United States |
08-May-18 | Evelo Biosciences, Inc. | $85 | Evelo has granted the underwriters a 30-day option to purchase up to an additional 796,875 shares of common stock at the initial public offering price, less the underwriting discounts and commissions, to cover over-allotments, if any. | Undisclosed | IPO | United States |
24-May-18 | Iterum Therapeutics PLC | $80 | Iterum Therapeutics plc (NASDAQ:ITRM), a clinical-stage pharmaceutical company developing anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens, today announced the pricing of its initial public offering of 6,150,000 ordinary shares at a price to the public of $13.00 per share, for total gross proceeds of approximately $80 million. | Leerink Partners | IPO | Ireland |
31-May-18 | Cortexyme, Inc | $76 | Cortexyme announced the successful completion of a placebo-controlled single ascending dose trial and a multiple ascending dose trial in healthy older volunteers of COR388, the company’s lead small molecule. COR388 is a first-in-class, orally administered bacterial protease inhibitor that targets a specific pathogen discovered in the brains of patients with Alzheimer’s | Takeda Pharmaceutical Company | Series B Financing | United States |
14-May-18 | MEI Pharma, Inc. | $75 | Proceeds from the financing will be used to fund continued clinical development of MEI-401, a selective oral inhibitor of phosphatidylinositol 3-kinase ("PI3K") delta that is expected to enter a single-agent registration study in 2018 for the treatment of adults with relapsed or refractory follicular lymphoma, and for general corporate purposes. | Vivo Capital | Private Placement | United States |
23-May-18 | Scholar Rock Holding | $75 | Scholar Rock Holding, a biotech targeting growth factor inhibition for spinal muscular atrophy, raised $75 million by offering 5.36 million shares at $14, within the range of $13 to $15. At that price, it commands a fully-diluted market value of $350 million. | Cowen and Company | IPO | United States |
16-May-18 | FogPharma | $66 | Proceeds from the Series B raise will enable the company to advance its first-in-class beta-catenin inhibitor (iCat) program into Phase 2 development for cancer indications involving Wnt pathway activation. The financing will also be used to advance clinical development of its first-in-class Cbl-b inhibitor program and a third as-yet-undisclosed program through IND-enabling studies, and FogPharma's drug discovery platform for three additional, distinct and differentiated forms of cell-penetrati | 6 Dimensions Capital | Series B Financing | United States |
15-May-18 | Celsius Therapeutics | $65 | Celsius’ fundamentally new approach aims to combine the power of single-cell genomic sequencing with computational algorithms to discover first-in-class precision therapies for which the company applies a systematic approach, starting with single-cell sequencing on defined patient samples to identify and understand the individual cells and their interactions that cause disease. | Third Rock Ventures | Series A Financing | United States |
22-May-18 | Sublimity Therapeutics Limited | $64 | The proceeds from the financing will support the clinical development of STI-0529. Sublimity intends to initiate a global Phase 2b dose-ranging study designed to evaluate the safety and efficacy of STI-0529 in patients with moderate to severe ulcerative colitis. | OrbiMed | Financing | Ireland |
03-May-18 | Casma Therapeutics | $59 | Casma is pioneering novel strategies to boost autophagy to arrest or reverse the progression of rare genetic diseases and broader pathologies, including neurodegeneration | Third Rock Ventures | Series A Financing | United States |
09-May-18 | Akili Interactive | $55 | The financing follows the positive top-line results in December 2017 from Akili’s multicenter, randomized, controlled pivotal study of AKL-T01, the Company’s flagship investigational product designed to treat pediatric attention deficit/hyperactivity disorder (ADHD). Akili is planning to file AKL-T01 for clearance by the U.S. Food and Drug Administration (FDA) in the coming months, which would enable it to be prescribed by physicians as a stand-alone treatment for children and adolescents with A | Temasek | Financing | United States |
01-May-18 | Neurimmune | $50 | Biogen will make a one-time $50 million payment to Neurimmune in exchange for a 5% reduction in the original royalty rates on potential commercial sales of aducanumab, which follows the 15% reduction in royalty rates announced in October 2017. | Biogen | Option Agreement | Switzerland |
09-May-18 | BioClin Therapeutics, Inc | $50 | The proceeds from this financing will be used to advance the company’s lead development candidate, B-701, for the treatment of patients with metastatic bladderncancer, or metastatic urothelial carcinoma (mUC). | Sofinnova Partners | Series B Financing | United States |
21-May-18 | Cidara Therapeutics, Inc. | $50 | The company is currently advancing its novel echinocandin antifungal, rezafungin acetate, formerly known as CD101 IV, through late stage clinical trials, and developing its antibody-drug conjugates for the treatment of multi-drug resistant Gram-negative bacterial infections. Cidara is developing its antibody-drug conjugates as part of its novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a | Biotechnology Value Fund | IPO | United States |
21-May-18 | Ardelyx, Inc. | $50 | Ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. Ardelyx's renal pipeline includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and RDX013, a potassium secretagogue program for the potential treatment of hyperkalemia. | Solar Capital Ltd. | Loan Agreement | United States |
15-May-18 | Nohla Therapeutics | $45 | Nohla intends to use the proceeds to complete the ongoing Phase 2 trials of its lead candidate, dilanubicel (NLA101), in allogeneic transplant and chemotherapy-induced myelosuppression, as well as support Phase 3 trial and commercial manufacturing needs. Proceeds will also be used to advance the company’s novel cell-based therapy platform and pipeline. | Celgene Corporation | Series B Financing | United States |
04-May-18 | Aslan Pharma | $42 | ASLAN expects to use the net proceeds from the offering to continue to invest in the clinical development of its product candidates, including for the following planned and ongoing clinical trials: global pivotal clinical trial for varlitinib in biliary tract cancer; China pivotal clinical trial for varlitinib in biliary tract cancer; global phase 2/3 clinical trial for varlitinib in gastric cancer; global clinical trials for ASLAN003 in AML; and ASLAN004 preclinical and phase 1 clinical trials. | Leerink Partners | IPO | Singapore |
09-May-18 | Escient Pharmaceuticals | $40 | Strategic focus on unleashing therapeutic potential of specific orphan GPCRs, including novel family of Mas-Related G-Protein Receptors (Mrgprs) | The Column Group | Series A Financing | United States |
18-May-18 | Accent Therapeutics | $40 | The company is using small molecule drugs that inhibit the enzymes that perform modifications on RNA. Accent Therapeutics was established to create innovative therapeutics in the rapidly advancing area of epitranscriptomics – the role of RNA structure, stability, function and translation in cell biology. Recent studies have linked certain human cancers to the activity of particular RMPs, providing a rich new target space for drug development. | The Column Group | Series A Financing | United States |
28-May-18 | HitGen | $39 | HitGen is a platform company based on its leading DNA-encoded library (DELs) technology for innovative drug discovery research. Its continuously expanding DELs consist of over 900 individual libraries with over 200 Bn novel small molecules, and is among the largest and most diverse screening libraries in the world. | CDH Investments | Series B Financing | China |
17-May-18 | HiFiBiO Therapeutics | $38 | HiFiBiO Therapeutics works on generating breakthrough immune modulators to address unmet medical needs around the world. The company continues to establish multiple strategic partnerships with leading pharmaceutical and biotechnology companies to drive an innovative pipeline of antibody drugs that leverage its proprietary single-B-cell functional antibody discovery CelliGOTM platform. | Sequoia China | Series B Financing | United States |
24-May-18 | Eiger Biopharmaceuticals Inc. | $37 | Eiger plans to use the net proceeds from the offering to fund its planned Phase 3 clinical trial of lonafarnib in Hepatitis Delta Virus infection, regulatory development of lonafarnib related to the treatment of Hutchison-Gilford Progeria Syndrome, and for working capital and other general corporate purposes. | Piper Jaffray & Co. | IPO | United States |
24-May-18 | Medigene AG | $37 | Medigene intends to use the net proceeds of this placement to expand the Company's ongoing clinical program with its T-cell receptor modified T cells (TCR-T) and to progress its pipeline of potential TCR-T candidates for future clinical development. | QVT Financial LP | Private Placement | Germany |
31-May-18 | CAMP4 Therapeutics, Inc. | $30 | CAMP4 is focusing its efforts to scale its proprietary 4-D Gene Circuity Platform across all human cell types relevant to disease. “The machinery that controls activation of the 24,000 genes in the human body can be codified by CAMP4’s platform into a discrete set of combinatorial rules using signaling pathways." | Andreessen Horowitz | Series A Financing | United States |
15-May-18 | Xenikos B.V. | $30 | Xenikos B.V. is a clinical-stage biopharmaceutical company which is currently focused on developing a novel therapy for treating acute graft-versus-host disease (aGVHD). Xenikos's lead product candidate, T-Guard, will be undergoing clinical Phase 3 registration trials in the US and EU, post this funding round. | Medicxi Ventures | Series B Financing | The Netherlands |
10-May-18 | The Ensign Group, Inc. | $29 | The Ensign Group, Inc.’s independent operating subsidiaries provide a broad spectrum of skilled nursing and assisted living services, physical, occupational and speech therapies, home health and hospice services and other rehabilitative and healthcare services at 234 healthcare facilities, 22 hospice agencies, 20 home health agencies and four home care businesses in California, Arizona, Texas, Washington, Utah, Idaho, Colorado, Nevada, Iowa, Nebraska, Oregon, Wisconsin, Kansas, South Carolina, a | National Health Investors, Inc. | Purchase Agreement | United States |
09-May-18 | NeuroproteXeon, Inc. | $28 | The agreement includes a multi-tiered royalty and 23 million euros in milestone payments. The two key milestone payments are on approval for PCAS from the European Medicines Agency ("EMA") and when Linde reaches cumulative sales of 100 million euros – provided this occurs in the first four years following approval. | Linde AG | Distribution Agreement | United Kingdom |
15-May-18 | CellCentric, Inc. | $26 | CellCentric has raised $26 million in private financing to fund clinical testing of its first-in-class oncology drug candidate CCS1477. The funds will be used to test the novel p300/CBP inhibitor in late stage, treatment-resistant prostate cancer (up to Phase IIb). | Morningside Venture Investments | Private Placement | United Kingdom |
02-May-18 | Refuge Biotech | $25 | The funds from the Series B will support advancement of cell therapies developed with Refuge's receptor-dCas platform, which utilizes a mutated or dead Cas9 (dCas) as a targeting mechanism to enable precision CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi). | 3SBio | Series B Financing | United States |
02-May-18 | Avedro, Inc. | $25 | “This new funding brings together an exceptional syndicate of investors who are committed to helping us achieve this goal. It will allow us to accelerate adoption of the only FDA-approved cross-linking treatment and the development of our next-generation corneal remodeling applications.” | Eli Lilly and Company | Financing | United States |
01-May-18 | Undisclosed | $24 | These are the largest awards specifically designed for brain tumour research in the UK, which encourage multidisciplinary approaches from scientists. The aim is to accelerate research in a bold and innovative way that would not be possible through traditional funding schemes. | Cancer Research UK, The Brain Tumour Charity | Grants & Awards | |
16-May-18 | EIP Pharma Inc. | $21 | Proceeds from the financing will be used to further advance development of neflamapimod, an oral small molecule inhibitor of the intra-cellular enzyme p38 MAP kinase alpha (p38 alpha) being studied in Alzheimer's disease. In times of stress and disease p38 alpha is expressed in neurons, and irregular p38 alpha activity within the neuron can contribute to synaptic dysfunction. | Access Industries | Series B Financing | United States |
30-May-18 | Propeller Health | $20 | Proceeds from the financing will support Propeller’s investment in its pipeline of digital therapeutics and additional connected devices for the treatment of chronic respiratory disease, an area of continued market growth for the company. Propeller will also begin to develop digital medicines for new therapeutic areas. | Aptar Pharma | Financing | United States |
15-May-18 | Surface Pharmaceuticals, Inc. | $20 | Surface Pharmaceuticals intends to use the proceeds of the Series A financing to advance its clinical development programs focused on ocular surface disease, including Dry Eye Disease treatments, by seeking FDA approval for three drug candidates. | Flying L Partners | Series A Financing | United States |
27-May-18 | Lion TCR | $20 | The proceeds from this fundraising will be primarily used to advance its on-going clinical trials of its lead candidate LioCyx™ (personalized HBV specific TCR T cell therapy against HCC) in major hospitals in China and Singapore, as well as for broadening its products pipeline to fight viral-related solid tumours and clearance of chronic hepatitis B. | Yashang Capital, Westlake Ventures Capital | Series A Financing | Singapore |
23-May-18 | Lava Therapeutics, Inc. | $19 | The funding will support development of LAVA’s proprietary pipeline of bispecific gamma-delta (??) T cell engagers for the treatment of cancer. ?? T cells are a potent class of proinflammatory immune effector cells and one of two main categories of T lymphocytes effective to treat both solid and hematological malignancies. | Gilde Healthcare | Financing | The Netherlands |
01-May-18 | Karyopharm Therapeutics Inc | $19 | Karyopharm intends to use the net proceeds of the offering: to support continued clinical development of selinexor in hematologic malignancies and solid tumors as a single agent and in combination with approved and experimental therapies; to conduct activities to support regulatory submissions for oral selinexor as a new treatment for patients with penta-refractory multiple myeloma | Canaccord Genuity | IPO | United States |
21-May-18 | Rain Therapeutics, Inc. | $18 | Rain plans to use the proceeds to advance the clinical development of its lead program, Tarloxotinib (Tarlox), in patients with EGFR and ErbB Exon 20 insertion mutations in non-small cell lung cancer (NSCLC). The company intends to commence a Phase 2 study in patients with EGFR and ErbB Exon 20 insertion mutations in NSCLC in the first half of 2019. | Biotechnology Value Fund | Series A Financing | United States |
23-May-18 | Kronos Bio, Inc. | $18 | Kronos is researching and developing first-in-class therapies against historically intractable targets through high-throughput screening strategies for chemical modulators of transcription factors and other recalcitrant targets in oncology. Kronos is currently advancing two preclinical programs built upon hits identified from the SMM platform, targeting MYC and the Androgen Receptor (AR). | Gilead Sciences | Seed Financing | United States |
14-May-18 | Oncobiologics, Inc. | $15 | Oncobiologics intends to use the net proceeds from the private placement primarily for the initiation of clinical trials for ONS-5010, an innovative monoclonal antibody (mAb) product candidate under development, the expansion of the BioSymphony™ Platform for providing contract development and manufacturing services (CDMO), and for working capital and general corporate purposes. | GMS Tenshi Holdings Pte. | Private Placement | United States |
02-May-18 | NOXXON Pharma AG | $13 | These funds will be used for the clinical development of NOX-A12 in advanced solid tumors, as the company proceeds to conduct the NOX-A12 clinical trial in collaboration with Merck & Co. Inc./MSD in patients with metastatic colorectal and pancreatic cancer who generally do not respond to checkpoint inhibitors alone. | Kreos Capital | Clinical Collaboration | Germany |
02-May-18 | SeneFill Facility | $12 | Novasep, a leading supplier of services and technologies for the life sciences industry, announces a €10M investment in a commercial fill & finish facility for viral vectors, mAbs and other low-volume biologics. The facility will be located in Seneffe (Belgium) and will be operational in H2 2019. This project is part of Novasep’s Rise-2 strategic growth cycle. It complements a €27M investment in a new commercial scale viral vector production facility in Seneffe (Belgium) that will be fully quali | Novasep Inc. | Manufacturing Investment | France |
30-May-18 | AbSci, Inc. | $12 | The financing will enable AbSci to expand its R&D and to scale up capacity in order to meet the growing demand from its large pharma and biosimilar partners. AbSci's breakthrough protein expression platform, SoluPro™, has demonstrated the ability to accelerate biopharmaceutical discovery and development timelines as well as dramatically reduce biopharmaceutical manufacturing costs. | Phoenix Venture Partners | Series C Financing | Canada |
14-May-18 | Acousia Therapeutics | $12 | The company’s most advanced drug candidate ACOU085 is being developed for clinical application in otoprotection (cisplatin-related) and will be profiled in functional improvement of hair cells. | LBBW Venture Capital | Series B Financing | Germany |
17-May-18 | OncoNano Medicine, Inc. | $12 | OncoNano is using pH variability, a simple and robust biomarker, to detect and treat diseased tissue. By targeting pH, a clear delineation between diseased and healthy tissue can be digitalized to develop a broad range of targeted applications. | Salem Partners | Series A Financing | United States |
01-May-18 | Icagen | $11 | The CF Foundation brings extensive resources and expertise to the project and, additionally, has awarded Icagen up to USD $11 million to support an integrated, multi-year drug discovery initiative. Icagen expects to screen over 2 million compounds as well as leverage its state-of-the-art in silico drug discovery platform to interrogate an additional ten million virtual structures for molecules that suppress nonsense mutations. | Cystic Fibrosis Foundation | Grants & Awards | United States |
11-May-18 | Vesper Medical, Inc. | $11 | Vesper Medical plans to use the proceeds from this financing to complete the development of its Vesper Duo Venous Stent System™ inclusive of the in vivo testing necessary to obtain the approvals required for clinical testing of the Vesper Duo™ stents. | New Enterprise Associates | Series A Financing | United States |
29-May-18 | Mesoblast Limited, Cartherics Pty Ltd. | $10 | Mesoblast will make an in-kind contribution of its allogeneic cell platform technology as well as providing scientific expertise. Mesoblast is a global leader in allogeneic cellular medicines with three Phase 3 trials in advanced heart failure, chronic lower back pain and acute graft versus host disease. | Australian Government | Collaboration | Australia |
03-May-18 | Starpharma | $9 | Mundipharma will register and launch VivaGel® BV as part of the popular BETADINE® range, which is sold in more than 120 countries. BETADINE® has a market leading position in Feminine Care and this licence enables Mundipharma to develop the consumer market for VivaGel® BV in rapidly developing markets across Asia, the Middle East, Africa and Latin America, where demand for trusted intimate health and hygiene products is growing. | Mundipharma | Licensing Agreement | Australia |
01-May-18 | Indiana University's Richard M. Fairbanks School of Public Health | $7 | Lilly and Indiana University’s Fairbanks School of Public Health at IUPUI are implementing the pilot with Eskenazi Health, Local Initiatives Support Corporation Indianapolis (LISC) and the Marion County Public Health Department. Borrowing from Lilly’s global health efforts, the pilot will deploy a model that uses newly hired community health care workers to help identify people with diabetes and connect them with quality care. | Eli Lilly and Company | Partnership | United States |
02-May-18 | OnKure, Inc. | $7 | OnKure's platform transforms naturally occurring, biologically active lead compounds into commercial drugs that address a variety of diseases with an emphasis on oncology. At the heart of OnKure's solution to Class 1 histone deacetylase inhibition is a molecule (OKI-179) that parallels the potency and selectivity of Romidepsin (Istodax), the most potent Class 1 biased histone deacetylase inhibitor currently approved by the FDA. | Delian Capital | Series A Financing | United States |
11-May-18 | CytRx Corp. | $7 | CytRx is rapidly expanding its pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies. Aldoxorubicin, CytRx's most advanced drug conjugate, is an improved version of the widely used anti-cancer drug | H.C. Wainwright & Co. | IPO | United States |
08-May-18 | NeuCyte Inc. | $7 | NeuCyte intends to use the proceeds of the Series A financing to further develop their SynFire® in vitro CNS drug discovery platform for the identification of novel drug targets for Fragile X Syndrome (FXS) and other genetically defined neurological disorders. NeuCyte is also seeking strategic partnerships to rapidly advance their programs to a clinical stage. | Cowin Venture | Series A Financing | United States |
30-May-18 | Harvard University | $7 | The LabXchange platform, which will launch with a focus in biology, will offer digital instruction and virtual lab experiences to high school and college students, enabling them to gain meaningful exposure to the scientific process. It will also include online networking focused on collaboration and mentoring. | Amgen | Grants & Awards | United States |
07-May-18 | Melinta Therapeutics | $6 | Melinta’s novel pyrrolocytosine compounds are a novel class of antibiotics from the company’s ESKAPE pathogen Program, a program based on Melinta’s proprietary drug discovery platform focused on developing breakthrough antibiotics for bacterial “superbugs” by targeting the bacterial ribosome. | Combating Antibiotic Resistant Bacteria Accelerator (CARB-X) | Partnership | United States |
02-May-18 | Casetabs | $6 | Launched in 2016, Casetabs’ award-winning surgery coordination application is changing how surgeries are coordinated by ensuring everyone involved in a case is continuously and instantly on the same page. In just two years, Casetabs has grown exponentially from five centers to 100 centers and 500 physician practices, almost entirely through referrals. | Nueterra Capital | Series A Financing | United States |
21-May-18 | Karo Pharma | $6 | In December 2011, Karo Pharma entered a research collaboration and licensing agreement with the American company Pfizer. The aim of this agreement is to discover and develop compounds that inhibit the activity of the nuclear hormone receptor RORgamma, for treatment of autoimmune diseases. The development is lead by Pfizer according to the terms of the agreement. Pfizer has global exclusive rights to use, dev | Pfizer Inc. | Milestone Payment | Sweden |
15-May-18 | Genoox | $6 | In the past year, Genoox has rapidly grown its customer base and initiated partnerships with medical centers and research facilities, including the Center for Genetic Medicine Research at Children's National Medical Center and the University of Michigan | Triventures | Financing | United States |
21-May-18 | Cidara Therapeutics, Inc. | $6 | The grant will fund the continued research and development of Cidara’s innovative Cloudbreak™ antibody-drug conjugate (ADC) platform to identify novel immunotherapy agents for the treatment and prevention of serious and life-threatening multi-drug resistant (MDR) Gram-negative bacterial infections in high-risk patient populations. | National Institute of Allergy and Infectious Diseases (NIAID) | Grants & Awards | United States |
15-May-18 | Marker Therapeutics | $5 | The proposed transaction will be a merger-of-equals under which the stockholders of TapImmune and Marker will each own approximately 50% of the combined company, prior to any issuances of additional shares in a contemplated financing. | TapImmune | Merger Agreement | United States |
14-May-18 | West Virginia University (WVU) | $5 | Collaboration aims to demystify STEM and broaden its perceived application. Program will leverage 4-H infrastructure and WVU STEM outreach, reaching every county in West Virginia. Mylan commits a $5 million charitable contribution over 10 years to empower West Virginia children to be Curious, Active, Resilient and Engaged (CARE). | Mylan N.V. | Collaboration | United States |
29-May-18 | Mobidiag Ltd. | $5 | By combining in-house expertise and unique patented technologies, Mobidiag has now the means to develop a revolutionary assay to detect sepsis causing microbes and antibiotic resistances directly from blood. | Business Finland | Financing | Finland |
30-May-18 | Novacyt (Primerdesign) | $5 | Novacyt, a global specialist in clinical diagnostics, announces that it has obtained on 29 May 2018 a new unsecured loan facility of 4.0 million euros from a French institutional investor | Undisclosed | Private Placement | France |
31-May-18 | SiSaf | $4 | The Company specializes in drug delivery technologies, and SiSaf’s ProSilic® bio-courier technology is a novel method of drug delivery that is based on a patented hybrid of porous silicon and liposomes. ProSilic® can take the most challenging molecules to their target and optimises their efficacy and safety | Vickers Venture Partners | Financing | United Kingdom |
18-May-18 | Exxel Pharma | $4 | Exxel Pharma is working to advance two in-licensed therapeutics that boost natural endocannabinoid signalling by FAAH inhibition. | Datinvest International | Acquisition | Canada |
16-May-18 | Flash Therapeutics | $4 | Flash Therapeutics is a new company developing proprietary RNA-based therapeutics and providing broad lentiviral development, manufacturing expertise and support. | Vectalys, FlashCell, AURIGA IV Bioseed | Merger Agreement | France |
08-May-18 | IntelGenx Technologies | $3 | IntelGenx Technologies Corp. announces the closing of the previously announced offering by way of private placement. In connection with the Offering, the Company issued 320 units at a subscription price of U.S.$10,000 per Unit for gross proceeds of U.S.$3,200,000. The Corporation intends to use the proceeds for its Montelukast phase 2a clinical trial and for general working capital purposes. | Cantone Research, Inc. | Private Placement | Canada |
14-May-18 | Polyneuron Pharmaceuticals | $3 | The proceeds will be used to advance its lead asset, PN-1007, to clinical development for the treatment of the rare nervous system disease, anti-MAG neuropathy, and advance additional applications of its Antibody-Catch™ technology platform. This technology enables the chemical design of injectable, biodegradable glycopolymers to eliminate autoimmune disease-causing autoantibodies, while leaving the immune system intact. | Zürcher Kantonalbank | Seed Financing | Switzerland |
01-May-18 | Arena Pharmaceuticals, Inc. | $3 | Arena's non-core, proprietary, preclinical compound provides strategic fit with Outpost Medicine's expertise in developing products for genitourinary disorders | Outpost Medicine | Licensing Agreement | United States |
19-Apr-18 | Oasmia Pharmaceutical | $3 | Oasmia Pharmaceutical AB (publ) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 26,000,000 with an interest rate of 8 per cent per year directed to and placed with a limited group of investors and paid in cash (the “Private Placement”). The convertible instrument issue is expected to provide the Company with SEK 26,000,000 before transaction related costs. | Undisclosed | Private Placement | Sweden |
17-May-18 | Indee Labs | $3 | Indee Labs received US$2.6M in venture financing extending its seed-stage funding to more than US$5.4M (AU$7.1M). This will accelerate the development of Indee Labs’ gene therapy manufacturing technology into a product that biotechnology companies can use for discovery-stage research. | Founders Fund’s Science, Main Sequence Ventures | Seed Financing | United States |
08-May-18 | Nanoco Group plc | $2 | The total value of milestones in this programme triggered to date is £2.6 million. The Partner is funding the capital expenditure required to expand the manufacturing capabilities of Nanoco's existing Runcorn facility in order to supply the Partner with commercial volumes of product. This process is already underway, with an agreement reached in March to take over 10,000 sq. ft. of additional space in Runcorn to build a state-of-the-art production facility in order to commence commercial supply | Undisclosed US-listed partner | Milestone Payment | United Kingdom |
22-May-18 | Canopy Biosciences | $2 | Canopy Biosciences is a fast-growing research tools company focusing on gene editing and expression analysis. The company seeks out advanced technologies for commercialization of high-tech products and services in the research tools space. Research tools have minimal development time and no regulatory risk. | BioGenerator, Kingdom Capital | Series A Financing | United States |
07-May-18 | Melinta Therapeutics | $2 | Melinta’s novel pyrrolocytosine compounds are a novel class of antibiotics from the company’s ESKAPE pathogen Program, a program based on Melinta’s proprietary drug discovery platform focused on developing breakthrough antibiotics for bacterial “superbugs” by targeting the bacterial ribosome. | Combating Antibiotic Resistant Bacteria Accelerator (CARB-X) | Partnership | United States |
09-May-18 | MannKind Corporation | $2 | Under the terms of the agreement, Cipla will be responsible for obtaining regulatory approvals to distribute Afrezza® in India, including approval from the Drug Controller General of India. Cipla will also be responsible for all marketing and sales activities of Afrezza in India. MannKind is responsible for supplying Afrezza to Cipla. | Cipla | Marketing Agreement | India |
21-May-18 | Scioto Biosciences | $2 | Scioto Biosciences offers a noteworthy solution with its microbiome platform to combat a serious condition impacting premature infants. Scioto Biosciences is a preclinical stage company developing innovative therapies devoted to having a transformative impact on the delivery of microbiome therapeutics. The Scioto Platform has the potential to enhance efficacy wherever probiotics are used such as diabetes, neurological disorders, gastrointestinal health, alternatives to in-feed antibiotics (in li | BioCrossroads | Series A Financing | United States |
14-May-18 | Bioasis Technologies, Inc. | $2 | The Company will use the net proceeds from the private placement to support ongoing research and development, clinical development, manufacturing and other activities in respect of the Company’s clinical development pipeline and for working capital and general corporate purposes. | Roth Capital Partners | Private Placement | Canada |
07-May-18 | CrystalGenomics | $2 | CG-806 is being developed as a highly potent, oral small molecule for acute myeloid leukemia (AML), B-Cell malignancies and other hematologic malignancies. | Aptose Biosciences Inc. | Option Agreement | South Korea |
30-May-18 | OptiBiotix Health | $2 | OptiBiotix Health plc is developing advances that use the human microbiome to tackle obesity, high cholesterol and diabetes. The proceeds from the financing will be used to develop cholesterol and blood pressure reducing strain LPLDL®. | Undisclosed | IPO | United Kingdom |
30-May-18 | Frequency Therapeutics | $2 | Research Award will support translational preclinical and early-stage clinical research to address hearing dysfunction resulting from military service-related injuries | U.S. Department of Defense | Grants & Awards | United States |
08-May-18 | The Cambridge Partnership Ltd | $2 | RxCelerate, one of the leading out-sourced drug discovery and development platforms in the United Kingdom, announced today it has hired Nick Tait as group Chief Financial Officer and also completed the acquisition of the biotech-specialised accounting and back-office services company, The Cambridge Partnership Ltd. | RxCelerate | Acquisition | United Kingdom |
21-May-18 | Association of Community Cancer Centers (ACCC) | $2 | The RFP seeks individual grant requests up to a maximum of $150,000. In total, Pfizer will provide $1.5 million in funding for these quality improvement grants. | Pfizer Inc. | Grants & Awards | United States |
22-May-18 | Envisagenics, Inc. | $2 | This grant will provide $1.5 million over two years for Envisagenics’ continued development of SpliceCore, a cloud-based drug discovery platform that analyzes RNA sequencing (RNA-seq) data to accelerate RNA therapeutics discovery using innovative machine learning and artificial intelligence to identify new biomarkers and drug targets. | National Institutes of Health (NIH) | Grants & Awards | United States |
16-May-18 | GeneNews Ltd | $1 | GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. In lieu of making a cash payment by the Company, certain arm's length providers will accept Units for an aggregate of Cdn$380,831, and a director, who is also a shareholder, will participate for Cdn$561,770 in lieu of repayment in cash. | Undisclosed | Private Placement | Canada |
14-May-18 | Emergex Vaccines Holding Limited | $1 | This grant will cover 70% of the cost of developing Emergex’s flu vaccine programme over a period of two years. It will be used to complete preclinical toxicology and validation studies and the manufacturing of the vaccine in accordance with current Good Manufacturing Practice (cGMP). This will result in clinical batches of the vaccine which are ready for Phase I clinical testing in the first half of 2020. | Innovate UK | Grants & Awards | United Kingdom |
07-May-18 | Aspect Biosystems | $1 | Aspect’s Lab-on-a-Printer™ 3D bioprinting platform technology enables the rapid creation of functional living tissues. The therapeutic applications are broad and profound and have attracted the attention of global pharmaceutical and biotechnology companies. | Genome BC | Financing | Canada |
30-May-18 | IONTAS Limited | $1 | This Grant Funding will be used to further develop IONTAS’ ion-channel targeting KnotBody antibody platform to block pain transmission via Nav1.7. IONTAS has developed a Nav1.7-targeted KnotBody to block pain transmission. | Innovate UK | Grants & Awards | United Kingdom |
24-May-18 | GeoVax Labs, Inc. | $1 | The grant, entitled “Advanced Preclinical Testing of a Novel Recombinant Vaccine Against Zika Virus”, supports advanced preclinical testing of GeoVax’s vaccine candidate (designated GEO-ZM02) in non-human primates in preparation for human clinical trials. GEO-ZM02 is a novel vaccine approach to protect against Zika virus (ZIKV), using GeoVax’s Modified Vaccinia Ankara (MVA) vector to express the ZIKV non-structural protein 1 (NS1). | National Institute of Allergy and Infectious Diseases (NIAID) | Grants & Awards | United States |
07-May-18 | Recursion Pharmaceuticals | $1 | The grant, awarded by the Bill & Melinda Gates Foundation, represents a collaborative effort between Recursion and the Winzeler Lab at UC San Diego School of Medicine to accelerate the discovery of drugs to treat malaria, and sets the stage for Recursion to further broaden its drug discovery platform into infectious disease. | Bill & Melinda Gates Foundation | Grants & Awards | United States |
01-May-18 | CF Patients | $0.40 | The Vertex All in for CF Scholarship program was established in 2017 to help people living with cystic fibrosis (CF) and their immediate family members pursue two-year, four-year or graduate degrees. Part of Vertex’s 10-year, $500 million corporate giving commitment, this year the company doubled the number of recipients to 80 to help more people in the CF community. | Vertex Pharmaceuticals | Financing | United States |
18-May-18 | EpiVax, Inc. | $0.33 | The funding will enable EpiVax to further develop the new Personalized Immunogenicity Assessment (PIMA) tool, for the individualized risk assessment of enzyme replacement therapy for Pompe Disease patients. | National Institutes of Health (NIH) | Grants & Awards | United States |
01-May-18 | Takeda Pharmaceutical Company Limited | $0 | Thermo Fisher will retain global commercialization rights for the test and will lead all filings of supplemental premarket approvals (sPMA) in order to seek approval from the U.S. Food and Drug Administration (FDA). Expansion of Oncomine Dx Target Test aligns with the company's strategic plan to further develop its test as a companion diagnostic (CDx) for multiple therapies. | Thermo Fisher Scientific | Commercialization Agreement | Japan |
01-May-18 | Wyss Institute at Harvard University | $0 | Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that they will collaborate to further advance the Wyss Institute’s efforts to recode the entire genome of cell lines derived from humans and other species, and to develop new tools and methods facilitating this goal. | Cellectis | Partnership | United States |
01-May-18 | Vascugen Inc. | $0 | Vascugen licensed the blood vessel formation technologies from the IU Innovation and Commercialization Office | Indiana University (IU) School of Medicine | Licensing Agreement | United States |
01-May-18 | BioAutomation Corporation | $0 | LGC has today announced a further strengthening of its nucleic acid chemistry (NAC) offering with the acquisition of BioAutomation Corporation (BioAutomation), manufacturer of the renowned MerMade oligo synthesis instruments. | LGC Limited | Acquisition | United States |
02-May-18 | SFJ Pharmaceuticals Group | $0 | Agreement enables Merck to further develop abituzumab through a novel risk-sharing collaboration agreement. SFJ Pharmaceuticals Group to develop abituzumab as a first-line treatment for metastatic colorectal cancer (mCRC) in combination with Erbitux® and chemotherapy. Clinical program will concentrate on patients with RAS wild-type left-sided tumors with high ???6 integrin expression. | Merck Group | Collaboration | United States |
02-May-18 | Telix Pharmaceuticals Limited | $0 | Telix Pharmaceuticals Limited (Telix), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), has selected Goodwin Biotechnology, Inc. (Goodwin) to optimize the process for cGMP manufacturing of its renal cancer imaging antibody drug conjugate TLX-250.The product will be used in Telix's Phase III clinical study for the diagnostic imaging and staging of patien | Goodwin Biotechnology, Inc. | Manufacturing Investment | Australia |
02-May-18 | NeuroVive Pharmaceutical AB | $0 | NeuroVive’s TBI drug NeuroSTAT is currently in phase II clinical development. NeuroSTAT has shown a good safety and pharmacokinetic profile in a recently completed phase II study in TBI patients conducted at Rigshospitalet in Copenhagen, Denmark. | TRACK-TBI | Partnership | Sweden |
02-May-18 | Kramer Laboratories | $0 | Kramer is a recognized leader in OTC foot care products. The Company's portfolio includes leading foot care brands such as The Original Fungi-Nail® Toe & Foot® and HC Max™, as well as the Safetussin® brand of specialty cough solutions. The Company's products are sold in over 60,000 stores nationwide, including major drug, food and mass merchandiser outlets. | Avista Capital Partners, Dana Holdings | Acquisition | United States |
02-May-18 | Bactevo Ltd | $0 | This collaboration leverages Bactevo’s revolutionary TIME (Totally Integrated Medicines Engine) platform designed specifically to combine medicinally-relevant ‘tagless’ chemical diversity with ultra-fast phenotypic or molecular target screening in human samples, to enhance speed, efficiency and quality of identifying novel in vivo enabled leads for undisclosed Boehringer Ingelheim programs of interest. | Boehringer Ingelheim | Collaboration | United Kingdom |
02-May-18 | ERS Genomics | $0 | Licence provides EVOTEC's partners with unique integrated solution to identify novel disease-modifying genes; builds upon existing expertise on phenotypic screening, IPSC and disease biology. The new licence from ERS Genomics Limited complements and expands Evotec's existing CRISPR licences through the Broad Institute with gene editing technology from Emmanuelle Charpentier and others. | Evotec AG | Licensing Agreement | Ireland |
02-May-18 | C4X Discovery | $0 | The collaboration utilises both companies’ drug discovery technologies, in particular C4XD’s Taxonomy3® novel target identification platform and ETX’s Network-driven Drug Discovery (NDD) capabilities. Teams from both companies will use the outputs from C4XD’s Taxonomy3® genetic analysis of PD and apply an NDD approach to identify novel intervention strategies which it is expected will lead to new approaches for the treatment of PD. | e-Therapeutics plc | Collaboration | United Kingdom |
02-May-18 | Endoceutics, Inc. | $0 | Intrarosa™ (Prasterone) has been developed for the treatment of women experiencing moderate to severe dyspareunia, which is an outcome of vulvovaginal atrophy that occurs due to menopause. Intrarosa™ is a unique non-estrogen product that is administered locally in order to exert an action limited to the vagina. | Mundipharma | Licensing Agreement | Canada |
02-May-18 | Quartzy | $0 | Through Quartzy, BioBuilt’s labs will be able to consolidate their purchasing workflows using the Quartzy Shop, the nation’s most comprehensive and diverse digital catalog of lab supplies containing more than two million products sourced from over 1,000 of the life science industry’s leading suppliers. The time-savings made possible by the Quartzy Shop will allow science teams to direct greater focus towards their research rather than wasting it managing multiple supplier relationships. | BioBuilt | Partnership | United States |
02-May-18 | aTen Therapeutics Limited | $0 | "IONTAS will apply its technologies to overcome limitations of other platforms to generate therapeutic leads against pre-defined specification from aTen, to help its current pipeline progress." | IONTAS Limited | Collaboration | United Kingdom |
02-May-18 | Genohm | $0 | Acquisition will enable Agilent to provide a single informatics solutionnacross laboratory and operational domains | Agilent Technologies | Acquisition | Switzerland |
02-May-18 | Flatiron Health | $0 | Bristol-Myers Squibb will use Flatiron’s real-world data to accelerate its research and development efforts, as well as improve its ability to generate additional evidence on the use of its cancer medicines outside of clinical trials. | Bristol-Myers Squibb | Collaboration | United States |
03-May-18 | Roivant Sciences | $0 | monARC activates disease-specific patient research networks to enable greater participation in clinical trials and provide pre-screening analytics. monARC’s clinical trial platform employs remote monitoring and digital communication to broaden patient access, reduce site visits, and enable virtual clinical trials. Roivant to leverage monARC digital engagement platforms and patient networks to improve clinical research and expand access to underserved communities. | monARC Bionetworks, Inc. | Integration Agreement | Switzerland |
03-May-18 | MenoGeniX, Inc | $0 | The National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant for the clinical development of MNGX-100, a version of a naturally-occurring human blood protein, for the treatment of menopausal hot flashes. | National Institute on Aging (NIA) of the National Institutes of Health (NIH) | Grants & Awards | Canada |
03-May-18 | Medpace | $0 | With support from Medpace, Ritter Pharmaceuticals will conduct a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in the United States, in approximately 525 patients to evaluate the efficacy, safety, durability, and tolerability of RP-G28 in patients with lactose intolerance (LI). | Ritter Pharmaceuticals, Inc. | Clinical Collaboration | United States |
04-May-18 | Microsoft Corp. | $0 | This week, Fred Hutchinson Cancer Research Center and its Seattle-area neighbor Microsoft Corp. announced a unique collaboration agreement to develop and pilot test technology to help cancer patients avoid the emergency room through better management of their chemotherapy side effects. | Fred Hutchinson Cancer Research Center | Collaboration | United States |
04-May-18 | Lonza Portsmouth Manufacturing Site | $0 | The new facilities have been designed to ensure reliable delivery of innovative medicines. With a strong focus on automation, Lonza is implementing full-suite process analytic technology (PAT) and advanced multi-variate analysis (MVA) to ensure consistent performance. | Lonza Pharma | Manufacturing Investment | United States |
04-May-18 | Leipzig University | $0 | The exclusive option agreement allows the Company to license rights to "LymPro Test 2.0" which incorporates LymPro Test results with those of amyloid PET imaging for the diagnosis of Alzheimer's disease. | Amarantus Bioscience Holdings, Inc. | Option Agreement | Germany |
04-May-18 | Zettlex | $0 | Celera Motion is a market leading provider of motion control components and subsystems for OEMs. The company offers precision encoders, motors, and customized mechatronic solutions that help customers solve challenging motion control problems. | Novanta Inc. | Acquisition | United Kingdom |
07-May-18 | Invitae Corporation | $0 | Sarepta's President and CEO - "Sarepta's goal is to treat 100% of eligible individuals with DMD and using the best tools to enable earlier genetic-based identification of patients is a necessary element to eventually achieving that aspiration." | Sarepta Therapeutics | Partnership | United States |
07-May-18 | Endo International plc | $0 | Lannett Company, Inc. (NYSE: LCI) today announced that it has acquired 23 approved and one pending drug product applications from a subsidiary of Endo International plc for an upfront payment plus future milestone payments. The portfolio primarily consists of oral solutions with a few semi-solid products. For the 12 months ended March 2018, combined sales of the acquired products were in excess of $175 million, according to IMS. | Lannett Company | Asset Acquisition | United States |
07-May-18 | Pear Therapeutics | $0 | Agreement intends to broaden Company’s product portfolio within women’s reproductive health with novel clinical candidate, positioning Company with first in class candidates in contraception, sexual health and vaginal health | Daré Bioscience | Merger Agreement | United States |
07-May-18 | Provention Bio, Inc. | $0 | Coxsackievirus B appears to be an important trigger for type 1 diabetes. PRV-101 will be developed using Intravacc’s proven and well-established platform technology, including certain proprietary cell lines and production processes. Provention, in partnership with Intravacc, Vactech and L2D is now developing its CVB vaccine for large scale manufacture of clinical trial material in accordance with current Good Manufacturing Practices (cGMP). | Intravacc | Manufacturing Investment | United States |
07-May-18 | Carna Biosciences, Inc | $0 | Under the agreement, National Cancer Center and Carna Biosciences will collaborate on drug discovery research to develop a novel anticancer drug with new mechanisms of action that have been discovered by Dr. Kenkichi Masutomi, Chief, Division of Cancer Stem Cell at National Cancer Center Research Institute. | National Cancer Center Japan | Research Agreement | Japan |
07-May-18 | Shuwen Biotech | $0 | Abcam, a global leader in the supply of life science research tools, today signed a Memorandum of Understanding (MoU) with Shuwen Biotech, a leading player in the development and commercialization of companion diagnostics (CDx). Through the agreement, Abcam and Shuwen will jointly leverage their respective capabilities, in producing high-quality antibodies and CDx kit development and commercialization, to better serve the needs of the pharma industry. | Abcam | Memorandum of Understanding | China |
08-May-18 | Evotec AG | $0 | Carna will access Evotec's INDiGO platform to accelerate the development of its programme CB-1763, which is being developed for the treatment of blood cancer. Carna has another reversible BTK inhibitor in pre-clinical development, AS-871, a novel non-covalent BTK inhibitor targeting autoimmune diseases. AS-871 is also undergoing IND-enabling studies in collaboration with Evotec. | Carna Biosciences, Inc. | Collaboration | Germany |
08-May-18 | MediciNova, Inc. | $0 | This randomized, double-blind, placebo-controlled, outpatient study plans to enroll 50 non-treatment seeking individuals with moderate-to-severe alcohol use disorder (AUD) | University of California, Los Angeles (UCLA) | Clinical Collaboration | United States |
08-May-18 | The Rockefeller University | $0 | The collaboration calls for scientists at Rockefeller to use Hemogenyx's new type of humanized mice for autoimmune disease modelling in an effort to develop new treatments for autoimmune diseases - specifically Lupus. | Hemogenyx Pharmaceuticals PLC | Research Agreement | United States |
08-May-18 | XtalPi Inc | $0 | Building upon XtalPi's existing relationship with Pfizer for crystal structure prediction (CSP), this research collaboration aims to help XtalPi and Pfizer further advance their capabilities in computation-based rational drug design and solid-form selection. | Pfizer Inc. | Collaboration | United States |
08-May-18 | GenomeDx Biosciences | $0 | GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics | Johnson & Johnson | Collaboration | United States |
08-May-18 | Dolomite Bio | $0 | Single cell data analysis enables researchers to gain useful insights into the diversity and state of single cells in a particular sample, which is fundamental for research into many diseases and immunity. However, analyzing single cell data can be challenging without prior advanced bioinformatics skills or in-house capabilities. | Partek Incorporated | Collaboration | United Kingdom |
08-May-18 | Lunatus | $0 | Under the terms of the partnership, INSYS Therapeutics’ responsibilities will include supplying SUBSYS® to Lunatus, whose responsibilities will include obtaining the required regulatory approvals to commercialize SUBSYS® in the licensed territory. | INSYS Therapeutics | Licensing Agreement | United Arab Emirates |
22-Jun-18 | Autolus Limited | $150 | Autolus Limited, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it has filed a registration statement on Form F-1 (“Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”) | Goldman Sachs | IPO | United Kingdom |
08-May-18 | CEVEC Pharmaceuticals GmbH | $0 | CAP(R)Go provides unique opportunity for CSL to develop highly differentiated recombinant C1 Esterase Inhibitor (C1-IHN) proteins for Hereditary Angioedema (HAE) and other potential indications | CSL Limited | Licensing Agreement | Germany |
08-May-18 | Geisinger Health System | $0 | Geisinger Health System announced at the HLTH conference in Las Vegas that it plans to expand its population health genomics program from research into clinical practice. It will do so by sequencing patient’s DNA as part of standard care. | Regeneron Pharmaceuticals, Inc. | Collaboration | United States |
08-May-18 | Cytox | $0 | The Cytox genoBAR research test is intended to help pharma, biotech, and sponsors of large cohort studies reduce the time and high cost associated with identifying and stratifying subjects for clinical trials. The work performed by Cytox and AKESOgen resulted in over 99% concordance between the SNPs used in the PRS identified from blood and saliva samples collected from the same subjects and run on the Cytox variaTECT™ microarray on the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrumen | AKESOgen | Collaboration | United Kingdom |
08-May-18 | PHAST GmbH | $0 | PHAST as a service provider for the research focused pharmaceutical industry has continuously grown over the past to meet the challenges of the market. The major increase of outsourcing activities are demanding a consistent expansion of the spectrum of analytical services as well as the laboratory capacity. To keep up with the market’s speed and the trend of consolidation, Eurofins’ support is highly welcomed. This includes both, speed in the field of IT integration and growth of additional lab | Eurofins BioPharma Services Holding GmbH | Acquisition | Germany |
09-May-18 | MacroGenics | $0 | Provention acquires PRV-031 (teplizumab) and plans to initiate pivotal Phase 3 clinical trial to intercept early-onset type 1 diabetes, a pediatric orphan indication. Provention licenses and plans to advance PRV-3279 (formerly MGD010) as a potential treatment for systemic lupus erythematosus | Provention Bio | Licensing Agreement | United States |
10-May-18 | PANTHERx | $0 | JYNARQUE™ is a selective vasopressin V2-receptor antagonist. This means it blocks vasopressin, an anti-diuretic hormone secreted by the pituitary gland, which plays a key role in the fluid balance of the kidneys. By blocking this hormone, the drug can decrease cyst-cell proliferation and fluid secretion, which ultimately can reduce cyst growth. | Otsuka Pharmaceutical | Distribution Agreement | United States |
10-May-18 | Aegerion Pharmaceuticals, Inc. (Novelion Therapeutics Inc.) | $0 | Amryt estimates there may be up to 450 additional patients who could benefit from treatment with Lojuxta across the countries covered by the extended agreement, representing an increase of approximately 25% in the total number of addressable patients in the Amryt territories. Amryt is actively seeking distribution partners in these new territories. | Amryt Pharma plc | Licensing Agreement | Japan |
11-May-18 | Iovance Biotherapeutics | $0 | Synergies between RXi's self-delivering RNAi (sd-rxRNA®) therapeutic platform and Iovance's TIL cell therapy approach will be explored preclinically. | RXi Pharmaceuticals Corporation | Research Agreement | United States |
14-May-18 | Catalent Pharma Solutions | $0 | Under the agreement, Catalent Biologics will provide cell line development and support cGMP manufacturing activities from Phase 1 through to commercial stages at its state-of-the-art biologics manufacturing facility in Madison, Wisconsin. | Valerius Biopharma AG | Collaboration | United States |
14-May-18 | Toyama Chemical Co., Ltd., Taisho Pharmaceutical Holdings Co Ltd. | $0 | FUJIFILM Holdings conducts its pharmaceutical business focused on the small molecule pharmaceutical products of TOYAMA CHEMICAL and the diagnostic and therapeutic radiopharmaceuticals of FUJIFILM RI Pharma. The merger company has been named as FUJIFILM Toyama Chemical Co., Ltd. | FUJIFILM Corporation | Merger Agreement | Japan |
14-May-18 | Harvard University | $0 | The licensed technology platform, which includes access to base editing and associated technologies that enhance the targeting scope of base editing, opens a wide range of human genetic conditions to the therapeutic promise of genome editing. | Beam Therapeutics | Licensing Agreement | United States |
14-May-18 | ScienceVision | $0 | Under the partnership, ScienceVision will commercialize and distribute the PierianDx Clinical Genomics Workspace™ (CGW) platform for clinical genomic informatics, classification, interpretation, and clinical reporting. Hospitals, cancer centers, and genomic laboratories throughout Malaysia and Southeast Asia will now have access to PierianDx’s CGW platform for clinical genomic analysis and insight. | PierianDx | Distribution Agreement | Malaysia |
14-May-18 | Case Western Reserve University | $0 | Together these have been shown to be highly accurate in detecting Barrett’s Esophagus, the primary precursor to the most common and lethal form of esophageal cancer caused by Gastroesophageal Reflux Disease (GERD), commonly known as heart burn or acid reflux. | PAVmed | Licensing Agreement | United States |
14-May-18 | Supply Chain Wizard | $0 | Partnering with Supply Chain Wizard equips QPSI with the latest and most effective IoT technology solutions, including a fully integrated Digital Factory suite of solutions (OEE Tracker, Scheduler and Digital Logbook for primary and secondary packaging operations). | Quality Packaging Specialists Int'l (QPSI) | Partnership | United States |
14-May-18 | Stelis Biopharma | $0 | Stelis chose Merck for its best-in-class single-use manufacturing components for flexible operations and better regulatory compliance. Merck will bring its process know-how and application knowledge from global experts to help establish the single-use platform technologies at Stelis. | Merck & Co. | Partnership | India |
14-May-18 | Uppsala University | $0 | The new extended research collaboration aims to develop innovative technologies to increase the passage of antibodies also into nerve cells. This can be of great value for the diagnosis and treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. | Bioarctic Neuroscience AB | Collaboration | Sweden |
15-May-18 | TEDOR Pharma, Inc., | $0 | DORA Ventures is a newly formed investment vehicle, owned and controlled by Laura Iorio, Chairwoman of TEDOR Pharma, and Doug Drysdale, President and CEO of TEDOR Pharma. Iorio has served as Chairwoman of TEDOR Pharma since 2009. Drysdale previously served as Chairman and CEO of Pernix Therapeutics (PTX) and as CEO of Alvogen, Inc. | DORA Ventures, Inc. | Financing | United States |
15-May-18 | DPS Group | $0 | DPS Group, the engineering and construction management firm with operations and projects across Europe and the US has been awarded a major contract from the global pharmaceutical company AstraZeneca to provide Engineering, Procurement, Construction Management and Validation (EPCMV) services for small and medium sized projects on AstraZeneca’s pharmaceutical site in Södertälje, Sweden. | AstraZeneca | Contract Agreement | Ireland |
15-May-18 | Edico Genome | $0 | Edico Genome’s DRAGEN® Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results. | Illumina | Acquisition | United States |
15-May-18 | International Association of Forensic Nurses | $0 | Elsevier, the information analytics business specializing in science and health, and part of RELX Group, announced today that it will collaborate with the International Association of Forensic Nurses (IAFN) to enhance Elsevier's Clinical Skills for emergency nursing. | Elsevier | Collaboration | United States |
15-May-18 | J. Kiffin Penry Epilepsy Education Programs | $0 | SK life science has a pipeline of six products in development for the treatment of CNS disorders including epilepsy, sleep disorder and attention deficit hyperactivity disorder, among others. The company's lead product is cenobamate, an investigational compound that is being studied as a potential treatment option for patients with epilepsy. | SK Life Science, Inc. | Grants & Awards | United States |
16-May-18 | AGC Biologics | $0 | AGC Biologics has provided comprehensive development and validation services for margetuximab since 2014, and plans to implement a transition to commercial supply services. Margetuximab is an investigational product that targets the human epidermal growth factor receptor 2, or HER2. HER2 is expressed by tumor cells in breast, gastroesophageal, bladder and other forms of solid tumor cancers, making it a key marker for biologic therapy. | MacroGenics | Commercialization Agreement | United States |
16-May-18 | Memorial Sloan Kettering Cancer Center (MSK) | $0 | The use of clonal master iPSC lines can overcome the complexity, heterogeneity and substantial costs associated with using cells from a patient or an allogeneic donor. Instead, iPSC-derived T-cell immunotherapies can be consistently and repeatedly mass produced and delivered in an off-the-shelf manner, significantly reducing the cost of, and time to, patient treatment. | Fate Therapeutics | Expansion | United States |
16-May-18 | Emulate | $0 | AstraZeneca has announced a collaboration with Emulate to develop and embed the start-up’s Organs-on-Chips technology within its Innovative Medicines and Early Development (IMED) Drug Safety organisation laboratories. | AstraZeneca | Partnership | United States |
16-May-18 | Ohr Pharmaceutical | $0 | Vitrisa is acquiring the clinical database in order to use the clinical data set to run virtual clinical trials and evaluate innovative clinical strategies in wAMD. | Vitrisa Therapeutics, Inc. | Option Agreement | United States |
16-May-18 | Washington University | $0 | The two-year collaboration will use Merck's genome-editing technology in research studies conducted by Dr. Jeffrey Gordon of the Washington University School of Medicine. The objectives of the research are to determine the differences between intestinal bacterial communities in healthy and malnourished children and to identify which characteristics of intestinal bacteria in healthy children are fundamental for healthy growth. | Merck Group | Collaboration | United States |
17-May-18 | ProMed BioSciences, Ltd. (Profectus BioSciences, Inc.) | $0 | The joint venture will leverage Profectus' vaccine R&D expertise, clinically validated vaccine platform technologies, and pipeline of vaccine products in development with Medisun's expertise, established clinical network, and knowledge of local clinical, regulatory, and market access capabilities and is expected to be operational in the latter half of 2018. | Medisun Holdings Limited | Joint Venture | Hong Kong |
17-May-18 | GeneNews Ltd | $0 | GeneNews, through Innovative Diagnostic Laboratory ("IDL"), its wholly-owned subsidiary in Richmond, Virginia, operates a full service reference lab focused on early cancer risk stratification and diagnosis and has a strong U.S. presence on the East and West coasts. AIM Laboratories operates a full service reference lab focused on routine blood testing and specializing in therapeutic drug monitoring for prescribed and illicit drugs and services about 20 States with particular strength in the M | AIM Laboratories | Partnership | Canada |
17-May-18 | Akums Drugs and Pharmaceuticals | $0 | Akums will manufacture and supply products containing OptiBiotix's LPLDL® throughout India to maximise the financial return for both parties. Products containing LPLDL® have a unique ability to increase 'HDL' and reduce both bad cholesterol (LDL) and blood pressure, providing a clinically proven natural product to help reduce cardiovascular risk factors in countries with a high prevalence of these conditions. | OptiBiotix Health | Manufacturing Investment | India |
18-May-18 | BrainScope | $0 | The BrainScope One system to be used in Prevacus' upcoming Phase 1b drug study provides a multi-dimensional assessment of brain function including EEG measures, cognitive performance tests, and standard, digitized concussion assessment tests to aid in standardizing data collection across clinical sites. | Prevacus Inc. | Partnership | United States |
18-May-18 | PharmOut | $0 | This new partnership offers a cost-effective and innovative validation solution to Australian companies. Combining the expertise of PharmOut's large team of validation consultants with the ValGenesis Validation Lifecycle Management System will deliver faster, cheaper validation services in Australia. | ValGenesis Inc | Partnership | Australia |
21-May-18 | Bioasis Technologies, Inc. | $0 | Through this partnership Bioasis will have access to WuXi Biologics’ extensive expertise and technologies from cell line construction and development, cell culture process development, purification process development and formulation development. WuXi Biologics will focus on ensuring that Bioasis’ drug product candidates are manufactured with optimal formulation, stability and exceptional quality for the clinic. | WuXi AppTec | Collaboration | Canada |
21-May-18 | Oasmia Pharmaceutical | $0 | With this move completed, AdvaVet, Inc. can begin to unlock value for Oasmia shareholders through the development and commercialization of two new chemotherapy drugs that specifically target companion animals. | AdvaVet, Inc. | Asset Acquisition | Sweden |
21-May-18 | Verge Genomics | $0 | This public-private consortium will combine VIB's cutting-edge single-nucleus RNA sequencing technology, UC San Diego's outstanding collection of tissue generously provided by patients and their families, and Verge's machine learning platform to generate and analyze new types of patient data at a resolution only recently made possible. | University of California San Diego, VIB | Partnership | United States |
22-May-18 | Aptinyx Inc. | $0 | Allergan was granted option rights to a limited number of small molecules from the Aptinyx discovery platform under a research collaboration initiated in conjunction with its 2015 acquisition of Naurex, the predecessor company from which Aptinyx and its platform were spun out. | Allergan plc | Research Agreement | Luxembourg |
22-May-18 | Qualia Pharma | $0 | Enzymatica has entered into a distribution agreement with Qualia Pharma for marketing and sales of ColdZyme® Mouth Spray on the Greek and Cypriot market. The background to the agreement is that Qualia Pharma acquired Life NLB on March 1, 2018. The distribution agreement that Enzymatica previously had with Life NLB is now being transferred to Qualia Pharma. | Enzymatica AB | Distribution Agreement | Greece |
22-May-18 | Eurofins Scientific | $0 | Eurofins Scientific announces that it has signed an outsourcing agreement with Astellas to outsource one of its internal testing laboratories Astellas Analytical Science Laboratories, Inc. | Astellas Pharma | Outsourcing Agreement | Luxembourg |
22-May-18 | Kura Oncology | $0 | OncoDNA will support patient enrolment for Kura’s ongoing HRAS tipifarnib trial in patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC). Tipifarnib is an inhibitor of farnesylation, a key cell signalling process implicated in cancer initiation and resistance to standard therapies. | OncoDNA | Clinical Collaboration | United States |
22-May-18 | Mayo Clinic | $0 | Cytox will assess genetic risk for developing Alzheimer’s disease using its current commercially available approaches developed to run on the Thermo Fisher Scientific Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrument platform, in addition to new approaches under development. Mayo Clinic’s Alzheimer’s Disease Research Center will provide biobank samples from research participants classified as clinically normal, diagnosed with mild cognitive impairment and diagnosed with mild Alzheimer | Cytox | Collaboration | United States |
22-May-18 | Antibody Solutions | $0 | The licensing agreement is for the use of The Trianni Mouse™, a best-in-class fully humanized transgenic mouse platform, to support its therapeutic antibody discovery programs. | Trianni, Inc. | Licensing Agreement | United States |
23-May-18 | mAbxience (Insud Pharma Group) | $0 | The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment | Amneal Pharmaceuticals | Licensing Agreement | Spain |
23-May-18 | ID Pharma | $0 | The new licence is an important addition to Evotec’s iPSC platform, one of the most comprehensive in the industry. It further enhances Evotec’s broad iPSC capabilities in early drug discovery for treatments of a variety of conditions including nervous system diseases and diabetes. | Evotec AG | Licensing Agreement | Japan |
23-May-18 | AcelRx Pharmaceuticals, Inc. | $0 | Leerink Revelation Partners and Industry Ventures, along with other investors, have acquired AcelRx Pharmaceuticals (AcelRx) from Three Arch Partners III, Three Arch Associates III, Three Arch Partners IV, and Three Arch Associates IV. AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company currently engaged in the development of two product candidates including DSUVIA™ (sufentanil sublingual tablet, 30 mcg) and Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg) for r | Leerink Partners | Private Placement | United States |
23-May-18 | Quartzy | $0 | This partnership follows the recent launch of Quartzy’s Redwood City fulfillment center. Located in close proximity to IndieBio’s labs, the new warehouse delivers a logistical advantage to the emergent biotech startups that often have limited lead time to spare on their orders and an unceasing need for consumables and reagents. | IndieBio | Partnership | United States |
23-May-18 | National Cancer Institute (NCI), Federal Communications Commission (FCC) | $0 | The L.A.U.N.C.H. (Linking & Amplifying User-Centered Networks through Connected Health) program will use human-centered design methodologies to identify the needs of patients, caregivers and healthcare providers. | Amgen | Collaboration | United States |
23-May-18 | Curevo | $0 | Curevo represents an important next step in GC Pharma's vaccine business. The new company will bring together GC Pharma's commercial scale vaccine development expertise and deep understanding of protein science with IDRI and MIBR's world class scientific expertise in vaccine, adjuvant and formulation development. Initial work will centre on advancing an innovative vaccine candidate against shingles to clinical stage. | Infectious Disease Research Institute, GC Pharma | Launch & Partnerships | United States |
24-May-18 | Eiger Biopharmaceuticals Inc. | $0 | Eiger BioPharmaceuticals, Inc., focused on the development and commercialization of targeted therapies for rare diseases, announced today that it has expanded its licensing agreement with Merck, known as MSD outside the United States and Canada, to include rights to develop the investigational farnesyltransferase inhibitor lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria), a rare and fatal genetic condition characterized by accelerated aging in children. Th | Merck & Co. | Licensing Agreement | United States |
24-May-18 | Pharmacyclics | $0 | Oncternal’s CIRLL study (Cirmtuzumab and Ibrutinib targeting ROR1 for Lymphoma and Leukemia) is now underway, enrolling approximately 117 patients with MCL and CLL/SLL who have not received previous BTK inhibitor therapy. CIRLL is a randomized, open label, dose-finding study designed to evaluate the safety and efficacy of cirmtuzumab when given in combination with ibrutinib. The objective is to demonstrate that even more patients treated with the combination of cirmtuzumab plus ibrutinib will ac | Oncternal Therapeutics, Inc., | Clinical Collaboration | United States |
24-May-18 | Merus | $0 | ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins, announced that the company achieved an undisclosed milestone payment from Merus N.V. based on Merus’ use of MCLA-158, a bispecific antibody utilizing the GlymaxX® antibody-dependent cell-mediated cytotoxicity (ADCC)-enhancing technology in Merus’ Phase I clinical trial. | ProBioGen AG | Milestone Payment | The Netherlands |
24-May-18 | Euroclone Diagnostica S.r.l | $0 | ICE COLD-PCR technology preferentially enriches mutant DNA sequences over wild-type (normal) DNA through selective amplification of the mutant DNA. | Precipio, Inc. | Distribution Agreement | Italy |
24-May-18 | Hadasit Medical Research Services and Development | $0 | Recipharm, the contract development and manufacturing organisation (CDMO), has partnered with Hadasit Medical Research Services and Development to offer combined clinical, biological and chemical services. | Recipharm | Partnership | Israel |
24-May-18 | Angsana Molecular & Diagnostics Laboratory | $0 | Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, and Angsana Molecular & Diagnostics Laboratory Pte Ltd, a subsidiary of Parkway Pantai, announce a partnership to market the MammaPrint® Breast Cancer Risk of Recurrence test and the BluePrint® Molecular Subtyping test to physicians across Southeast Asia, including Singapore, Malaysia, Vietnam, Brunei and Myanmar. | Agendia | Marketing Agreement | Singapore |
24-May-18 | ePatientFinder | $0 | This acquisition will enhance Elligo’s trial matching process by incorporating ePatientFinder’s technology platform. Using this platform, Elligo will streamline patient identification and feasibility through automation using electronic health record (EHR) data within Elligo’s network of providers. | Elligo Health Research | Asset Acquisition | United States |
25-May-18 | Bicycle Therapeutics | $0 | THR-149 is a novel plasma kallikrein inhibitor identified and optimized by the Bicycle technology platform. The open-label, multicenter, dose escalation study will evaluate the safety of intravitreally administered THR-149 for the treatment of diabetic macular edema (DME). Initial study results are anticipated in mid-2019. | ThromboGenics NV | Milestone Payment | United Kingdom |
25-May-18 | Sandoz | $0 | The proposed acquisition of Novartis Technical Operations' sterile manufacturing facility and the adjacent Sandoz Development Center located on the Sandoz Canada campus in Boucherville, Quebec, is expected to be finalized in the next few months, following the completion of a number of closing conditions including receipt of anti-trust approvals. | Avara Pharmaceutical Service | Manufacturing Investment | Canada |
28-May-18 | Beactica AB | $0 | The collaboration agreement under which Beactica and Sanofi will work is based on previous work by Beactica scientists who have supported Sanofi with analysis of the interaction kinetics between insulin analogues and their two binding sites on the full-length insulin receptor. The present agreement extends towards research on the characterization of interactions between novel therapeutics under development at Sanofi and their target proteins. | Sanofi | Collaboration | Sweden |
29-May-18 | Centogene | $0 | Under the terms of the agreement, CENTOGENE will collaborate with Aldeyra to globally identify patients with SLS and to understand the clinical spectrum of this disease. The goal of the agreeement is to support physicians and patients with early diagnosis through genetic testing that could potentially lead to the identification of novel therapeutic developments and raise awareness of the disease. | Aldeyra Therapeutics Inc. | Collaboration | Germany |
29-May-18 | Adaptive Biotechnologies | $0 | Through this collaboration, the parties will work together to evaluate the clinical value of monitoring MRD negativity in isatuximab-treated MM patients. Adaptive will be responsible for seeking regulatory approvals for and commercialization of the clonoSEQ Assay in MM for select geographies. Adaptive will receive upfront payments and potential future milestone payments. Financial terms of the agreement were not disclosed | Sanofi | Collaboration | United States |
29-May-18 | Halma | $0 | The partnership combines the strength of OurCrowd’s global network, robust deal flow pipeline and growing portfolio of 150 promising startups along with the reach and business objectives of Halma to seek innovative products and services in digital health, infrastructure and environmental analytics and insights. | OurCrowd | Partnership | Israel |
29-May-18 | Pharmanest AB | $0 | SHACT is a novel technology that provides pain relief on vaginal mucosal tissue. In a clinical study conducted in Sweden, the SHACT treatment was associated with significant reduction of pain and discomfort in women undergoing gynecological interventions without causing bothersome side effects. | Acerus Pharmaceuticals Corporation | Commercialization Agreement | Canada |
29-May-18 | Ipsen | $0 | MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization. | Institute for Applied Cancer Science (MD Anderson) | Partnership | France |
29-May-18 | Adaptive Biotechnologies | $0 | Through this collaboration, the parties will work together to evaluate the clinical value of monitoring MRD negativity in isatuximab-treated MM patients. Adaptive will be responsible for seeking regulatory approvals for and commercialization of the clonoSEQ Assay in MM for select geographies. Adaptive will receive upfront payments and potential future milestone payments. Financial terms of the agreement were not disclosed | Sanofi | Collaboration | United States |
30-May-18 | Keio University Hospital, Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma | $0 | With the aim of curing intractable immune-mediated inflammatory diseases, reverse translational research* for drug discovery research is being conducted worldwide using data on clinical samples analyzed with the latest technologies. Daiichi Sankyo defines the intractable and rare diseases that are difficult to be cured with current standards of care (SOC) as “New Horizon Areas,” and it aims to offer a new treatment option for patients by continuously creating advanced pharmaceuticals that will t | Daiichi Sankyo | Collaboration | Japan |
30-May-18 | Centre for Drug Research and Development | $0 | Schrödinger will support hit triage, prioritization through prediction of physico-chemical liabilities, and antibody humanization. CDRD will provide a portfolio of targeted antibodies for undisclosed oncology indications. CDRC will provide a portfolio of targeted antibodies and Schrödinger will apply its advanced computation platform in order to prioritize these drug candidates and otherwise accelerate discovery. | Schrödinger, Inc. | Collaboration | Canada |
30-May-18 | Harbour BioMed | $0 | Co-offering combines AbCellera’s microfluidic single-cell screening platform with Harbour’s H2L2 transgenic mouse technology to create an end-to-end solution for the discovery of fully-human lead therapeutic antibodies. | AbCellera Biologics | Technology Agreement | United States |
30-May-18 | Nektar Therapeutics | $0 | Syndax and Nektar have entered into a non-exclusive, clinical collaboration to evaluate the safety and efficacy of Nektar's NKTR-214, a CD122-biased agonist, in combination with entinostat, Syndax's oral, small molecule Class 1 specific HDAC inhibitor, in patients with metastatic melanoma who have previously progressed on treatment with an anti-PD-1 (programmed death receptor-1) agent. | Syndax Pharmaceuticals | Clinical Collaboration | United States |
30-May-18 | BDD Pharma | $0 | BDD's proprietary OralogiK™ technology enables the oral delivery of single, multi-dose or combination drugs at pre-determined times between one and 12 hours after administration to the patient. | Novartis | Licensing Agreement | Scotland |
30-May-18 | Zai Lab Limited | $0 | Crescendo Biologics has granted to Zai Lab a worldwide exclusive license to develop and commercialize its drug candidate for all indications. Zai Lab will be responsible fornconducting all regulatory filings, clinical studies, and commercialization activities. Crescendo's proprietary Humabody® therapeutics target a range of Autoimmune and Infectious Disease Indications. | Crescendo Biologics | Licensing Agreement | China |
31-May-18 | Evotec AG, Fred Hutchinson Cancer Research Center | $0 | LAB591 aims to accelerate research discoveries at Fred Hutch and leverage these discoveries to form new companies focused on cancer and infectious disease drug development. Arix, Evotec and Fred Hutch plan to jointly select promising LAB591 research projects from the Fred Hutch labs. After developing a research validation plan, Evotec will conduct research in collaboration with the Fred Hutch faculty which will be seed funded by Arix. Once completed, and subject to the results, Arix and Evotec h | Arix Biosciences | Collaboration | United States |
31-May-18 | Premier Inc. | $0 | Merck and Premier® will develop and test the combination of a software-based platform and a coordinator to provide surveillance, consultation, support and education to patients with C. diff at participating Premier member health systems. | Merck & Co. | Collaboration | United States |
31-May-18 | MD Anderson | $0 | The collaborations will focus on Amgen's bispecific T cell engager (BiTE®), chimeric antigen receptor (CAR) T cell and small molecule programs. Amgen is advancing both types of T cell therapies against different targets and, in some cases, the same target. | Amgen | Collaboration | United States |
31-May-18 | FORMA Therapeutics, Inc. | $0 | FORMA Therapeutics and HitGen Initiate Multiyear Research Collaboration with which FORMA expands external discovery research footprint with dedicated unit at HitGen. | HitGen Ltd | Collaboration | United States |
31-May-18 | Takeda Pharmaceutical Company Limited | $0 | Relugolix (TAK-385) is being developed as a gonadotropin-releasing receptor antagonist to be taken orally once daily against uterine fibroids, endometriosis and prostate cancer. | ASKA Pharmaceutical Co., Ltd. | Licensing Agreement | Japan |
31-May-18 | Bayer | $0 | Bayer is collaborating with the U.S. Department of Energy's Oak Ridge National Laboratory, based in Oak Ridge, TN, to produce actinium-227 (227Ac), the key radioisotope used in the production of the company's prostate cancer treatment Xofigo® (radium Ra 223 dichloride). | U.S. Department of Energy's Oak Ridge National Laboratory | Partnership | United States |
31-May-18 | Novartis | $0 | The five products acquired by NTC from Novartis include Colircusi Gentadexa (aminoglycoside), Colircusi gentamicin and Oftalmolosa Cusi gentamicina (aminoglycoside), Oftalmolosa cusi erythromycin (macrolide), Oftalmolosa cusi aureomycin (tetracycline), and Oftacilox (fluoroquinolone) and are the most recent additions to the NTC portfolio | NTC Pharma | Asset Acquisition | Switzerland |
29-Jun-18 | Alcon Inc., | $5,000 | The planned spinoff would enable both Novartis and Alcon to focus fully on their respective growth strategies. The ophthalmology pharmaceuticals business will continue to develop as part of Novartis, with RTH258 (brolucizumab) in development for neovascular AMD and diabetic macular edema. | Novartis | Spin off | United States |
19-Jun-18 | Cotiviti Holdings, Inc. | $4,900 | Together, the companies are expected to have greater impact in the healthcare IT market by increasing affordability, reducing waste and offer new opportunities to create substantial value for clients, including complementary solutions across multiple intervention points in the payment process. | Verscend Technologies, Inc., Veritas Capital | Acquisition | United States |
29-Jun-18 | Recordati S. p. A. | $3,530 | Recordati is a very carefully managed, international pharma company with a broad platform of products and a strong geographical footprint in primary care. Over the last decade Recordati has built up a very attractive rare disease business which we look forward to expanding in addition to the core business. | CVC Capital Partners | Acquisition | Italy |
06-Jun-18 | Johnson & Johnson | $2,700 | Advanced Sterilization Products (ASP) provides innovative sterilization and disinfection solutions and pioneered low-temperature hydrogen peroxide sterilization technology. ASP’s products include the STERRAD system for sterilizing instruments and the EVOTECH and ENDOCLENS systems for endoscope reprocessing and cleaning. | Fortive Corporation | Acquisition | United States |
19-Jun-18 | Foundation Medicine, Inc. | $2,400 | Together, the companies will leverage expertise in genomics and molecular information to enhance the development of personalised medicines and care for patients with cancer to drive ubiquity of Foundation Medicine’s high quality comprehensive genomic profiling (CGP) testing and innovative data services. | Roche | Acquisition | United States |
28-Jun-18 | Sanofi | $2,220 | Zentiva stands apart with the expertise and agility to tailor customer-centric solutions in the three European generics market archetypes (pharmacy, physician and tender/wholesaler). The acquisition will lead to the transfer of the Zentiva business to Advent during the course of the fourth quarter of 2018. | Advent International | Acquisition | France |
26-Jun-18 | Akebia Therapeutics, Inc. | $1,300 | Keryx’s Auryxia® (ferric citrate) is an FDA-approved medicine to treat dialysis dependent CKD patients for hyperphosphatemia and non-dialysis dependent CKD patients for iron deficiency anemia (IDA). Akebia’s vadadustat is an investigational Phase 3 medicine for the treatment of patients with anemia due to CKD, which is an oral alternative of injectable erythropoietin-stimulating agents (ESAs). | Keryx Biopharmaceuticals, Inc. | Merger Agreement | United States |
26-Jun-18 | Calico | $1,000 | Working together with AbbVie, Calico pursues discovery-stage research and development. AbbVie provides scientific and clinical development support and will lend its commercial expertise to lead future development and commercialization activities. | AbbVie | Collaboration | United States |
06-Jun-18 | Oxford BioMedica | $843 | Axovant Sciences will fund all clinical development costs and manufacturing process development and scale-up activities for AXO-Lenti-PD. The agreement also allows for both parties to put in place a clinical and commercial supply agreement for GMP manufacturing of AXO-Lenti-PD at Oxford BioMedica. Axovant Sciences expects to initiate a Phase I/II dose escalation study of AXO-Lenti-PD in patients with advanced Parkinson’s disease by the end of 2018. | Axovant Sciences | Licensing Agreement | United Kingdom |
11-Jun-18 | Translate Bio | $805 | The three-year collaboration is focused on developing vaccines for up to five infectious disease pathogens will bring together Sanofi Pasteur’s leadership in vaccines with Translate Bio’s expertise in mRNA research and development | Sanofi | Collaboration | United States |
29-Jun-18 | Samsung Bioepis | $700 | Biogen will pay Samsung BioLogics approximately $700 million to increase its ownership in Samsung Bioepis to approximately 49.9%, This option suggests that Biogen, a leader in multiple sclerosis and other neurological disorders, is significantly increasing its interest in biosimilars. | Biogen | Option Agreement | South Korea |
06-Jun-18 | Pfizer Inc. | $600 | Pfizer can support a broad array of early neuroscience research and product development opportunities, which are critical in the nascent area of science - Neuroscience Investment Strategy. | Pfizer Inc. | Investment | United States |
13-Jun-18 | Sage Therapeutics | $575 | The collaboration with Shionogi is intended to accelerate development of SAGE-217 in key Asian markets and supports Sage’s mission to bring transformational medicines to patients around the world | Shionogi & Co., Ltd. | Collaboration | United States |
06-Jun-18 | Microbiotica | $534 | Microbiotica will utilise its precision metagenomics microbiome platform to analyse patient samples from clinical trials of Genentech’s investigational IBD medicines, in order to identify microbiome biomarker signatures of drug response, novel IBD drug targets and live bacterial therapeutic products. Microbiotica will receive an undisclosed upfront payment and is eligible to receive research, development and commercialisation milestone payments up to $534 million based on achievement of certain | Roche | Collaboration | United Kingdom |
15-Jun-18 | AMAG Pharmaceuticals | $530 | “The divestiture of CBR is an important step as we execute on AMAG’s strategic plan, which includes leveraging our proven expertise in drug development and commercialization to bring innovative products to patients with unmet medical needs,” said William Heiden, president and chief executive officer at AMAG | GI Partners | Acquisition | United States |
05-Jun-18 | Hookipa Biotech AG | $400 | Hookipa and Gilead will jointly research and Hookipa will manufacture arenavirus-based vectors for clinical development by Gilead. The deal expands the relationship between Hookipa and Gilead following Gilead's participation in Hookipa's Series C financing in December 2017. | Gilead Sciences | Collaboration | Austria |
07-Jun-18 | TMS Co., Ltd. | $357 | TMS-007 is designed to restore blood flow following acute stroke, with an extended treatment window versus current standard of care. Biogen to pay $4 million upfront and $18 million upon exercise of the option, plus potential milestones of up to $335 million and royalties. Agreement reinforces Biogen’s commitment to stroke within its acute neurology portfolio, a strategic emerging growth area. | Biogen | Option Agreement | Japan |
04-Jun-18 | Advance Medical | $352 | Founded in 1999 by Marc Subirats and Carlos Nueno, Advance Medical is a worldwide leader in telemedicine and expert medical opinion services. The acquisition of Advance Medical expands Teladoc’s international footprint, broadens its breadth of medical services and its physician network, and extends the company’s market leadership. | Teladoc | Acquisition | United States |
25-Jun-18 | Dementia Discovery Fund (DDF) | $350 | The fundraising far exceeded its initial target of $200 million (£130 million), making it the first and largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease. The fund is managed by SV Health and was formed through the collaboration of leading pharmaceutical companies (Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and Takeda), the UK Department of Health and Social Care and the charity Alzhe | U.K. government’s Department of Health, Alzheimer’s Research UK (ARUK) | Research Agreement | United Kingdom |
04-Jun-18 | Blueprint Medicines | $346 | This is exclusive collaboration and license agreement for the development and commercialization of avapritinib, BLU-554 and BLU-667 in Mainland China, Hong Kong, Macau and Taiwan, either as monotherapies or combination therapies. Discovered and developed by Blueprint Medicines, avapritinib, BLU-554 and BLU-667 are potent and highly selective investigational kinase medicines that have each demonstrated clinical proof-of-concept in genomically defined subsets of patients with cancer. | Cstone Pharmaceuticals | Licensing Agreement | United States |
05-Jun-18 | EPD Solutions | $292 | The acquisition will complement Philips’ portfolio of interventional imaging systems, smart catheters, planning and navigation software, and services, and will allow the company to introduce new solutions in the EUR 2+ billion market [2] for image-guided treatment of cardiac arrhythmias, which is growing at a double-digit rate. | Royal Philips | Acquisition | United States |
22-Jun-18 | Biologicals Development Center | $271 | New Biologicals Development Center in Biberach, Germany bundles biologics development, increases capacity and expands clinical supply network. Increased development capacities reflect research pipeline growth and free up capacity for contract manufacturing and adds to a number of major recent investments into the global Boehringer Ingelheim biopharmaceuticals development network aiming to further increase the company’s mammalian cell culture capabilities. | Boehringer Ingelheim | Research Agreement | Germany |
27-Jun-18 | Tricida, Inc. | $256 | The closing of its initial public offering of 13,455,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 1,755,000 shares of common stock for total gross proceeds of approximately $255.6 million. | Goldman Sachs | IPO | United States |
25-Jun-18 | Exosome Diagnostics | $250 | Exosome Diagnostics markets a urine-based test, ExoDx® Prostate(IntelliScore) (EPI), to assist physicians in determining the need for a prostate biopsy in patients with an ambiguous PSA test result. | Bio-Techne Corporation | Acquisition | United States |
29-Jun-18 | I-Mab Biopharma | $220 | The completion of Series C financing for USD 220 million will be used primarily to advance the pre-clinical and clinical development of ten Best-in-Class investigational drugs in the pipeline. | Hillhouse Capital | Series C Financing | China |
15-Jun-18 | CORD:USE Cord Blood Bank, Inc. | $200 | Cryo-Cell International, Inc. is the world's first private cord blood bank. Cryo-Cell's mission is to provide clients with state-of-the-art stem cell cryopreservation services and advancing regenerative medicine. Cryo-Cell operates in an FDA registered, cGMP-/cGTP-compliant facility. | Cryo-Cell International, Inc. | Acquisition | United States |
20-Jun-18 | Novimmune SA | $185 | The companies will jointly collaborate on the development and commercialization of Novimmune’s novel first-in-class anti-CD47/anti-CD19 bispecific antibody known as TG-1801 (previously NI-1701). | TG Therapeutics | Collaboration | Switzerland |
11-Jun-18 | Deciphera Pharmaceuticals | $172 | Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the closing of its previously announced underwritten public offering of 4,300,000 shares of its common stock at a public offering price of $40.00 per share for aggregate gross proceeds of $172 million. | Canaccord Genuity | IPO | United States |
06-Jun-18 | Mirati Therapeutics, Inc | $139 | Mirati's precision oncology clinical programs utilize next-generation genomic testing to identify and select cancer patients who can benefit from targeted drug treatment. Mirati is advancing clinical programs that improve the immune environment of tumor cells to expand the efficacy of existing immunotherapy medicines used in combination. | Cowen, Barclays and SunTrust Robinson Humphrey | IPO | United States |
27-Jun-18 | Forty Seven | $129 | Forty Seven has granted the underwriters a 30-day option to purchase up to an additional 1,055,250 shares of common stock solely to cover over-allotments, if any, at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market. | Morgan Stanley | IPO | United States |
14-Jun-18 | Aptose Biosciences | $125 | CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-kinase inhibitor. Aptose has been conducting Investigational New Drug enabling studies with CG-806. CG-806 demonstrated superior potency than all other FLT3 inhibitors evaluated in a recent clinical trial for patients with Acute Myeloid Leukemia. | CrystalGenomics, Inc. | Licensing Agreement | United States |
27-Jun-18 | Translate Bio | $115 | Translate Bio has announced the pricing of its initial public offering of 9,350,000 shares of its common stock at a price to the public of $13.00 per share, for total gross proceeds of approximately $121.6 million. | Citigroup; Leerink Partners | IPO | United States |
14-Jun-18 | Kadmon Corporation | $113 | Proceeds from the offerings will be used for preclinical and clinical development of Kadmon’s lead product candidates, discovery, research and preclinical studies of its other product candidates and for other general corporate purposes. | Vivo Capital | IPO | United States |
26-Jun-18 | Precision BioSciences | $110 | Precision plans to utilize the proceeds from this financing to accelerate and expand its product portfolio. Specifically, Precision targets taking its lead, off-the-shelf CAR-T product into the clinic while advancing both its lead in vivo gene therapy program into IND-enabling studies and its flagship food program into field trials. | Franklin Templeton Investments | Series B Financing | United States |
25-Jun-18 | Kaleido Biosciences | $101 | Kaleido is redefining traditional R&D with its unique discovery and development model that enables product candidates to advance rapidly into the clinic, dramatically reducing time and cost. | Abu Dhabi Investment Authority (ADIA) | Series C Financing | United States |
11-Jun-18 | RegenXBio | $100 | Novartis now holds exclusive rights to the NAV Technology Platform for developing treatments for SMA, including AVXS-101, which uses REGENXBIO's NAV AAV9 vector. In April 2018, AveXis reported that six SMA patients who had completed one month after gene transfer in the AVXS-101 trial were exhibiting motor function improvements. | Novartis | Licensing Agreement | United States |
18-Jun-18 | Stealth BioTherapeutics | $100 | The proceeds from the financings will be used to initiate a phase 2b clinical trial of Stealth's lead compound, elamipretide, in intermediate dry age-related macular degeneration, for which positive interim results were recently reported | Atlantis Investment Management | Research Agreement | United States |
13-Jun-18 | Eisai Center for Genetics Guided Dementia Discovery | $100 | Eisai Co., Ltd. has announced that it has decided to establish the Eisai Center for Genetics Guided Dementia Discovery (“G2D2”), a new exploratory research facility focused on immuno-dementia based on human genetics, aimed at innovative drug discovery in the field of dementia, in Cambridge, Massachusetts, the United States. Using genetic information as a starting point, G2D2 is aiming to control neural inflammation which is a primary cause of dementia along with amyloid beta (A?) and tau, and br | Eisai Co., Ltd. | Research Agreement | United States |
29-Jun-18 | Neon Therapeutics | $100 | The gross proceeds from the offering were $100.0 million before deducting underwriting discounts and commissions and estimated offering expenses. In addition, the underwriters have a 30-day option to purchase up to 937,500 additional shares of common stock at the initial public offering price less underwriting discounts and commissions. All of the shares in the offering were offered by Neon Therapeutics. | Morgan Stanley | IPO | United States |
20-Jun-18 | Xeris Pharmaceuticals | $86 | To develop and commercialize ready-to-use injectable and infusible drug formulations | RBC Capital Markets | IPO | United States |
07-Jun-18 | SutroVax | $85 | Proceeds of the financing will be used to advance the company’s potentially best-in-class broad-spectrum pneumococcal conjugate vaccine (PCV) candidate through mid-stage clinical development and continue to expand its pipeline of novel vaccines. | TPG Growth | Series C Financing | United States |
29-Jun-18 | Jazz Pharmaceuticals | $80 | Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S. | TerSera Therapeutics LLC | Asset Acquisition | Ireland |
20-Jun-18 | Kezar Life Sciences | $75 | To advance KZR-616 for the treatment of lupus and lupus nephritis through its KZR-616-002 Phase 1b/2 clinical trial and for the treatment of idiopathic inflammatory myopathies and up to three additional autoimmune indications into Phase 1b or Phase 2 clinical trials. | Jefferies LLC | IPO | United States |
18-Jun-18 | Evotec AG | $71 | Evotec will accelerate the infectious disease research pipeline development and initiate new open innovation R&D initiatives in anti-infectives. The initial focus areas will be on antimicrobial resistance and superbug infections, Tuberculosis and Malaria, as well as the creation of novel antiviral therapies with new mechanisms of action. | Sanofi | Collaboration | Germany |
26-Jun-18 | Cibus | $70 | The funding will be used to commercialize Cibus’ first commercial product, SU Canola — a non-transgenic (non-GMO) sulfonylurea tolerant weed control crop — and to accelerate research and development of an expanding portfolio of impactful, high-value, non-transgenic crops, including early releases of canola, flax, rice and potato followed by traits in every major crop. In its first two years on the market, SU Canola has sold out of inventory, and experienced triple digit sales growth, with contin | Fidelity Management | Series C Financing | United States |
06-Jun-18 | Metacrine, Inc., | $65 | Metacrine’s lead program is focused on the farnesoid X receptor (FXR). FXR represents a promising target to treat non-alcoholic steatohepatitis (NASH), a debilitating condition that is becoming a leading cause for liver transplant. Proceeds will support clinical development of FXR program in NASH and GI diseases. | Venrock Healthcare Partners | Series C Financing | United States |
19-Jun-18 | Alpha Biopharma Inc. | $65 | The proceeds from this financing will be used to conduct a global multi-center Phase II clinical study of AZD3759, AlphaBio's lead product, as well as expansion of AlphaBio's product pipeline. | Qiming Capital | Series A Financing | China |
05-Jun-18 | Nimbus Therapeutics | $65 | “We have made substantial progress across our entire portfolio, including inhibitors of Tyk2 (tyrosine kinase 2) and antagonists of STING (stimulator of interferon genes), both under our immunology alliance with Celgene. Additionally, our wholly owned STING agonist program has generated novel, highly potent, bona fide small molecules with compelling preclinical data.” Tyk2 is an important signal-transduction kinase for key pro-inflammatory cytokine receptors, including IL-23, IL-12 and interfero | Atlas Venture | Financing | United States |
11-Jun-18 | Massachusetts Mfg Facility | $60 | WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit patients around the world. | WuXi AppTec | Manufacturing Investment | United States |
26-Jun-18 | Skyhawk Therapeutics, Inc | $60 | The collaboration grants Celgene the exclusive option to in-license worldwide intellectual property rights associated with therapeutic candidates for up to five programs with potential utility in the treatment of amyotrophic lateral sclerosis (ALS), Huntington's Disease, and additional neurological disorders. | Celgene Corporation | Commercialization Agreement | United States |
20-Jun-18 | Pacira Pharmaceuticals, Inc. | $58 | The aim of the collaboration is to advance the development and commercialization of EXPAREL® (bupivacaine liposome injectable suspension) in China. | Nuance Biotech Co. Ltd | Licensing Agreement | United States |
19-Jun-18 | Decibel Therapeutics | $55 | The proceeds from the financing will be used to advance Decibel’s clinical and preclinical product candidates as well as to build out its comprehensive hearing drug discovery and development platform and capabilities | Third Rock Ventures | Series C Financing | United States |
27-Jun-18 | Carisma Therapeutics | $53 | Carisma Therapeutics' discovery and development efforts are focused on their proprietary CAR-Macrophage platform – the first technology to combine antigen recognition with the effector function of macrophages. The proposed dual mechanism of action includes the ability to directly kill targeted cells and the ability to leverage antigen-presenting cell biology to mount an adaptive immune response. | AbbVie | Series A Financing | United States |
11-Jun-18 | Juvenescence AI | $50 | Juvenescence has built an outstanding team of researchers and drug developers, led by Dr Declan Doogan and Dr Annalisa Jenkins. The company’s partnership and licensing model targets projects where Juvenescence holds a significant interest in promising novel technologies, using its world-class team to help to shepherd these therapies towards clinical proof of concept and commercialisation. | Institutional Investors | Series A Financing | Isle of Man |
03-Jun-18 | Quantum Surgical | $50 | Quantum Surgical is developing next-generation robotic solutions for minimally invasive cancer therapies. Quantum's predecessor company Medtech SA, a leading French neurosurgical robotics company, was acquired by global orthopaedics giant Zimmer Biomet in 2016 after an investment from ABG in 2015. | Ally Bridge Group | Series A Financing | France |
12-Jun-18 | Universidade Católica Portuguesa | $50 | The Project Consortium aims to explore means of using waste from fermentation to develop new products and applications from co-products. This valorization of co-products is expected to significantly reduce production cost and create additional sustainability in the production process. | Amyris, Inc. | Partnership | Portugal |
27-Jun-18 | Ligand Pharmaceuticals | $47 | Ligand will continue to be eligible to earn royalties at the same rate and terms as the previous agreement and the pre-defined contract payments have been eliminated. With this new business relationship, WuXi Bio believes it will be able to increase the number of OmniAb antibodies it discovers for its clients in China and around the world. | WuXi AppTec | Licensing Agreement | United States |
04-Jun-18 | Enyo Pharma | $47 | ENYO Pharma lead candidate, EYP001, is an orally bioavailable small molecule currently being evaluated in phase Ib in patients with chronic hepatitis B. EYP001 is a synthetic non-steroidal, non-bile acid FXR agonist with a very good tolerability profile. | Andera Partners | Series B Financing | France |
14-Jun-18 | Verastem Oncology | $43 | Verastem Oncology, a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, announced a registered sale to funds of 7,166,666 shares of the Company’s common stock at a price of $6.00 per share. The gross proceeds to Verastem Oncology from the offering are expected to be approximately $43.0 million. | Consonance Capital | IPO | United States |
27-Jun-18 | Starpharma | $40 | Starpharma licenses VivaGel® BV to Mundipharma for Europe, Russia, CIS1 and the balance of Latin America to be marketed as part of the popular BETADINE® Feminine Care portfolio | Mundipharma | Licensing Agreement | Australia |
26-Jun-18 | Skyhawk Therapeutics, Inc | $40 | Skyhawk launched earlier this year with a focus on the development of small molecule therapeutics that correct RNA mis-splicing that is typically called "exon skipping." That error occurs when key regions on the RNA are left out during the RNA splicing process. Skyhawk is developing proprietary technology that “enables the rational design of small molecules that target specific binding pocket regions on RNA, using both sequence and structural specificity, at particular moments in the RNA splic | Alexandria Venture Investments | Equity Investment | United States |
19-Jun-18 | Emulate | $36 | The proceeds will expand product suite and commercialization of Human Emulation System™ as a comprehensive platform for use across the entire drug discovery and development process | Founders Fund | Series C Financing | United States |
05-Jun-18 | Hangzhou Just Biotherapeutics | $35 | To enhance R&D capabilities and accelerate clinical trials globally | Hillhouse Capital | Series B Financing | China |
13-Jun-18 | Pharnext SA | $24 | The financing consists of three tranches of bonds with an annual interest rate of EURIBOR+11%. The first tranche of €11.5 million will be issued on June 30, 2018 at the latest, the second tranche of €3.5 million will be issued on July 30, 2018 at the latest and the third tranche of €5 million could be issued at Pharnext’s will and following top-line results from Pharnext’s ongoing pivotal Phase 3 trial of PXT3003, its lead drug candidate for the treatment of Charcot-Marie-Tooth disease type 1A ( | IPF Partners | Financing | France |
29-Jun-18 | Broad Institute of MIT and Harvard | $22 | Research in the newly launched Precision Cardiology Laboratory will bring scientists from both organizations into an integrated work space at the Broad Institute, effectively combining Broad’s innovative methods for basic scientific discovery and the clinical expertise of its practicing physician/researchers with Bayer’s long history of drug development. | Bayer | Launch & Partnerships | United States |
28-Jun-18 | NBE-Therapeutics | $20 | NBE develops next-generation ADCs based on its proprietary site-specific SMAC-conjugationTM technology and a novel ultra-potent anthracycline-based toxin platform with the objective to develop first- and best-in-class ADC product candidates against tumor targets in cancer indications of high, unmet medical need. | PPF Capital Partners Fund (PPF) | Series B Financing | Switzerland |
07-Jun-18 | Oncologie | $17 | Building a pipeline of First and Best-in-Class clinical stage drug candidates through licensing and partnering, Oncologie is leveraging the recent regulatory changes in China to conduct parallel clinical development in China and the US to bring the next wave of Immuno-Oncology products to the two most important markets simultaneously. Oncologie is developing multiple global programs currently in Phase 2 and Phase 3 whose mechanisms are designed to combine with immune checkpoint inhibitors to imp | Pivotal bioVenture Partners | Seed Financing | China |
11-Jun-18 | Complement Pharma | $16 | The aim of this partnership to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders. C6 inhibition prevents the formation of the destructive membrane attack complex (MAC), a complex of terminal complement proteins that mediate cellular injury following complement activation, and has the potential to treat a variety of central nervous system disorders. | Alexion Pharmaceuticals | Partnership | The Netherlands |
25-Jun-18 | InVivo Therapeutics Holdings Corp. | $15 | InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. | Ladenburg Thalmann & Co. Inc | IPO | United States |
28-Jun-18 | Lupin Limited | $15 | Through the partnership agreement, Mylan will commercialize Lupin's proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia. | Mylan N.V. | Partnership | India |
28-Jun-18 | Nuance Biotech Co. Ltd | $15 | Series B fundraising led by C-Bridge Capital to commercialize high-value pharmaceutical | C-Bridge Capital | Series B Financing | China |
14-Jun-18 | Benchling | $15 | The new funding comes as the company’s ARR skyrocketed 500% and its customer base tripled year-over-year. Today, more than 100,000 scientists across enterprises and academia are using Benchling. Since its last funding round in 2016, Benchling has seen leading pharmaceutical and biotech customers, such as Regeneron Pharmaceuticals, Incyte, Editas Medicine, Agenus, Zymergen, and Obsidian Therapeutics, standardize on its R&D platform. | Benchmark | Series B Financing | United States |
26-Jun-18 | Agios | $12 | This is an exclusive collaboration and license agreement for the development and commercialization of ivosidenib (TIBSOVO®; AG-120) in Mainland China, Hong Kong, Macau and Taiwan (“Territory”), either as a monotherapy or in combination with other therapies. Discovered and developed by Agios, ivosidenib is an investigational, first-in-class, oral, targeted inhibitor of the mutant isocitrate dehydrogenase-1 (IDH1) enzyme. CStone Pharmaceuticals will be responsible for conducting the development an | CStone Pharmaceuticals | Licensing Agreement | United States |
15-Jun-18 | Recipharm | $11 | SERB has in parallel entered into a long term manufacturing agreement with Recipharm for the supply of the product. Recipharm will continue to use its expertise in manufacturing to serve the market with a very important product whereas SERB, who specializes in the area of emergency care, can further develop the market for ThyroSafe® | SERB Pharmaceuticals | Divestment | Sweden |
27-Jun-18 | argenx | $10 | Over the course of the past two years, argenx has been eligible to receive two preclinical milestones of $ 10 million each. The second milestone was achieved for the molecule ARGX-115. ARGX-115 was discovered under argenx’s Innovative Access Program with the de Duve Institute / Université Catholique de Louvain / WELBIO and exclusively licensed under a research and option agreement in 2013. | AbbVie | Milestone Payment | The Netherlands |
19-Jun-18 | PureTech Health | $8 | Trust Award to Advance Karuna’s lead product candidate KarXT (Karuna-Xanomeline-Trospium)Phase 2 Product Candidate for the Treatment of Schizophrenia | Wellcome Trust | Grants & Awards | United States |
11-Jun-18 | RSP Systems | $8 | The proceeds of this round will be used to fund more extensive clinical trials, allowing RSP Systems to prepare for regulatory approval and market launch with a stand out product that will revolutionize the way diabetes is managed. | Jürgen Hambrecht (BASF) | Series B Financing | Denmark |
05-Jun-18 | Hancock Jaffe Laboratories | $8 | Gross proceeds from the IPO amount to $7,500,000 before underwriting discounts and commissions. | Network 1 Financial Securities, Inc. | IPO | United States |
01-Jun-18 | Processa Pharmaceuticals | $7 | The Company intends to use all proceeds from the private placements to fund the research and development (Phase 2 related activities) of its lead product candidate, PCS-499, and for general corporate purposes. | Undisclosed | Private Placement | United States |
26-Jun-18 | PharmaMar | $4 | PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3,000,000 from Chugai | Roche | Licensing Agreement | Spain |
25-Jun-18 | Evotec AG | $4 | Evotec receives € 3 million payment from Sanofi. This milestone was triggered after Evotec met pre-agreed critical success criteria for a potential manufacturing process for generation of human induced pluripotent stem cell (iPSC)-derived beta cells, including the demonstration of upscaling potential and suitability of the cell product for encapsulated beta cell function in diabetes models. The goal of the collaboration is to develop a beta cell replacement therapy based on beta cells derived fr | Sanofi | Collaboration | Germany |
19-Jun-18 | Winpoint Health LLC | $2 | The acquisition of Winpoint Health LLC offers strategic synergies with our HealthDatix Inc. subsidiary, providing a new and unique opportunity for physicians to identify patients eligible for Annual Wellness Visits as well as Chronic Care Management, both of which are reimbursed by Medicare. | iGambit, Inc. | Acquisition | United States |
18-Jun-18 | Elucidata Corporation | $2 | Elucidata’s tools allow drug discovery scientists to analyze complex datasets and effectively enable drug discovery. PollyTM, the company’s cloud-based data analytics platform, can drastically transform the end-to-end drug discovery process and allow for more rapid data turnaround and analysis. | Hyperplane Venture Capital | Seed Financing | United States |
01-Jun-18 | Undisclosed | $0 | Upsher-Smith will register the products with the U.S. Food and Drug Administration (FDA) and market and distribute them under its own label in thenU.S. upon FDA approval. The partner company will develop and manufacture the product exclusively for Upsher-Smith. | Upsher-Smith Laboratories, LLC | Distribution Agreement | |
01-Jun-18 | Unilabs | $0 | The purpose of the collaboration is to expand access to commercialization channels for companion diagnostics in North America and Europe, and accelerate the adoption of companion diagnostics. The companies will use globally harmonized processes to simplify the technical, regulatory and clinical complexities associated with these critical assays. | LabCorp Diagnostics | Collaboration | Switzerland |
01-Jun-18 | Addario Lung Cancer Medical Institute (ALCMI) | $0 | The goal of the study is to use Inivata's highly sensitive InVision analysis to determine the potential role for ctDNA in measuring minimal residual disease in patients following surgical resection in non-small cell lung cancer (NSCLC) to identify those patients who are in need of further therapy, and also to explore the value of ctDNA in monitoring for relapse. | Washington University, Inivata | Collaboration | United States |
01-Jun-18 | Pharmaceutical Product Development, LLC | $0 | As part of the collaboration, NeoGenomics will provide a wide range of lab testing services to support PPD® Laboratories’ oncology clinical trial activities in the U.S., Europe and Asia. | NeoGenomics | Collaboration | United States |
01-Jun-18 | Nobles Medical Technologies II, Inc. | $0 | The company is building a growth strategy with this expansion further into the European Market and The Netherlands is a key territory with the continued growth of PFO closures in Holland. NMT 2 has partnered with one of the top distributors in the region, Angiocare B.V. | Angiocare B.V. | Launch & Partnerships | The Netherlands |
01-Jun-18 | Nerviano Medical Sciences | $0 | The collaboration between Nerviano Medical Sciences and Merck will initially focus on one target and shall encompass two stages. Nerviano Medical Sciences and Merck will first conduct research work in close collaboration with each other and Merck will subsequently further develop, manufacture and commercialize selected collaboration compounds. | Merck & Co. | Collaboration | Italy |
01-Jun-18 | Medical Specialties Distributors | $0 | McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. | McKesson Corporation | Acquisition | United States |
02-Jun-18 | Digital Health Nokia | $0 | The sale is part of Nokia's honed focus on becoming a business-to-business and licensing company. We create the technology to connect the world. Powered by the research and innovation of Nokia Bell Labs, we serve communications service providers, governments, large enterprises and consumers, with the industry's most complete, end-to-end portfolio of products, services and licensing. | Eric Carreel (Withings) | Divestment | Finland |
04-Jun-18 | Centurion BioPharma Corporation, | $0 | Centurion BioPharma's LADR™ (Linker-Activated Drug Release) oncology drug candidates, LADR-7, LADR-8, LADR-9, and LADR-10, were developed by its team of discovery scientists at its German laboratories and are eligible to advance into Investigational New Drug (IND)-enabling studies. Each of the candidates are rationally designed using Centurion BioPharma's novel LADR™ technology, which enables drug compounds to be molecularly bound to albumin in the body's bloodstream and controls its release | CytRx Corporation, NantCell, Inc | Launch & Partnerships | United States |
04-Jun-18 | Veloxis Pharmaceuticals A/S | $0 | To Award First Annual ASTS-Veloxis Fellowship in Transplantation | American Society of Transplant Surgeons | Partnership | Denmark |
04-Jun-18 | Aravive Biologics, Inc. | $0 | Aravive’s lead program is focused on inhibition of the GAS6-AXL signaling axis, which is a known target associated with the growth and proliferation of multiple tumor types. In preclinical studies, GAS6-AXL inhibition has shown activity, whether achieved by a single agent or in combination with a variety of anticancer therapies including radiation therapy, immuno-oncology agents, and drugs that affect DNA replication and repair. | Versartis, Inc. | Merger Agreement | United States |
04-Jun-18 | Bio2Source CDMO | $0 | The Bio2Source initiative is facilitated by GMS Tenshi, a significant strategic investor both in Stelis Biopharma and Oncobiologics Inc. GMS Tenshi, based in Singapore is a joint-venture between Tenshi Life Sciences Private Limited, an India based life sciences company and GMS Holdings, a Jordan based group with diversified assets across the pharmaceutical and biopharmaceutical space. | Stelis Biopharma, Oncobiologics, Inc. | Launch & Partnerships | United States |
05-Jun-18 | LG Chem, Ltd. | $0 | IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by LG Chem, Ltd. and to further prove the biological activity of the antibodies. | IONTAS Limited | Collaboration | South Korea |
05-Jun-18 | Roche | $0 | TESARO and Genentech are also working together to evaluate the combination of ZEJULA and atezolizumab in patients with metastatic bladder cancer as a part of MORPHEUS, Roche's novel cancer immunotherapy development platform. MORPHEUS is a Phase 1b/2 adaptive platform to develop combinations of cancer immunotherapies more rapidly and efficiently. The planned trial will be conducted by Genentech and is expected to begin by the end of 2018. | TESARO, Inc. | Collaboration | United States |
05-Jun-18 | HPGC Medical Co., Ltd. | $0 | Wize Pharma, Inc., a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that it has signed an exclusive distribution agreement with HPGC Medical Co., Ltd. (HPGC) for the distribution in China by HPGC of a formula known as LO2A, a drug developed for the treatment of dry eye syndrome (DES), and other ophthalmological illnesses, including Conjunctivochalasis (CCH) and Sjögren's syndrome (Sjögren's). | Wize Pharma, Inc. | Distribution Agreement | China |
05-Jun-18 | IONTAS Limited | $0 | IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by LG Chem, Ltd. and to further prove the biological activity of the antibodies. | LG Chem, Ltd. | Collaboration | United Kingdom |
05-Jun-18 | Harbour BioMed | $0 | Collaboration combines Harbour’s proprietary H2L2 transgenic mouse platform for generating fully human monoclonal antibodies with Wistar’s cancer biology, immunology expertise | The Wistar Institute | Partnership | The Netherlands |
05-Jun-18 | Harbour BioMed | $0 | Harbour BioMed announced today that it has licensed its patented H2L2 fully human antibody discovery platform to Celsius Therapeutics, a newly launched company translating single-cell genomic insights into precision therapeutics. The license was issued through Harbour BioMed’s wholly owned subsidiary, Harbour Antibodies BV. | Celsius Therapeutics | Licensing Agreement | The Netherlands |
05-Jun-18 | Chong Kun Dang | $0 | Eisai wants Chong Kun Dang to concentrate on sales for clinics, and use its salespersons to focus on large-scale clients such as general hospitals and nursing hospitals. | Eisai Co., Ltd. | Distribution Agreement | South Korea |
06-Jun-18 | MetaSafe AB | $0 | MetaSafe is especially focusing on clinical phase drug metabolism studies from safety perspective, but also provides services for preclinical stage of drug development. This acquisition will strengthen Admescope's drug metabolism services further to clinical phase projects, as well as gives the benefit of having another high-quality laboratory facility. | Admescope Ltd | Acquisition | Sweden |
06-Jun-18 | Bio CDMO | $0 | Bio CDMO refers to i) outsourcing of biologic cell line development and production process, etc., and ii) manufacture outsourcing of non-clinical material, clinical material, and commercialized material. | Celltrion | Launch & Partnerships | South Korea |
06-Jun-18 | AMRI Global | $0 | AMRI the development and manufacture of active pharmaceutical ingredients (API) and drug product for Phase I clinical studies. The bulk of AMRI’s work will occur at the company’s Albany, New York, facilities. | National Institute of Allergy and Infectious Diseases (NIAID) | Contract Agreement | United States |
06-Jun-18 | Oklahoma Health Care Authority | $0 | The parties intend for initial research projects to use de-identified claims data to gain insights about medication adherence, missed diagnoses, heightened disease risk and other clinical indicators in Oklahoma's SoonerCare population. Disease states of special interest to each participant include autoimmune diseases, bone health/osteoporosis, migraine and oncology care. | Amgen | Collaboration | United States |
07-Jun-18 | Precision Medical Products, Inc., (PMP) | $0 | This acquisition will allow us to significantly strengthen the position of Röchling as a provider of sophisticated medical technology products and implement our growth strategy in the USA | Röchling Advent Tool & Mold, Inc | Acquisition | United States |
08-Jun-18 | Crawford Healthcare | $0 | With the acquisition of Crawford, Acelity expands its portfolio of advanced wound dressings (AWD), further strengthening its position as the global leader in advanced wound healing | Acelity L.P. Inc | Acquisition | United Kingdom |
11-Jun-18 | Harbour BioMed | $0 | LakePharma and Harbour Antibodies BV, a Harbour BioMed subsidiary, today announced a technology partnership providing LakePharma the right to utilize Harbour Antibodies' patented, H2L2 transgenic mouse platform in its therapeutic antibody discovery service offerings to clients in pharmaceutical and therapeutic biotechnology companies. | LakePharma | Partnership | The Netherlands |
11-Jun-18 | Insilico Medicine | $0 | The funding is intended to enhance Insilico Medicine's work in the innovative approaches to the generation of novel molecules using a variety of machine learning and deep learning techniques, as well as to expand a variety of the biomarker discovery initiatives. | WuXi AppTec | Research Agreement | United States |
11-Jun-18 | Sciformix Corporation | $0 | Sciformix’s offerings include post-marketing safety and risk management, clinical development support services, regulatory affairs and operations, technology services, and real-world evidence solutions. The majority of Sciformix’s 1,100 employees are based in Asia, accelerating Covance’s global expansion. | Covance | Acquisition | United States |
11-Jun-18 | Natural Point S.r.l. | $0 | Recordati announces the acquisition of 100% of the share capital of Natural Point S.r.l., an Italian company, based in Milan, active in the food supplements market. The company realized sales of € 15 million in 2017 and has an excellent profitability profile. The signing and closing of the transaction took place at the same time. | Recordati | Acquisition | Italy |
13-Jun-18 | HelioMetrics®n | $0 | Pharmacolog AB and HelioMetrics today announced a new partnership that will deliver solutions designed to stop drug diversion and provide safe administration of IV medications for hospitals and pharmacies in the United States. | Pharmacolog AB | Partnership | United States |
13-Jun-18 | MEDNAX, Inc. | $0 | The ERACS™ program will encompass comprehensive educational and clinical implementation pathways. The overarching goals will be to educate clinical teams, shorten the length of postoperative hospital stays, reduce the use of opioid analgesics and improve postoperative pain control. In addition, MEDNAX and Pacira will monitor a series of clinical quality, safety and value-based performance indicators including: reduced serious maternal and infant morbidity, reduced postoperative nausea and vomiti | Pacira Pharmaceuticals, Inc. | Collaboration | United States |
13-Jun-18 | LEO Pharma | $0 | The partnership marks the first step in an alliance to measure soluble biomarkers from the skin surface of atopic dermatitis patients using a non-invasive skin test technology developed by FibroTx in Estonia | FibroTx LLC | Partnership | Denmark |
13-Jun-18 | Sanofi | $0 | The acquisition of Sanofi’s manufacturing centre and business located in Holmes Chapel provides Recipharm with a solid platform to take further advantage of the growing respiratory drug market. It also adds additional inhalation commercial drug product manufacturing capabilities | Recipharm | Acquisition | France |
13-Jun-18 | KAN Research Institute, Inc. (Eisai Co., Ltd.) | $0 | This joint research project was selected by the Japan Agency for Medical Research and Development (AMED) for its Cyclic Innovation for Clinical Empowerment (CiCLE) grant program. Believing that creating innovation through industry-academia-government collaboration is an important initiative, Eisai is currently advancing multiple projects, with this project aimed at creating a Japan-originated nucleic acid drug through industry-academia-government collaboration. | Japan Agency for Medical Research and Development (AMED), Cyclic Innovation for Clinical Empowerment (CiCLE) | Research Agreement | Japan |
13-Jun-18 | Intabio, Inc. | $0 | Intabio's Blaze™ utilizes a proprietary microchip technology to separate, quantitate, and seamlessly transfer intact biotherapeutic proteins by electrospray into a mass spectrometer for molecular identification. Bruker will provide support for Intabio's development of the hardware and software to integrate the Blaze instrument to a Bruker MS. | Bruker Corporation | Collaboration | United States |
14-Jun-18 | K2 Biomedical | $0 | The acquisition will add drug development capabilities to Orion Biotechnology in Europe. K2Biomedical was initially focused on the prevention of Sexually Transmitted Infections (STIs), including HIV. With this acquisition K2Biomedical becomes Orion Biotechnology Poland SP. Z O.O. | Orion Biotechnology | Acquisition | Poland |
14-Jun-18 | InnovoCommerce | $0 | The relationship brings the convenience and security of Exostar's identity and access management platform, leveraged by nearly half of the world’s 20 largest pharmaceutical companies and the Shared Investigator Platform initiative for clinical trials, to InnovoCommerce's investigatorFIRST clinical and safety document exchange portal – providing the life sciences community with unparalleled convenience, while also meeting the need for strict controls, auditing, and security. | Exostar | Partnership | United States |
14-Jun-18 | ABS Laboratories | $0 | ABS Laboratories specializes in complex assay method development and validation for the quantification of drugs, metabolites and biomarkers in biological samples for preclinical and clinical trials including final regulatory submission. | ACM Global Laboratories (Rochester Regional Health) | Acquisition | United Kingdom |
14-Jun-18 | Celegence | $0 | The partnership between ArisGlobal and Celegence also means that life sciences companies can start to leverage the business process-as-a-service (BPaaS) model for Regulatory Affairs operations. | ArisGlobal | Partnership | United States |
15-Jun-18 | Precision Medical Products, Inc., (PMP) | $0 | Röchling Medical Lancaster will join Röchling Medical's other North American operation, New York-based Röchling Medical Rochester, formerly known as Röchling Advent Tool & Mold. The Röchling Medical Division also includes entities in Germany and China. | Röchling Group | Acquisition | United States |
18-Jun-18 | TLV | $0 | The agreement allows for reimbursement of ORKAMBI for people with cystic fibrosis who have two copies of the F508del mutation from July 1 | Vertex Pharmaceuticals | Access Agreement | Sweden |
18-Jun-18 | Translate Bio | $0 | Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has launched an initial public offering of 7,700,000 shares of its common stock. | Citigroup | IPO | United States |
18-Jun-18 | University of Adelaide | $0 | Microbiotica will analyse clinical samples from the Adelaide FMT study to identify the specific bacteria which successfully treated the condition. Microbiotica has developed the leading platform for culture-based precision metagenomics, enabling large-scale strain-level characterisation of microbiome profiles linked to patient phenotype. | Microbiotica | Collaboration | United Kingdom |
18-Jun-18 | Nichi-Iko Pharmaceutical | $0 | Developed by YL Biologics, a joint venture between Lupin’s subsidiary Lupin Atlantis Holdings SA (LAHSA) and Yoshindo, the product will be launched by Nichi-Iko after receiving approval from the Pharmaceuticals and Medical Devices Agency (PMDA). | Lupin Limited | Commercialization Agreement | Japan |
19-Jun-18 | TBD Biodiscovery | $0 | Collaboration Combines Expertise in Novel Chemical Compound Synthesis with GMP Manufacture in Drug Discovery with the aim to manage the transition of chemical synthesis of novel intermediates from laboratory to bulk scale under GMP standards utilizing Enamine’s know-how and process development expertise. | Enamine | Collaboration | Estonia |
19-Jun-18 | Kallyope Inc. | $0 | Novo Nordisk has an option to license exclusive worldwide rights to develop and commercialize up to six products discovered in the collaboration. Kallyope will receive a license fee if Novo Nordisk chooses to exercise an option to a therapeutic discovered and validated in the joint research plan and potential research, development, and sales milestones. | Novo Nordisk | Collaboration | United States |
19-Jun-18 | Medisafe | $0 | nMedisafe's Medication Management Platform to Increase Adherence, Education and Awareness of Treatments Including Pradaxa® (dabigatran etexilate mesylate) | Boehringer Ingelheim | Partnership | United States |
19-Jun-18 | Crown BioScience | $0 | CrownBio boasts the world’s largest collection of patient-derived xenograft (PDX) models and is a leading provider of humanized solutions for immuno-oncology drug development. Leveraging these exclusive capabilities, CrownBio will engraft PDX models selected by Pierre Fabre into CD34+ humanized mouse models. These customized, humanized models will be used to accelerate Pierre Fabre’s innovative immuno-oncology drug discovery pipeline. | Pierre Fabre Research Institute | Partnership | United States |
21-Jun-18 | Yiling Wanzhou International Pharmaceuticals (Shijiazhuang Yiling Pharmaceutical Co. Ltd.) | $0 | The FDA approved entecavir in 2005 for the treatment of chronic hepatitis B viral (HBV) infection.1 Entecavir is an HBV nucleoside analog reverse transcription inhibitor that interferes with HBV replication. The FDA approved cilostazol in 2006 for the reduction of symptoms of intermittent claudication.2 Cilostazol is a PDE-III inhibitor. Cilostazol inhibits platelet aggregation, improves endothelial cell function, and acts as a vasodilator enabling blood to move more easily through peripheral bl | CASI Pharmaceuticals | Contract Agreement | United States |
21-Jun-18 | Syneos Health | $0 | The collaboration will seek to build a centrally managed infrastructure and regulatory research system around physicians and patients, including deploying expert staff and providing the training and regulatory guidance needed to run a trial, removing physician burden and focusing the experience around the patient. | Elligo Health Research | Collaboration | United States |
22-Jun-18 | Molecular Neurobiology Laboratory at the University of Barcelona, Cellular and Molecular Pharmacology Laboratory of the University of Ferrara | $0 | Phytoplant Research S.L. participated in a first-ever pioneering collaborative project to investigate the ability of cannabinoid cannabigerol (CBG), the molecular precursor of ?9-tetrahydrocannabinol (? 9-THC) and cannabidiol (CBD). The study investigated the ability of the above to modulate the affinity and functionality of type-1 and type-2 cannabinoid receptors (CB1 and CB2, respectively) and CB1–CB2 heteroreceptor complexes. | Phytoplant Research S.L. | Collaboration | Spain |
22-Jun-18 | Diakonos Research, Ltd. | $0 | This new path breaking technology effectively targets and activates the tumor antigen specific CTL-response and is differentiated from peer technologies in its ability to generate durable immunological memory. | APAC Biotech | Licensing Agreement | United States |
25-Jun-18 | Janssen Pharmaceuticals | $0 | The acqusition adds OTC brand Nizoral to Kramer's portfolio. Nizoral is one of the most widely-recognized and highly-trusted brands in therapeutic hair care. | Kramer Laboratories, Avista Capital Partners | Asset Acquisition | Belgium |
25-Jun-18 | BioCryst Pharmaceuticals | $0 | The Phase 3 trial design agreed upon for Japan, APeX-J, is a randomized, placebo-controlled double-blind trial of 24 weeks duration with a 28-week safety extension. Approximately 24 Japanese subjects with HAE will be enrolled. The APeX-J trial design closely follows the design of APeX-2, a Phase 3 clinical trial being conducted in the U.S., Canada and European countries. APeX-J tests the same dose levels of BCX7353 as in APeX-2, 110 mg daily and 150 mg daily, and the endpoints are identical to t | Pharmaceuticals and Medical Devices Agency (PMDA) | Clinical Collaboration | United Kingdom |
25-Jun-18 | Gossamer Bio | $0 | The two companies have agreed that the development and commercialization of Aerpio’s HIF-1 alpha stabilizer, AKB-4924, along with other related compounds. AKB-4924 (to be known as GB004) is an investigational hypoxia-inducible factor-1 alpha (HIF-1 alpha) stabilizer in development for IBD. Unlike other HIF stabilizers in clinical development, which stabilize HIF-2 and stimulate erythropoiesis, GB004 preferentially stabilizes HIF-1 alpha, and has profound anti-inflammatory and mucosal wound heali | Aerpio Pharmaceuticals, Inc. | Licensing Agreement | United States |
25-Jun-18 | Tissue Regenix | $0 | Tissue Regenix has been granted a Human Tissue Authority (HTA) license (The HTA license will initially be used for the import of the CellRight 'BioRinse' portfolio of osteoinductive bone products from the San Antonio, Texas manufacturing facility into the UK.) to import and distribute its' portfolio of Human tissue derived products from the US for use in the UK market | Jefferies LLC | Distribution Agreement | United States |
25-Jun-18 | Transcend Nutressential International Ltd | $0 | This partnership will enable NUTRESSENT to focus on new formulations and applications for natural Astaxanthin which would be exclusive property of NUTRESSENT. Under this collaboration, AstaReal will contribute scientific and technical support to NUTRESSENT in building the science and technology of natural Astaxanthin and various exclusive formulations to the market. | AstaReal | Partnership | India |
25-Jun-18 | Synteract | $0 | At iCAN, we are dedicated to advancing the health and well-being of children around the world. An important part of that is collaborating with established partners, such as Synteract in the pediatric clinical trials space | International Children’s Advisory Network (iCAN) | Collaboration | United States |
25-Jun-18 | Harbour BioMed | $0 | For the development and manufacturing of Harbour’s leading HCAb antibody. The collaboration with WuXi Biologics will support the supply of Harbour’s products for clinical trials under Investigational New Drug (IND) applications in China and worldwide. | WuXi AppTec | Partnership | China |
25-Jun-18 | Novartis | $0 | FGF401 is being evaluated in Phase I/II clinical trials across the U.S., Europe and Asia as a potential new treatment for hepatocellular carcinoma (HCC) and other solid tumors positive for FGFR4 and KLB (klotho beta) expression. | EverNov (Everest Medicines), C-Bridge Capital | Licensing Agreement | Switzerland |
25-Jun-18 | Calibr (Scripps Research) | $0 | This collaboration broadens AbbVie's oncology research to access advanced precision medicine technology to expand the development of potentially life-changing treatments for patients with cancer. | AbbVie | Collaboration | United States |
25-Jun-18 | WCG® (WIRB-Copernicus Group®) Clinical Services Division | $0 | Under the strategic partnership, WCG and InformedDNA will launch the Center for Genetics and Precision Medicine in Clinical Trials, which will unite InformedDNA’s substantial genetics resources and expertise with WCG’s global network of 550 experts in clinical trial optimization and its proprietary industry Knowledge Base™. | InformedDNA | Clinical Collaboration | United States |
26-Jun-18 | US WorldMeds, LLC | $0 | Valeant and US WorldMeds, LLC together announced that they have entered into an exclusive agreement to co-promote US WorldMeds' LUCEMYRA™ (lofexidine). LUCEMYRA is the first and only non-opioid medication approved by USFDA for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. | Salix Pharmaceuticals | Development Agreement | United States |
26-Jun-18 | Ascletis Pharma Inc | $0 | Ganovo®, Ascletis' first innovative drug and the first direct-acting anti-viral agent developed by a domestic company in China, The two parties will work closely in distribution networks and end-user services, to prepare for the launch of Ganovo®(danoprevir). | CR Pharmaceutical Commercial Group Co., Ltd | Cooperation Agreement | China |
26-Jun-18 | Mundipharma | $0 | Mundipharma has announced the extension of its strategic partnership with Kolon Life Science to market Invossa-K in Saudi Arabia and United Arab Emirates. Invossa-K is an intra-articular injection that is non-surgical treatment option, demonstrating sustained pain reduction and functional improvement of articular joint for two years following a single injection in a US phase II clinical trial and one year in a Korean phase III clinical trial. | Kolon Life Science | Partnership | Germany |
26-Jun-18 | ArisGlobal | $0 | APCER has already been using ARISg™, ArisGlobal's on-premise safety database. The decision to adopt ArisGlobal's Multi-tenant LifeSphere® Safety MultiVigilance is rooted in its cost performance and compliance. APCER's customers will now have a more integrated solution from clinical to post-marketing PVG. | APCER Life Sciences | Launch & Partnerships | United States |
26-Jun-18 | Arcus Biosciences, Inc. | $0 | The collaboration will evaluate IPI-549 in combination with AB928, Arcus's dual adenosine receptor antagonist, and AB122, Arcus's anti-PD-1 antibody, as well as IPI-549 in combination with AB928 and chemotherapy in patients with triple negative breast cancer (TNBC) or ovarian cancer in four separate cohorts. | Infinity Pharmaceuticals, Inc. | Clinical Collaboration | United States |
26-Jun-18 | CR Pharmaceutical Commercial Group Co., Ltd. | $0 | The two parties will work closely in distribution networks and end-user services, to prepare for the launch of Ganovo®(danoprevir). | Ascletis BioScience Co., Ltd. | Cooperation Agreement | China |
26-Jun-18 | Amyris, Inc. | $0 | The joint venture named as Microbiome JV seeks to combine Amyris’s best-in-class science and technology with BGI’s gene sequencing expertise, data and analytics. The goal will be to develop health products for the Greater China market using natural products including traditional Chinese medicinal ingredients produced with sustainable resources and through Amyris’s proprietary clean fermentation capabilities. | BGI Genomics | Joint Venture | United States |
26-Jun-18 | Nektar Therapeutics | $0 | Through this collaboration, IsoPlexis will employ its IsoCode Chip's single-cell functional profiling in collaboration with Nektar Therapeutics to profile the effects of NKTR-214 in both monotherapy and combination immunotherapy in a clinical setting. IsoPlexis' platform has previously highlighted the potential of polyfunctional T cells, those cells secreting multiple cytokines, as a promising correlate to clinical patient outcome in a variety of immunotherapies. | IsoPlexis Corporation | Collaboration | United States |
26-Jun-18 | TraceLink | $0 | IBI Lorenzini, IBIGEN group, is an Italian-based, family-run pharmaceutical company and contract manufacturing organization (CMO) that was founded over 100 years ago. TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced that IBI Lorenzini has selected TraceLink's solutions to ensure compliance with global serialization regulations. | IBI Lorenzini | Supply Agreement | United States |
27-Jun-18 | AstraZeneca | $0 | The center will be based around LUMICKS' C-Trap™ optical tweezers-fluorescence microscope, which for the first time enables real-time observation and probing of biomolecular interactions. The approach will be pioneered in several pharmacology and biology assays with the aim of accelerating the discovery of potential new drugs. | LUMICKS | Collaboration | United Kingdom |
27-Jun-18 | Berkeley Lights, Inc. | $0 | Through the collaboration the companies will combine BLI’s antibody discovery platform for B cells with ChemPartner’s expertise in assay development. The Beacon platform is capable of automatically screening thousands of plasma B cells or gene-edited cells, which speeds up a traditionally time-consuming, manual process. | ChemPartner Co., Ltd. | Collaboration | United States |
27-Jun-18 | Antibióticos de León (ADL Biopharma) | $0 | Amyris is now expanding its production contract with ADL in order to provide additional, cost-effective manufacturing capability to meet the higher than expected demands from its partners. ADL Biopharma is one of the first CMOs that Amyris has used to successfully produce farnesene. | Amyris, Inc. | Contract Agreement | Spain |
28-Jun-18 | Helsinn Group | $0 | Helsinn has worked with Eisai since 2003 on ALOXI®, a trusted anti-emetic for helping adult patients prevent nausea and vomiting, when it happens right away or later (up to five days) with certain chemotherapy medications, and the product has become the preferred treatment in the national guidelines for chemotherapy-induced nausea and vomiting (CINV) in the U.S. | Eisai Co., Ltd. | Distribution Agreement | United States |
28-Jun-18 | PillPack | $0 | PillPack is a pharmacy designed to provide the best possible customer experience in the U.S. for people who take multiple daily prescriptions. PillPack delivers medications in pre-sorted dose packaging, coordinates refills and renewals, and makes sure shipments are sent on time. | Amazon.com Inc. | Acquisition | United States |
28-Jun-18 | Menarini Asia-Pacific | $0 | Singapore based A. Menarini Asia-Pacific Holdings Pte Ltd (“Menarini Asia-Pacific”) and Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”) have signed a multi-year exclusive licensing agreement for Menarini Asia-Pacific to assume the sales, marketing and distribution of the oral, once-daily, direct factor Xa inhibitor, edoxaban (brand name; LIXIANA®), in the Philippines, Malaysia and Singapore, following respective regulatory approvals in those countries. | Daiichi Sankyo | Licensing Agreement | Singapore |
28-Jun-18 | Royal Philips | $0 | Philips IntelliSite Pathology Solution is the first, and currently the only, digital pathology solution marketed for primary diagnostic use in the US. Through the implementation of the Philips IntelliSite Pathology Solution , LabCorp will incorporate digitized workflows within its anatomic pathology services, which are an integral component of its comprehensive clinical laboratory and end-to-end drug development services. | LabCorp Diagnostics | Collaboration | United States |
28-Jun-18 | RedHill Biopharma | $0 | Mytesi® is the fourth product to be promoted by RedHill's gastrointestinal-focused U.S. salesforce, setting the stage for potential U.S. launch of RedHill’s late clinical-stage products, including TALICIA® (RHB-105) for H. pylori infection, with confirmatory Phase III study top-line results expected in Q4/2018 | Napo Pharmaceuticals (Jaguar Health, Inc.) | Development Agreement | Israel |
28-Jun-18 | Kymab Group Ltd | $0 | Under this Clinical Trial Collaboration Agreement, Roche will provide its PD-L1 blocking antibody atezolizumab for use in combination with Kymab's lead investigational anti-ICOS antibody therapy KY1044 in Kymab's upcoming Phase I/II clinical studies in patients with advanced solid cancers. | Roche | Clinical Collaboration | United Kingdom |
28-Jun-18 | Prestige BioPharma | $0 | The partnership arrangement includes the exclusive rights for Alvogen to commercialize Hervelous (trastuzumab) in all of its CEE markets, leveraging the company's strong sales and marketing capabilities and experience in successfully bringing new biosimilars to market. | Alvogen | Licensing Agreement | Singapore |
28-Jun-18 | ProZyme, Inc. | $0 | ProZyme is an industry leading developer and manufacturer of glycan reagents, kits and standards, which are required for efficient sample prep in the analysis of free glycans. Glycans play diverse roles in biotherapeutics, novel drug development, the study of bacterial physiology, and proteomics research. | Agilent Technologies | Acquisition | United States |
28-Jun-18 | HumanCode | $0 | Illumina’s personal genomics spinout Helix is expanding its senior commercial leadership team, alongside the acquisition of smartphone application developer HumanCode, adding to its momentum following a planned $200 million venture capital round. HumanCode has previously partnered with Helix, but now its staff will join the company to help build out its end-to-end, customer-facing platforms. | Helix Biosciences | Acquisition | Canada |
29-Jun-18 | DSM Sinochem Pharmaceuticals | $0 | DSM Sinochem Pharmaceuticals (“DSP”) develops, produces and sells intermediates, active pharmaceutical ingredients and finished dosage form pharmaceuticals. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, and Sinochem Group, a Fortune 500 enterprise. Bain Capital Private Equity has partnered closely with management teams to provide the strategic resources to companies and works together to create value for its portfolio compa | Bain Capital Private Equity | Acquisition | Singapore |
29-Jun-18 | FLAVORx | $0 | MEDISCA, the industry leader in providing high quality compounding solutions and services to pharmacists worldwide, proudly announced today that through its collaboration with FLAVORx, it will now provide this exclusive product offering to the Canadian market. This agreement is based on a successful three-year collaboration with FLAVORx in the United States, for which MEDISCA holds exclusive distribution rights for the pharmaceutical compounding industry. | MEDISCA | Distribution Agreement | United States |
29-Jun-18 | Undisclosed | $0 | Both the parties shall establish a jointly-owned new Israeli entity, which will initially be controlled 50/50 by each of the parties. The new entity will focus on exploring the potential of alleviating the effects of eye disorders and infections using cannabinoids, while reducing use of steroid based products which are currently widely used. | Cannabics Pharmaceuticals Inc. | Memorandum of Understanding | |
29-Jun-18 | Consortia Health | $0 | Consortia will offer its patients vFit PLUS™ to help enhance vaginal wellness and improve sexual function post Consortia's training program. vFit PLUS is the world's first patented home-use feminine rejuvenation device using red-light (LED) technology. | Joylux, Inc. | Partnership | United States |
29-Jun-18 | Peptonic Medical AB | $0 | Peptonic Medical AB announced today that they have entered a tech transfer agreement with Orion CMO to prepare for the commercial manufacture of VagiVital™ - a product that Peptonic plans to launch in 2018. | Orion Corporation | Distribution Agreement | Finland |
19-Jul-18 | MorphoSys AG | $1,095 | This is an exclusive global license agreement with Novartis, for MOR106, a monoclonal antibody directed against IL-17C, will be developed further in atopic dermatitis (AtD) and potentially other indications. Novartis will bear all future research, development, manufacturing and commercialization costs related to MOR106 and will be exclusively holding all rights for commercialization of the products. | Novartis | Licensing Agreement | Germany |
23-Jul-18 | Anima Biotech | $1,050 | The multi-year agreement is structured as an exclusive collaboration around several undisclosed Lilly targets. Anima will use its technology platform to discover lead candidates that are translation inhibitors of the Lilly targets. Lilly will be responsible for clinical development and commercialization of products resulting from the collaboration. | Eli Lilly and Company | Collaboration | United States |
20-Jul-18 | PureTech Health | $1,000 | PureTech’s milk exosome-based technology is designed to facilitate the oral administration of complex payloads such as nucleic acids, peptides, and small molecules. The exosome platform aims to package up drugs with large or complex payloads in a way that allows them to move through the digestive system without degrading so they can reach the target cell or tissue. Through the Collaboration, PureTech Health will receive up to $36 million upfront and will be eligible to potentially receive develo | Roche | Collaboration | United States |
19-Jul-18 | Agilis Biotherapeutics, Inc. | $945 | The lead gene therapy candidate, GT-AADC, has compelling clinical data in treating Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency. AADC Deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. | PTC Therapeutics | Acquisition | United States |
24-Jul-18 | Protalix BioTherapeutics, Inc. | $760 | Protalix to receive $25 million upfront, an additional up to $20 million in development costs and an additional up to $760 million in potential regulatory and commercial milestone payments for the U.S. rights. The focus of the Partnership is on the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease. | Chiesi Farmaceutici S.p.A. | Supply Agreement | Israel |
26-Jul-18 | Chugai Pharmabody Research Pte. Ltd. | $555 | CPR was established in 2012 to conduct research focused on the discovery of novel antibody drugs by utilizing innovative antibody engineering technologies owned by Chugai. | Roche | Expansion | Singapore |
18-Jul-18 | Revolution Medicines | $500 | In the collaboration, the companies will jointly develop SHP2 inhibitors, which are designed to reduce cell growth signaling that is overactive in cancer. Both parties will contribute to the research and development program, with REVOLUTION Medicines continuing to lead research and early clinical development, and Sanofi leading later development activities for the program. | Sanofi | Partnership | United States |
24-Oct-18 | Innovent Biologics | $421 | The IPO prospectus has not specified the size and pricing of the offering yet but an earlier report by Reuters said the Suzhou, Jiangsu province-based company is seeking to raise up to $500 million. Innovent has raised almost $600 million through five rounds of equity funding since its inception seven years ago. In April, Temasek joined a $150-million Series E funding round in the company. | Temasek Holdings (Private) Ltd | IPO | China |
24-Jul-18 | Modular Aseptic Processing (MAP) Unit | $465 | Known as Modular Aseptic Processing (MAP), the new, multi-story, 400,000-square-foot production facility will also support the area economy by creating an estimated 450 new jobs over the next several years. This expands Pfizer’s presence in Portage, located in Kalamazoo County, where the company now employs more than 2,200 people at one of its largest plants. | Pfizer Inc. | Manufacturing Investment | United States |
20-Jul-18 | Swedish Orphan Biovitrum AB (publ) (Sobi™) | $450 | Strategic partnership to develop and commercialise emapalumab, a highly attractive late stage orphan drug candidate that addresses a high unmet medical need in primary Haemophagocytic lymphohistiocytosis | Novimmune SA | Licensing Agreement | Sweden |
11-Jul-18 | Visterra Inc. | $430 | Visterra’s Hierotope platform comprises novel computational and experimental technologies, which enables the design and engineering of precision antibody-based therapies that specifically bind to disease targets. Visterra’s pipeline includes programs targeting IgA nephropathy and other kidney diseases, cancer, chronic pain and infectious diseases. Otsuka’s research areas are in psychiatric and neurological diseases, hematological cancers, with an emphasis on proprietary drug discovery and develo | Otsuka Pharmaceutical | Acquisition | United States |
23-Jul-18 | Halo Pharma | $425 | With the acquisition of Halo, Cambrex will enter the large and growing finished dosage form CDMO market. Halo provides drug product development and commercial manufacturing services, specializing in oral solids, liquids, creams, sterile and non-sterile ointments. Halo’s core competencies include developing and manufacturing highly complex and difficult to produce formulations, products for pediatric indications and controlled substances. | Cambrex Corporation | Acquisition | United States |
19-Jul-18 | Ascletis Pharma Inc | $400 | Ascletis, which makes anti-viral, cancer and liver disease drugs, sold 224 million new shares, or 20 percent of its enlarged share capital, at HK$14 ($1.78) each, the middle of a price range of HK$12 to HK$16, the people said. The deal values the company at $2 billion. Ascletis's lead products are Ganovo ® and ravidasvir, which are novel anti-viral drugs. Singapore sovereign wealth fund GIC Pte Ltd [GIC.UL] last week committed to buy $75 million worth of shares as a cornerstone investor. | GIC Private Limited | IPO | China |
12-Jul-18 | GlaxoSmithKline | $330 | Tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), has been tested as a topical treatment in more than 800 patients in phase 1 and 2. In a dose-ranging study involving 227 adults with plaque psoriasis, tapinarof brought about "clinically meaningful, dose-dependent improvements." | Dermavant Sciences | Asset Acquisition | United Kingdom |
31-Jul-18 | Bayer | $323 | Bayer’s global medical dermatology portfolio, which includes prescription treatment solutions for acne (Skinoren®), fungal skin infections (Travogen® and Travocort®) and rosacea (Finacea®), and a range of topical steroids (Advantan®, Nerisona®, and Desonate®). The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin infections and rosacea, and a range of topical steroids. | Leo Pharma | Business Unit Acquisition | United States |
11-Jul-18 | Forbion IV Fund | $312 | Forbion IV, like its predecessor fund, Forbion III, will primarily focus on EU and the UK (together c. 80% of investment), with the remainder of the fund targeting opportunities in North America, and will have an even sharper focus on biotech. | Forbion | Financing | The Netherlands |
25-Jul-18 | 23andMe | $300 | The collaboration will combine 23andMe’s large-scale genetic resources and advanced data science skills, with the scientific and medical knowledge and commercialisation expertise of GSK. The goal of the collaboration is to gather insights and discover novel drug targets driving disease progression and develop therapies for serious unmet medical needs based on those discoveries. | GlaxoSmithKline | Collaboration | United States |
23-Jul-18 | Rubius Therapeutics | $274 | Rubius Therapeutics is pioneering the development of a new class of medicines, Red Cell Therapeutics, or RCTs. Rubius has designed a proprietary platform to genetically engineer and culture RCTs that are selective, potent and ready-to-use cellular therapies. | J.P. Morgan | IPO | United States |
23-Jul-18 | Long Hill Capital Fund 2 | $265 | Long Hill Capital has rapidly emerged to become a leader in healthcare and consumer investing in China, bringing total capital under management to over $400 million. | New Enterprise Associates | Financing | China |
27-Jul-18 | Reata Pharmaceuticals | $249 | Reata intends to use the net proceeds from the offering for working capital to advancing the development of bardoxolone methyl and omaveloxolone through clinical trials, preparing to file one or more New Drug Applications, and planning for commercialization of its potential products. | Jefferies LLC | IPO | United States |
10-Jul-18 | Center for Veterinary Public Health | $231 | The company will establish the new site in the French Rhône-Alpes region, which is known as the European “vaccine valley”. With this investment, Boehringer Ingelheim’s Animal Health division will be able to respond to the growing global demand for foot-and-mouth disease and Bluetongue virus control. | Boehringer Ingelheim | Manufacturing Investment | France |
23-Jul-18 | Gossamer Bio | $230 | Gossamer Bio is a San Diego-based biopharmaceutical company focused on discovering, developing, and commercializing immunology-based therapeutics in the autoimmune, allergy/inflammation, and immuno-oncology disease areas. The Company intends to use the proceeds from this financing for progress in the clinical trials for multiple early and late-stage drug candidates, and to secure additional business development opportunities. | Hillhouse Capital | Series B Financing | United States |
24-Jul-18 | Cheplapharm Arzneimittel GmbH | $210 | Atacand (candesartan cilexetil) is a selective, AT1 subtype angiotensin II receptor antagonist blocker (ARB) that is indicated for the treatment of hypertension and heart failure. | Cheplapharm Arzneimittel GmbH | Divestment | Germany |
05-Jul-18 | West Greenwich Facility | $200 | The new plant is the first-of-its-kind in the U.S. and will use Amgen's proven next-generation biomanufacturing capabilities to manufacture products for the U.S. and global markets. | Amgen | Manufacturing Investment | United States |
25-Jul-18 | Smithfield, Rhode Island Facility | $155 | The new facility will help the company scale its manufacturing process in order to produce large quantities of Red Cell Therapeutic product candidates and lentiviral vectors needed to encode biotherapeutic proteins inside or on the surface of each Red Cell Therapeutic. The facility will be customized to contain multiple manufacturing suites, which will enable Rubius to conduct its manufacturing operations in a cGMP compliant manner for clinical supply and, if approved, for the commercial supply | Rubius Therapeutics | Purchase Agreement | United States |
04-Jul-18 | LinkDoc Technology Ltd. | $151 | LinkDoc collects and standardizes healthcare data, covering more than 3,000 diseases, from hospitals and provides customized data for healthcare regulators, researchers, insurers and pharmaceutical companies. It has partnered with about 500 first-tier hospitals in more than 30 provinces and regions in China. | China Investment Corporation (CIC) | Series D Financing | China |
17-Jul-18 | Ascentage Pharma | $150 | Ascentage Pharma has 16 active clinical trials in the U.S., Australia, and China, which the Company believes makes it one of the few companies with a robust portfolio of active clinical programs focused on both intrinsic and extrinsic apoptotic pathways. The Company's R&D products are aimed towards realizing the full potential of protein-protein inhibition in addressing promising targets in cancer. | Oriza Seed Venture Capital | Series C Financing | China |
27-Jul-18 | Curon Biopharmaceutical | $150 | Curon Biopharma currently holds multiple promising novel cancer immuno-therapeutic agents in its pipeline, and is committed to bring next generation cancer immunotherapies to patients. Proceeds from the financing will be used to accelerate Curon’s pipeline assets into pre-clinical and clinical phases. | 6 Dimensions Capital | Series A Financing | China |
31-Jul-18 | Medlinker | $147 | Medlinker is specially designed for doctors who can share their expertise, experiences, and opinions with other elites in the industry through the platform. It connects over 500,000 verified doctors with healthcare institutions, pharmaceutical companies, patients and insurance firms, according to its website. | China Capital Zhongcai Fund | Series D Financing | China |
03-Jul-18 | Juniper Pharmaceuticals, Inc. | $140 | The acquisition combines Catalent’s existing industry-leading drug development and manufacturing capabilities in the U.S. and Europe with of Juniper will expand and strengthen Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing, and will complement its integrated global clinical and commercial supply network. | Catalent Pharma Solutions | Acquisition | United States |
12-Jul-18 | Compass Therapeutics | $132 | Compass is pioneering a new approach to identifying antibody drug candidates that engage all targets in the biologically complex human immune synapse, with an initial focus on T cells, NK cells and macrophages. The company’s lead product platform StitchMabs™ is a novel and proprietary high-throughput bispecific screening platform, enables the rapid identification of synergistic bispecific activity. | F-Prime Capital Partners | Series A Financing | United States |
12-Jul-18 | Arcus Biosciences, Inc. | $130 | AB928 is an orally bioavailable, highly potent antagonist of the adenosine 2a and 2b receptors. The activation of these receptors by adenosine interferes with the activity of key populations of immune cells and inhibits an optimal anti-tumor immune response. | Taiho Pharmaceutical Co., Ltd. | Option Agreement | United States |
24-Jul-18 | Essen Technology | $129 | Essen Technology is a specialized enterprise of drug-eluting stents. Terumo has grown rapidly in China selling interventional products, such as guidewires and balloon catheters. Terumo has expanded its drug eluting stents' sales coverage to include Japan, Europe, Asia, and Latin America, for a total of over 40 countries. | Terumo Corporation | Acquisition | China |
10-Jul-18 | BpiFrance | $116 | Sanofi has signed a memorandum of understanding with Bpifrance to launch InnoBio 2. By providing € 50 million to this fund, which will invest particularly in the digital sector, the company supports the development of innovative companies in the field of health, in France and Europe. | Sanofi | Joint Venture | France |
18-Jul-18 | Janssen Pharmaceuticals | $115 | SYLVANT® is the only FDA and EMA approved treatment for the rare disorder, idiopathic multicentric Castleman’s disease (iMCD). The acquisition of Sylvant leverages EUSA Pharma’s commercial and medical expertise in rapidly advancing therapies to address unmet patient needs and boosts EUSA Pharma’s presence in oncology and rare disease. | Eusa Pharma | Asset Acquisition | Ireland |
24-Jul-18 | Beijing Allcure Medical Technology Co., Ltd. | $103 | China Health Industry Investment Fund Co.Ltd., a fund established by China Electronics Corporation Data (CEC Data), and Shanghai Jinpu Jiangfu Equity Management also participated in the round, according to Allcure Medical’s announcement. | China Capital Investment Group (CCIG) | Series B Financing | China |
17-Jul-18 | Crinetics Pharmaceuticals | $102 | Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. | J.P. Morgan | IPO | United States |
25-Jul-18 | Replimune Group, Inc. | $101 | Replimmune's Immulytic™ technology platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. | J.P. Morgan | IPO | United Kingdom |
02-Jul-18 | Athenex, Inc. | $100 | The investment is part of the efforts to establish a joint venture with Xiangxue Life Sciences, a wholly-owned subsidiary of Guangzhou Xiangxue Pharmaceutical Co., Ltd. (Xiangxue Pharmaceutical), for the research, development and commercialization of T-cell receptor-engineered T cells (TCR-T), a cancer immunotherapy technology, based on the novel approach on high-affinity TCR developed by Xiangxue Life Sciences; | Perceptive Advisors | Investment | United States |
26-Jul-18 | I-Mab Biopharma | $100 | The two companies also agreed on a collaboration to co-develop additional bispecific antibodies (BsAb) as part of the partnership. The partneship focuses on ABL Bio to in-license the global rights excluding Greater China to I-Mab's bispecific antibodies (BsAb) of undisclosed target with licensing payments. | ABL Bio Corporation | Partnership | China |
11-Jul-18 | Federal Communications Commission | $100 | The $100 million telehealth initiative announced by the Federal Communications Commission (FCC) early July will largely focus on delivering virtual medical technologies directly to low-income patients in remote areas of the country, according to Commissioner Brendan Carr. | Universal Service Fund | Grants & Awards | United States |
24-Jul-18 | Zavante Therapeutics | $98 | The Acquisition adds Zavante’s CONTEPO™, potential first-in-class in the United States injectable antibiotic for cUTIs, to Nabriva’s late-stage anti-infective portfolio. | Nabriva Therapeutics plc | Acquisition | United States |
03-Jul-18 | Sinovac Biotech Ltd. | $87 | Through the Private Placement, Vivo Capital and Advantech Capital Each Hold an Approximately 8.3% Stake in Sinovac and will fund the Improvement and Construction of Facilities for R&D Relating to Quality Control and Production of New Vaccines Projects. | Advantech Capital; Vivo Capital | Private Placement | China |
16-Jul-18 | Apotex International Inc. | $86 | This acquisition will accelerate Aurobindo's European growth strategy, by strengthening its geographic reach and commercial infrastructure, particularly in the generics market of Eastern Europe; diversify Aurobindo's European product portfolio by adding over 200 generics and more than 80 over-the-counter (OTC) products that had total sales of EUR 133 million. | Aurobindo Pharma | Business Unit Acquisition | Canada |
31-Jul-18 | TherapeuticsMD, Inc. | $85 | TherapeuticsMD intends to use the proceeds of the offerings to fund a portion of the costs for the commercial launch of its recently FDA approved product, IMVEXXY™ (estradiol vaginal inserts) for moderate-to-severe dyspareunia and to fund a portion of the costs for pre-commercialization and commercialization activities for TX-001HR, its bio-identical hormone therapy combination of 17-ßestradiol and progesterone in a single, oral softgel drug candidate. | Goldman Sachs | IPO | United States |
23-Jul-18 | TxCell S.A. | $84 | The Proposed Acquisition Would Combine Sangamo's Ex Vivo Gene Editing Capabilities and TxCell's Treg Expertise and Would Position Sangamo as a Leader in CAR-Treg Development | Sangamo Therapeutics, Inc. | Acquisition | France |
03-Jul-18 | SmartAnalyst, Create NYC | $82 | Create NYC offers the tactical execution of sales and marketing materials for its international pharmaceutical clients. SmartAnalyst provides strategic consulting services to pharmaceutical and biotech companies to support disease, asset, and portfolio level decisions. SmartAnalyst also provides Health Economics and Outcomes Research (HEOR) services, which uses evidence based data and analytics to demonstrate the value of products and to support market access and reimbursement with payors. | UDG Healthcare | Acquisition | United States |
02-Jul-18 | Global R&D Operations Hub | $77 | The Hub will support the clinical research and development of Sanofi's innovative drugs by focusing on the management of global multi-center clinical trials data and files. The Chengdu Hub will target diseases that affect millions of people across our therapeutic areas: diabetes and cardiovascular diseases, vaccines, oncology, immunology and inflammation, rare diseases, multiple sclerosis and neurology. | Sanofi | Manufacturing Investment | China |
31-Jul-18 | Daiichi Sankyo | $76 | Daiichi Sankyo has examined the business optimization of domestic long-listed products. The agreement entitles inventories of a total of 41 products, which comprise 35 of Daiichi Sankyo’s long-listed products and six of Daiichi Sankyo Espha’s long-listed products, to be be transferred to Alfresa Pharma from March 2019, for which Daiichi Sankyo and Daiichi Sankyo Espha are expected to receive payment of ¥8.42 billion. | Alfresa Pharma Corporation | Spin off | Japan |
12-Jul-18 | Spero Therapeutics, Inc. | $75 | Spero is a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections. | Cowen and Company | Series A Financing | United States |
10-Jul-18 | Natera Inc | $75 | Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. | J.P. Morgan | IPO | United States |
16-Jul-18 | Pliant Therapeutics | $62 | The funds will support the initiation and proof-of-conceptnclinical trials in idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), as well asnongoing drug discovery programs targeting other fibrotic diseases. | Cowen Healthcare Investments | Series B Financing | United States |
30-Jul-18 | Omniome, Inc. | $60 | The company will continue to optimize the novel Sequencing By Binding™ (SBB™) technology while accelerating prototype development of commercially-impactful sequencing platforms. | Hillhouse Capital | Series B Financing | United States |
11-Jul-18 | Nohla Therapeutics | $56 | Dilanubicel is a universal, off-the-shelf stem and progenitor cell therapy designed to provide short-term bone marrow function, while also providing long term immunologic benefits with the potential for improved survival | Fidelity Management | Series B Financing | United States |
06-Jul-18 | Dynacure | $55 | This financing will support clinical development of lead antisense oligonucleotide candidate for centronuclear myopathy (CNM), and additional preclinical research programs for other orphan disorders. | Andera Partners | Financing | France |
16-Jul-18 | Spero Therapeutics, Inc. | $54 | The funding will support the further clinical development of Spero’s oral carbapenem product candidate, SPR994, for the treatment of complicated urinary tract infections (cUTIs) caused by antibiotic resistant Gram-negative bacteria. This is an exclusive inter-agency collaboration among BARDA, DTRA, USAMRIID and Spero to fund further clinical development of product candidate SPR994 and Initiate activity towards planned pivotal Phase 3 trial of SPR994 on track to initiate around year-end 2018. | Biomedical Advanced Research and Development Authority (BARDA) | Grants & Awards | United States |
12-Jul-18 | Immatics Biotechnologies GmbH | $54 | Genmab gains exclusive access to multiple novel proprietary tumor targets identified by Immatics Biotechnologies’ XPRESIDENT® technology. Genmab will be responsible for development, manufacturing and commercialization worldwide | Genmab A/S | Partnership | Germany |
05-Jul-18 | Adlai Nortye Biopharma Co. | $53 | Adlai Nortye is advancing a robust pipeline of more than 10 diverse product candidates, focusing on novel treatments for cancer, with primary concentration on immuno-oncology. Adlai Nortye has two clinical stage immune-oncology product candidates. Reolysin®, an intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors is ready to enter Phase III study. | YuanMing Capital | Series B Financing | China |
25-Jul-18 | Veracyte, Inc. | $51 | Veracyte may also use a portion of the net proceeds from the offering to acquire or invest in complementary businesses, technologies or other assets, although it has no present commitments or agreements to do so. | Leerink Partners | IPO | United States |
26-Jul-18 | Nabriva Therapeutics | $50 | Nabriva Therapeutics is a clinical stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections. | Morgan Stanley | IPO | Ireland |
30-Jul-18 | Liquidia Technologies, Inc. | $50 | Liquidia applied its engineering platform to the ingredient, treprostinil, to create trefoil-shaped, uniformly-sized particles. Liquidia thinks the tweaks may reduce the particle deposition in the upper airways that occurs when Tyvaso is delivered via nebulizers, resulting in more of the active ingredient penetrating deep into the lungs. | Cowen AND Jefferies | IPO | United States |
12-Jul-18 | Atlantic Island Cannabis (FSD Atlantic Pharma) | $48 | Through its FV Pharma unit, the company holds a producer’s license from Health Canada and is headquartered in the former Kraft plant about an hour outside Toronto in Cobourg, Ontario. | FSD Pharma | Acquisition | Canada |
10-Jul-18 | Transgene | $48 | Transgene is transferring its 50% share of the current Transgene-Tasly joint venture (Transgene Tasly (Tianjin) BioPharmaceutical Co., Ltd.) to Tasly Biopharmaceuticals, making it the 100% owner of the joint venture entity and the greater China patent rights to T601. | Tasly Biopharmaceuticals | Partnership | France |
10-Jul-18 | Cue Health Inc. | $45 | Cue Health Inc. (“Cue”) is an ISO 13485 certified company focused on developing and manufacturing consumer and professional medical diagnostic products that can be used in clinical or at-home settings. Cue’s mission is to create tools that empower physicians and consumers by increasing their access to actionable health data. | Johnson & Johnson | Series B Financing | United States |
17-Jul-18 | HotSpot Therapeutics | $45 | Regulatory hotspots offer a privileged subset of allosteric sites that remain unexplored for drug discovery and represent a major opportunity to create first-in-class medicines across multiple disease areas. This allows us to create medicines that work through exactly the same mechanisms, offering the same degree of precision and potency. | Atlas Venture | Series A Financing | United States |
23-Jul-18 | World Health Organisation (WHO) | $41 | Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally. | Novartis | Research Agreement | United States |
11-Jul-18 | Mitra Biotech (Mitra RxDx) | $40 | Mitra's CANscript™ platform delivers powerful, individualized treatment response predictions — with exceptionally high correlation to clinical outcomes — to inform patient-specific cancer treatment selection and support more effective and efficient cancer drug development. | Northpond Ventures | Financing | United States |
18-Jul-18 | Neuraly | $36 | The company’s pipeline is centered around NLY01, a potent, brain-penetrant long-acting Glucagon-like peptide-1 receptor (GLP-1R) agonist that has demonstrated promise as a neuroprotective agent for neurologic disorders such as Alzheimer’s disease and Parkinson’s disease. | Smilegate Investment | Financing | United States |
12-Jul-18 | Mirren (Pty) Ltd | $33 | According to Cipla, the transaction will enhance Cipla’s OTC portfolio by adding Mirren’s well-established brands such as Bronco! cough syrup, Coryx, Tensopyn and Ultimag. The deal will also increase Cipla’s manufacturing footprint in Africa. | Cipla | Acquisition | South Africa |
12-Jul-18 | Cue Health Inc. | $30 | The Cue Health Monitoring System centers around a connected diagnostic device, which enables a range of in-home and in-clinic diagnostics. It uses a custom designed reader to test clinical samples in a disposable test cartridge and then sends the results to a mobile application. | Biomedical Advanced Research and Development Authority (BARDA) | Grants & Awards | United States |
16-Jul-18 | Lyvgen Biopharma | $30 | Lyvgen’s leading cross-link antibody (xLinkAb) platform and co-stimulation agonist antibodies is readily utilizable for developing first-in-class and best-in-class therapeutics for major diseases, such as cancer. Lyvgen’s xLinkAb technology has shown to selectively activate specific receptors in the tumor microenvironment, while reducing immune-related adverse effects in the healthy tissue. | 6 Dimensions Capital | Series B Financing | China |
24-Jul-18 | Adaptimmune Therapeutics | $28 | GSK ‘794 is an engineered T-cell therapy, for which a patient’s own cells have been genetically modified to express a T-cell receptor (TCR) recognizing with high affinity the tumor-specific antigen, NY-ESO. | GlaxoSmithKline | Asset Acquisition | United Kingdom |
12-Jul-18 | AcelRx Pharmaceuticals, Inc. | $20 | AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. | Cantor Fitzgerald & Co. | IPO | United States |
24-Jul-18 | Cannara Biotech (FSD Pharma Inc.) | $18 | FSD is a significant Cannara shareholder and has applied for a second site license at the Cannara facility. FSD made an investment of $1 million dollars in this round of financing. First Republic Capital Corp. was the sole broker for the offering, the proceeds of which will support the first Phase build-out at Cannara’s Farnham, Quebec facility, as well as fund product development. | First Republic Capital | Financing | Canada |
23-Jul-18 | Click Therapeutics | $17 | Click will use this financing to continue advancing its proprietary platform and pipeline of prescription digital therapeutics to treat a wide range of diseases. Recent notes were converted to equity as part of the financing. | Sanofi | Financing | United States |
17-Jul-18 | EOS Imaging | $17 | EOS imaging designs, develops and markets EOS®, a major innovative medical imaging solution dedicated to osteoarticular pathologies and orthopedics combining equipment and services. | Shanghai Fosun Pharmaceutical Group | Equity Investment | France |
02-Jul-18 | Seventh Wave Laboratories, LLC | $16 | By combining offerings, the two companies expect to capitalize on their collective skill sets, expertise, and assets to create a comprehensive portfolio | Bioanalytical Systems, Inc. | Asset Acquisition | United States |
13-Jul-18 | Modus Therapeutics | $16 | Modus's lead candidate drug sevuparin is an innovative, proprietary polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. Currently being evaluated in a Phase II clinical study, sevuparin has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. | HealthCap | Financing | Sweden |
11-Jun-18 | Orig3n | $15 | The Series B financing will support Orig3n's international and domestic expansion as well as continued R&D development, empowering customers to access information about their genes to make educated, proactive choices about their lifestyles. Furthermore, the funding will also allow Orig3n to advance its breakthrough regenerative medicine treatments using the world's largest allogenic bank of cells that is HLA-matched to 90% of the U.S. population. | Haitong International | Series B Financing | United States |
12-Jul-18 | Octave Bioscience | $14 | This financing will allow the company to complete development of its proprietary, first-in-class platform and begin to evaluate the impact of the platform in its initial disease state, multiple sclerosis. Octave Bioscience was founded to deliver an end-to-end care management platform for multiple sclerosis and other neurodegenerative diseases. | BCBS Venture Partners | Series A Financing | United States |
09-Jul-18 | MabVax Therapeutics | $11 | The asset acquisition is separate and distinct from other programs under development at MabVax, enabling MabVax to retain all rights to its lead HuMab-5B1antibody program which is in Phase 1 clinical trials as a therapeutic product and as a diagnostic product, as well as other antibody discovery programs from the Company's rich antibody discovery portfolio targeting other cancer antigens. | Boehringer Ingelheim | Asset Acquisition | United States |
08-Jul-18 | Benitec Biopharma | $10 | License grants Axovant worldwide rights to AXO-AAV-OPMD, an investigational Silence-and-Replace gene therapy program which suppresses mutant protein production while restoring expression of functional protein. Axovant and Benitec plan to initiate placebo-controlled study of AXO-AAV-OPMD in patients with oculopharyngeal muscular dystrophy (OPMD) in 2019 | Axovant Sciences | Licensing Agreement | Australia |
12-Jul-18 | Antoxerene (Ichor Therapeutics, Inc) | $10 | The joint venture, called FoxBio, Inc., will develop Antoxerene’s collection of small molecules that target senescent cells. Antoxerene, Inc., a portfolio company of Ichor Therapeutics, is a small molecule drug discovery platform. Juvenescence Limited is an investment company focused on therapies to increase human longevity and complementary investments in related sectors. | Juvenescence Limited | Joint Venture | United States |
18-Jul-18 | Pneuma Respiratory | $8 | Pneuma Respiratory, Inc. ("Pneuma") has developed the PNEUMAHALER™ Breath Activated Digital Inhaler (BDI) to solve the problems of existing metered dose, dry- powder, and soft-mist inhalers to improve the efficacy of currently available airway medications. | Undisclosed | Series A Financing | United States |
05-Jul-18 | Nextbiotix | $8 | It is Nextbiotix’s ambition to bring gut microbiota back into the therapeutic equation using a bacterium called Faecalibacterium prausnitzii. Nextbiotix is developing microbiome-based therapies using single microbial strains that interact with human cells in the gut. Acting more effectively on immunomodulatory pathways, they are intended to significantly improve the lives of patients suffering from inflammatory bowel diseases. | Auriga Partners | Series A Financing | France |
11-Jul-18 | Cingulate Therapeutics | $8 | The company has now raised over $16M as it positions itself for continued growth. Proceeds will be used to advance Cingulate's two (2) proprietary, first-line medications for the treatment of ADHD, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), through investigational new drug applications and Phase I/II clinical trials. | Werth Family Investment Associates | Equity Investment | United States |
24-Jul-18 | Greifswald Mfg Site | $7 | The extension with state-of-the-art office space will be completed by the end of 2019. Thus, the pharmaceutical company has enough space for a total of 250 employees on approximately 8,000 square meters. | Cheplapharm Arzneimittel GmbH | Manufacturing Investment | Germany |
25-Jul-18 | Inversago Pharma | $7 | Inversago’s technology, based on the work by CB1 world expert George Kunos at the National Institute of Health (NIH/NIAAA), has demonstrated that in preclinical models, peripherally restricted CB1 blockade provides a clear therapeutic potential to treat conditions like obesity, NASH, liver fibrosis and diabetes, without causing the CNS or behavioural effects associated with the earlier generations of CB1 blockers. | Genesys Capital | Series A Financing | Canada |
17-Jul-18 | Presage Biosciences | $6 | Presage's CIVO platform has been developed for Phase 0 trials, also known as exploratory investigational new drug applications. The CIVO platform Phase 0 studies use minute amounts of experimental drugs to assess pharmacodynamics effects in patients. The use of the platform reduces toxicity concerns in traditional Phase I trials, the company said, as intratumoral microdosing uses approximately 100-fold lower doses of drug candidates. | Takeda, Celgene | Series D Financing | United States |
09-Jul-18 | Isotopen Technologien München AG (ITM) | $6 | ITG will provide Endocyte with 100% of thehighly purified, no-carrier-added Lutetium-177 (177Lu) EndolucinBeta® to support clinical and commercial supply of 177Lu-PSMA-617 required for the phase 3 VISION trial. | Endocyte, Inc. | Supply Agreement | Germany |
19-Jul-18 | LexaGene Holdings Inc. | $6 | The Company intends to use the net proceeds of the Offering to advance the commercializing process of the Company's Microfluidic technology. | Canaccord Genuity | Private Placement | Canada |
02-Jul-18 | Doctor Anywhere | $6 | The funding round will enable the start-up to expand the team, explore new business verticals, develop more healthcare solutions and thereby continue developing its products and services that will boost healthcare accessibility in Singapore, | Kamet Capital Partners | Series A Financing | Singapore |
30-Jul-18 | HealthSignz | $5 | The funds raised will be used to build additional features for Health Intelligence Engine (HIE) and to enhance services from HealthSignz platform to reach all healthcare providers. | Nirvana Health Group | Financing | India |
02-Jul-18 | ABL Bio | $4 | Through the agreement, TRIGR gets global commercial rights to ABL Bio’s pipeline of novel therapeutic antibodies to treat cancer. These therapeutic antibodies include ‘blood-brain barrier (BBB)’ penetrating bispecific antibodies (BsAb) (VEGF/undisclosed BBB target BsAb, undisclosed target/undisclosed BBB target BsAb); immune cell engaging bispecific antibodies (4-1BB/undisclosed target BsAb, 4-1BB/ undisclosed target BsAb); and a monoclonal antibody against undisclosed target. | TRIGR Therapeutics | Collaboration | South Korea |
05-Jul-18 | Fibrocell Science | $4 | Fibrocell intends to use the net proceeds from this offering for the continued clinical and pre-clinical development of its product candidates, FCX-007 and FCX-013. | H.C. Wainwright & Co. | IPO | United States |
16-Jun-18 | Cyrcadia Asia | $4 | The Pre-A funding will enable Cyrcadia to complete product development and launch into Hong Kong and other Asian markets in late 2018. | iFlytek | Investment | Hong Kong |
31-Jul-18 | HealthPlix | $3 | HealthPlix will use the funds to strengthen its technology and expand its team and services in other geographical markets. | IDG Ventures India | Series A Financing | India |
10-Jul-18 | DNA Script | $3 | DNA Script is one of eight companies to receive an award for the "Concours d'Innovation 2018" of Bpifrance in the "Healthcare" division. DNA Script introduces a novel biochemical process for DNA and RNA synthesis based on the use of highly efficient enzymes. It will enable the production of long DNA constructs, which are key components of cell and gene therapies. | Bpifrance | Grants & Awards | France |
16-Jul-18 | Bioasis Technologies, Inc. | $2 | Bioasis will use the net proceeds from the private placement to support ongoing research and development, clinical development, manufacturing and other activities in respect of the Company’s clinical development pipeline | Undisclosed | Private Placement | Canada |
23-Jul-18 | DILIsym Services, Inc., | $2 | The goal of this project is to provide software that can be used in drug development efforts to predict a drug’s potential to cause drug-induced kidney injury, as well as assess and improve the understanding of mechanisms of drug-induced kidney injury. | National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) | Grants & Awards | United States |
04-Jul-18 | MedTech and Pharma Growth Centre (MTPConnect) | $2 | MTPConnect - the Australian Government's Medical Technology, Biotechnology, and Pharmaceutical (MTP) Industry Growth Centre - in conjunction with the Western Australian Government and The University of Western Australia (UWA), is delighted to announce the establishment of the Western Australian Node (the WA Node) of MTPConnect in Perth, to support the state's burgeoning life sciences sector. | Government of Western Australia, The University of Western Australian | Collaboration | Australia |
17-Jul-18 | Curious2018 – Future Insight Prize | $1 | The prize will be presented to researchers who will make outstanding contributions to enable innovations important for the future of humanity in the categories of health, nutrition and energy. | Merck Group | Grants & Awards | Germany |
24-Jul-18 | A-Alpha Bio | $0.23 | The National Science Foundation grant will be used to commercialize a synthetic biology platform for cancer drug development. | National Science Foundation Phase I Small Business Innovation Research | Grants & Awards | United States |
17-Jul-18 | Cannevert Therapeutics Ltd. (Veritas Pharma) | $0.16 | Veritas through its subsidiary company, Cannevert Therapeutics Ltd., will apply its pharmacological methods on cannabis strain lead selection to assist Sativa’s application to the UK Home Office Drugs Licensing and Compliance Unit for a medicinal cannabis growing license. | Sativa Investments PLC | Letter of Intent | Canada |
01-Jul-18 | Sastomed GmbH | $0 | The deal adds new, award-winning products to Molnlycke's offer – enabling it to further help healthcare professionals and patients by accelerating the wound healing process and treating chronic wounds. SastoMed GmbH joins the Molnlycke family, bringing two innovative and complementary products to Molnlycke's wound care portfolio: Granulox and Granudacyn. | Molnlycke | Acquisition | Germany |
01-Jul-18 | Adamis Pharmaceuticals Corporation | $0 | Sandoz will obtain the United States commercial rights to Symjepi in exchange for an upfront fee and potential performance-based milestones payments. Sandoz will have commercial rights to the FDA-approved Symjepi (epinephrine) Injection 0.3mg product, as well as the Symjepi (epinephrine) Injection 0.15mg product if approved by the FDA. | Novartis | Distribution Agreement | United States |
02-Jul-18 | PV Nano Cell Ltd. | $0 | PV Nano Cell is the developer of the state-of-the-art Sicrys™ conductive inks based on single crystal nano particles of silver and copper. The performance material division of Merck is evaluating Sicrys single crystal metal particles with different, unique and patented technologies and applications. | Merck & Co. | Supply Agreement | Israel |
02-Jul-18 | AXM Pharma, Inc. | $0 | The shares of the Common stock representing 70% of the outstanding Capital Stock of AXM Pharma to be issued to Mr. Emmanuel Neossi for the acquisition of ASIC in the merger will be restricted, therefore there will be no change in the public float of the Company and there will be no reverse stock split either. The transaction is accretive to the current shareholders of AXM Pharma, Inc. as it also remains beneficial to the target on the other hand. | Mr. Emmanuel Neossi (AS Industries Cameroon) | Merger Agreement | United States |
02-Jul-18 | Array Biopharma | $0 | BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) were approved by The U.S. Food and Drug Administration (FDA) on June 27, 2018 based on clinical data from the Phase 3 COLUMBUS study. They are prescribed to treat patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test. | Onco360 | Distribution Agreement | United States |
02-Jul-18 | Acentrus Specialty | $0 | LicenseLogix provides comprehensive business licensing solutions, including tracking of pharmacy licensure changes, research of license requirements, filing of new applications, and full outsourcing of all license renewals with access to the web-based Client License Information Center—CLiC. | LicenseLogix | Partnership | United States |
02-Jul-18 | Center for Pharmacy Practice Accreditation (CPPA) | $0 | CPPA is a partnership established by ASHP (American Society of Health-System Pharmacists), the American Pharmacist Association (APhA), and the National Association of Boards of Pharmacy (NABP) to oversee accreditation of pharmacy practice sites. CPPA develops standards and provides accreditation programs for specialty, community, and telehealth pharmacy practices. | Acentrus Specialty | Partnership | United States |
02-Jul-18 | Institute of Molecular Biotechnology GmbH (Medical University of Vienna) | $0 | The agreement grants APEIRON an exclusive worldwide license to a novel immunotherpay product targeting casitas B cell lymphoma-b. The immunotherapeutic APN401 works by inhibiting Cbl-b which not only distinctly activates immune cells but can deactivate other relevant checkpoints, including CTLA-4 and PD-L1/PD-1. Hence, Apeiron regards it as the “master checkpoint” in cancer immunotherapy. | APEIRON Biologics AG | Licensing Agreement | Austria |
02-Jul-18 | Fullerton Healthcare Corporation Ltd. | $0 | The parties signed a Memorandum of Understanding (MoU) that will see Microsoft as a partner in driving the transformation of Fullerton Health's existing technology infrastructure, as well as introducing intelligent services such as Artificial Intelligence (AI) in their existing processes. The partnership also aims to drive innovation within the healthcare sector through co-creation of scalable solutions. | Microsoft Asia Pacific | Memorandum of Understanding | Singapore |
02-Jul-18 | HIMSS Asia Pacific | $0 | HIMSS AsiaPac18 will be convened under the theme Healthcare Anytime, Anywhere. The key topics that the event will be addressing are Connect – Telehealth, Interoperability, Health Information Exchange, Integrated Care; Consumer-Partnership – Engagement, Connected Health, Team-Based Care, Consumer-Centred Care; Sustainability – Innovative Business Models, Value-Based Care, Margin and Outcome Management, Collaboration; Data – Genomics, Cybersecurity, Artificial Intelligence, Internet of Things, Blo | eHealth Queensland | Partnership | Australia |
02-Jul-18 | Mercy (IBM Watson Health) | $0 | Together, the companies will utilize an established data platform launched by Mercy (IBM Watson Health) that uses real-world clinical data to evaluate medical device performance. | Johnson & Johnson | Collaboration | United States |
03-Jul-18 | A. Menarini Asia-Pacific Holdings Pte Ltd | $0 | This multi-year licensing agreement enables Menarini Asia-Pacific to distribute and commercialize several of Orion's Easyhaler® products in China, Hong Kong, Philippines, Malaysia, Indonesia, Thailand, Singapore, Vietnam, Taiwan, and South Korea. Orion's proprietary dry-powder inhaler Easyhaler® is used for administering medication for the treatment of asthma and COPD. | Orion Corporation | Licensing Agreement | Singapore |
03-Jul-18 | Fertility.com | $0 | Fertility.com is designed with convenience and easy navigation in mind, ensuring that patients and physicians can easily access the information they need, anytime and everywhere. This new online platform demonstrates Merck’s commitment to continuing to support people trying to conceive, whilst also offering HCPs a scientific platform with the latest advances in reproductive medicine. | Merck Group | Launch & Partnerships | Germany |
03-Jul-18 | A*STAR's Institute of Molecular and Cell Biology (IMCB), Indivumed GmbH | $0 | This contributes to Indivumed’s global cancer database solution “IndivuType”, funded by the European Investment Bank and private investors. IndivuType combines comprehensive cell biological information such as genomic, transcriptomic, proteomic, precision proteomic, and digital histopathology data with extensive clinical information from thousands of patients. | European Investment Bank (EIB) | Research Agreement | Singapore |
04-Jul-18 | AMW GmbH - Arzneimittelwerk Warngau | $0 | AMW GmbH is a specialty pharmaceuticals company headquartered in Warngau near Munich, Germany. It develops, produces and sells drug delivery systems with a focus on biodegradable implants and transdermal treatment systems. The company was founded in 2008 and develops solutions for use in oncology, neurology, dermatology and pain management applications. | Yunfeng Capital, Hybio Pharmaceutical | Acquisition | Germany |
04-Jul-18 | Mitsui Chemicals Agro, Inc. | $0 | Bayer to expand its strong parasiticide portfolio for companion animals with new compounds derived from MCAG’s chemical library / License agreement is the result of the long-term collaboration between Bayer and MCAG | Bayer | Licensing Agreement | Japan |
04-Jul-18 | Kent Imaging | $0 | This is a great partnership between one of the leaders in building wound care teams and an innovative tissue assessment technology that is easy to use, convenient, and cost effective. SerenaGroup® will adopt Kent Imaging's technology as the standard of care for assessing wound oxygenation thus wound health. Kent will be integrated into each of the SerenaGroup® managed facilities, included in Hyperbaric training courses curriculum, as well as included in future clinical and preclinical resear | SerenaGroup | Partnership | Canada |
05-Jul-18 | Neovii pharmaceuticals AG | $0 | The agreement gives Mundipharma the rights to develop and distribute Neovii's polyclonal antibody immunosuppressant, Grafalon®, in China and Japan from end October. | Mundipharma | Licensing Agreement | Switzerland |
05-Jul-18 | Technische Universität Dresden (TU Dresden) | $0 | At the centre of the R&D Collaboration is the team of denovoMATRIX employed by TU Dresden which will conduct examinations into the tentative synergy between Cellect's ApoGraft™ and the denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine. To that end, a denovoMATRIX scientist will conduct a line of experiments in Cellect's R&D facility in Israel. | Cellect Biotechnology Ltd. | Collaboration | Germany |
06-Jul-18 | Cleara Biotech | $0 | Cleara has partnered with Dr. Peter de Keizer from the University Medical Center in Utrecht, Dr. Marco Demaria from the University Medical Center in Groningen, and Dr. Tobias Madl from the Medical University of Graz to engage in its discovery operations. Cleara’s initial funding was led by founding investor Apollo Ventures. | Apollo Ventures, University Medical Center Utrecht, University Medical Center Groningen | Collaboration | The Netherlands |
06-Jul-18 | Memorial Sloan Kettering Cancer Center (MSK) | $0 | Grant intended to evaluate the utility of MVT-2163 to improve pre-operative staging of patients with pancreatic cancer. MabVax Therapeutics discovered the HuMab-5B1 antibody from patients treated at MSK with a vaccine developed by Dr. Philip Livingston. In collaboration with MSK, the Company established the preclinical proof of concept for using the HuMab-5B1 immunoPET imaging agent for improving the visualization of pancreatic cancer. | National Institutes of Health | Grants & Awards | United States |
06-Jul-18 | Isotopen Technologien München AG (ITM) | $0 | This partnership aims to meet the medical community’s growing demand for radionuclides for use in Targeted Radionuclide Therapies. N.c.a. Lutetium-177 will be produced at Bruce Power’s CANDU reactors while development, processing, and global distribution of n.c.a. Lutetium-177 will be managed by ITM. | Bruce Power | Memorandum of Understanding | Germany |
06-Jul-18 | Glenmark Pharmaceuticals | $0 | Glenmark will be responsible for product supply and Seqirus will be responsible for regulatory filing and commercialization of the product in Australia and New Zealand. Ryaltris (olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)) is a novel, investigational, fixed-dose combination nasal spray of an antihistamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age. | Seqirus Pty. Ltd. | Licensing Agreement | India |
06-Jul-18 | Predicine, Inc. | $0 | The aim of the partnership is to increase the speed and efficiency of biomarker-driven global clinical trials for Kintor's novel oncology drugs and the development of companion diagnostics for FDA and CFDA approvals. Kintor will leverage Predicine's ctRNA + ctDNA liquid biopsy technology, GeneRADAR, and expertise in genomics and molecular information to advance the development of its oncology pipeline. | Suzhou Kintor Pharmaceuticals | Partnership | United States |
09-Jul-18 | Cellect Biotechnology | $0 | This Agreement secures exclusive clinical production capacity of the main active ingredient in Cellect's ApoGraft™. The FasL protein is a key active ingredient in Cellect's product line and technology for cell separation and functional selection of stem cells. As Cellect advances in its product development, it becomes essential to secure a consistent and reliable supply of pharma-grade FasL. | Swiss Biotech Center | Supply Agreement | Israel |
09-Jul-18 | Pluristem Therapeutics Inc. | $0 | The collaboration combines Thermo Fisher’s experience in cell therapy development and bioproduction scaleup with Pluristem’s expertise in cell therapy manufacturing, clinical development and quality control. | Thermo Fisher Scientific | Collaboration | Israel |
09-Jul-18 | University of British Columbia (UBC) | $0 | TxCell's TX200 is a HLA-A2 CAR-Treg program which originated in the laboratories of Dr. Megan Levings, UBC in Vancouver, Canada, who established the first preclinical proof of concept with human HLA-A2-specific CAR-Treg cells in a preclinical model of Graft vs. Host Disease. | TxCell SA | Licensing Agreement | Canada |
09-Jul-18 | BioVaxys LLC | $0 | BioVaxys’ immunotherapeutic approach is based on the established immunological concept that modifying proteins with simple chemicals called haptens makes them more visible to the immune system. This exclusive worldwide license agreement is for a technology comprising highly-targeted, patient-specific, immunotherapeutic vaccines to treat ovarian cancer, melanoma, and other solid tumor types. | Thomas Jefferson University | Licensing Agreement | United States |
09-Jul-18 | TVA Medical, Inc. | $0 | The addition of TVA Medical enables BD to offer the everlinQ™ endoAVF System, a new endovascular arteriovenous (AV) fistula creation technology that adds to the company's ESRD portfolio of dialysis catheters, drug coated balloons, standard angioplasty balloons and endovascular stent graft products. | Becton Dickinson | Acquisition | United States |
09-Jul-18 | Optivia Biotechnology | $0 | The announced acquisition of Optivia strengthens BioIVT's transporter sciences capabilities and enables it to partner with customers on new drug applications. BioIVT's portfolio now includes all of Optivia's products, including its Opti-Expression™ technology, Opti-Target™, Opti-DDI™, and Opti-ADME™ Transporter Services Panels, and its TransFlex™ Single Transporter and Multi-Transporter Assay Plates. | BioIVT | Acquisition | United States |
09-Jul-18 | ONO Pharmaceutical Co., Ltd. | $0 | CluePoints and ONO will now continue to work in close partnership over the next four years to build on the success of the pilot program. Experts from CluePoints in Japan will deliver on-site training and provide ongoing support to the ONO team to ensure the adoption of the RBM approach delivers the best possible results. | CluePoints | Partnership | Japan |
10-Jul-18 | Adlai Nortye Biopharma Co. | $0 | Buparlisib (BKM120) is an oral pan-PI3K inhibitor that targets all class 1 PI3K isoforms and is active in both hematologic malignancies and solid tumors. This License Agreement grants Adlai Nortye the exclusive rights to develop and commercialize buparlisib worldwide for all the therapeutic, prophylactic and/or diagnostic uses in humans. | Novartis | Licensing Agreement | China |
10-Jul-18 | FSD Pharma | $0 | FSD Pharma will provide Canntab with up to 10,000 square feet of space at the FSD Facility. Canntab will build and install, at its expense, its own manufacturing facility within the larger FSD Facility that will operate in accordance with Good Manufacturing Practices, at which it will produce a suite of novel cannabis oral dose delivery platforms, including gel capsules and tablets, and other types of cannabis-based products, including sleep aids and pain relievers. FSD Pharma and Canntab see tr | Canntab Therapeutics | Collaboration | Canada |
10-Jul-18 | Berkeley Lights, Inc. | $0 | Catalent Biologics will adopt Beacon®optofluidic platform to accelerate its cell line development workflow. he Beacon platform is capable of screening thousands of clones in parallel. The four integrated workflows of the Beacon platform – import, culture, assay, and export, will be applied to Catalent Biologics’ GPEx®cell line development platform, as well as Catalent’s ongoing research and development activities. | Catalent Biologics (Catalent Pharma Solutions) | Partnership | United States |
10-Jul-18 | Genevant Sciences | $0 | BioNTech and Genevant will develop five products for rare diseases with high unmet medical need under the 50/50 co-development and co-commercialization collaboration, combining Genevant’s industry-leading lipid nanoparticle (LNP) delivery technology with BioNTech’s cutting-edge mRNA drug discovery platform to develop best-in-class therapeutics. | BioNTech AG | Collaboration | Switzerland |
10-Jul-18 | 4D Molecular Therapeutics (4DMT) | $0 | The collaboration will leverage 4DMT’s expertise in vector discovery and engineering, optimization and process development. MedImmune will conduct product development beginning from early clinical stages, drawing on the company’s extensive expertise in respiratory science. | AstraZeneca | Collaboration | United States |
10-Jul-18 | ReCor Medical, Sofinnova Partners | $0 | ReCor Medical is an innovative medical device company that developed the Paradise® System, a proprietary ultrasound ablation system for renal denervation - a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. | Otsuka Pharmaceutical | Acquisition | United States |
10-Jul-18 | Ajinomoto Co., Inc. | $0 | The Collaboration is primarily for the development of FB-2710 for Radiation-Induced Oral Mucositis. FB-2710 is designed for optimal bioavailability and cellular uptake of glutamine, a critical nutrient and energy source for rapidly-dividing cells that regenerate the lining of the gastrointestinal tract. | Filament BioSolutions | Collaboration | Japan |
10-Jul-18 | Pionyr Immunotherapeutics | $0 | ProBioGen will perform process development and GMP manufacturing on a second antibody from the Pionyr pipeline using their high performance CHO.RiGHT® expression platform. Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline, enabling a rapid advance to clinical trials. | ProBioGen AG | Licensing Agreement | United States |
10-Jul-18 | ETHOS Health Communications | $0 | ETHOS has an authority in understanding and translating the science of medicine into high-level strategy and tactical execution. With a track record of long-tenured relationships with major biopharmaceutical companies and leading biotechnology firms, ETHOS has established a leadership position in the delivery of strategic scientific and medical communications and training solutions. | Precision Medicine Group, Inc. | Acquisition | United States |
10-Jul-18 | SRI International | $0 | SRI's proprietary FOX Three Molecular Guidance cellular targeting system (MGS) can deliver more than a dozen different types of payloads - from functional enzymes, antibodies and DNA, to liposomes and nanoparticles - to targeted, intracellular molecular-target locations previously considered undruggable. | Ionis Pharmaceuticals | Collaboration | United States |
10-Jul-18 | Yale University School of Medicine | $0 | NuMedii will work with the Yale School of Medicine with the goal of utilizing single-cell sequencing to identify novel precision therapies and biomarkers in idiopathic pulmonary fibrosis (IPF) - an orphan chronic fatal interstitial lung disease. | NuMedii, Inc. | Collaboration | United States |
10-Jul-18 | 908 Devices | $0 | HJB has recently launched a world-class pharmaceutical development facility in Hangzhou, Zhejiang where only leading-edge technologies — including the 908 Devices ZipChip® platform — will be integrated into their on-site processes. 908 Devices also announced the availability of their ZipChip platform in China. | Hangzhou Just Biotherapeutics (HJB) | Partnership | United States |
10-Jul-18 | Highmark Inc. | $0 | The contract focuses on an analysis of the total cost of care for adults with type 2 diabetes and established cardiovascular disease who have been prescribed Jardiance, compared with people who have not been prescribed Jardiance. | Boehringer Ingelheim | Contract Agreement | United States |
11-Jul-18 | Innovative Medicines; Established Medicines; Consumer Healthcare | $0 | Pfizer Inc. announced that it will organize itself into three businesses: a science-based Innovative Medicines business that would include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an off-patent branded and generic Established Medicines business operating with substantial autonomy within Pfizer and a Consumer Healthcare business. These changes will be effective at the beginning of the company’s 2019 fiscal year. | Pfizer Inc. | Business Reorganization | United States |
11-Jul-18 | Boehringer Ingelheim | $0 | The collaboration builds upon the efforts to market two new oral anti-diabetics drugs, Gibtulio Met (Empagliflozin+ Metformin) and Ajaduo (Empagliflozin +Linagliptin), which were recently approved by the Drugs Controller General of India. The two products will be co-marketed simultaneously by Boehringer Ingelheim and Lupin across India under different brand names. | Lupin Limited | Marketing Agreement | India |
11-Jul-18 | EUSA Pharma | $0 | The transaction includes a portfolio of products, which are marketed across a range of countries, and EUSA's field-based critical care sales teams in the UK, France, Netherlands, Belgium and Poland. The portfolio is based around COLLATAMP®, which is marketed for the prevention of infection during surgery across Europe and a wide range of countries outside the United States, including South Korea and South Africa. | SERB Pharmaceuticals | Definitive Agreement | United Kingdom |
11-Jul-18 | ResMed | $0 | Combining ResMed’s expertise in sleep apnea and Verily’s advanced health data analytics technologies, the U.S.-based joint venture will study the health and financial impacts of undiagnosed and untreated sleep apnea, and develop software solutions that enable healthcare providers to more efficiently identify, diagnose, treat and manage individuals with sleep apnea and other breathing related sleep disorders. | Verily Life Sciences | Joint Venture | United States |
11-Jul-18 | Blink Health Partners | $0 | Through Blue Eagle, Blink Health is able to offer its pharmacy partners complete transparency into how much they will be paid for every prescription | Blue Eagle Health | Partnership | United States |
11-Jul-18 | BMG Pharma S.p.A. | $0 | The new company will give BMG the opportunity to rapidly complete the development of a number of new patent protected products with topical and subcutaneous applications, which it will be able to offer to its network of global marketing partners for the benefit of patients globally. | Sigea S.r.l., BMG Pharma S.r.l., | Launch & Partnerships | Italy |
11-Jul-18 | BioAgilytix | $0 | Through this partnership, Bioasis will have access to BioAgilytix’s extensive bioanalytical expertise, particularly in ligand binding assays, anti-drug antibody detection, stability assessments across complex matrices and highest quality GLP validation of complex assays. | Bioasis Technologies, Inc | Collaboration | Germany |
11-Jul-18 | Scientist.com | $0 | The partnership between Scientist.com and HealthEconomics.Com will provide an effective method to connect RWE researchers with service providers to simplify the research sourcing process, save money and enhance market access. | HealthEconomics.Com | Partnership | United States |
11-Jul-18 | CAS, American Chemical Society (ACS) | $0 | This agreement provides enterprise-wide access to the newest solution in the SciFinder® family, SciFindern. With SciFindern, scientists can quickly find the most relevant, actionable answers for their scientific inquiries to accelerate their research outcomes. | Sumitomo Dainippon Pharma | Access Agreement | United States |
11-Jul-18 | Mission: Cure | $0 | In Stage One of the PerlQuest, Perlara will engineer ?F508 and 26 other cystic fibrosis transmembrane conductance regulator (CFTR) disease-causing variants in yeast YOR1 models of CFTR deficiency and then complete drug repurposing and drug discovery screens with the ?F508 model and another mutant, e.g., class III or class IV. The goal is to discover compounds for rapid testing in patient-matched organoid models. | Perlara | Partnership | United States |
12-Jul-18 | COFCO Corporation | $0 | This strategic cooperation will be started with a two-week blood sugar monitoring project. Both the companies, COFCO Corp. and iCarbonX, are dedicated to build an individualized accurate blood sugar management model through long-term monitoring, observation, analysis and evaluation on abnormal blood glucose patients, so as to give personalized intervention and treatment plans for those specific groups, and effectively achieve their goal of health management. | iCarbonX | Cooperation Agreement | China |
12-Jul-18 | Xian Janssen Pharmaceuticals Ltd. | $0 | Through this agreement, the two companies will work closely together on future development, distribution, promotion, access, marketing and sales of INVOKANA® (canagliflozin) in the country and Merck will hold the exclusive rights for INVOKANA® (canagliflozin)'s promotion in China. | Merck Group | Licensing Agreement | China |
12-Jul-18 | OrigiMed | $0 | OrigiMed agrees to develop and promote its advanced molecular clinical tumor applications to the public based on the Next Generation Sequencing (NGS) technology of Illumina. | Illumina | Collaboration | China |
12-Jul-18 | Sensile Medical | $0 | The combination of the two companies will enable Gerresheimer to enhance its Drug Delivery offering for its Pharmaceutical and Biotech partners, especially with new digital and electronic capabilities. | Gerresheimer AG | Acquisition | Switzerland |
12-Jul-18 | Miltenyi Biotec GmbH | $0 | The agreement provides combined use of MACSQuant® Tyto® Cell Sorter and cellenONE® X1 single-cell deposition unit allows for time- and cost-efficient production of high-expressing and fast-expanding monoclonal cell lines. | Cellenion (Scienion AG) | Marketing Agreement | Germany |
12-Jul-18 | Glooko, Inc. | $0 | Insulet’s partnership with Glooko is further proof of its commitment to putting customers first, as it ensures Insulet can continue to be closer to the diabetes community and provide personalised support for Podders™ across Europe. | Insulet Corporation | Partnership | United States |
12-Jul-18 | Chiba Plant Facility | $0 | Major expansion of facilities at its Chiba Plant that will result in an approximately tenfold increase in the company's GMP(*1)-compliant synthetic pharmaceutical intermediate and active ingredient (*2) production capacity. T | AGC Group | Manufacturing Investment | Japan |
13-Jul-18 | Arcus Biosciences, Inc. | $0 | Taiho Pharmaceutical has obtained the exclusive right to develop and commercialize Arcus’s adenosine receptor antagonists (AB928) in Japan and certain other territories in Asia. AB928 is an orally bioavailable small molecule compound which inhibits the adenosine 2a and 2b receptors. The activation of these receptors by adenosine on tumor infiltrating immune cells is thought to be one of the key mechanisms of immuno-suppression in the tumor microenvironment. | Taiho Pharmaceutical Co., Ltd. | Commercialization Agreement | United States |
13-Jul-18 | Alliance Global FZ | $0 | This is a provider agreement with Alliance Global FZ, LLC to market and distribute Biocept's Target Selector™ liquid biopsy tests in the United Arab Emirates and select countries in the Middle East, North & Sub-Saharan Africa, and Southeast Asia (MEAA) region. | Biocept | Distribution Agreement | United Arab Emirates |
13-Jul-18 | Biosensia | $0 | This acquisition demonstrates Kypha's commitment to meet the need for universally accessible, reliable and timely immune status results in virtually any setting from acute hospital care, to centralized laboratories, physician offices and home use. | Kypha | Acquisition | Ireland |
16-Jul-18 | Storz & Bickel GmbH | $0 | The Co-development agreement is focused on combining Tetra Bio's PPP001 prescription drug (a future proprietary cannabinoid formulation) with the Mighty Medic - a portable herbal vaporizer for cannabis use approved by Health Canada as a Class 11 medical device and as such, is eligible for reimbursement. The agreement allows Tetra to effectively bring PPP001 to patients suffering from fibromyalgia and other chronic pain conditions, significantly expanding the market potential for PPP001. | Tetra Bio-Pharma Inc | Development Agreement | Germany |
17-Jul-18 | Calibra Medical, Inc. (LifeScan, Inc.) | $0 | The transaction includes an exclusive worldwide license for the wearable, on-demand insulin delivery system previously known as OneTouch Via™. The Calibra system enables people with diabetes to discreetly and conveniently deliver rapid-acting insulin at mealtime. | CeQur Corporation | Asset Acquisition | United States |
17-Jul-18 | Sinovant Sciences | $0 | Renexxion has granted Sinovant an exclusive license for the development and commercialization of naronapride in the People's Republic of China, Hong Kong, Macau, and Taiwan. Sinovant intends to initially develop naronapride in irritable bowel syndrome with constipation (IBS-C). | Renexxion | Partnership | China |
17-Jul-18 | Sinovant Sciences | $0 | Backed by Roivant Sciences and CITICPE, Sinovant began operations in 2017 and is led by co-founders Dr. Canwen Jiang and Dr. Xinan Chen. Sinovant has built a pipeline of 11 investigational biopharmaceutical products. The current pipeline consists of Derazantinib, a fibroblast growth factor receptor (FGFR) inhibitor for intrahepatic cholangiocarcinoma (iCCA), Lefamulin, an antibiotic targeted against community-acquired bacterial pneumonia (CABP). | Roivant Sciences | Launch & Partnerships | China |
17-Jul-18 | Mylan | $0 | AbbVie will grant Mylan a non-exclusive license on specified dates to AbbVie's intellectual property relating to HUMIRA in the United States and in various other countries around the world in which AbbVie has intellectual property, excluding Europe. | AbbVie | Licensing Agreement | United States |
17-Jul-18 | Eureka Therapeutics | $0 | The licensed TCRm antibodies were developed from Eureka’s proprietary E-ALPHA® antibody discovery platform, which comprises a highly diverse human-derived antibody phage library containing over 100 billion clones with unique antibody sequences and a robust workflow with specificity screens designed to develop highly specific antibodies against target antigens. Boehringer Ingelheim has elected to exercise an option for the exclusive license of novel human TCR-mimicking (TCRm) antibodies against a | Boehringer Ingelheim | Option Agreement | United States |
17-Jul-18 | Capricor Therapeutics | $0 | CAP-2003 is derived from Capricor’s proprietary cardiosphere-derived cells (CDCs), which comprise adult cardiac progenitor cells from donor heart tissue. CAP-2003 has shown promising results in various pre-clinical experiments using established animal models of diseases by exerting anti-inflammatory, anti-fibrotic, pro-angiogenic, and anti-apoptotic effects. | U.S. Army Institute of Surgical Research (USAISR) | Collaboration | United States |
17-Jul-18 | Puma Biotechnology | $0 | Strata will exclusively refer HER2-mutated advanced cancer patients identified through the Strata Trial for consideration of enrollment to Puma’s SUMMIT Trial for neratinib. The Strata Trial is a screening protocol providing comprehensive tumor molecular profiling to advanced cancer patients at no cost and proactive enrollment support for a portfolio of pharma-sponsored precision therapy trials. | Strata Oncology, Inc | Collaboration | United States |
18-Jul-18 | Axis Therapeutics Ltd. (Athenex, Inc.) | $0 | Axis Therapeutics, a newly established joint venture to be owned as 55% by Athenex and 45% by Xiangxue Life Sciences (a wholly-owned subsidiary of Xiangxue Pharmaceutical Co., Ltd.), will be primarily focused on the research, development and commercialization of T-cell receptor-engineered T cells (TCR-T), a form of cancer immunotherapy. | Hong Kong Polytechnic University | Memorandum of Understanding | United States |
19-Jul-18 | Theramex | $0 | Intrarosa is a unique non-estrogen prescription therapy approved for the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women experiencing moderate to severe symptoms. The countries within the license agreement are: Australia, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Poland, Romania, Serbia, Slovakia, Slovenia, United Kingdom, the Russi | Endoceutics Inc | Licensing Agreement | United Kingdom |
19-Jul-18 | Gadeta B.V. | $0 | Gadeta has developed a proprietary technology to engineer alpha beta T cells with gamma delta TCRs, called TEGs, for the potential treatment of various hematological cancers and solid tumors. This platform has the potential to combine the advantages of conventional T cells, which express alpha and beta TCR chains, with TCRs derived from gamma delta T cells that recognize novel targets in cancer cells, according to preclinical models evaluating the lead TEG candidates. | Gilead Sciences | Collaboration | The Netherlands |
19-Jul-18 | Asian Eye Institute | $0 | Novotech works in partnership with leading medical institutions across Asia to accelerate quality clinical research. The Asian Eye Institute, Inc (AEI) partnership is designed to give Novotech clients faster start-up times and access to the AEI patient database, and leading principal investigators. | Novotech (Australia) Pty Limited | Partnership | Philippines |
19-Jul-18 | CCM Pharma Solutions | $0 | Nesvik Pharmaceuticals and CCM Pharma Solutions have agreed to work together to reformulate four new drug compounds (to be known as BSEM-120, BSEM-125, BSEM-130, and BSEM-135) via the 505(b)(2) pathway for U.S. FDA approval. These reformulations allow increased availability and delivery of widely known and used drugs in patients who are unable to take tablets or capsules. | Nesvik Pharmaceuticals (BioStem Technologies) | Asset Acquisition | Malaysia |
20-Jul-18 | Antengene Corporation | $0 | Through the R&D Collaboration, WuXi STA will provide Antengene an integrated solution in process R&D and manufacturing, using the MAH scheme to accelerate new drug development. Antengene and WuXi STA will also explore expanding the collaboration to commercial stage assets as Antengene prepares for the commercialization of its late-stage pipeline agents. | WuXi AppTec | Manufacturing Investment | China |
24-Jul-18 | Shyft Analytics | $0 | Novartis will use the following SHYFT solutions: STRATA Data Platform to aggregate and manage a growing number of third party and proprietary commercial data sources, LUMEN Insights Platform to deliver intuitively-designed analytics to drive the “next-best-actions” for commercial teams. | Novartis | Partnership | United States |
24-Jul-18 | Shyft Analytics | $0 | Shyft has evolved a variety of modules for its Intelligent Platform: Strata, for data analytics; Lumen, for data visualization (Tetraphase will be using these two products); Quantum, for performing analytics retrospectively, and Nova, for patient care coordination. | Tetraphase Pharmaceuticals | Launch & Partnerships | United States |
24-Jul-18 | Tsinghua University | $0 | The Innovation Center for Immune Therapy of Tsinghua University will conduct research on projects and Bristol-Myers Squibb will have an option to exclusively license therapeutic agents discovered by Tsinghua University. BMS collaboration with Tsinghua University focuses on the discovery of therapeutic agents against novel targets for autoimmune diseases and cancers. | Bristol-Myers Squibb | Collaboration | China |
25-Jul-18 | Advanced Therapeutics | $0 | Since partnering with WayPoint Capital Partners, DME Express has continued its rapid organic and acquisition-based growth strategy, completing four add-on transactions and adding over 4,000 new patient census across several markets. Advanced Therapeutics' strong reputation and established relationships in the area, combined with its experienced staff, provide a solid platform for DME Express to further expand in the Mid-Atlantic and other parts of the country. | DME Express | Acquisition | United States |
26-Jul-18 | InnoCore Pharmaceuticals | $0 | Merck and InnoCore Pharmaceuticals have entered into a global cooperation agreement to provide InnoCore’s proprietary SynBiosys® biodegradable polymer platform. The drug delivery platform can be used to develop sustained release solutions for biologicals in injectable formulations. | Merck Group | Cooperation Agreement | The Netherlands |
27-Jul-18 | MannKind Corporation | $0 | The agreement covers markets outside of the US where the product is yet to be registered. Under the terms of the deal, Tanner Pharma Group’s wholly-owned subsidiary TannerGAP will manage the distribution. | Tanner Pharma Group (TannerGAP, Inc.) | Distribution Agreement | United States |
27-Jul-18 | Steward Health Care International | $0 | The Letter of Intent outlines the willingness of both parties to co-operate in good faith with openness and transparency – all within the governing laws of Croatia, and the European Union informing a detailed assessment of the country's health care needs. As an integrated health care system, Steward's model addresses the wider health care needs of the populations and all ways to keep people healthy. | Croatian Ministry of Health | Letter of Intent | United States |
27-Jul-18 | Beckman Coulter | $0 | The iQ Workcell pairs two of the world's most highly regarded automated urine analyzers: the Beckman Coulter Iris iQ200 Digital Flow Morphology system and the ARKRAY AUTION MAX AX-4030 fully automated urine analyzer. This total urinalysis offering will be available in the U.S. exclusively through Beckman Coulter. | U.S. ARKRAY, Inc. | Launch & Partnerships | United States |
30-Jul-18 | Glycotope GmbH | $0 | The Global licensing agreement entitles Daiichi Sankyo to develop an antibody drug conjugate (ADC) by combining Daiichi’s proprietary ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab (formerly PankoMab-GEX®), building on a previous 2017 option agreement. | Daiichi Sankyo | Licensing Agreement | Germany |
30-Jul-18 | HiFiBiO Therapeutics | $0 | According to the agreement, scientists from both companies will work together to discover antibodies against Takeda’s targets using HiFiBiO Therapeutics’ single-cell screening capabilities. Takeda will be responsible for the preclinical and clinical development of the discovered antibodies. | Takeda Pharmaceutical Company | Research Agreement | China |
30-Jul-18 | Dana-Farber Cancer Institute | $0 | Dana-Farber researchers continue to be granted permission to conduct independent pre-clinical and clinical studies on select Lilly compounds. All compounds evaluated through this collaboration will continue to be fully owned by Lilly. | Eli Lilly and Company | Collaboration | United States |
30-Jul-18 | Zarbee's, Inc. | $0 | The acquisition will include the full line of Zarbee's Naturals™ products for children and adults. Zarbee's Naturals™ has grown into a broad-based health and wellness brand and has disrupted the cough, sleep, immune support and vitamin categories with its portfolio of family-friendly products. | Johnson & Johnson | Acquisition | United States |
31-Jul-18 | Laekna Inc. | $0 | The candidates are oral pan-Akt kinase inhibitors. Over ten clinical Phase I/II studies for afuresertib (ASB183) and uprosertib (UPB795) have been conducted in several cancer indications including ovarian and gastric cancer, multiple myeloma, melanoma, and other indications. | Novartis | Commercialization Agreement | China |
31-Jul-18 | Eisai Co | $0 | The agreement grants exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride (generic name, product name US - BELVIQ®, BELVIQ XR, “lorcaserin”) in China. | CY Biotech | Collaboration | Japan |
31-Jul-18 | Centrillion Genomics Technologies | $0 | The strategic cooperation agreement includes a multi-million US dollar investment by WeDoctor and establishes with Centrillion (Hangzhou) Co., Ltd. a joint venture to provide the most advanced DNA chips and genomic analysis services. | WeDoctor Holdings Limited | Cooperation Agreement | Taiwan |
31-Jul-18 | Centrillion Genomics Technologies | $0 | As the largest chipset provider for big data, AI, and the Internet of Things (IoT), Arm is bringing compute power to genomics and healthcare management to accelerate growth opportunities and technology innovation. Arm IoT Fund, sponsored by Arm Holdings is the world’s leading semiconductor intellectual property (IP) supplier for digital electronic products. | Arm IoT Fund | Financing | Taiwan |
27-Aug-18 | Affimed N.V. | $5,000 | Affimed will apply its proprietary Redirected Optimized Cell Killing (ROCK®) platform, which enables the generation of both NK cell and T cell-engaging antibodies, to discover and advance innate immune cell engager-based immunotherapeutics of interest to Genentech. | Roche | Collaboration | Germany |
30-Aug-18 | K2M Group Holdings | $1,400 | The combined business will have a competitive portfolio across Stryker's Spine product categories and leverage a more powerful commercial engine. | Stryker | Acquisition | United States |
17-Aug-18 | Mologen AG | $1,160 | In the co-development agreement, the companies aim to finalize the IMPALA study, gain an opportunity to fully realize the potential of lefitolimod in combination with other immuno-oncology drugs and in additional indications outside the colorectal cancer maintenance setting. Success in additional indications would bring in additional milestones and royalties representing substantial value for MOLOGEN. | Oncologie, Inc. | Commercialization Agreement | Germany |
08-Aug-18 | BeiGene | $903 | BeiGene intends to use net proceeds from the Offering for clinical trials, preparation for registration filings, and for the launch and commercialization of its core product candidates (zanubrutinib, tislelizumab, and pamiparib). | Morgan Stanley | IPO | China |
17-Aug-18 | Ziylo | $800 | Ziylo's glucose binding molecules are synthetic molecules designed by Professor Anthony Davis at the University of Bristol. The combination of this technology with state-of-the-art insulin engineering pioneered by Novo Nordisk aspires to realise the world's first glucose responsive insulin and transform the treatment of diabetes. | Novo Nordisk | Acquisition | United Kingdom |
28-Aug-18 | Adapt Pharma | $735 | The acquisition of Adapt Pharma adds NARCAN Nasal Spray to Emergent’s portfolio of only-in-class products with applications in both government and commercial markets. NARCAN Nasal Spray became commercially available in early 2016 after receiving FDA approval in November 2015. | Emergent BioSolutions | Acquisition | United States |
16-Aug-18 | Illumina, Inc. | $650 | Illumina intends to use the net proceeds of the offering to repurchase approximately $102.7 million of its common stock | Undisclosed | IPO | United States |
22-Aug-18 | argenx | $625 | ARGX-115 employs argenx’s SIMPLE Antibody™ technology and binds specifically to the protein glycoprotein A repetitions predominant (GARP), which plays a key role in the regulation of production and release of active transforming growth factor beta (TGF-beta). | AbbVie | Option Agreement | Belgium |
31-Aug-18 | Genea IVF | $509 | The 31-year-old Sydney-based Genea provides reproductive technology services including infertility, in-vitro fertilization (IVF) and other assisted conception treatment. The company developed technology including culture media and embryo transfer catheters is currently applied in more than 600 clinics across 60 countries. | WeDoctor (Weiyi Group) | Acquisition | Australia |
16-Aug-18 | BioNTech AG | $425 | BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. | Pfizer Inc. | Collaboration | United States |
24-Aug-18 | JW Pharmaceutical | $402 | LEO Pharma will obtain exclusive rights to develop and commercialize JW1601 - an innovative new drug candidate which has a dual mechanism of action that blocks the activation and migration of the immune cells that cause atopic dermatitis by selectively acting on the histamine H4 receptor and inhibiting the histamine signaling that causes itching. | Leo Pharma | Licensing Agreement | South Korea |
14-Aug-18 | Oscar Health | $375 | When seniors in the US turn 65, they can choose to be part of either traditional Medicare or Medicare Advantage, which is operated through private insurers like Oscar and often provides additional healthcare benefits. | Capital G Venture Capital ; Verily Life Sciences | Investment | United States |
19-Aug-18 | Sichuan Kelun-Biotech Biopharmaceutical (Kelun Pharmaceutical Group) | $350 | A167 is an anti-PD-L1 monoclonal antibody in Phase 2 clinical trials discovered and developed by Kelun-Biotech in China, with potential to treat multiple solid tumor and hematological cancers. | Harbour Antibodies BV | Partnership | China |
06-Aug-18 | Greater Pacific Capital | $300 | From the first fund, GPC had invested in several companies, including in Edelweiss Financial Services Ltd and Torrent Pharma Ltd. “The plan is to have a corpus of $1 billion to deploy in India. This would include some commitments from LPs as well who want to co-invest in deal opportunities along with the fund,” an executive said. | Undisclosed | Investment | United Kingdom |
01-Aug-18 | Chinese Diagnostics Medical Corporation | $293 | Chinese Diagnostics Medical Corporation specializes in the design and development of diagnostic testing reagents. Its products include biochemical, chemiluminescence, radioactive reagents. | Legend Capital | Private Placement | China |
01-Aug-18 | Biotest USA (Biotest Pharmaceuticals Corporation) | $286 | BPC will continue to operate as Biotest Pharmaceuticals Corporationuntil all FDA regulatory approvals have been obtained. The plasma collected at Biotest Plasma Centers is used to manufacture critical care therapies that treat life threatening disorders in a variety of therapeutic areas. | Grifols Shared Services North America, Inc. | Acquisition | United States |
09-Aug-18 | PaxVax | $270 | This acquisition will broaden Emergent’s development pipeline with the addition of a next generation adenovirus 4/7 vaccine candidate which is intended to meet the government’s stated requirement of protecting the U.S. military against common causes of acute respiratory disease. | Emergent BioSolutions | Acquisition | United States |
02-Aug-18 | Medall Healthcare | $212 | This will be the largest investment in an Indian diagnostics company to date. As of the date of this announcement, subject to closing, Constellation is expected to be the only India-focused healthcare services company to be publicly listed outside of India. | Constellation Alpha Capital | Acquisition | India |
22-Aug-18 | Gilead Sciences | $198 | Momelotinib has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a potentially differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive spleen and constitutional symptom control. | Sierra Oncology | Asset Acquisition | United States |
23-Aug-18 | Rakuten Aspyrian | $150 | The financing will also support manufacturing scale-up for the commercialization of ASP-1929 and corporate growth including the initial buildup of commercial operations to support the launch of ASP-1929 in the United States, Japan and Europe. | Hiroshi Mikitani (Rakuten Inc.) | Series C Financing | United States |
23-Aug-18 | Ironshore Pharmaceuticals & Development, Inc. | $143 | With the FDA approval of JORNAY PM™ in hand, Ironshore's primary focus has shifted to ensuring an optimal commercial launch of this innovative drug with its unique value proposition. JORNAY PM is the only stimulant medication that is dosed once daily in the evening and was developed to help patients with Attention Deficit Hyperactivity Disorder (ADHD) obtain better control over the disruptive impairments. | Undisclosed | Private Placement | Cayman Islands |
23-Aug-18 | Roche | $127 | Through this licensing agreement, GBT will develop and commercialize inclacumab, a novel fully human monoclonal antibody against P-selectin. GBT also plans to develop inclacumab as a treatment for vaso-occlusive crises (VOC) in patients with sickle cell disease (SCD). | Global Blood Therapeutics, Inc. | Licensing Agreement | Switzerland |
06-Aug-18 | Glenmark Pharmaceuticals | $120 | Harbour BioMed will lead the clinical development and commercialization of GBR 1302, with the option to manufacture GBR 1302 for the Greater China market. GBR 1302, Glenmark's lead immuno-oncology candidate, works by stimulating the patient's immune system against HER2 overexpressing tumor cells. | Harbour Antibodies BV | Licensing Agreement | India |
10-Aug-18 | Quethera Limited | $111 | Quethera is a gene therapy company headquartered in the United Kingdom, that is focused on developing novel treatments for ocular disorders, such as glaucoma. Through this transaction, Astellas has acquired Quethera's ophthalmic gene therapy program, which uses a recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes into target retinal cells for the treatment of glaucoma. | Astellas Pharma | Acquisition | United Kingdom |
10-Aug-18 | Aralez Pharmaceuticals Inc. | $110 | Nuvo would acquire Aralez's Canadian specialty pharmaceutical business, formerly known as Tribute Pharmaceuticals Canada Inc. which includes Cambia®, BlextenTM, SuvexxTM (sold as Treximet® in the USA), as well as the Canadian distribution rights to Resultz,® and would create a platform for Nuvo to acquire and launch additional commercial products in Canada. The funding of the proposed Acquisition to be provided by Deerfield. | Nuvo Pharmaceuticals Inc., Deerfield Management Company | Acquisition | Canada |
29-Aug-18 | Tempus | $110 | Tempus is in partnership with the American Society of Clinical Oncologists (ASCO), leading academic medical centers and NCI designated cancer centers, hospital networks and community physicians across the United States. | T. Rowe Price, Revolution Growth | Series E Financing | United States |
08-Aug-18 | TOT BIOPHARM Company Limited | $102 | TOT BIOPHARM focuses on the R&D, manufacturing and marketing of high-end anti-tumor drugs. The company now has over 10 drugs in the R&D stage, including three biologics and three small molecules, which have received investigational new drug application (IND) approvals, as well as one antibody-drug conjugate (ADC), which is expected to receive approval soon. | China Universal (Cayman) GP Limited | Series B Financing | China |
08-Aug-18 | Dongpu Pharmaceutical | $102 | "This round of financing will accelerate the development of our key pipelines. Dongpu will seize the opportunity of China's anti-tumor drug market to grow at a high speed. In the future, it will also take advantage of its existing industrial chain platform to expand its multi-directional direction. Multi-level international links and cooperation make the benefits of resource integration more significant." | Yuanda Financial Holdings Group | Series B Financing | China |
06-Aug-18 | bluebird bio., Inc | $100 | The collaborators will specifically leverage Regeneron's VelociSuite® platform discovering and characterising fully human antibodies & T cell receptors (TCRs) directed against tumor-specific proteins and peptides. The collaborators have jointly selected six initial targets and will equally share the costs of research and development up to the point of submitting an Investigational New Drug (IND) application. | Regeneron Pharmaceuticals, Inc. | Commercialization Agreement | United States |
08-Aug-18 | Ambys Medicines | $100 | Ambys is pioneering the application of cell and gene therapies, and gain-of-function drug therapy, to frame restorative liver treatments and preventative therapeutics to address multiple liver diseases that are untreatable or poorly treated today. | Takeda Pharmaceutical Company | Partnership | United States |
28-Aug-18 | Dermavant (Roivant Sciences) | $100 | Frank Torti, MD, has joined the company as Vant Investment Chair for Roivant Pharma. In this role, he is expected to be responsible for the oversight of biopharmaceutical companies in the Roivant family and to serve as one of two Roivant-appointed representatives on company boards. Roivant also announced that NovaQuest Capital Management has made a $100 million strategic investment in Dermavant in exchange for conditional milestone payments achieved by tapinarof, a Phase 3-ready investigational | NovaQuest Capital Management LLC | Investment | United States |
30-Aug-18 | Arvinas | $100 | Arvinas focuses on developing a new class of drugs based on protein degradation. At its most basic, this involves attaching a molecule to an unwanted protein, bringing it to the attention of the cell’s garbage disposal, the proteasome. | Undisclosed | IPO | United States |
21-Aug-18 | Solids Launch facility | $99 | This new Solids Launch facility will focus on development activities for drugs in tablet form and manufacture them for worldwide market launches. | Boehringer Ingelheim | Manufacturing Investment | Germany |
21-Aug-18 | TraceLink | $93 | This investment will fuel the digitalization of the global pharmaceutical supply chain through the integration of real-time information-sharing, in order to create a highly predictable supply chain for the industry. | Georgian Partners | Investment | United States |
10-Aug-18 | Glenmark Pharmaceuticals | $91 | Glenmark’s orthopaedic and pain management business, valued at Rs. 635 cr., will be transferred to a new entity to-be incorporated by True North. New entity wouldnbe named as ‘Integrace Private Limited’. Integrace will market the product portfolio in India and Nepal. | True North Capital | Collaboration | India |
26-Aug-18 | Harbour BioMed | $85 | Harbour BioMed has integrated its proprietary Harbour Mice technologies into its newly built antibody technology and discovery biology, preclinical and clinical development operations and entered into multiple license and collaboration agreements for Harbour Mice. | GIC Private Limited | Series B Financing | China |
10-Aug-18 | Artios Pharma | $84 | Artios is actively developing a pipeline of highly promising first-in-class DDR therapies identified from a global network of leading researchers in the DDR field, including through Cancer Research UK. The inhibition of novel DNA repair targets like Pol?, in tumours where DNA damage response factors have been lost or down regulated, will lead to cancer cells being selectively killed without harming normal cells. | Andera Partners | Series B Financing | United Kingdom |
07-Aug-18 | Can-Fite BioPharma Ltd | $75 | The main aim of the agreement includes the commercialization of Can-Fite’s Piclidenoson for the treatment of rheumatoid arthritis and psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). | CMS Medical (China Medical System Holdings Limited) | Distribution Agreement | Israel |
08-Aug-18 | SQZ Biotechnologies | $72 | Proceeds from the financing support SQZ's most advanced programs in solid tumors and auto-immunity. The Company's lead program in antigen presenting cells (APCs) for oncology will have its first application in multiple HPV+ tumor indications; future applications will address solid tumors across cancer types. | Illumina Ventures | Series C Financing | United States |
14-Aug-18 | SalvaRx Limited (SalvaRx Group plc) | $72 | SalvaRx's strategy is to invest in a portfolio of companies involved in novel cancer immunotherapies and develop them up to clinical proof of concept. SalvaRx's management team have a proven track record of discovering and commercialising drugs in the area of cancer immunotherapy with Bristol-Myers Squibb and Johnson & Johnson. | Portage Biotech | Acquisition | United Kingdom |
07-Aug-18 | Synergy Pharmaceuticals | $68 | The Agreement grants exclusive rights to Luoxin to develop and commercialize Synergy’s lead product TRULANCE® (plecanatide) for the treatment of adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in mainland China, Hong Kong and Macau. | Luoxin Pharmaceutical Group Co., Ltd. | Licensing Agreement | United States |
08-Aug-18 | Ambys Medicines | $60 | Ambys Medicines is pursuing multiple strategies to develop innovative new medicines for patients suffering from chronic liver diseases, including cell therapy for hepatocyte transplantation, gene therapy for liver regeneration, and drug therapy to replace lost protein function. | Third Rock Ventures | Series A Financing | United States |
09-Aug-18 | Therachon AG | $60 | Therachon plans to use the proceeds to advance the company’s lead pipeline candidate TA-46, a novel protein therapeutic for achondroplasia, the most common form of disproportionate short stature in humans, as well as to support the expansion of its rare disease pipeline. TA-46 is being developed as a weekly subcutaneous therapy for children and adolescents living with achondroplasia. | Novo Holdings | Financing | Switzerland |
08-Aug-18 | Apexigen | $58 | Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for oncology with lead product APX005M - a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. | 3E Bioventures Capital | Series C Financing | United States |
06-Aug-18 | BioCryst Pharmaceuticals | $58 | BioCryst expects to use the net proceeds of this offering for general corporate purposes, which may include, but are not limited to, funding worldwide development, manufacturing, regulatory and commercial activities for the prophylactic and acute BCX7353 programs, focusing primarily on the United States, European Union and Japan; the advancement of development activities of our fibrodysplasia ossificans progressiva (“FOP”) and other preclinical rare disease program; post-approval commitments for | Undisclosed | IPO | United States |
01-Aug-18 | ReViral | $55 | The new funding will enable ReViral to progress its lead drug candidate (RV521), a highly potent and orally bioavailable potential treatment for RSV infections, into Phase IIa paediatric and adult trials, and to continue the development of a novel series of antiviral inhibitors targeting RSV replication. RV521 is soon expected to enter an international multicentre Phase IIa paediatric trial. | New Leaf Venture Partners | Series B Financing | United Kingdom |
30-Aug-18 | Jacobio Pharmaceuticals | $55 | Jacobio’s lead drug, JAB-3068, inhibits PTPN11, an enzyme believed to play a role in several blood cancers. | Qiming Capital | Series C Financing | China |
03-Aug-18 | Acer Therapeutics | $46 | Acer intends to use the net proceeds from this offering to fund its research and development efforts, to seek regulatory approval for EDSIVO™, to invest in pre-commercial activities for EDSIVO™, to advance development of ACER-001, to acquire or in-license product candidates, and for general corporate purposes, including working capital and other general and administrative purposes. | Roth Capital Partners | IPO | United States |
24-Aug-18 | Cipla | $45 | The drug maker, majority-owned by India’s pharmaceutical giant Cipla, makes a range of drugs including antiretrovirals, anti-malaria and Hepatitis B and C drugs which it sells mostly in sub-Saharan African countries. Cipla, according to a statement, will still maintain a majority stake even after the IPO . | Undisclosed | IPO | Uganda |
02-Aug-18 | BioTime | $43 | Juvenescence management, through their previous roles in pharmaceutical companies with marketed products, have taken multiple products to commercialization with annual peak sales aggregating well over $70 billion. Juvenescence has, in its short existence, already sourced and created a pipeline of exciting therapeutic candidates, all of which have the potential to positively modify aging. | Juvenescence Limited | Partnership | United States |
09-Aug-18 | Vernalis plc | $43 | The acquisition of Vernalis would provide Ligand with a portfolio of more than 8 fully-funded partnered programs, or shots on goal, including programs in the respiratory, oncology and Central Nervous System areas. | Ligand Pharmaceuticals Incorporated | Acquisition | United Kingdom |
02-Aug-18 | Karuna Pharmaceuticals | $42 | Karuna plans to use the proceeds from the financing to advance its lead product candidate, KarXT (Karuna-xanomeline-trospium chloride), including the initiation of a Phase 2 trial in patients with schizophrenia in the third quarter of 2018 and the expansion into other therapeutic areas, including a non-opiate pain indication. | ARCH Venture Partners | Series A Financing | United States |
06-Aug-18 | Editas Medicine | $40 | The joint collaboration reinforces both Allergan's and Editas' continued commitment to developing innovative treatments for unmet needs in eye care. EDIT-101 is Editas Medicine's experimental CRISPR genome editing medicine for the treatment of Leber Congenital Amaurosis type 10 (LCA10). | Allergan plc | Option Agreement | United States |
09-Aug-18 | Vaccinex | $40 | Vaccinex intends to use the net proceeds of this offering to fund its ongoing development of certain therapies, to repay certain debt obligations, to fund continued preclinical research discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. | Oppenheimer Holdings | IPO | United States |
16-Aug-18 | Profectus BioSciences, Emergent BioSolutions | $36 | The grant funding by CEPI is for the purpose of advancing the development and manufacture of a vaccine against the Lassa virus—an estimated 100,000 to 300,000 cases of Lassa virus infection occur each year. | Coalition for Epidemic Preparedness Innovations (CEPI) | Grants & Awards | United States |
25-Aug-18 | Big Beat Challenge | $35 | Unveiled at this year’s European Society of Cardiology Congress in Munich, the £30 million award will be one of the largest and most ambitious of its kind; a challenge to scientists, clinicians, innovators and entrepreneurs to look beyond incremental gains and accelerate breakthroughs that could transform lives across the globe. | British Heart Foundation | Grants & Awards | United Kingdom |
21-Aug-18 | Recombinetics | $34 | Proceeds will be used to accelerate new research and development by adding scientists and expertise focused on emerging science, including regenerative medicine; to continue to add to our robust intellectual property and patent portfolio; expand the laboratory, animal care and advanced reproductive facilities; and build out the business development, product marketing and management team to take advantage of licensing and co-development opportunities. | Gundersen Health | Series A Financing | United States |
27-Aug-18 | Dubai Science Park Generics Manufacturing Facility | $34 | The custom-built factory is the first advanced manufacturing facility to be opened in Dubai Science Park and is equipped with the latest European technology, meeting stringent global regulatory standards, the company said in a statement. Pharmax said it will produce medications targeting chronic conditions common in the Middle East and other developed markets, including cardiovascular diseases, psychiatric and neurological disorders. | Pharmax Pharmaceuticals | Manufacturing Investment | United Arab Emirates |
29-Aug-18 | KaNDy Therapeutics | $32 | The proceeds will enable KaNDy Therapeutics to advance its breakthrough non-hormonal drug candidate, NT-814, for treatment of multiple symptoms of the menopause, through a multi-country Phase 2b dose-ranging study due to start recruiting patients in Q4 2018 with headline results expected in late 2019. | Longitude Capital | Series C Financing | United Kingdom |
13-Aug-18 | Magnolia Neurosciences Corporation | $31 | Magnolia Neurosciences Corporation is a drug discovery and development company focused on the creation of a novel class of neuroprotective medicines. | Accelerator Life Science Partners | Series A Financing | United States |
03-Aug-18 | IMPACT Therapeutics | $30 | The proceeds from the series C will be used for the clinical development of IMP4297, a potential best-in-class PARP inhibitor, and to advance IMPACT's integrated programs targeting DNA Damage Response (DDR). | Eli Lilly and Company | Series C Financing | China |
08-Aug-18 | Lacerta Therapeutics | $30 | The Lacerta relationship expands Sarepta’s gene therapy pipeline to up to 11 unique candidates focused on CNS gene therapy targets. Lacerta will manage the majority of pre-clinical development while Sarepta will lead clinical development and commercialization. Sarepta will owe development and sales-based milestones to Lacerta and pay single-digit royalties on net sales. | Sarepta Therapeutics | Licensing Agreement | United States |
08-Aug-18 | Lacerta Therapeutics | $30 | Lacerta is a clinical-stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. | Sarepta Therapeutics | Licensing Agreement | United States |
09-Aug-18 | OvaScience, Millendo Therapeutics | $30 | OvaScience will merge with Millendo in an all-stock transaction. The merged company will focus on advancing Millendo’s pipeline of distinct and transformative treatments for orphan endocrine diseases. Upon shareholder approval, the combined company is expected to operate under the name Millendo Therapeutics | New Enterprise Associates | Merger Agreement | United States |
14-Aug-18 | Genome Protection, Inc. (Cleveland Biolabs, Everon BioSciences) | $30 | GPI signed a Simple Agreement for Future Equity (SAFE) with Norma Investments. GPI's goal is to develop and commercialize drugs for anti-aging applications capable of prolonging human health and life-span. GPI granted Norma the right to purchase shares of GPI's capital stock in exchange for the payment of up to $30 million, of which $10.5 million was paid shortly after the execution of the SAFE. | Norma Investments Limited | Joint Venture | United States |
23-Aug-18 | Gritstone Oncology | $30 | Gritstone Oncology will leverage its proprietary EDGE™ artificial intelligence platform to analyze specific tumor types to identify tumor-specific targets and natural T-cell receptors (TCRs) directed to selected targets for use in bluebird bio’s established cell therapy platforms. | bluebird bio, Inc. | Series C Financing | United States |
30-Aug-18 | Reata Pharmaceuticals | $30 | The payment was received following the initiation of AYAME, a Phase 3 clinical trial to assess the efficacy and safety of bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease in Japan. Bardoxolone is an experimental, oral, once-daily activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. | Kyowa Hakko Kirin | Milestone Payment | United States |
13-Aug-18 | Aridis Pharmaceuticals | $26 | Aridis Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. | Maxim Group | IPO | United States |
14-Aug-18 | RedHill Biopharma | $25 | The Company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund clinical development programs, including preparations for a second Phase III study with RHB-104 for Crohn’s disease, initiation of a pivotal Phase III study with RHB-204 for NTM, for commercial operations including TALICIA® (H. pylori) launch preparations | Ladenburg Thalmann & Co. Inc | IPO | Israel |
01-Aug-18 | Mammoth Biosciences | $23 | Mammoth is exploring the use for CRISPR as the search engine for biology. The CRISPR-Cas complexes are fitted with a guide-RNA, which tells them what specific sequence to look for in the DNA or RNA sample. | Mayfield Partners | Series A Financing | United States |
13-Aug-18 | Windlass Healthcare Private Limited (WHPL) | $22 | Windlas Healthcare has a robust manufacturing infrastructure with a USFDA inspected oral solids manufacturing facility. WHPL also has a dedicated R&D facility for formulations development and has developed four First-to-File ANDAs in the last two years. The strategic deal allows Cadila Healthcare to expand its existing manufacturing base. The cost of acquisition is Rs. 155.55 crore and the deal will be completed by the end of September 2018. | Cadila Healthcare Ltd | Acquisition | India |
06-Aug-18 | Protagonist Therapeutics | $22 | Protagonist Therapeutics is a clinical stage biopharmaceutical company discovering and developing novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-100 is an oral alpha-4-beta-7 integrin antagonist peptide that is under evaluation for potential treatment of inflammatory bowel diseases. Proceeds from the financing will be used to advance development of drug candidate PTG-100. | BVF Partners L.P. | Financing | United States |
22-Aug-18 | Exicure | $22 | Exicure expects to use the proceeds from this offering for advancing the development of Exicure’s drug candidates - AST-008 - an SNA consisting of toll-like receptor 9 (TLR9) agonists designed for immuno-oncology applications; XCUR17 - an antisense SNA that targets the mRNA encoding IL-17RA, an essential initiation protein. | Sphera Global Healthcare | Private Placement | United States |
02-Aug-18 | Depomed, Inc. | $20 | Products covered by the Royalty Agreement and amendment include Glumetza® and its authorized generic, Jentadueto XR®, Invokamet XR® and Synjardy XR®. | PDL BioPharma, Inc. | Financing | United States |
24-Aug-18 | Forbius (Formation Biologics) | $19 | The new CPRIT grant award follows a successful completion of an AVID100 Phase 1 clinical trial. The grant will support operations and Phase 2a development of AVID100, a highly potent anti-EGFR antibody-drug conjugate, in three cancer indications with significant unmet medical need. | Cancer Prevention and Research Institute | Grants & Awards | United States |
02-Aug-18 | Akcea Therapeutics (Ionis Pharmaceuticals) | $18 | TEGSEDITM (inotersen), a product of Ionis' proprietary antisense technology, is an antisense oligonucleotide (ASO) inhibitor of human transthyretin (TTR) production and was developed by Ionis. WAYLIVRATM, a product of Ionis' proprietary antisense technology, is under regulatory review in the U.S., E.U. and Canada as a treatment for familial chylomicronemia syndrome (FCS). | PTC Therapeutics | Licensing Agreement | United States |
02-Aug-18 | Lenus Therapeutics (GtreeBNT) | $18 | EB is a rare genetic disease that most often appears in the skin, although it can also affect internal organs. There are currently no medications approved for the treatment of EB. RGN-137, a topical gel initially developed by RegeneRx Biopharmaceuticals, Inc., is the one of the only late stage treatment candidates and currently the subject of clinical trials in the United States. | RegeneRx Biopharmaceuticals, Inc. | Joint Venture | South Korea |
06-Aug-18 | Pharmaxis | $17 | The funds raised will be used to strengthen the Pharmaxis balance sheet as the Company conducts partnering negotiations for its clinical development program into Lysyl Oxidase 2 Inhibitors (LOXL2) expected to occur in 2H18. The company will have a A$54m pro?forma cash balance (30 June 2018 post raising). In addition, the funds will be used to further invest in pre?clinical programs and general working capital. | Arix Biosciences | Private Placement | Australia |
15-Aug-18 | BioNano Genomics | $16 | The biotech would raise about $16 million at the midpoint of the range. | Roth Capital Partners | IPO | United States |
08-Aug-18 | Apexigen | $15 | Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for oncology with lead product APX005M - a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M and the Company’s additional preclinical programs were discovered using APXiMAB™, Apexigen’s proprietary product discovery platform. | Decheng Capital | Series B Financing | United States |
09-Aug-18 | EdiGene | $15 | EdiGene Inc leverages its proprietary platforms to develop gene-editing therapies for a wide range of diseases, and to conduct high-throughput genome screening to enable dissection of functional big data in biological contexts. | Eli Lilly and Company | Series B Financing | China |
30-Aug-18 | Genomics plc | $14 | Scientists from Vertex and Genomics will work closely together to incorporate their deep understanding of human genetics into research and development related to target discovery and target validation in certain diseases. Both companies will also have the opportunity to suggest additional diseases for the collaboration, where human genetic evidence may be particularly powerful. | Vertex Pharmaceuticals | Financing | United Kingdom |
06-Aug-18 | ContraVir Pharmaceuticals | $13 | ContraVir previously announced it is ready to initiate the dosing of HBV patients in a dose-ranging study with an optimized formulation of TXL™ to allow for more efficient, predictable and precise delivery while reducing drug burden and maintaining consistent efficacy. The objective of the next clinical trial with TXL™ will be to characterize the pharmacokinetic profile of the new formulation in HBV patients and to select the target dose to be advanced into Phase 3. | Maxim Group | Financing | United States |
09-Aug-18 | Akili Interactive | $13 | Akili’s digital medicines embed specific stimuli, designed to engage targeted areas of the brain, into immersive action video game experiences to treat medical conditions across neurology and psychiatry. Akili’s lead digital treatment in development, AKL-T01 in pediatric ADHD, is now under review by the FDA. | CLSA | Series C Financing | United States |
14-Aug-18 | Blueberry Therapeutics | $13 | Blueberry Therapeutics will use the net proceeds of the Series B Fundraising to fund its development programme for BB2603 for the treatment of onychomycosis and tinea pedis, as well as progressing its earlier stage acne, topical analgesia and atopic dermatitis programmes. | China Medical System Holdings | Series B Financing | United Kingdom |
14-Aug-18 | AxiaMed | $12 | AxiaMed’s Payment Fusion platform has become the healthcare industry’s preferred SaaS-based payment platform and is used by hundreds of hospitals and thousands of ambulatory providers. Payment Fusion enables healthcare software vendors to integrate secure payment technology into their applications, lessening the risks of payment data breaches, and reducing compliance burdens while improving the financial performance of providers by expanding payment options available to patients. | Health Enterprise Partners | Investment | United States |
02-Aug-18 | American Cancer Society | $10 | The new funding will be raised to support cancer patient services programs, breakthrough research, and cancer prevention efforts, including tobacco control. According to the American Cancer Society, almost 30 percent of cancer deaths this year will be caused by cigarette smoking. | CVS Health | Financing | United States |
06-Aug-18 | Washington University School of Medicine in St. Louis | $10 | The partnership will fund projects based on competitive review by a governance committee composed of leaders from both institutions. Mallinckrodt plans to fund two types of grants while also supporting direct collaboration with Washington University School of Medicine, guided by a joint steering committee with representatives from both parties. | Mallinckrodt | Collaboration | United States |
09-Aug-18 | Citius Pharmaceuticals | $10 | The gross proceeds of the Offering are expected to be approximately $10.0 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. Citius intends to use the net proceeds from this Offering for general corporate purposes, including its Phase 3 clinical Mino-Lok trial for the treatment of catheter related bloodstream infections and its Phase 2b clinical trial of Hydro-Lido cream for the treatment of hemorrhoids, and working capital and capital expenditure | H.C. Wainwright & Co. | IPO | United States |
13-Aug-18 | Pneuma Respiratory | $10 | Haisco Pharmaceutical Group will receive the rights to distribute the pharmaceutical products of Pneuma Respiratory in China. Haisco will be responsible for financing the regulatory records of China. | Haisco Pharmaceutical Group | Distribution Agreement | United States |
14-Aug-18 | Mobilize AZ | $10 | With BCBSAZ investing $10 million over three years, the initiative will support prevention, treatment, and recovery programs to help providers and local organizations fight against the opioid epidemic. Mobilize AZ includes tailored strategies to including a grant program that will award a minimum of $1 million each year to community organizations involved in education, treatment, and recovery from opioid misuse. | Blue Cross Blue Shield | Investment | United States |
28-Aug-18 | SAB Biotherapeutics | $10 | SAB’s unique immunotherapy platform is the only one in the world to produce human polyclonal antibodies—the natural way to fight disease—on a commercial scale without using humans. SAB expects to enter two new Phase 1 and 2 trials during the next 18 months for severe hospitalized influenza and MERS-CoV respectively | T. Denny Sanford (Sanford Health System) | Series A Financing | United States |
08-Aug-18 | VolitionRx Limited | $9 | As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. | Undisclosed | Private Placement | Belgium |
09-Aug-18 | Human Cell Atlas | $9 | Wellcome is committing £7 million to the Human Cell Atlas, a global endeavour to map every single cell type in the human body. The £7m in new funding will enable the UK researchers to generate data from millions of human cells, towards the aim of creating a reference map of every single cell type in the human body. | Wellcome Sanger Institute | Grants & Awards | United Kingdom |
14-Aug-18 | Bugworks Research | $9 | Bugworks' novel bacterial topoisomerase inhibitor (NBTI) is highly effective against a very broad spectrum of multi-drug resistant bacterial pathogens. This potent first-in-class antibiotic was designed using ELUDE, Bugworks' proprietary efflux-pump avoidance platform. | University of Tokyo Edge Capital (UTEC) Japan | Series A Financing | United States |
09-Aug-18 | Ampio Pharmaceuticals | $8 | Ampio intends to use the net proceeds from this offering for continued preclinical development of Ampion and funding an Ampion clinical trial, if required. | Canaccord Genuity | IPO | United States |
29-Aug-18 | Sempre Health | $8 | Sempre Health's innovative and dynamic discount programs enable health plans to financially align members with broader clinical priorities by allowing them to pay less for filling their prescriptions on time. Proceeds will be used to further build out Sempre's two-sided network of payers and pharma manufacturers. | Social Capital | Series A Financing | United States |
01-Aug-18 | Angiochem Inc | $8 | With this latest financing, the company is on track to further develop ANG1005. This compound has already delivered promising results and now, we are gearing up for a pivotal Phase 3 trial that will hopefully lead to a long awaited therapeutic solution for patients with breast cancer who suffer from brain metastases and leptomeningeal carcinomatosis | Undisclosed | Series C Financing | Canada |
09-Aug-18 | Modulus Discovery | $7 | Modulus will use the proceeds to accelerate its drug discovery research through leveraging the company’s proprietary computational platform and efficient virtual pharma operating model. | Fast Track Initiative, Inc. | Series A Financing | Japan |
30-Aug-18 | RootPath | $7 | The company was launched in 2017 by life sciences venture capital and incubation firm Nest.Bio. RootPath will use its proceeds to advance its immuno-oncology programs and obtain key data on accuracy, efficacy and safety in animal models. Founded by scientists and bioengineers instrumental in the development of synthetic biology, gene editing and single-cell sequencing technologies, RootPath continues to build on the collective expertise and insights from its founders, Drs. Xi Chen, Le Cong, Yinq | Sequoia China | Seed Financing | United States |
16-Aug-18 | University of British Columbia (UBC) | $7 | Genomics Application Partnership Program (GAPP), which supports university-industry collaborations to bridge the gap between basic research and commercialization. In this partnership program, AbCellera will apply its microfluidic single-cell platform to the discovery and engineering of large panels of antibodies against three novel targets. Lead candidates from the discovered antibodies will be selected by UBC and then functionally tested in genetically modified animal models. | Genome Canada; AbCellera Biologics | Partnership | Canada |
16-Aug-18 | National Disease Research Interchange (NDRI) | $7 | A unique element of NDRI’s work supported through this agreement is provision and distribution for neurological research through the National Institute of Neurological Disorders and Stroke (NINDS). In the last five years, NDRI has provided 884 neurological biospecimens to 79 researchers, including normal and pathological tissues representative of 20 distinct diseases, including ALS, Alzheimer’s disease, Parkinson’s disease, muscular dystrophy, pure autonomic failure, Lewy body dementia, and spin | National Institutes of Health (NIH) | Grants & Awards | United States |
23-Aug-18 | Novaremed AG | $6 | The proceeds of the financing will be used to prepare for a global Phase 2b clinical study of its lead compound, NRD.E1, a novel, first-in-class, small molecule for patients suffering from diabetic neuropathic pain (DNP). Together with CHF 4.44 million raised in April 2018, the company will be well capitalized to prepare for a global Phase 2b clinical study, which is expected to be initiated in H2 2019. | Undisclosed | Financing | Israel |
01-Aug-18 | DSM Biomedical | $6 | Aerie will immediately have a worldwide exclusive license for all ophthalmic indications to DSM’s polyesteramide polymer technology for an unlimited number of compounds. Aerie and DSM will continue collaborative research activities including the transfer of DSM’s formulation technology. Aerie will gain access to DSM’s preclinical stage latanoprost implant with the potential for initial clinical studies in glaucoma patients in 2019. | Aerie Pharmaceuticals, Inc. | Option Agreement | The Netherlands |
17-Aug-18 | AVEO Pharmaceuticals | $6 | The net proceeds of the offering are expected to be used for working capital and general corporate purposes, including development and pre-commercial expenses incurred in connection with the ongoing Phase 3 clinical trial of tivozanib in the third-line treatment of patients with advanced renal cell carcinoma (“aRCC”) as well as the ongoing Phase 1b/2 clinical trial of tivozanib in combination with OPDIVO® (nivolumab). | Piper Jaffray & Co. | IPO | United States |
30-Aug-18 | Lunaphore Technologies SA | $5 | The funding will be used to enhance the market launch and drive market adoption of the first Lunaphore products*, a precision medicine solution that performs ultra-rapid immunostainings and holds the potential to improve patient outcomes. | Occident Group | Series B Financing | Switzerland |
30-Aug-18 | DURECT Corporation | $5 | DURECT Corporation received a $5 million milestone payment from Indivior PLC triggered by Indivior's approval of the New Drug Application (NDA) for PERSERIS™ (risperidone) in July 2018. Indivior made an upfront non-refundable payment to DURECT of $12.5 million and also agreed to make an additional $5 million payment to DURECT contingent upon NDA approval of PERSERIS, which occurred in July 2018. | Indivior PLC | Milestone Payment | United States |
29-Aug-18 | Nebula Genomics | $4 | The funds will support the company’s mission to usher in the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data | Khosla Ventures | Seed Financing | United States |
01-Aug-18 | Forge Therapeutics | $4 | Forge Therapeutics' CARB-X pipeline includes Forge's LpxC antibiotic and continues to expand with new mechanisms of action, new treatment modalities and increased funding. CARB-X is the world's largest public-private partnership accelerating early development antibacterial research and development. CARB-X is investing more than $500M to support innovative antibiotics and is supported by its partners around the globe including BARDA, NIH, Wellcome Trust, California Life Science Institute, RTI, | Combating Antibiotic Resistant Bacteria Accelerator (CARB-X) | Grants & Awards | United States |
15-Aug-18 | Agenus | $4 | Merck initiated a Phase I clinical trial of an undisclosed antibody candidate discovered by Agenus, under the two companies license and research collaboration. | Merck & Co. | Milestone Payment | United States |
23-Aug-18 | ApoGen Biotechnologies | $4 | The company intends to use the funding from the expanded Series A to hire additional staff and establish a laboratory in Seattle. ApoGen is initially focusing its drug development efforts on an antiviral component of the human innate immune system, the APOBEC cytidine deaminases, which have been implicated as a prominent source of mutations in cancers. | Merck Group | Series A Financing | United States |
28-Aug-18 | Children's Hospital of Philadelphia, NeuroVive Pharmaceutical AB | $4 | The extensive program evaluating preclinical efficacy and exploring viable future clinical endpoints for the NVP015 program. The studies under the grant from the U.S. Department of Defense CDMRP will be the third, and most extensive, collaboration between NeuroVive and CHOP. | Department of Defense, Office of the Congressionally Directed Medical Research Programs (CDMRP) | Grants & Awards | United States |
14-Aug-18 | BioBeats | $3 | BioBeats creates evidence-based wellbeing products that help transform people’s lives for the better. Through harnessing user data, artificial intelligence, and human insight, BioBeats provides an ever-improving cycle of evidence-based interventions, finding patterns that link stress to health risks and physical outcomes. | Oxford Sciences Innovation | Financing | United States |
20-Aug-18 | Curation of Real World Data for Rare Disease Research (RDMD) | $3 | “RDMD was born out of my own personal journey with a rare disease called neurofibromatosis type 2, a disease that affects only 1 in 30,000 people,” said Onno Faber, RDMD founder, chairman and head of product. RDMD aims to partner with rare disease biopharmaceutical companies to provide deep clinical electronic health record (EHR) data from patients, rare disease doctors, and foundations. The company’s proprietary database of research-and-regulatory-grade evidence can be leveraged to gain insight | Lux Capital | Seed Financing | United States |
23-Aug-18 | Revive & Restore Catalyst Science Fund | $3 | The Catalyst Science Fund will invest primarily in proof of concept projects applied toward high impact solutions to conservation challenges. The Catalyst Science Fund will build on the strengths of both organizations, including a network of scientists and conservationists to provide diverse insights into opportunities presented by recent biotech advances, as well as entrepreneurial expertise and perspective to make the most strategic investments to advance the development of the field. | Promega Corporation | Grants & Awards | United States |
14-Aug-18 | Capillary Biomedical | $3 | CapBio has developed the SteadiSettm infusion set with SteadiFlowtm technology, a patented design that addresses several key failure points with current infusion sets that dramatically affect the health, quality of life, and cost for the 1.2 million worldwide insulin pump users. | Cove Fund | Seed Financing | United States |
06-Aug-18 | Almac Discovery, Elasmogen | $3 | The £2M peer reviewed collaborative project entitled ‘A Technology Platform for Next Generation VNAR based Oncology Medicines’, plans to utilise the highly selective, high affinity and yet low molecular weight non-antibody VNAR protein scaffold and build a versatile platform to facilitate the discovery and development of targeted oncology therapeutics. | Innovate UK | Grants & Awards | United Kingdom |
30-Aug-18 | rqmicro AG | $3 | A key factor to assure the safety of drinking and industrial water is the detection of dangerous pathogenic bacteria such as Legionella bacteria, which pose an emerging threat to public health. This financial support accelerates the development and market launch of a revolutionary solution for the rapid detection of more pathogenic microorganisms. | European Commission | Grants & Awards | Switzerland |
07-Aug-18 | Agilvax | $2 | AX09 is being developed as an immunotherapeutic agent for the treatment of TNBC by inhibiting the function of xCT - a biomarker associated with tumor growth and metastatic progression. The grant will provide up to $2.3 million in funding for preclinical studies, cGMP manufacturing and a nonclinical toxicology study that will enable an investigational new drug application (IND) submission for Agilvax’s lead immunotherapy product, AX09. | National Cancer Institute | Grants & Awards | United States |
01-Aug-18 | Marshall Health | $2 | With a $2 million grant from the Foundation payable over four years, the System is an innovative, comprehensive approach that aims to reduce opioid overdoses and overdose deaths, improve access to substance abuse prevention and treatment services, and help reduce the rising rates of HIV and hepatitis C infections. | Merck & Co. | Grants & Awards | United States |
01-Aug-18 | Phico Therapeutics | $2 | Phico is developing SASPject PT3.8, an antibacterial therapy for the systemic treatment of severe Pseudomonas aeruginosa (P. aeruginosa) infections with a high mortality rate. As clinical trials are expanded, it is anticipated that the product will also be used in situations where a P. aeruginosa infection is suspected but yet to be confirmed, further extending the market opportunity for SASPject PT3.8. | Innovate UK | Grants & Awards | United Kingdom |
16-Aug-18 | PURE Bioscience | $2 | PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily based on silver dihydrogen citrate, or SDC - is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. | Undisclosed | Private Placement | United States |
03-Aug-18 | EyePoint Pharmaceuticals | $1 | EyePoint Pharmaceuticals is a specialty biopharmaceutical company developing and commercializing innovative ophthalmic products for serious eye disorders. | Undisclosed | IPO | United States |
30-Aug-18 | University of North Carolina Wilmington (UNCW), Alcami Corporation | $1 | "Partnership for Workforce Development in the Biopharmaceutical Industry" is a comprehensive laboratory, lecture, and internship series approved by NIIMBL's Project Call 1.0 that address biomanufacturing technology and workforce development issues. NIIMBL's governing committee chose the Alcami-UNCW proposal for its thorough, well-qualified, and innovative approach to workforce development. | National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) | Grants & Awards | United States |
03-Aug-18 | Titan Pharmaceuticals | $1 | The loan, if made (the "Convertible Loan"), will convert automatically into shares of Titan common stock upon the issuance by the EMA of marketing approval for Probuphine at a conversion price per share equal to the lower of (i) the closing price on the loan funding date and (ii) the closing price on the conversion date. In the event the EMA has not granted marketing approval by December 31, 2019, the Convertible Loan will become due and payable, together with accrued interest at the rate of o | L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. | Asset Acquisition | United States |
07-Aug-18 | DermaXon | $1 | Along with help by the universities, DermaXon worked with skincare company Rodan + Fields and Galderma and MD Anderson Cancer Center, where they were able to learn more about how other substances and medications affect the brain, such as oral medications and cannabinoids found in cannabis. | Montana Board of Research and Commercialization Technology (MBRCT) | Grants & Awards | United States |
13-Aug-18 | Bioasis Technologies, Inc. | $1 | As previously disclosed, the net proceeds from the private placement will be used to support ongoing research and development, clinical development, manufacturing and other activities in respect of the Company’s clinical development pipeline based on developing the xB3 TM platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders. | Undisclosed | Private Placement | Canada |
01-Aug-18 | HealthFin | $1 | Healthfin, which offers financial assistance to patients who do not have medical insurance or those who are under-insured, will use the funds for tech upgrades and hiring. | Sprout Venture Partners | Series A Financing | India |
08-Aug-18 | Indee Labs | $0.4 | This preclinical study will pave the way for biopharmaceutical companies to transition away from using viruses. The aim is to enable gene-modified cell therapy manufacturing with open source biology to provide patients with improved access to curative therapies for blood cancer. | NSW Medical Device Fund | Grants & Awards | United States |
03-Aug-18 | Advanced Proteome Therapeutics Corporation | $0.3 | Advanced Proteome Therapeutics Corporation is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential. | Undisclosed | Private Placement | Canada |
16-Aug-18 | Mor Research Applications (Clalit Health Services) | $0.3 | Under the strategic alliance agreement with Mor, FSD Pharma and SciCann will execute a series of rigorous, randomized, placebo-controlled clinical studies to demonstrate the safety and efficacy of these products, in order to bring to market advanced and innovative cannabinoid-based products that are backed up by solid clinical data achieved through the highest standards of rigorous and objective clinical research typical for the development process of pharmaceutical products. | FSD Pharma | Collaboration | Israel |
01-Aug-18 | Albumedix | $0 | Novartis will evaluate molecules in combination with Albumedix´s engineered albumin variants for enhanced delivery. Beyond the modulation of pharmacokinetic profiles, the potential for novel routes of administration and mechanisms of action will be assessed across multiple therapeutic areas. | Novartis | Collaboration | United Kingdom |
01-Aug-18 | BioNTech AG | $0 | Following the completion of successful process evaluations involving leading fill-/finish-machine manufacturers, SMP and BioNTech want to explore and develop superior packaging as well as application devices manufactured by SMP for a range of BioNTech products. | SiO2 Medical Products, Inc. | Partnership | Belgium |
01-Aug-18 | Fraunhofer IME | $0 | This Licensing Agreement allows LenioBio to utilize Fraunhofer's proprietary vector solution and technology for the cryopreservation of cell lysates. | LenioBio GmbH | Licensing Agreement | Germany |
01-Aug-18 | AMRI Global | $0 | The agreement will capitalize on AMRI’s process chemistry expertise in the synthesis and formulation of Nemus’ proprietary prodrug of tetrahydrocannabinol (THC). This molecule forms the basis of NB1111, Nemus’ compound in development for the treatment of glaucoma. | Nemus Bioscience | Development Agreement | United Kingdom |
01-Aug-18 | Qiagen N.V. | $0 | QIAGEN’s Day-One Lab Readiness initiative with SRL includes strategic planning for market access to companion diagnostics, filing for reimbursement, and alignment of medical communication by SRL, QIAGEN and pharmaceutical partners. | SRL, Inc. | Collaboration | The Netherlands |
01-Aug-18 | Lineage Biosciences | $0 | Lineage Biosciences, a Palo Alto-based start-up, was founded based on technology for the profiling of antibody responses using next-generation sequencing of immunoglobulin genes (Ig-SEQ). Ig-SEQ enables deep analysis of antibodies generated by natural immune responses during infection, autoimmune disease, cancer, immunization, and vaccination. | AbCellera Biologics | Acquisition | United States |
02-Aug-18 | D. Western Therapeutics Institute (DWTI) | $0 | Glaukos and DWTI will conduct joint research for the development of novel intraocular products for the treatment of glaucoma using compounds from DWTI’s proprietary ROCK inhibitor compound library, one of DWTI’s fundamental technologies, and potentially design and synthesize new compounds for this collaboration. Glaukos will conduct the evaluation and development of the compounds. | Glaukos Corporation | Development Agreement | Japan |
02-Aug-18 | Advantia Health | $0 | Through its partnership with Elligo, Advantia’s health care practices will be able to join Elligo’s Research Ready™ network, offer their patients access to clinical research as a care option and enroll them into studies. As a result, patients will have access to state-of-the-art treatments closer to home and remain under the care of their trusted physician. | Elligo Health Research | Partnership | United States |
02-Aug-18 | Science Exchange | $0 | Reveal’s AI-based tissue analysis utilizes trained pathology models to recognize disease patterns in whole slide digital images. This service can be applied to tumor profiling, quantitative immunohistochemistry, NASH, toxicology and quantitative multiplexing. | Reveal Biosciences | Partnership | United States |
02-Aug-18 | Charcot-Marie-Tooth Association (CMTA) | $0 | This collaboration with the Charcot-Marie-Tooth Association aims to validate the role of HDAC6 in multiple forms of Charcot-Marie-Tooth (CMT) disease and evaluate the efficacy ofricolinostat, a selective HDAC6 inhibitor, in animal models. | Regenacy Pharmaceuticals | Collaboration | United States |
02-Aug-18 | Sectra | $0 | Sectra PACS is optimized for high production environments and designed to shorten report turnaround times, enhance result distribution workflows, and improve communication between radiology and referring departments. For five continuous years in the US, Sectra PACS has won the customer satisfaction award 'Best in KLAS' for large hospitals. | Stanford Health Care | Contract Agreement | United States |
02-Aug-18 | Rfxcel Corporation | $0 | The alliance was created to implement and support new compliance management and serialisation processing software to ensure full compliance with current and future international legislative requirements ahead of the 2019 EU Falsified Medicines Directive (FMD) deadline. | Abdi Ibrahim | Compliance Agreement | United Kingdom |
03-Aug-18 | Oncologie | $0 | Through the partnership, the companies agreed to partner on the development of biomarkers associated with Oncologie’s Immuno-oncology pipeline. | HTG Molecular Diagnostics, Inc. | Partnership | China |
03-Aug-18 | Andor Pharmaceuticals | $0 | Andor's pending Abbreviated New Drug Application (ANDA) of Methylphenidate included all bioequivalence metrics recommended by FDA and is expected to be approved as an AB-rated generic equivalent to the brand Concerta®. Under the agreement, Lannett will primarily provide sales, marketing and distribution support of Andor's Methylphenidate ER product, for which it will receive a percentage of the net profits. | Lannett Company | Licensing Agreement | United States |
03-Aug-18 | Cedars-Sinai Medical Center | $0 | Under the terms of the agreement, the lab of world-renowned microbiome researcher Mark Pimentel, M.D., executive director of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai Medical Center, will focus on the discovery of new therapeutic treatments related to conditions of the gut microbiome. Dr. Pimentel has played an integral role in advancing science's understanding of the gut microbiome including his widely-accepted research on a methanogen as an agent for causi | Valeant Pharmaceuticals | Collaboration | United States |
06-Aug-18 | Yale University School of Medicine | $0 | This is an ongoing multi-year collaboration with Yale’s Division of Neurocognition, Neurocomputation, and Neurogenetics (N3) on the neurobiological basis of dysregulated mood and behavior in humans. BlackThorn is licensing GEMINI-DOT (Gene Expression Mapping Integrated with Neuro-Imaging for Discovery Of Therapeutics) - which can bi-directionally map gene expression patterns and neuroimaging features to optimize the selection of drug targets and clinical populations. | BlackThorn Therapeutics | Licensing Agreement | United States |
06-Aug-18 | Antares Pharma, Inc. | $0 | The aim of the Agreement is to develop a combination drug device rescue pen which will utilize the Antares QuickShot® auto injector and an undisclosed Pfizer drug. | Pfizer Inc. | Development Agreement | United States |
06-Aug-18 | Cystic Fibrosis Gene Therapy Consortium, Oxford BioMedica, Imperial Innovations | $0 | The new collaboration is a joint initiative of Boehringer Ingelheim’s Respiratory Therapeutic Area and Research Beyond Borders (RBB) in which it has received an option to license the exclusive global rights to develop, manufacture, register, and commercialise this lentiviral vector-based gene therapy for the treatment of cystic fibrosis. Boehringer Ingelheim will provide its multinational industry expertise, including a rich heritage in the respiratory field, to drive the product towards the cli | Boehringer Ingelheim | Partnership | United Kingdom |
06-Aug-18 | The University of Texas MD Anderson Cancer Center | $0 | The joint effort brings together MD Anderson's translational medicine and clinical research capabilities with Jazz's hematology/oncology portfolio. The initial focus of the collaboration is to evaluate and generate additional data for Vyxeos® (daunorubicin and cytarabine) liposome for injection, in new patient populations and in combination with other therapies. | Jazz Pharmaceuticals | Collaboration | United States |
06-Aug-18 | Nordion Medical Isotopes (Sotera Health) | $0 | With the sale, BWXT now owns Nordion’s former medical isotopes business, including the radiochemical and contract manufacturing operations in Kanata, Ontario, and the isotope production facility in Vancouver, British Columbia | BWX Technologies | Divestment | United States |
06-Aug-18 | California Cryobank, Cord Blood Registry | $0 | Recognized as the world’s premier donor sperm and donor egg bank, California Cryobank has been an industry leader and innovator since 1977. GI Partners combined California Cryobank and CBR under the California Cryobank Life Sciences platform, bringing together best-in-class organizations to provide enhanced domestic and international expansion opportunities in both the donor reproductive tissue and newborn stem cell industries. | GI Partners | Merger Agreement | United States |
06-Aug-18 | Selvita S.A. | $0 | MEN1703/SEL24 is a first-in-class orally available dual PIM/FLT3 kinase inhibitor with a unique activity profile currently investigated for the treatment of AML and with preclinical data suggesting potential activity in other hematological malignancies and solid tumors. | Menarini Ricerche (Menarini Group) | Clinical Collaboration | Poland |
07-Aug-18 | Oxford Genetics | $0 | Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, has secured a multi-million pound contract with a leading multi-billion dollar global ecommerce provider of reagents and tools to the research and clinical community. | Undisclosed | Supply Agreement | United Kingdom |
08-Aug-18 | CertiRx Corporation “Verinetics” | $0 | ACG Inspections is looking forward to implementing an add-on security layer to provide Multi-Factor Authentication to the end consumer. Falsified medications are one of the major problems faced by the global pharmaceutical industry. Verinetics patent-protected software product, TraxSecur™ is a next-generatio n solution for detecting and deterring fraud in the supply chain. | ACG Inspection | Partnership | United States |
08-Aug-18 | Ausway Pharmaceutical | $0 | Ausway specialises in the supply and distribution of vitamins and dietary supplements both in Australia and overseas with a particular emphasis on its e-commerce platform which sells directly into China. Ausway currently generates revenues in excess of $18 million with positive earnings. | Star Combo Pharma Limited | Acquisition | Australia |
08-Aug-18 | Gibraltar Laboratories | $0 | Gibraltar Laboratories is a leading outsourced provider of microbiology and analytical chemistry testing for pharmaceutical and medical device manufacturers. “In addition to its testing expertise, Gibraltar’s facilities are located in the Northeast pharmaceutical corridor, home to many of the top pharmaceutical manufacturers in the United States, "said Michael B. Petras Jr., CEO of Sotera Health. | Sotera Health | Acquisition | United States |
09-Aug-18 | Prescription Pharmaceuticals Business | $0 | Perrigo's Prescription Pharmaceuticals (Rx) business serves patients and health systems with 'extended topicals' medications, to treat ailments at more affordable prices. The differentiated and diversified portfolio includes topical generic medicines in multiple dosage forms, including creams, foams, mousses, gels, liquids and inhalable products. | Perrigo Company plc | Spin off | Ireland |
09-Aug-18 | Maricopa Integrated Health System | $0 | “This agreement strengthens Trans-Hit Bio’s presence in the USA and is a valuable addition to our worldwide network of academic and hospital-based biobanks for sourcing high-grade biospecimens. We take great pleasure in working with the MIHS team who is very motivated, knowledgeable and professional, as they are also well versed to Good Clinical Practices,” said Dr. Pascal Puchois, Chief Executive Officer at Trans-Hit Bio. | Trans-Hit Bio | Commercialization Agreement | United States |
09-Aug-18 | Astarte Biologics | $0 | Memphis-based Key has established itself as a trusted supplier of critical raw materials, specifically human cells used in fundamental research, cell therapy manufacturing and process development, and commercial immunotherapies. Astarte brings highly complementary immunology expertise that will play a valuable role in expanding the combined company’s cell characterization, custom cell line and assay development capabilities. With the merger the company now has footprints in both Memphis and Sea | Ampersand Capital Partners, Key Biologics | Merger Agreement | United States |
09-Aug-18 | Perrigo Company plc | $0 | Perrigo holds exclusive rights to market, sell, and distribute a non-prescription version of Nasonex® OTC in the United States following Perrigo's receipt of all necessary regulatory approvals. Nasonex® is currently available by prescription only. Annual prescription brand and generic market sales for the 12 months ending June 2018 were approximately $214 million as measured by IQVIA. | Merck & Co. | Licensing Agreement | Ireland |
10-Aug-18 | Showcase | $0 | The Company’s Apeaz® drug continues to be in demand in both the United States and Canadian markets as a arthritis pain relief medicine. | Innovus Pharmaceuticals | Purchase Agreement | Canada |
13-Aug-18 | Florida Pharmaceutical Products, Inc. | $0 | Florida Pharmaceutical Products, Inc., focuses on improving patient outcomes with generic medications spanning a broad therapeutic range. Investments fund research to identify new treatments and guiding strong product candidates through the development lifecycle. | Woodfield Distribution, LLC | Acquisition | United States |
13-Aug-18 | St. Jude Children’s Research Hospital | $0 | The Agreement is for developing a first-in-class ex vivo lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (X-SCID). X-SCID is the most common form of SCID, affecting approximately one in 50,000 to 100,000 newborns worldwide. The therapy includes a low dose of busulfan prior to reinfusion of the patients’ own gene-modified blood stem cells. | Mustang Bio (Fortress Biotech) | Licensing Agreement | United States |
13-Aug-18 | Baylor College of Medicine | $0 | VistaGen and Baylor are collaborating on a first-step study with healthy volunteer Veterans to test potential anti-suicidal effects of VistaGen’s AV-101. AV-101 is an oral, non-opioid, non-sedating NMDA receptor glycine B (NMDAR GlyB) antagonist that offers the potential to be a new at-home treatment for multiple CNS indications with high unmet medical need. | VistaGen Therapeutics | Collaboration | United States |
13-Aug-18 | TheLeukemia & Lymphoma Society | $0 | The Company is partnering with TheLeukemia & Lymphoma Society to develop STRO-001, Sutro’s CD74-targeting antibody-drug conjugate, to treat relapsed and/or refractory multiple myeloma and non-Hodgkin’s lymphoma. Sutro intends to use the funding for a Phase 1 study, initiated in April of this year, to evaluate STRO-001 for treating multiple myeloma, diffuse large B-cell lymphoma, mantle cell lymphoma andindolent lymphomas, such asfollicular lymphoma | Sutro Biopharma | Partnership | United States |
14-Aug-18 | Desert Oasis Healthcare | $0 | Through a value-based contract, Desert Oasis Healthcare joins a select group of health systems in the U.S. who use Digital Medicines to focus on improving outcomes in high-risk patients. Proteus has conducted several clinical studies demonstrating the clinical and economic benefits of using Digital Medicines to improve outcomes in these patients, including a successful randomized control trial in patients with uncontrolled hypertension and type 2 diabetes | Proteus Digital Health | Contract Agreement | United States |
14-Aug-18 | Psyadon Pharmaceuticals | $0 | Ecopipam is a potent, selective antagonist of the human D1 receptor family being developed for the treatment of pediatric TS. TS is a childhood-onset neurodevelopmental condition, characterized by motor and vocal tics, for which there exists an unmet need for new therapies. | Emalex Biosciences (Paragon Biosciences) | Acquisition | United States |
14-Aug-18 | Haplogen Bioscience | $0 | The goal of the research alliance is to develop new antiviral compounds addressing the high unmet medical need in reducing COPD exacerbations. | Bayer | Collaboration | Austria |
14-Aug-18 | Napa Therapeutics | $0 | Napa Therapeutics is based on groundbreaking research in NAD metabolism conducted in the lab of Eric Verdin, MD, President and CEO of the Buck Institute. The Verdin lab will collaborate with Napa, using Insilico's drug development engine to speed the discovery of new compounds. | The Buck Institute for Research on Aging, Insilico Medicine, Juvenescence Ltd | Launch & Partnerships | United Kingdom |
15-Aug-18 | Ubiquigent Limited | $0 | This latest grant and investment provides additional support for the advancement of one of our key programmes. The programme is now well underway, and we look forward to reaching our endpoint of developing novel compounds in this disease area much sooner than originally planned. The team is now even better placed to support our existing and new partners focused on ubiquitin system drug discovery. | IP Group plc, Innovate UK | Grants & Awards | United Kingdom |
15-Aug-18 | SNBL U.S.A. | $0 | This acquisition will add comprehensive preclinical safety testing services to Altasciences’ current full-service clinical and bioanalytical offerings. Altasciences will now support all crucial steps in early-stage drug development, from lead candidate selection to proof of concept. | Altasciences | Acquisition | United States |
15-Aug-18 | Shanghai Model Organisms Center (GCOS) | $0 | GCOS leverages the expertise of several gene editing technologies to develop conventional knockout (KO), conditional KO, transgenic knock-in and humanized models. These capabilities are now exclusively available to CrownBio's global customers for custom model generation, selection, IVF, rapid expansion and re-derivation. | Crown Bioscience | Partnership | China |
15-Aug-18 | Helsinn Group | $0 | ALOXI® (palonosetron hydrochloride), a 5-HT3 receptor antagonist was approved in Vietnam. Mundipharma consistently delivers high-quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthc | Mundipharma | Licensing Agreement | Switzerland |
15-Aug-18 | US Oncology Research | $0 | The collaboration is based on the PANOVA-3 trial which is a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer. | Novocure | Collaboration | United States |
15-Aug-18 | Karolinska Institutet | $0 | This collaboration will explore RXi's sd-rxRNA compounds against targets involved in T cell and NK cell differentiation and/or in the immune cell tumor-induced stress response with the aim of producing anti-tumor adoptive cell therapy grafts with improved functionality and persistence. | RXi Pharmaceuticals Corporation | Collaboration | Sweden |
15-Aug-18 | Fox Chase Cancer Center | $0 | The Partnership focuses on the study will use Natera's proprietary customized assay and next-generation sequencing (NGS)-based technology to determine whether Signatera (RUO) can be used to distinguish between the recurring and non-recurring kidney cancer cases. | Natera | Collaboration | United States |
15-Aug-18 | Stratford Pharmaceuticals | $0 | The acquisition of Stratford fits into Eli's strategy to enter the global animal health industry. Stratford currently provides a wide arrangement of dermatology products to over 10,000 veterinary hospitals in the US and 8 other countries. Stratford will continue to operate independently under the leadership of its Founder and CEO Brian Nugent out of its Oldsmar, FL corporate headquarters. | Eli Global | Acquisition | United States |
16-Aug-18 | Escape Therapeutics | $0 | The Company plans to utilize the technology in conjunction with its pluripotent stem cell platform for applications in regenerative medicine. The initial priority of the agreement will be to utilize the technology in advancing our two lead programs AGEX-BAT1 and AGEX-VASC1 for age-related metabolic and vascular disease respectively. | AgeX Therapeutics (BioTime, Inc.) | Licensing Agreement | United States |
16-Aug-18 | Viscogliosi Brothers | $0 | "This transaction allows Ember to continue to focus on our exciting late stage osteoarthritis (OA) program which offers the potential of addressing the actual cause of this debilitating disease by regrowing cartilage in the knee. The previously commercialized OP-1 product portfolio had at one point generated approximately $100M in annual revenues for Stryker and had been viewed as a formidable competitor to Medtronic's Infuse. | Ember Therapeutics | Divestment | United States |
16-Aug-18 | Cyclica | $0 | Through a multi-phase collaboration, WuXi will leverage and evaluate Cyclica’s cloud-based proteome Ligand Express™ screening platform to investigate the off-target profiles of small molecules, apply Cyclica’s novel and proprietary advanced AI technology to create state of the art predictive models for ADMET properties, and support the testing and optimization of Cyclica’s next generation AI-based de novo drug design technology. | WuXi AppTec | Collaboration | Canada |
17-Aug-18 | Healthy Interactions | $0 | Map4health is designed as a platform to help improve the quality of diabetes patient support in between in-person coaching sessions by enabling patients to connect with educators through text and video-chat, as well as providing weekly digital activities to sustain patient engagement. | Merck & Co. | Launch & Partnerships | United States |
17-Aug-18 | Tolero Pharmaceuticals (Sumitomo Dainippon Pharma) | $0 | The clinical collaboration aims for exploring the potential of combination therapy with AbbVie's venetoclax and Tolero's investigational agent, alvocidib, for the treatment of relapsed/refractory acute myeloid leukemia (AML). | AbbVie | Clinical Collaboration | United States |
17-Aug-18 | OHSU School of Medicine | $0 | Supported by funding from JDRF, the leading global organization funding type 1 diabetes (T1D) research, OHSU is conducting a Phase 1 single-center, randomized, three-way, controlled, crossover clinical study to test the efficacy of a new closed-loop algorithm for managing blood glucose in people with T1D before and after exercise. | Xeris Pharmaceuticals | Commercialization Agreement | United States |
20-Aug-18 | Invicro (Konica Minolta Company) | $0 | EBG will be responsible for providing data from their affiliate companies; Cerveau Technologies, Inc. and Meilleur Technologies, Inc.; novel Tau tracer (MK-6240) and Amyloid tracer (NAV-4694); respectively. Both parties will utilize the AmyloidIQ and TauIQ platforms to provide the pharmaceutical industry access to improved informatics and analytics capabilities together with a more streamlined approach to supporting neurodegenerative disease modifying therapy development. | Enigma Biomedical | Collaboration | United States |
20-Aug-18 | Anthem, Inc | $0 | The Anthem-Walmart program, launching in January 2019, will enable consumers who are enrolled in Anthem’s affiliated Medicare Advantage (MA) plans. The new collaboration is expected to improve access to these items while significantly reducing the out-of-pocket costs for those enrolled in Anthem’s affiliated MA plans. | Walmart | Collaboration | United States |
20-Aug-18 | Jerome Stevens Pharmaceuticals | $0 | With more than 120 million prescriptions per year, Levothyroxine is the most prescribed drug in the United States, and we see exciting opportunities to grow market share, given the evolving market dynamics in the manufacturing and validation challenges associated with this product. | Amneal Pharmaceuticals | Supply Agreement | United States |
20-Aug-18 | Citation Clinical Labeling Systems | $0 | Citation provides clinical trial labels for pharmaceutical and biotechnology companies, clinical research organizations, and clinical packagers. This acquisition strengthens AWT’s commitment to the global healthcare labeling market and will allow AWT to take advantage of growth opportunities in the clinical trial label markets. | AWT Labels and Packaging | Acquisition | United States |
21-Aug-18 | Merck & Co. | $0 | The collaborators aim to evaluate the combination of Rexahn's RX-5902 and Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 2 trial in patients with metastatic triple negative breast cancer (TNBC). The clinical trial evaluate the safety and efficacy of the combination of RX-5902 and KEYTRUDA in patients with metastatic TNBC who have progressed following at least one prior treatment. | Rexahn Pharmaceuticals | Clinical Collaboration | United States |
21-Aug-18 | Centre for the Commercialization of Antibodies and Biologics (CCAB) | $0 | The initiative merges CCAB’s business acumen with its research and technical expertise to support the co-development of new biological therapeutics and build viable companies around ImmunoBiochem’s novel breast cancer therapeutic candidate. ImmunoBiochem is developing novel potentiated biologics to treat triple-negative breast cancer (TNBC), an aggressive form of breast cancer for which there are currently no targeted biological treatment options. | ImmunoBiochem | Development Agreement | Canada |
21-Aug-18 | Rexahn Pharmaceuticals | $0 | The Collaboration Agreement is based on the aim to evaluate the combination of Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 2 trial in patients with metastatic triple negative breast cancer (TNBC). | Merck & Co. | Clinical Collaboration | United States |
21-Aug-18 | Medigene AG | $0 | In this research collaboration, Medigene will supply Structured Immunity with a lead TCR candidate for a high-profile solid tumor target. Structured Immunity will evaluate the TCR's specificity and recognition properties using their established structural immunology technologies. | Structured Immunity | Collaboration | Germany |
21-Aug-18 | Primity Bio | $0 | Primity Bio is a leading provider of cutting-edge flow cytometry services with deep expertise in assay development, early drug discovery, pre-clinical animal sample analysis, biomarker discovery, and advanced human clinical sample analysis. Using the latest in single-cell analysis technologies, Primity specializes in highly complex immunophenotyping, intracellular signaling, cell sorting (FACS), and high-parameter CyTOF (mass cytometry) analysis. | Caprion Biosciences | Acquisition | United States |
21-Aug-18 | TrialAssure | $0 | TrialAssure will provide a software-as-a-service (SaaS) solution to Otsuka, allowing their internal disclosure experts the ability to use proven reporting tools, built-in validation, the ability to integrate with their master data system, and the ability to retool core data for application to multiple registries, meeting global reporting requirements for ClinicalTrials.gov, EudraCT, and other global registries. | Otsuka Pharmaceutical | Partnership | United States |
21-Aug-18 | Science Exchange | $0 | Taconic recently added an innovative Easi-CRISPR technology to its gene-modifying toolkit by acquiring a worldwide, non-exclusive license from the University of Nebraska. Leveraging the most comprehensive model generation toolkit, Taconic employs all major gene-editing technologies including homologous recombination, pronuclear injection (PNI), shRNAi, CRISPR, and Easi-CRISPR. | Taconic Biosciences | Collaboration | United States |
22-Aug-18 | Evotec AG | $0 | Evotec will apply its drug discovery platform, especially in ligand-based design, to seek to design novel, safe and efficacious products to address diabetes and associated morbidities. Once suitable pre-clinical candidates are selected, Novo Nordisk will use Evotec’s INDiGO platform to move through pre-clinical studies to enter IND registration. | Novo Nordisk | Partnership | Germany |
22-Aug-18 | Exact Sciences Corp. | $0 | Pfizer will join Exact Sciences' sales representatives in reaching both physicians and health systems and will also actively participate in extending and deepening the Cologuard marketing campaign. | Pfizer Inc. | Development Agreement | United States |
23-Aug-18 | National Institute for Biotechnology in the Negev (NIBN) | $0 | The Companies collaborated with National Institute for Biotechnology, Negev to develop and commercialize a novel alginate scaffold technology for cell transplantation, with an initial focus on autoimmune diseases. | Orgenesis Inc., BGN Technologies | Licensing Agreement | Israel |
23-Aug-18 | Amarex Clinical Research | $0 | In celiac disease, larazotide is the only drug which has successfully met its primary endpoint with statistical significance in a Phase 2b efficacy clinical trial (342 patients). Amarex will provide Innovate with electronic data capture solutions and associated services for data management and biostatistics to Innovate Biopharma to support Amarex's Phase 3 trial. | Innovate Biopharmaceuticals, Inc. | Contract Agreement | United States |
23-Aug-18 | Bradley Martin, University of Arkansas for Medical Sciences (UAMS) | $0 | In acquiring the Opioid Risk Prediction Tool, TrestleTree also has developed a preventive approach to combating opioid abuse and addiction, specifically by combining the tool’s predictive modeling capability with the company’s unique and proven behavior change model. | TrestleTree (Harvard Pilgrim) | Letter of Intent | United States |
23-Aug-18 | US Oncology Research | $0 | By capturing genomic and clinical data from all ethnicities, ages, genders, and from patients with co-morbidities, the FLEX database provides valuable opportunities to accelerate breast cancer research. It will also enable researchers to investigate the differences and trends between sub-groups and, importantly, to focus on smaller, more diverse, patient populations. | Agendia | Clinical Collaboration | United States |
27-Aug-18 | CENTOGENE AG | $0 | The collaboration brings together Evotec’s leading induced pluripotent stem cell (“iPSC”) platform and broad drug discovery capabilities with CENTOGENE’s unique medical and genetic insights. Evotec and CENTOGENE initiated the collaboration to develop a strategic high-throughput platform for testing novel small molecules in rare hereditary metabolic diseases. | Evotec AG | Partnership | Germany |
27-Aug-18 | Panacea Biotec, Natco Pharma | $0 | Azacitidine is a nucleoside metabolic inhibitor indicated for the treatment of patients with the B myelodyplastic syndrome (MDS), Natco has provided the technology for manufacturing Azacitidine to Panacea Biotec's facility located at Baddi, Himachal Pradesh, India. Panacea Biotec will be responsible for manufacture and supply of the product, which will be marketed, sold and distributed by Breckenridge in the U.S. | Breckenridge Pharmaceutical | Manufacturing Investment | India |
27-Aug-18 | Undisclosed | $0 | Allergen immunotherapy, a time-tested clinical approach, can reduce or eliminate allergy and asthma symptoms by lowering the levels of specific cellular proteins known as immunoglobulin E (IgE) molecules that activate the immune system and trigger immune responses. Through these partnerships, doctors prescribing Arrayit allergy tests gain access to a portfolio of safe & effective allergy medicines for allergy and asthma patients, including custom immunotherapy products formulated upon review of | Arrayit Corporation | Partnership | |
27-Aug-18 | JS InnoPharm (Shanghai) Ltd | $0 | Through this partnership, both companies will leverage their comprehensive knowledge, broad expertise, drug candidates, and networks in the global development of multiple therapeutics. The Strategia Holdings group currently consists of three biopharmaceutical companies; Spirita Oncology, LLC, Mirata BioPharma, LLC, and Strategia Pharmaceuticals, LLC which will work closely together with JS InnoPharm under the Strategic Partnership Alliance. | Strategia Holdings | Partnership | China |
28-Aug-18 | Ion Channel Innovations | $0 | Urovant has licensed global rights for the development and commercialization of hMaxi-K from Ion Channel Innovations. Urovant plans to meet with the FDA and initiate a Phase 2 clinical study in 2019 to investigate hMaxi-K as a novel treatment for OAB patients who have not responded to other pharmacological therapies. | Roivant Sciences | Licensing Agreement | United States |
28-Aug-18 | ProstaGene | $0 | CytoDyn will acquire substantially all of the assets of ProstaGene, including the transfer or assignment of certain intellectual property rights held by ProstaGene and Dr. Pestell. CytoDyn also confirms that Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., Founder and Chief Executive Officer of ProstaGene, will join CytoDyn as Interim Chief Medical Officer. Upon the closing of the acquisition, which is expected in November, Dr. Pestell will become Chief Medical Officer. | CytoDyn | Acquisition | United States |
28-Aug-18 | Institute for In Vitro Sciences | $0 | Scientists at BASF and Givaudan have developed the Kinetic Direct Peptide Reactivity Assay (Kinetic DPRA), a non-animal test to predict allergic reactions in the skin known as sensitization. However, the Kinetic DPRA has the potential to go beyond a yes/no answer and predict the potency of a sensitizer, which is required by some regulatory agencies. The validation project, designed by BASF and Givaudan, will be conducted over the course of 2018 | BASF, Givaudan | Collaboration | United States |
28-Aug-18 | Biopharmaceutical Testing Laboratory | $0 | The new laboratory will complement the existing 800m2 facility and offer the new services for high order structure analysis of biologics, including circular dichroism (CD), Fourier-transform infrared spectroscopy (FTIR), extrinsic and intrinsic fluorescence, analytical ultracentrifugation (SV-AUC), size exclusion chromatography with multi-angle light scattering (SEC-MALS), dynamic light scattering (DLS) and differential scanning calorimetry (DSC). | SGS | Research Agreement | Switzerland |
28-Aug-18 | Beactica AB | $0 | The funds raised will accelerate the pipeline development over the coming 12 months. This will include the advancement of Beactica's LSD1 programme through an in vivo proof-of-concept study in glioblastoma, and with studies in other indications to follow. | ALMI Invest | Financing | Sweden |
28-Aug-18 | Epinomics | $0 | The acquisition will give 10x Genomics ATAC-seq technology and fundamental IP to accelerate discoveries and further research in epigenomics, paving the way for a new understanding of disease, diagnostics and therapeutics. | 10x Genomics | Acquisition | United States |
29-Aug-18 | Centre for Probe Development and Commercialization (CPDC) | $0 | The agreement enables the supply of ImaginAb’s clinical-phase Positron Emission Tomography (PET) imaging agent Zr-89 IAB22M2C to key global geographies. Zr-89 IAB22M2C is a clinical stage CD8 T Cell imaging agent designed to non-invasively determine changes in CD8+ T cell tumor infiltrates induced by immuno-oncological treatments. This approach has the potential to guide the development of immuno-modulatory agents as well as provide an early assessment of whether a patient responds to such a tre | ImaginAb | Supply Agreement | United States |
29-Aug-18 | Undisclosed | $0 | Tiotropium Bromide DPI is a generic version of Boehringer Ingelheim’s Spiriva® Handihaler. The product is used in the treatment of chronic obstructive pulmonary disease (COPD). This is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol dry powder inhaler. | Glenmark Pharmaceuticals | Licensing Agreement | |
29-Aug-18 | Rfxcel Corporation | $0 | rfxcel's dynamic traceability platform enables companies to protect patients, comply with regulatory mandates and gain visibility into their supply chain. The Minnesota Multistate Contracting Alliance for Pharmacy (MMCAP) is a free, voluntary group purchasing organization for government facilities that provide healthcare services. | Minnesota Multistate Contracting Alliance for Pharmacy (MMCAP) | Contract Agreement | United Kingdom |
29-Aug-18 | Hesperos | $0 | The AD model will be a three-organ system that includes brain cells (cortical neurons) and functioning liver and blood-brain-barrier constructs, as well as re-circulating blood and cerebral spinal fluid surrogates. This will enable scientists to study the body’s systemic response to any chemical introduced into the model, including how it metabolizes in the liver, and how it penetrates into the brain through the blood-brain barrier. | National Institute on Aging of the National Institutes of Health | Grants & Awards | United States |
30-Aug-18 | National Institutes for Quantum and Radiological Science and Technology | $0 | This collaborative research project focuses on efficacy evaluation of the compound KPO1143, developed by KinoPharma, to prevent the accumulation of protein called tau (hereafter "tau protein") (*1), which is considered a cause of Alzheimer's disease (AD). | KinoPharma | Collaboration | Japan |
30-Aug-18 | Alkermes | $0 | VIVITROL® (naltrexone for extended-release injectable suspension) is medication is a non-addictive, once-monthly treatment proven to reduce the risk of relapse in opioid-dependent patients when used with counseling following detoxification. | UPMC Health Plan | Contract Agreement | Ireland |
30-Aug-18 | University of Indianapolis, Ascend Indiana | $0 | Roche Diagnostics and the University of Indianapolis are partnering to create a custom talent pipeline for biomedical equipment technicians through the newly created Roche Academy. The partnership was co-developed with Ascend Indiana, a Central Indiana Corporate Partnership (CICP) initiative. | Roche | Partnership | United States |
30-Aug-18 | RxBIO Corp. | $0 | Celling products are designed to collect, process and deliver autologous cells to the patient at the point of care to accelerate the body's natural healing process. The Autologous Regenerative Therapies family of concentration systems recovers a high percentage of nucleated, progenitor and other cells by allowing selection of the cell concentrate from user-defined portions of a centrifuged stack. | Celling Biosciences | Licensing Agreement | United States |
30-Aug-18 | CHDI Foundation | $0 | Evotec provides CHDI with a full range of research activities and expertise in the neuroscience area, including integrated biology and chemistry supported by compound and library management, target validation, stem cell research, high-content screening, computational chemistry, in vitro pharmacokinetics, proteomics and protein production. | Evotec AG | Collaboration | United States |
31-Aug-18 | DZS Clinical Services | $0 | Through this acquisition, WDBMD will enable DZS Clinical Services to bolster its full-service CRO capabilities and provide more comprehensive and global services to U.S. companies with coverage in Europe and Japan. | WDB Medical Data (WDB Holdings Co., Ltd.) | Acquisition | United States |
18-Sep-18 | Hillhouse Fund IV (Hillhouse Capital) | $10,600 | Hillhouse plans to invest in companies focused on healthcare, consumer, technology and services sectors globally, although mostly in Asia. It has made investment in well-known companies like search engine Baidu, AirBnB and Uber Technologies. | Undisclosed | Financing | Hong Kong |
06-Sep-18 | KKR | $7,400 | KKR has a risk-based, rather than a sector-based, approach to infrastructure investing. KKR will be investing $358 million (KKR Global Infrastructure Fund) alongside external investors through KKR’s balance sheet and employee commitments. | Undisclosed | Financing | United States |
20-Sep-18 | Mazor Robotics | $1,640 | Medtronic’s acquisition of Mazor strengthens Medtronic’s position as a global leader in enabling technologies for spine surgery, and drives Mazor Robotics’ vision towards the global market. Mazor‘s proprietary core platforms include the Mazor X™ Robotic Guidance System and the Renaissance® Surgical-Guidance System. | Medtronic PLC | Acquisition | Israel |
19-Sep-18 | Elanco Animal Health | $1,510 | The offering is expected to represent an ownership stake of less than 20 percent in Elanco. The number of shares to be offered and the price range for the offering have not yet been determined. The company expects to complete the IPO process before the end of 2018. | Goldman Sachs | IPO | United States |
26-Sep-18 | Syntimmune | $1,200 | Syntimmune's lead candidate, SYNT001, is a humanized monoclonal antibody that inhibits the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes in a number of rare IgG-mediated diseases. SYNT001 is currently being evaluated in Phase 1b/2a studies in warm autoimmune hemolytic anemia and pemphigus vulgaris. | Alexion Pharmaceuticals | Acquisition | United States |
06-Sep-18 | Sandoz | $1,000 | Aurobindo Pharma USA will acquire selected portions of Novartis' Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio. The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, the Sandoz US generic and branded dermatology businesses, Sandoz' dermatology development center and the manufacturing facilities in Wilson, NC, as well as Hicksville and Melville, NY. | Aurobindo Pharma | Acquisition | United States |
06-Sep-18 | Oberland Capital | $800 | Fund II will target investments between $20 million and $150 million with a focus on commercial stage or near-commercial stage biopharmaceutical, medical device and diagnostic companies and royalty-bearing products. | Undisclosed | Financing | United States |
11-Sep-18 | Regeneron | $800 | Regeneron Pharmaceuticals will invest $800 million and hire an additional 1,500 employees in East Greenbush, New York, as the drug maker increases production over the next seven years. The expansion plans will include construction of 350,000 square feet of manufacturing space and 240,000 square feet of office and laboratory space. | Regeneron Pharmaceuticals, Inc. | Manufacturing Investment | United States |
28-Sep-18 | Tusk Therapeutics, Droia Oncology Ventures | $655 | Tusk has developed an antibody with a novel mode of action aimed at depleting regulatory T-cells (Tregs). Tregs suppress immune responses, including those against cancer cells. Roche will further develop this novel antibody and drive the development ahead. The remaining portfolio of our immune-oncology targets will be further developed by Black Belt Therapeutics, a newly formed company spun out of Tusk Therapeutics.” | Roche | Acquisition | United Kingdom |
11-Sep-18 | Vivo Opportunity Fund | $635 | As a long-only public equity fund, the Fund plans to invest the capital in small to mid-cap public life sciences companies through follow-on financings, private placements, initial public offerings to be invested in private and public therapeutics companies. The Fund is focused on investing in companies bringing innovative products to the market. | Vivo Capital | Financing | United States |
10-Sep-18 | Siga Technologies | $629 | Siga has signed a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA) for the delivery of oral and intravenous (IV) formulations of TPOXX® to the Strategic National Stockpile. The contract also covers advanced development of the IV formulation and post-marketing activities. | Biomedical Advanced Research & Development Authority | Contract Agreement | United States |
06-Sep-18 | Augmenix | $600 | Acquisition expands portfolio of men's health in-office procedures with adjunctive therapy for prostate cancer patients: The SpaceOAR hydrogel is CE Marked, cleared by the FDA and has been used in more than 30,000 patients worldwide. As a result of commercial adoption, expanded U.S. reimbursement and a total addressable market valued at $750 million, product sales are estimated to reach $50 million in 2018, and approach $90 million in 2019. | Boston Scientific | Acquisition | United States |
05-Sep-18 | Novartis | $463 | Mylan closed an agreement with Novartis to purchase the worldwide rights to commercialize their global cystic fibrosis products consisting of TOBI Podhaler® and TOBI® solution, which will further enhance Mylan’s respiratory portfolio in the U.S., Europe and certain RoW markets. | Mylan N.V. | Commercialization Agreement | Switzerland |
20-Sep-18 | Nationwide Children’s Hospital, Celenex | $452 | The ten programs are licensed to Amicus from Nationwide Children’s Hospital through the acquisition of Celenex, a private, clinical stage gene therapy company. The lead programs in CLN6, CLN3, and CLN8 Batten disease are potential first-to-market curative therapies for these rare, devastating diseases. | Amicus Therapeutics, BioPharma Credit | Asset Acquisition | United States |
12-Sep-18 | Xynomic Pharmaceuticals | $450 | Xynomic will merge into Bison Capital Merger Sub Inc with Xynomic continuing as the surviving company. Xynomic focuses on orally delivered small molecule drugs in oncology through both in-licensing from strategic partners supported by its scientists with expertise in tyrosine kinase inhibition and epigenetic modification. | Bison Capital Acquisition Corp. | Merger Agreement | China |
12-Sep-18 | Precision BioSciences | $445 | Precision will be primarily responsible for the development, formulation, and preclinical evaluation of the investigational nucleases, and Gilead will be responsible for the clinical development and commercialization of potential therapies. | Gilead Sciences | Collaboration | United States |
20-Sep-18 | IbexTM Design, IbexTM Develop | $403 | The two new IbexTM Solutions, IbexTM Design and IbexTM Develop, announced today are designed to meet the evolving needs of biotech companies with antibodyntherapies, from the preclinical stage through to commercialization. | Lonza | Manufacturing Investment | Switzerland |
04-Sep-18 | Teva Pharmaceuticals | $400 | Teva is engaging in the Offers to reduce its total debt and decrease its overall interest expense. Teva expects to fund the Offers with available cash on hand. | Undisclosed | IPO | Israel |
17-Sep-18 | Lung Biotechnology PBC (United Therapeutics) | $340 | SM04646, a Wnt pathway inhibitor, is currently undergoing a phase 1 clinical trial. Under the terms of the agreement, United Therapeutics' subsidiary, Lung Biotechnology PBC, will conduct and fund all further development, regulatory and commercialization activities in the U.S. and Canada. | Samumed | Licensing Agreement | United States |
19-Sep-18 | Molecular Template | $338 | Takeda and Molecular Templates will further develop the ETBs for the treatment of multiple myeloma under this new license, development and commercialization agreement. Molecular Template's developed CD38-targeted ETBs recognize the protein and deliver a modified bacterial toxin that enters the myeloma cells and destroys them through the enzymatic and irreversible destruction of ribosomes. | Takeda Pharmaceutical Company | Commercialization Agreement | United States |
05-Sep-18 | Inaugural Fund | $320 | The founding team will include industry veterans and managing directors, Beth Seidenberg, M.D. – general partner at Kleiner Perkins and former chief medical officer and head of global development at Amgen – and Sean Harper, M.D., executive vice president and head of R&D at Amgen who will move to the firm in January 2019. | Westlake Village BioPartners | Financing | United States |
19-Sep-18 | Life Healthcare Group Holdings | $293 | Life Healthcare, one of South Africa’s largest private healthcare providers, announced it has accepted an offer from KKR to acquire its 49.7% stake in Max Healthcare Institute Limited. KKR is a leading global investment firm that manages multiple alternative asset classes. | KKR | Acquisition | South Africa |
26-Sep-18 | Velo Bio | $288 | AMAG Pharmaceuticals has acquired global rights to develop and market digoxin immune Fab (ovine) (DIF), a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women. | AMAG Pharmaceuticals | Option Agreement | United States |
07-Sep-18 | NHS England | $258 | The Government is planning to make more than £200 million available to a group of NHS trusts to boost the development of digital technology for healthcare, along with the publication of new standards to promote the interoperability of systems. | Government of UK | Financing | United Kingdom |
26-Sep-18 | ACEA Biosciences | $250 | ACEA Biosciences is a company known for developing highly innovative products, which are used in academia, as well as the biotech and pharmaceutical industries. In recent years, the ACEA xCELLigence® RTCA technology has blazed a trail in immuno-oncology, pre-clinical drug discovery and development, as well as in basic academic research. | Agilent Technologies | Acquisition | United States |
29-Sep-18 | Butterfly Network | $250 | The new device, named Butterfly iQ, was inspired by Rothberg's own personal experiences. His daughter was born with a disease called tuberous sclerosis, which creates tiny tumors all over the body. The treatment procedure for this requires the use of a high-frequency ultrasound and MRI-imaging. | Fidelity Management | Series D Financing | United States |
13-Sep-18 | ViraTherapeutics, EMBL Ventures | $245 | VSV-GP is a highly potent oncolytic virus, which leads to an enhanced immune response that works together with the direct viral anti-tumour effect. ViraTherapeutics' lead candidate leverages the VSV-GP platform, a next generation oncolytic viral therapy, which has shown promising results in pre-clinical models, especially in combination with key immune modulatory principles. | Boehringer Ingelheim | Acquisition | Austria |
06-Sep-18 | Zealand Pharma | $205 | “The licensing agreement with Sanofi has provided Zealand significant funding since 2003. However, since we do not have influence on the commercialization, nor visibility over future revenue, the monetization provides financial certainty and independence,” added Mats Blom, Executive Vice President and Chief Financial Officer at Zealand. | Royalty Pharma, Sanofi | Financing | Denmark |
27-Sep-18 | Alvotech | $200 | This collaboration aligns the interests and strengths of Alvotech and CCHN, where a new state-of-the-art biologics drugs manufacturing facility will be built in Changchun, China. | Changchun High & New Technology | Joint Venture | Iceland |
26-Sep-18 | Alachua-Florida Facility | $200 | Brammer is conducting a further expansion of its first commercial facility, located in Cambridge, Mass., increasing the number of commercial suites from 7 to 12, supporting up to 2,000-liter suspension and adherent processes. Construction of this additional capacity will be completed in the first half of 2019. | Brammer Bio | Financing | United States |
14-Sep-18 | Bonti | $195 | Following completion of the acquisition, Allergan will obtain global rights to Bonti's pipeline consisting of two botulinum neurotoxin serotype E (BoNT/E) programs currently in Phase 2 development, EB-001A (aesthetic) and EB-001T (therapeutic). The active ingredient in both programs, EB-001, is a novel botulinum neurotoxin serotype E (BoNT/E). | Allergan plc | Acquisition | United States |
11-Sep-18 | Invuity | $190 | "The combination of Stryker's established leadership in minimal access surgery paired with Invuity’s suite of enabling visualization and surgical devices should facilitate better patient outcomes and operating room efficiencies in women’s health, general surgery, electrophysiology and orthopedics," said Scott Flora, Invuity’s Interim Chief Executive Officer. | Stryker Corporation | Acquisition | United States |
13-Sep-18 | Biscayne Neurotherapeutics | $183 | Supernus will obtain worldwide rights (excluding certain markets in Asia where rights have been out-licensed) to Biscayne’s product candidate. The development program which will be referred to as SPN-817 will utilize a novel synthetic form of huperzine A which is a potent acetyl cholinesterase inhibitor with pharmacological activities in CNS conditions such as epilepsy. SPN-817 will have a new chemical entity status (NCE) in the U.S. market. | Supernus Pharmaceuticals | Acquisition | United States |
21-Sep-18 | Viking Therapeutics | $176 | Viking currently intends to use the net proceeds from the offering for continued development of its VK5211, VK2809 and VK0214 programs and for general research and development | William Blair & Company | IPO | United States |
10-Sep-18 | Endocyte | $175 | Endocyte intends to use the net proceeds from the proposed offering, if completed, to fund the continued clinical development of its pipeline products and preparation for the commercial launch of 177Lu-PSMA-617, if approved, as well as for working capital. | Undisclosed | IPO | United States |
19-Sep-18 | Galera Therapeutics | $150 | Galera plans to use the proceeds of the combined equity and royalty financings to advance the clinical development of GC4419 into and through a pivotal Phase 3 clinical trial for the treatment of severe oral mucositis (SOM) in patients with head and neck cancer. | Clarus | Series C Financing | United States |
25-Sep-18 | Fate Therapeutics | $144 | Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of clinical product candidates and the conduct of preclinical research and development. | Piper Jaffray; Jefferies | IPO | United States |
26-Sep-18 | Urovant Sciences | $140 | Urovant’s lead product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. | J.P. Morgan | IPO | Switzerland |
04-Sep-18 | Jianke Pharmaceutical | $130 | Jianke is the largest online B2C pharmacy in China, offering 680,000 SKUs and a robust set of healthcare advisory services. Jianke leads its competitors in terms of brand name recognition, number of users, user acquisition costs, product & service offerings, and online traffic as measured by Alexa indexes. | HBM Healthcare Investments, GTJA Investment Group | Series B Financing | China |
11-Sep-18 | Atreca | $125 | This first candidate, generated by the company's unique Discovery Engine and through its proprietary Immune Repertoire Capture (IRC™) technology, represents a new potentially fundamental new class of oncology immunotherapeutics. Atreca is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications. | Wellington Partners | Series C Financing | United States |
27-Sep-18 | Focal Therapeutics | $125 | Focal generated approximately $16 million of revenue in the last 12 months. The acquisition, which is expected to close in early October, is estimated to be neutral to Hologic’s non-GAAP earnings per share in fiscal 2019, and accretive thereafter. | Hologic | Acquisition | United States |
06-Sep-18 | Allogene Therapeutics | $120 | Allogene is advancing its allogeneic CAR T cell portfolio, which includes rights to 16 preclinical CAR T cell therapy targets and U.S. rights to UCART19, an allogeneic CAR T cell therapy candidate that is being developed for the treatment of CD19-expressing hematological malignancies. | Cowen and Company | Financing | United States |
26-Sep-18 | Arvinas | $120 | Arvinas is focused on the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. | Goldman Sachs | IPO | United States |
14-Sep-18 | Hua Medicine | $110 | Shanghai-based Hua Medicine is a leading, innovative development company, currently focused on developing a global first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes, and mGLUR5, a potential novel drug candidate for the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID). | Goldman Sachs | IPO | China |
19-Sep-18 | Aralez Pharmaceuticals Inc. | $110 | Assuming completion of the Transaction, Nuvo would acquire Aralez's Canadian specialty-pharmaceutical business, which was formerly known as Tribute Pharmaceuticals Canada Inc. (Tribute). This is a growing business that includes Cambia®, BlextenTM, SuvexxTM (sold as Treximet® in the U.S.), as well as the Canadian distribution rights to Resultz,® and would create a platform for Nuvo to acquire and launch additional commercial products in Canada. | Nuvo Pharmaceuticals Inc., Deerfield Management Company | Acquisition | Canada |
13-Sep-18 | Principia Biopharma | $106 | Principia Biopharma, which is developing oral small molecule therapies for pemphigus, immune thrombocytopenic purpura and MS, raised $106 million by offering 6.3 million shares at $17, the high end of the range of $15 to $17. Insiders intend to purchase up to $26 million of the IPO (25% of the deal). | Undisclosed | IPO | United States |
17-Sep-18 | 111, Inc. (New Peak Group) | $101 | The company intends to use about US$50.8 million of the net proceeds for selling and marketing to expand its customer base and another US$ 38.1 million will be allocated to research and development, and invest in technologies such as artificial intelligence, big data, and cloud-based solutions. | Undisclosed | IPO | China |
05-Sep-18 | Adaptimmune Therapeutics | $100 | Net proceeds of the offering will be used to advance the company’s wholly owned pipeline of SPEAR T-cell candidates through clinical trials as well as for other general corporate purposes. | Matrix Capital | IPO | United Kingdom |
06-Sep-18 | Dicerna Pharmaceuticals | $100 | Dicerna intends to use the net proceeds from this offering for preclinical studies and clinical trials, and to use the remainder of any net proceeds for continued technology platform development, working capital and general corporate purposes. | H.C. Wainwright & Co. | IPO | United States |
12-Sep-18 | HLS Therapeutics | $100 | HLS Therapeutics is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets focused on indications in the Central Nervous System and Cardiovascular segment. | Silicon Valley Bank | Financing | Canada |
14-Sep-18 | Allogene Therapeutics | $100 | Allogene Therapeutics, with headquarters in South San Francisco, is a clinical stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (CAR T) therapies for cancer. | Goldman Sachs | IPO | United States |
28-Sep-18 | Gritstone Oncology | $100 | Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - Gritstone EDGE™ and the ability to develop and manufacture potent immunotherapies using tumor-specific neoantigens. | Goldman Sachs | IPO | United States |
20-Sep-18 | Y-mAbs Therapeutics | $96 | Y-mAbs Therapeutics, a phase 2 biotech developing monoclonal antibody therapies for pediatric cancers. YMAB has a strong collaboration partnership with the Memorial Sloan Kettering Cancer Center and top tier investors. | Bank of America Merrill Lynch | IPO | United States |
04-Sep-18 | MannKind Corporation | $95 | United Therapeutics will be responsible for global development, regulatory and commercial activities with regard to the development and commercialization of a dry powder formulation of treprostinil currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. | United Therapeutics Corporation | Licensing Agreement | United States |
05-Sep-18 | 4D Molecular Therapeutics (4DMT) | $90 | The proceeds from this financing will be used to advance its proprietary Therapeutic Vector Evolution platform and pipeline of next-generation AAV gene therapeutics. The company’s lead intravitreally-delivered AAV gene therapy asset for choroideremia is expected to enter clinical trials in 2019. | Viking Global Investors | Series B Financing | United States |
07-Sep-18 | Kodiak Sciences | $90 | Kodiak Sciences is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. It raised $90 million in the IPO. The company had a net loss of $27.9 million and no revenue in 2017, compared with a loss of $17.1 million and no revenue in 2016. | Morgan Stanley | IPO | United States |
26-Sep-18 | Sutro Biopharma | $85 | Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated cell-free protein synthesis platform, XpressCF™, to create a broad variety of optimally designed, next-generation protein therapeutics for cancer and autoimmune disorders, today announced the pricing of its initial public offering of 5,667,000 shares of its common stock at a price to the public of $15.00 per share. | Cowen and Company | IPO | United States |
18-Sep-18 | ChemoCentryx | $85 | The increased investment follows the establishment of a partnership with ChemoCentryx since May 2016. Under the terms of the current in-licensing agreements, Vifor Pharma Group has the exclusive rights to commercialize avacopan and CCX140 for orphan and rare renal diseases in all markets outside of the United States. | Vifor Pharma Group | Equity Investment | Switzerland |
21-Sep-18 | uBiome | $83 | uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. The Company’s commercial products include SmartGut™, a doctor-ordered stool test that identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease and ulcerative colitis. | Y Combinator | Series C Financing | United States |
05-Sep-18 | Fulcrum Therapeutics | $80 | Fulcrum is pioneering a small molecule, precision medicine approach to address serious monogenic and prevalent diseases of gene misregulation. The proceeds from the financing will be used to advance Fulcrum’s lead program in facioscapulohumeral muscular dystrophy (FSHD) into clinical testing, and to progress its pipeline of therapeutics for rare, genetically-based neuromuscular, central nervous system and hematologic disorders. | Foresite Capital | Series B Financing | United States |
25-Sep-18 | Morphic Therapeutic | $80 | To fund its two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic. | Omega Funds, Novo Holdings | Series B Financing | United States |
28-Sep-18 | KSQ Therapeutics | $80 | KSQ will advance its first drug program into the clinic within the next 18 months and up to three additional oncology drug programs into IND-enabling studies. The company’s first drug program is a modified adoptive T-cell immunotherapy which has shown efficacy in multiple animal models of PD-1 resistance. | Baillie Gifford | Series C Financing | United States |
19-Sep-18 | Shield Therapeutics | $79 | This long-term exclusive licence grants Norgine the right to commercialise Feraccru® in the UK, France, Germany, Italy, Spain and all other European countries which are not already covered by Shield’s previously announced licence agreements with AOP Orphan Pharmaceuticals AG and Ewopharma AG, as well as in Australia and New Zealand (the “Licensed Territories”). | Norgine B.V. | Licensing Agreement | United Kingdom |
04-Sep-18 | Principia Biopharma | $75 | Principia Biopharma is developing oral small molecule therapies in the areas of oncology and immunology. The company plans to use $50 million of the stock offering’s proceeds to complete mid-stage studies for its lead drug candidate, PRN1008, and advance it into Phase 3 testing. | Bank of America Merrill Lynch | IPO | United States |
18-Sep-18 | Entasis Therapeutics | $75 | The firm is advancing a pipeline of drug candidates for the treatment of various antibiotic-resistant infections. The company’s lead product candidate ETX2514, as well as one of their other product candidates, ETX0282 are B-Lactamase Enzymes inhibitors [BLIS]. Their name originates from their ability to inactivate B-Lactam antibiotics, one of the most commonly used classes of antibiotics. | Credit Suisse | IPO | United States |
27-Sep-18 | Aldeyra Therapeutics | $72 | Aldeyra anticipates using the net proceeds from the offering for the continued development of Aldeyra's lead compound reproxalap and other product candidates, as well as for debt maintenance, working capital, and other general corporate purposes. | Citigroup | IPO | United States |
20-Sep-18 | MeMed | $70 | MeMed will use the proceeds to advance in three areas: (i) Market adoption of MeMed BV™; (ii) Complete development, upscale manufacturing and clearance of MeMed Key™, a pioneering point-of-care protein measurement platform; and (iii) Expand its pipeline of immune-based measurements to tackle big clinical challenges. | Voyager Therapeutics; Ping An Global | Financing | Israel |
06-Sep-18 | Twentyeight-Seven Therapeutics | $65 | 28-7’s initial focus is on modulating miRNAs, which are short ncRNAs that inhibit target gene expression by suppressing mRNA translation and/or promoting mRNA decay. It is now well recognized that miRNAs are directly involved in cancer initiation, progression, and metastasis. | MPM Capital | Series A Financing | United States |
12-Sep-18 | Mithra Pharmaceuticals | $64 | Estelle is a combined oral contraceptive containing 15 mg estetrol (E4) and 3 mg drospirenone. | Gedeon Richter | Licensing Agreement | Belgium |
05-Sep-18 | KalVista Pharmaceuticals | $64 | KalVista intends to use the net proceeds from this offering to fund late-stage development of KVD900, including beyond anticipated Phase 3 data and a potential larger Phase 2 trial and other activities to accelerate the timeline for a new drug application, and to support accelerated development of additional hereditary angioedema (HAE) and oral diabetic macular edema (DME) programs. | Undisclosed | IPO | United States |
27-Sep-18 | Valneva SE | $58 | The offering proceeds raised will be used to pursue the clinical development of the Company's pipeline candidates, notably its vaccine candidates against Lyme and Chikungunya. | Groupe Grimaud | Investment | France |
10-Sep-18 | Clarify Health | $57 | The Clarify platform seamlessly integrates powerful analytics, artificial intelligence, real-time patient navigation, and smart workflows to guide patients and their caregivers proactively through personalized care journeys. Clarify's team has a track record of achieving over $1 billion in improvement at more than 125 health systems, payers, and pharmaceutical companies. | KKR | Series B Financing | United States |
10-Sep-18 | Valeant Pharmaceutical | $53 | Xenon Pharmaceuticals' agreement with Valeant is aimed to buy out all milestone payments and royalties with respect to XEN1101, which is a Kv7 potassium channel opener being developed by Xenon for the treatment of epilepsy. | Xenon Pharmaceuticals | Financing | Canada |
11-Sep-18 | Tianjin Tasly Pharma | $50 | According to data from the phase-two clinical study of T89, the change of Total Exercise Duration (TED), the gold endpoint in clinical trials of T89 for the prevention and treatment of recurrence of stable angina pectoris, is of both statistical and clinical significance. | Arbor Pharmaceuticals | Research Agreement | China |
26-Sep-18 | Chugai Pharmaceutical | $50 | OWL833 is Chugai’s oral non-peptidic GLP-1 receptor agonist. OWL833 is a Phase 1-ready asset that is being studied for the treatment of type 2 diabetes. Lilly will receive worldwide development and commercialization rights to OWL833. | Eli Lilly and Company | Licensing Agreement | Japan |
14-Sep-18 | CASI Pharmaceuticals | $49 | CASI intends to use the net proceeds from the offering principally to support a broad and evolving platform, including its in-licensed products, EVOMELA®, MARQIBO® and ZEVALIN®, are all currently in various regulatory stages for market approval in China. | Undisclosed | Private Placement | United States |
19-Sep-18 | Silverback Therapeutics | $48 | Silverback's proprietary ImmunoTAC technology and integrated R&D approach enables the design of product candidates that can be administered systemically, but that act only at the sites of disease. The approach is designed to spare healthy tissues from unwanted side effects, while modifying disease processes in a potent and targeted manner. | OrbiMed | Series A Financing | United States |
06-Sep-18 | Medexus | $46 | By combining Pediapharm’s Canadian pediatric speciality pharmaceutical business with the Canadian diversified speciality pharmaceutical business of Medexus and the U.S. rheumatology speciality pharmaceutical business of Medac Pharma, the Acquisitions and Offering will create a leading North American commercial-stage specialty pharmaceutical company strategically positioned for future growth. | Pediapharm | Acquisition | Canada |
03-Sep-18 | Evox Therapeutics | $45 | Proceeds from this financing will support the advancement of Evox's exosome-based therapeutics pipeline, including progression of several proprietary rare disease assets towards the clinic, and continued development of its world-leading exosome drug platform. Evox is developing its own proprietary pipeline of exosome-based therapeutics for the treatment of rare, life-threatening diseases with significant unmet need. | Redmile Group | Series B Financing | United Kingdom |
20-Sep-18 | Molecular Template | $45 | Molecular intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund: its ongoing Phase Ib and Phase II clinical studies and planned additional Phase II clinical studies for MT-3724 in DLBCL; its share of development expenses in its CD38 collaboration with Takeda; its programs targeting HER2 and PD-L1; further preclinical development and drug discovery activities in its other programs | UBS Group AG | IPO | United States |
14-Sep-18 | Endotronix | $45 | This financing supports the commercialization of the Cordella™ Heart Failure System (Cordella System) and clinical development of the Cordella™ Pulmonary Artery Sensor (Cordella Sensor) through CE Marking and FDA Premarket Approval (PMA). | LSP Health Economics Fund 2 | Series D Financing | United States |
03-Sep-18 | IDA Ireland | $43 | The Drug Product Filling Project investment estimated at approximately $43 million, which is projected to create an additional 51 roles across all disciplines, will augment the site’s Drug Substance Manufacturing and Secondary Packaging and Labelling capability. | BioMarin | Manufacturing Investment | Ireland |
11-Sep-18 | OncoResponse | $40 | The proceeds will be used to advance the company’s five drug candidates into preclinical and clinical development. All drug candidates were derived from OncoResponse’s discovery platform, which mines the immune systems of patients who have responded exceptionally well to cancer immunotherapies. | RiverVest Venture Partners | Series B Financing | United States |
12-Sep-18 | Fullerton Healthcare Corporation Ltd. | $40 | The IFC investment will help improve the provision of affordable, quality healthcare in the Philippines and enhance efficiencies in the health maintenance organisation ("HMO") market through increased integration between the financing and provision of healthcare. | International Finance Corporation | Financing | Philippines |
27-Sep-18 | Nicox SA | $40 | Naproxcinod, a Cyclooxygenase-Inhibiting Nitric Oxide (NO)-Donating (CINOD) naproxen, is a non-steroidal anti-inflammatory product candidate originally discovered and developed by Nicox. A broad clinical package already exists for naproxcinod in osteoarthritis, including three phase 3 studies with over 2,700 patients. | Fera Pharmaceuticals | Development Agreement | France |
27-Sep-18 | Cellular Biomedicine Group | $40 | "This collaboration with Novartis reflects our shared commitment to bringing the first marketed CAR-T cell therapy Kymriah, a transformative treatment option currently approved in the United States, European Union and Canada for two difficult-to-treat cancers, to China where the number of patients in need remains the highest in the world," said Tony Liu, Chief Executive Officer, CBMG. | Novartis | Licensing Agreement | China |
26-Sep-18 | Valneva SE | $40 | The offering proceeds, amounting to €37.7 million, raised will be used to pursue the clinical development of the Company's pipeline candidates, notably its vaccine candidates against Lyme and Chikungunya. | Guggenheim Securities | Private Placement | France |
18-Sep-18 | Fundación Científica de la Asociación Española Contra el Cáncer, Associazione Italiana per la Ricerca sul Cancro | $40 | In partnership with the leading cancer research charities in Spain and Italy, Cancer Research UK is building international research networks to forge new scientific collaborations in the fight against cancer. The Accelerator Award supports cross-institutional collaborations across a wide range of research areas, including pre-clinical studies, biomarkers, imaging, radiotherapies, engineering, physical sciences and many others. | Cancer Research UK | Grants & Awards | Italy |
25-Sep-18 | Ceribell | $35 | Ceribell raised $35 million to fund commercialization of its rapid response EEG system, which can quickly diagnose patients suspected of having nonconvulsive seizures with no visual symptoms, for use in neurological intensive care units and emergency rooms. | Optimas Capital Partners Fund | Series B Financing | United States |
05-Sep-18 | PhaseBio Pharmaceuticals | $34 | PhaseBio plans to use the proceeds from the Series D financing to advance the clinical development of its lead product candidate PB2452. Additionally, the company plans to initiate a Phase 2 clinical study of its ELP-based therapy PB1046 in pulmonary arterial hypertension in the third quarter of 2018. | AstraZeneca | Series D Financing | United States |
18-Sep-18 | Immune-Onc Therapeutics | $33 | “As we prepare to move from translational research into the clinic, Adrian and An’s decades of industry expertise in drug development will be critical in advancing our mission to develop novel biotherapeutics for hard-to-treat cancers,” said Charlene Liao, Ph.D., co-founder, president and chief executive officer of Immune-Onc Therapeutics. | Northern Light Venture Capital | Series B Financing | United States |
26-Sep-18 | IDX | $33 | The company's first diagnostic system, IDx-DR, is the only AI system cleared by the FDA to detect diabetic retinopathy without requiring a clinician to interpret the image or results. This enables health care providers who are not normally involved in eye care to use the AI system to test for this leading cause of blindness during routine office visits. | 8VC | Financing | United States |
18-Sep-18 | Immune-Onc Therapeutics | $33 | Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. | Northern Light Venture Capital | Series B Financing | United States |
06-Sep-18 | Civica Rx | $30 | Civica Rx has identified 14 hospital-administered generic drugs as its initial focus, seeking to stabilize the supply of essential medications, many of which have fallen into chronic shortage situations. The company expects to release its first products as early as 2019. | Laura and John Arnold Foundation, Peterson Center on Healthcare, Gary and Mary West Foundation | Launch & Partnerships | United States |
27-Sep-18 | Akrevia Therapeutics | $30 | Akrevia’s Aklusion platform allows potently active biological molecules to be inactive until they encounter the tumor microenvironment. With a potential best-in-class anti-CTLA4 antibody as validation, the technology can be applied broadly to highly-potent cytokines and chemokines which currently have limited or no clinical utility due to toxicities. | F-Prime Capital Partners | Series A Financing | United States |
26-Sep-18 | Lyra Therapeutics | $30 | The Series B financing provides Lyra with the funding for the planned Phase 2 study of LYR-210 in chronic rhinosinusitis (CRS), a debilitating disease caused by inflammation of the paranasal sinus tissues. | Perceptive Advisors | Series B Financing | United States |
05-Sep-18 | Alpha Tau Medical | $29 | Alpha DaRT (D?ffus?ng Alpha-em?tters Rad?at?on Therapy) enables the first alpha-radiation-based cancer treatment for various types of solid tumors. The company has started clinical trials with leading research centers throughout the world to investigate Alpha DaRT as a treatment for cancer using different protocols across a variety of indications, including Pancreatic, Breast, Head and neck, Prostate and Gynecological cancer | Shavit Capital | Private Placement | Israel |
25-Sep-18 | Ichorion Therapeutics | $27 | Ichorion has established a unique pipeline which augments the existing neurology assets in Cerecor’s pipeline, adding multiple substrate replacement therapies with the potential to leverage the 505(b)(2) pathway to accelerate development and approval. | Cerecor, Inc. (CERC) | Acquisition | United States |
17-Sep-18 | ViaCyte | $25 | ViaCyte’s lead product candidate "PEC-Direct" is currently being evaluated clinically. PEC-Direct is being developed as a therapy for the subset of patients with type 1 diabetes at high risk for acute complications. | CRISPR Therapeutics | Collaboration | United States |
26-Sep-18 | Minoryx Therapeutics | $24 | MIN-102 is a novel, orally bioavailable and selective PPAR gamma agonist with a superior profile for central nervous system-related diseases. It is currently in a phase 2/3 clinical trial for the treatment of adrenomyeloneuropathy. | SFPI-FPIM | Series B Financing | Spain |
20-Sep-18 | Xylaze (PharmaMar Group) | $22 | PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. | AkzoNobel | Divestment | Spain |
07-Sep-18 | Novate Medical | $20 | Novate has developed Sentry, the first bioconvertible inferior vena cava (IVC) filter, which has recently been granted 510(k) regulatory clearance in the US. | BTG | Acquisition | Ireland |
10-Sep-18 | Biodesy | $20 | Biodesy is using the proceeds to expand its scientific and commercial operations team, demonstrate further value in the discovery and development of novel therapeutics, and leverage its core technology via strategic partnerships. The new CEO appointment and financing round will enable the company to drive biopharmaceutical adoption of its technology platform. | Alexandria Venture Investments | Series C Financing | United States |
12-Sep-18 | Coda Biotherapeutics | $19 | CODA’s chemogenetic platform aims to control the activity of neurons and other cells to treat diseases. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. | MPM Capital | Series A Financing | United States |
17-Sep-18 | Cancer Research UK City of London Centre | $18 | The new Cancer Research UK City of London Centre* brings together world-leading researchers from UCL, King’s College London, Queen Mary University of London and the Francis Crick Institute. It will become a global centre of excellence for biotherapeutics, a pioneering field of cancer research. | Cancer Research UK | Financing | United Kingdom |
28-Sep-18 | China SXT Pharmaceuticals | $17 | China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces. | Boustead Securities | IPO | China |
12-Sep-18 | Novocure | $15 | Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, including the brand name Optune®, in China, Hong Kong, Macau and Taiwan. Optune (Tumor Treating Fields) currently marketed in the U.S., the EU and Japan for the treatment of glioblastoma and in advanced clinical development for multiple solid tumor indications | Zai Lab | Licensing Agreement | United States |
21-Sep-18 | Agenus | $15 | Agenus, an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies, today announced the closing of its non-dilutive royalty transaction with XOMA Corporation (XOMA), where XOMA purchased a minority interest in the royalties and milestones that Agenus is eligible to receive from Incyte and Merck. | XOMA Corporation | Financing | United States |
19-Sep-18 | Medical Aesthetics Innovation Center | $15 | The Medical Aesthetics Innovation Center to be located at the High-Tech Zone of Chengdu, will feature a world-class training center for medical aesthetics healthcare professionals, as well as an education and product experience center for medical aesthetics consumers. | Allergan plc | Cooperation Agreement | China |
27-Sep-18 | Janssen Vaccines & Prevention B.V., The Jenner Institute | $15 | New collaboration with Coalition for Epidemic Preparedness Innovations (CEPI) and The Jenner Institute is latest example of Johnson & Johnson’s ongoing commitment to global pandemic preparedness efforts | Coalition for Epidemic Preparedness Innovations (CEPI) | Collaboration | United Kingdom |
14-Sep-18 | Industrial Biotechnology Innovation Centre | $14 | “Scotland has the natural resources and infrastructure that make it the perfect place for Industrial Biotechnology to thrive, bringing significant economic benefits. I am pleased to confirm that the Scottish Government, through our national agencies, is able to invest £11.1million to support IBioIC to drive forward Scotland’s Industrial Biotechnology sector.” | Scottish Government’s National Plan for Biotechnology | Financing | United Kingdom |
26-Sep-18 | Zosano Pharma Corporation | $14 | “This new financing partnership with Trinity provides support for commercial manufacture of M207 and is part of our planned technology transfer and scale up activities now underway,” said John Walker, chief executive officer and chairman of the board at Zosano. | Trinity Capital Investment | Investment | United States |
26-Sep-18 | General Practice Committee | $13 | The Winter Indemnity Scheme will be used to cover the costs of professional indemnity for the extra services provided by GPs, giving them the freedom to work extra sessions securely and without extra costs. | NHS England | Grants & Awards | United Kingdom |
10-Sep-18 | Arecor | $13 | Arecor’s next-generation diabetes product pipeline represents exciting new progress in the field of diabetes that will enable important new treatment regimens. Pipeline includes Proprietary formulations of insulin analogues and artificial pancreas development. | Calculus Capital | Financing | United Kingdom |
15-Sep-18 | MJ Freeway | $10 | “The industry is maturing rapidly and needs software that can handle increasing complexity, with state-of-the art functionality and data security,” said Jessica Billingsley, Co-Founder & CEO of MJ Freeway. “With adult-use permitted in 9 states and medical in 30 states, MJ Freeway is uniquely enabled to support regulation at every level. | Batu Capital Investments | Series C Financing | United States |
05-Sep-18 | Antibe Therapeutics | $10 | ATB-346 is a novel anti-inflammatory drug, designed to spare the gastrointestinal (“GI”) tract of the ulcers and bleeding normally associated with non-steroidal anti-inflammatory drugs (“NSAIDs”). Antibe recently completed a Phase 2B study for ATB-346 that demonstrated unequivocal superiority in GI safety compared to naproxen, the most prescribed NSAID in the United States. | Kwang Dong Pharmaceutical | Licensing Agreement | Canada |
12-Sep-18 | CorFlow Therapeutics AG | $10 | The seed proceeds will finance the First-in-Man MOCA I (MVO with CoFITM System Assessment) clinical trial in Europe. The MOCA I trial is a safety and feasibility study of the newly developed CorFlow Controlled Flow Infusion (CoFITM) system which will be studied in 40 acute heart attack patients. | Undisclosed | Seed Financing | Switzerland |
20-Sep-18 | Titan Pharmaceuticals | $10 | Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura™ long-term, continuous drug delivery technology. The company's lead product is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. | CIM Securities | IPO | United States |
20-Sep-18 | Tvardi Therapeutics | $9 | Series A funding is expected to enable the completion of ongoing Phase 1 studies for Tvardi’s lead compound TTI-101 in solid tumor cancers, and the completion of IND-enabling studies of a second product for use in non-cancer indications, including cachexia. | Undisclosed | Series A Financing | United States |
10-Sep-18 | Titan Pharmaceuticals | $7 | The fund has been granted for the development of a ProNeura™ based six-month implantable formulation of Nalmefene, an opioid antagonist, intended for the prevention of relapse to opioid addiction, following opioid detoxification. | National Institutes of Health's National Institute on Drug Abuse (NIDA) | Grants & Awards | United States |
06-Sep-18 | Elevian | $6 | Elevian's founders, working at Stanford and then Harvard, discovered the regenerative effects of young blood using a model called parabiosis. Elevian is on a path to make commercially viable drugs to treat major diseases of aging. Current areas of focus include Coronary Artery Disease, Alzheimer's Disease, Type 2 Diabetes and Sarcopenia (age-related muscle dysfunction). | Bold Capital | Seed Financing | United States |
14-Sep-18 | CEL-SCI Corporation | $5 | CEL-SCI's Phase 3 study is the largest Phase 3 study in the world for the treatment of head and neck cancer. Per the study's protocol, newly diagnosed patients with advanced primary squamous cell carcinoma are treated with the Multikine treatment regimen for 3 weeks prior to the Standard of Care (SOC) which involves surgery, chemotherapy and/or radiation. | Undisclosed | Financing | United States |
04-Sep-18 | Cadrock | $5 | Cadrock Pty Ltd owns an investigational prevention and treatment therapy for coronary artery disease (CAD). Cadrock data is backed by a clinical trial treating CAD as an infection with an antibiotic therapy in London, UK, which demonstrated a 36% reduction in Major Cardiac Events (MCEs) (STAMINA). | Undisclosed | Seed Financing | Australia |
05-Sep-18 | SAVSU Technologies | $5 | The 18-month purchase option provides BioLife, at its sole discretion, with the right to acquire the 56% of SAVSU not already owned. SAVSU will use the investment to scale up its operations and inventory to support increased demand for its evo®Dry Vapor Shippers and other precision temperature controlled shipping containers for cell and gene therapies. | BioLife Solutions | Financing | United States |
06-Sep-18 | Imperial College London | $5 | The money will be used to fund a virtual lab, led by Imperial, to apply Process Systems Engineering (PSE) methods to the pharmaceutical industry. PSE uses computer assisted methods and models to design, control and optimise processes. The approach has previously been used in the petrochemical, chemicals, and consumer goods industries. | Eli Lilly and Company | Grants & Awards | United Kingdom |
07-Sep-18 | BloodCenter of Wisconsin | $5 | As part of the consortium, BloodCenter of Wisconsin's Blood Research Institute will receive approximately $5 million for its own Program for Career Development in Glycosciences. BloodCenter of Wisconsin Program for Career Development in Glycosciences (BloodCenter of Wisconsin, Medical College of Wisconsin, Virginia Commonwealth University and Roswell Park Cancer Institute) | National Heart, Lung and Blood Institute (NHLBI-NIH) | Grants & Awards | United States |
17-Sep-18 | Agenus | $5 | "This is the fourth antibody from our partnered programs that has advanced into clinical trials, once again proving our commitment to deliver on our existing partnerships," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "In addition to this milestone, INCAGN2390 (anti-TIM-3) is expected to enter the clinic later this year, which would trigger an additional milestone payment to Agenus." | Incyte | Milestone Payment | United States |
20-Sep-18 | Merrimack Pharmaceuticals | $5 | "Since the start of the third quarter, Merrimack has received $38 million in non-dilutive capital, including two milestone payments from Shire totaling $23 million," said Richard Peters, M.D., Ph.D., President and Chief Executive Officer of Merrimack. "We are pleased to further strengthen the Company's cash position as we continue advancing our wholly-owned clinical and preclinical pipeline." | Shire PLC | Milestone Payment | United States |
26-Sep-18 | Virion Therapeutics | $5 | The Virion technology is built on a two-prong strategycombining the use of replication-incompetent chimpanzee adenoviral vectors with concomitant expression of glycoprotein D (gD), a novel checkpoint inhibitor that blocks suppression of T-cell production. ChiVax vaccines overcome a key limitation of human adenovirus-based vaccines, whose efficacy can be limited by pre-existing natural immunity against human adenoviruses. | Robin Hood Ventures | Series A Financing | United States |
05-Sep-18 | Forendo Pharma | $5 | The financing will enable Forendo Pharma to accelerate the development of its innovative women’s health portfolio. The Company also announces today that its lead program FOR-6219, a HSD17B1 inhibitor for the treatment of endometriosis , has commenced a Phase Ia study focusing on safety, tolerability and pharmacokinetics. | Vesalius Biocapital III Partners | Financing | Finland |
20-Sep-18 | Opiant Pharmaceuticals | $5 | “This $4.6 million BARDA contract, combined with the recently awarded $7.4 million grant we received from the National Institute on Drug Abuse (NIDA), further validates the potential of nasal nalmefene to be a vital life-saving product, both to reverse opioid overdose and to counter bioterrorism attacks. We expect to begin the pivotal pharmacokinetic study required for approval of OPNT003 by the U.S. Food and Drug Administration in 2019.” | Biomedical Advanced Research & Development Authority | Contract Agreement | United States |
06-Sep-18 | Hesperos | $4 | An 18-month $2 million Direct-to-Phase II SBIR grant from NCATS was awarded in 2016 to support development of advanced manufacturing techniques for a human-on-a-chip system being jointly developed by the University of Central Florida and Cornell. Hesperos was founded in 2014 to commercialize its novel human-on-a-chip technology, and prepare its systems for regulatory approval utilizing advanced PKPD modeling capabilities. | National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) | Grants & Awards | United States |
05-Sep-18 | Immusoft Corporation | $4 | Immusoft’s Phase II grant follows an earlier Phase I grant the company received to conduct studies to express IDUA in B cells using the Sleeping Beauty Transposon System, which delivers genes into cells without using a virus. As part of the Phase II, Immusoft will pursue a strategy for facilitating enhanced delivery across the blood-brain barrier and delivery of the IDUA enzyme. | National Institutes of Health (NIH) | Grants & Awards | United States |
10-Sep-18 | Tarsius Pharma | $3 | Tarsius is an Israel based early stage research and development company focusing on development of drug candidates in the field of Ophthalmology. Tarsius Pharma Ltd. develops a novel treatment for uveitis based on technology inspired by biomimetics. Biomimetic drugs are developed by emulating nature's models and processes to promote better medical treatment. | Sun Pharmaceutical Industries Ltd. | Acquisition | Israel |
13-Sep-18 | Wacker Biotech GmbH (Wacker Chemie AG) | $3 | WACKER has enhanced its production facilities for biopharmaceuticals – also known as biologics – with new equipment. The suite enables independent cell-bank production and expands storage capacity for customer cell banks. The company invested €2.5 million in, among other things, a fully automated fermentation plant including a new bioreactor with a capacity of 350 liters, a new separator for efficiently isolating cells and a new GMP cell-bank suite. | Wacker Chemie AG | Manufacturing Investment | Germany |
26-Sep-18 | Carmel Biosciences | $3 | Nutriband will acquire the NDA and ownership rights to FDA approved Prexxartan™, the ownership and rights to develop and market Carmel's pipeline including CAR-509, CAR-510, CAR-511 and CAR-512 currently in Pre IND phase. | Nutriband Inc. | Acquisition | United States |
13-Sep-18 | OEB4 Facility | $3 | CatSci is currently investing in three new laboratories: an OEB4 facility, a compact large-scale laboratory and a dedicated analytical laboratory to support drug substance development and testing. This will enable the kilogram supply of non-GMP candidate drugs to customers for toxicity studies. | CatSci | Manufacturing Investment | United Kingdom |
13-Sep-18 | Prokaryotics | $2 | The two-year agreement will fund research by Prokaryotics on a natural product cell wall synthesis inhibitor targeting antimicrobial-resistant Neisseria gonorrhoeae. | National Institute of Allergy and Infectious Diseases (NIAID) | Grants & Awards | United States |
13-Sep-18 | Pherin Pharmaceuticals | $2 | The license agreement was signed for granting VistaGen exclusive worldwide rights to develop and commercialize PH94B nasal spray, a Phase 3-ready drug candidate for as-needed (PRN) treatment of Social Anxiety Disorder (SAD). | VistaGen Therapeutics | Licensing Agreement | United States |
21-Sep-18 | GI Dynamics | $2 | The funds raised under the first tranche of the Placement will be used by GI Dynamics to fund the continued development of EndoBarrier, to prepare for the U.S. pivotal trial of EndoBarrier | Undisclosed | Private Placement | United States |
24-Sep-18 | Arizona State University-Tempe Campus | $2 | phase 2 study of oral vancomycin for the treatment of primary sclerosing cholangitis – $2 million over four years | USFDA | Grants & Awards | United States |
24-Sep-18 | Cedars-Sinai Medical Center | $2 | phase 2 study of seliciclib for the treatment of Cushing disease | USFDA | Grants & Awards | United States |
24-Sep-18 | Oncolmmune | $2 | CD24Fc is OncoImmune’s lead compound which is designed to treat graft-versus-host disease, a rare condition in which cells in a bone marrow transplant view the recipient’s tissues as foreign and mount an attack. The company was awarded $2 million in order to continue its Phase IIb study program for CD24Fc. | USFDA | Grants & Awards | United States |
24-Sep-18 | University of North Carolina at Chapel Hill | $2 | phase 2 study of sildenafil for the prevention of bronchopulmonary dysplasia – $2 million over four years | USFDA | Grants & Awards | United States |
05-Sep-18 | RxHealth | $2 | Rx.Health's Bulk Prescription allows health care teams to prescribe digital therapeutics and patient-centered care plans to entire cohorts of patients through a single click. The funding will be used to diversify Rx.Health's client base and support its first-to-market Bulk Prescription™ digital therapeutics and patient engagement tool. | Mount Sinai Innovation Partners | Seed Financing | United States |
11-Sep-18 | Norman Lee, George Washington University | $2 | The grant was awarded to investigate the mechanisms driving dysregulation splicing factor expression. RNA splicing i.e. the editing of nascent precursor messenger RNA causes exons to join together to form mature mRNA, the different combinations of exons can lead to the formation of different functional proteins. | National Institutes of Health | Grants & Awards | United States |
24-Sep-18 | Alkeus Pharmaceuticals | $2 | Alkeus Pharmaceuticals was awarded $1.75 million to continue Phase II development of its Stargardt disease treatment, ALK-001. Stargardt disease is a form of inherited macular degeneration which affects just 30,000 individuals in the US. No treatments exist for this rare form of blinding eye disease, making the development of ALK-001 – a form of vitamin A – important for this underserved patient community. | USFDA | Grants & Awards | United States |
06-Sep-18 | APDA Centers for Advanced Research | $2 | Our funding support will help investigate new biomarkers of Parkinson’s disease, examine the scientific basis for gender differences in PD, and probe the differences in PD among people of varying ethnicities, among many other worthy projects that will have an impact on the future of PD research” - Rebecca Gilbert, MD, PhD, Vice President and Chief Scientific Officer, APDA. | American Parkinson Disease Association (APDA) | Grants & Awards | United States |
21-Sep-18 | Auctus Biologics (Ichor Therapeutics) | $2 | The company will develop RPtag, a hyper-stable antibody mimetic scaffold to take on conventional clinical antibody therapy as an orally bioavailable formulation. | Undisclosed | Seed Financing | United States |
24-Sep-18 | Emory University School of Medicine | $2 | For phase 1/ 2 study of Ad/PNP fludarabine for the treatment of head and neck squamous cell carcinoma | USFDA | Grants & Awards | United States |
25-Sep-18 | Fibrocell Science | $1 | The Grant will enable Fibrocell’s continued clinical development of FCX-007, the Company’s gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a devastating, rare skin blistering disease with high mortality. | FDA's Office of Orphan Products Development (OOPD) | Grants & Awards | United States |
24-Sep-18 | Patagonia Pharmaceuticals | $2 | This non-dilutive funding will help support our clinical development of PAT-001, a proprietary topical formulation of isotretinoin in development for Congenital Ichthyosis. | USFDA | Grants & Awards | United States |
06-Sep-18 | Protagonist Therapeutics | $1 | The objective of the SBIR-funded research is to develop methods for characterizing in vivo target engagement, including pharmacokinetic and pharmacodynamic methods to characterize PTG-300 interactions, effects on pathway and disease biomarkers, and effects in pre-clinical disease models. | National Institutes of Health - National Heart, Lung and Blood Institute | Grants & Awards | United States |
24-Sep-18 | University of Minnesota | $1 | phase 2a study of subcutaneous hydrocortisone infusion pump for the treatment of congenital adrenal hyperplasia – $1.4 million over 3years. | USFDA | Grants & Awards | United States |
24-Sep-18 | General Hospital Corporation | $1 | phase 2 study of kisspeptin for the treatment of dopamine agonist intolerant hyperprolactinemia – $1.4 million over four years | USFDA | Grants & Awards | United States |
19-Sep-18 | Medicines Discovery Catapult | $1 | The partners (OptibriumTM, Intellegens and Medicines Discovery Catapult) are developing an AI platform that drug discovery companies – particularly UK SMEs – can use under licence. | Innovate UK | Grants & Awards | United Kingdom |
13-Sep-18 | India Globalization Capital | $1 | India Globalization Capital (IGC Pharma) is a company engaged in the development and commercialization of cannabinoid-based alternative therapies for medical conditions including Alzheimer’s disease, Parkinson’s disease, and pain, announced that it raised $1.0 million in a private placement of restricted shares. The net proceeds from the offering are for marketing and working capital associated with the commercialization of Hyalolextm. | Bradbury Investment Fund (Bradbury Group) | Private Placement | United States |
24-Sep-18 | Johns Hopkins University | $1 | phase 1/2 study of CD8-reduced T cells for the treatment of myelodysplastic syndrome or acute myeloid leukemia – $750,000 over three years | USFDA | Grants & Awards | United States |
25-Sep-18 | Cobra Biologics, Centre for Process Innovation, GE Healthcare Life Sciences | $1 | The three-way partnership, funded by a £570K Innovate UK grant, aims to increase the robustness and reduce costs for the manufacturing of adeno-associated virus (AAV) vectors, a delivery vehicle used for emerging gene therapy treatments. | Innovate UK | Grants & Awards | United Kingdom |
05-Sep-18 | Knopp Biosciences | $1 | Knopp is directing its Kv7 potassium channel activator program to the discovery and development of best-in-class small-molecule drug candidates, consistent with the goals of the NIH BPN. The BPN, part of the NIH Blueprint for Neuroscience Research, is a collaboration of NIH Institutes and Centers that supports research on the nervous system with the goal of developing new neurotherapeutic drugs. | National Institutes of Health Blueprint Neurotherapeutics Network (BPN) | Grants & Awards | United States |
05-Sep-18 | Phoenix Pharma | $0.19 | The grant will fund additional studies to determine if PPL-103 has potential to be used for treatment of cocaine addiction. Results from earlier in vivo studies conducted by Phoenix with NIDA support have demonstrated that PPL-103 is effective for opioid addiction therapy. | National Institutes of Health (NIH)/National Institute for Drug Abuse (NIDA) | Grants & Awards | United States |
02-Sep-18 | Dr. Aline Betancourt (Tulane University) | $0 | Acquisition of the Patent Portfolio will enable SanBio to expand its development pipeline into areas of inflammatory disorders and cancer targeted by SB623. SanBio is currently conducting phase 2 clinical trials of regenerative cell medicine SB623 which consists of mesenchymal stem cells derived from adult bone marrow that undergo a genetic modification. | SanBio Group | Licensing Agreement | United States |
03-Sep-18 | Vertex Pharmaceuticals | $0 | This agreement means lumacaftor/ivacaftor will be listed on the Pharmaceutical Benefits Scheme (PBS) from 1 October and follows a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC). A pathway to access for future Vertex CF medicine, tezacaftor/ivacaftor, has been established as part of this process. | Australian Government | Reimbursement Agreement | United Kingdom |
03-Sep-18 | Mahad API Manufacturing facility | $0 | Olon S.p.A., CDMO acquired a local generics chemical operations API manufacturing facility in Mahad, India, as part of a continuing expansion of its global footprint. As part of the asset purchase agreement, the parties have committed to sign a long-term supply contract to guarantee continuous supply of Sandoz products manufactured in Mahad. | Olon S.p.A. | Acquisition | India |
03-Sep-18 | Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO) | $0 | With state-of-the art facilities of 1,300m2 (12,000ft2) at the Campus Berlin-Buch, EPO offers, in particular, a comprehensive range of well characterized syngeneic tumor models, Patient Derived Xenograft (PDX) models and humanized tumor models. Citoxlab carries out studies in general and reproductive toxicology, carcinogenicity, immunology, pharmacology, pharmacokinetics and bioanalysis/biomarkers. | Citoxlab | Partnership | Germany |
04-Sep-18 | OS Therapies | $0 | OS Therapies, in collaboration with the Children’s Oncology Group (COG)1, will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. | Advaxis | Licensing Agreement | United States |
04-Sep-18 | Tsinghua University | $0 | Scientists will work in the Boehringer Ingelheim-Tsinghua University Joint Research Center for Immuno-Infection to harness the mechanisms of immune modulation to combat infectious diseases. The collaboration brings together the leading expertise of Tsinghua University in infectious disease research and immunology with Boehringer Ingelheim’s experience in the development of novel therapies for cancer immunology and immune modulation. | Boehringer Ingelheim | Collaboration | China |
04-Sep-18 | La Jolla Institute for Allergy and Immunology | $0 | Turnstone will utilize La Jolla Institute’s proprietary neoantigen identification methodology to select personalized neoantigens to target with its proprietary viral technologies for the development of new cancer immunotherapies. | Turnstone Biologics | Licensing Agreement | United States |
04-Sep-18 | Trianni | $0 | Trianni's lead technology is a next-generation transgenic discovery platform enabling efficient generation of fully-human monoclonal antibodies. This license agreement grants Gilead the use of the Trianni transgenic human monoclonal antibody discovery platform to support the company’s drug discovery efforts. | Gilead Sciences | Licensing Agreement | United States |
04-Sep-18 | Center for Medicinal Cannabis Research (CMCR) at UC San Diego School of Medicine | $0 | Insys has ongoing clinical trials of CBD oral solution as an investigational treatment for childhood absence epilepsy (Phase 2), infantile spasms (Phase 3) and Prader-Willi syndrome (Phase 2). The two organizations announced plans for a CMCR study of CBD from INSYS in pediatric patients with autism. | INSYS Therapeutics | Collaboration | United States |
04-Sep-18 | Clinerion | $0 | The companies will collaborate using Clinerion’s intelligent, patented Patient Network Explorer platform and Patient iP’s proprietary daTAscape asset to better target clinical trial sites and accelerate trial enrollment on a global scale. | Patient iP | Partnership | Switzerland |
04-Sep-18 | Sartorius Stedim Biotech | $0 | Through the partnership, Sartorius Stedim Biotech and Repligen will further collaborate to equip SSB’s recently launched ambr® 250ht perfusion single-use mini bioreactor system with Repligen’s KrosFlo® hollow fiber filter technology. The bioreactor system will be sold by SSB as a complete single-use assembly. | Repligen Corporation | Collaboration | Germany |
04-Sep-18 | Blood Centers of America | $0 | The agreement will enable deeper support of joint research and product development and provide valuable expertise needed for commercial therapies. Working together, the organizations will focus on removing barriers to the supply of critical raw materials needed for pre-clinical research and for clinical manufacturing of cell-based therapies. | Key Biologics | Partnership | United States |
04-Sep-18 | Celltheon Corporation | $0 | This partnership aligns Pall Biotech equipment and consumables with the Celltheon SMART™ Expression Platform to deliver integrated manufacturing solutions for customers developing biotherapeutics. It is part of Pall’s strategic approach to forming key partnerships that help enable better, safer and faster biologic production. | Pall Biotech | Partnership | United States |
04-Sep-18 | Plasticell Ltd | $0 | Plasticell will deploy its combinatorial stem cell screening platform, CombiCult®, to develop technologies for the conversion of pluripotent stem cells into platelets that promote tissue recovery and regeneration. | Ministry of Defence (MoD) | Contract Agreement | United Kingdom |
04-Sep-18 | IRBM | $0 | For this project, IRBM will be applying its expertise in phage display peptide library design and screening and in chemical peptide synthesis and optimization, to identify potential peptide leads for a specific Merck target. | Merck & Co. | Collaboration | Italy |
04-Sep-18 | Ossianix | $0 | Ossianix will use its patented single domain VNAR antibodies to deliver a predefined number of therapeutic agents of Novo Nordisk. Novo Nordisk will be responsible for the development and commercialization of the therapeutic products. | Novo Nordisk | Option Agreement | United Kingdom |
04-Sep-18 | University of Pennsylvania | $0 | The agreements between Precision and Penn include a Research, Collaboration and License Agreement (RCLA) with funding provided to Penn and a license to certain technology invented under the RCLA. The collaboration will include three gene knock-out programs and up to three gene knock-in or gene repair programs. | Precision BioSciences | Licensing Agreement | United States |
04-Sep-18 | Nevada Center for Behavioral Health (NCBH) | $0 | The company's collaboration with Nevada Center for Behavioral Health (NCBH) aims to evaluate a medication-assisted treatment (MAT) program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients within the State of Nevada criminal justice system. | Titan Pharmaceuticals | Collaboration | United States |
04-Sep-18 | Enamine | $0 | The collaboration provides StarDrop™ users with easy access to EnamineStore, a database of their commercially available screening compounds and chemical building blocks and this latest partnership further extends the wealth of information available to users through StarDrop and its capabilities for small molecule design, optimisation and data analysis in drug discovery. | Optibrium | Collaboration | Ukraine |
04-Sep-18 | Pall Corporation | $0 | This partnership aligns Pall Biotech equipment and consumables with the Celltheon SMART™ Expression Platform to deliver integrated manufacturing solutions for customers developing biotherapeutics. | Celltheon Corporation | Partnership | United States |
04-Sep-18 | Repligen Corporation | $0 | Sartorius Stedim Biotech and Repligen will collaborate to equip SSB’s recently launched ambr® 250ht perfusion single-use mini bioreactor system with Repligen’s KrosFlo® hollow fiber filter technology. The bioreactor system will be sold by SSB as a complete single-use assembly. | Sartorius Stedim Biotech | Partnership | United States |
05-Sep-18 | Checkmate Pharmaceuticals | $0 | The agreement entails the evaluation of CMP-001, a TLR9 agonist, in combination with avelumab*, a human anti-PD-L1 antibody. The collaboration will evaluate the safety and effectiveness of CMP-001 administered in combination with avelumab in patients with advanced squamous cell cancer of the head and neck (SCCHN) resistant to a prior PD-1/PD-L1 inhibitor. | Merck Group, Pfizer | Clinical Collaboration | United States |
05-Sep-18 | Cook Biotech | $0 | Both companies will collaborate in the advancement of AcuityBio’s ABC103 lead product for lung cancer, which will utilize Cook Biotech’s proprietary extracellular matrix (ECM) technology. | AcuityBio | Collaboration | United States |
05-Sep-18 | AstraZeneca | $0 | The Agreement is for the development and commercialization rights to AZD3241, an oral myeloperoxidase (MPO) inhibitor that AstraZeneca progressed through Phase 2 clinical trials. Biohaven plans to conduct a Phase 3 clinical trial of this product candidate for the treatment of multiple system atrophy (MSA) | Biohaven Pharmaceutical Holding Company Ltd. | Commercialization Agreement | Sweden |
05-Sep-18 | NHS England | $0 | The landmark deal means young people with a form of leukaemia are set to receive CAR-T (a chimeric antigen receptor T-cell) therapy within weeks, after NICE also green-lighted the treatment for entry into the reformed NHS Cancer Drugs Fund. The Tisagenlecleucel form of CAR-T, also known as Kymriah, is the first in a wave of treatments in a new era of personalised medicine and part of the NHS’s long term plan to upgrade cancer services. | Novartis | Commercialization Agreement | United Kingdom |
05-Sep-18 | ZeOmega | $0 | EmpiRx Health is revolutionizing the pharmacy benefits arena as a risk-bearing PBM that offers best-in-class pharmacy care management. EmpiRx will deploy the case management capabilities within Jiva—including identification and stratification of patients with complex case management needs. | EmpiRx Health | Collaboration | United States |
05-Sep-18 | AMRI Global | $0 | The alliance will promote Metrion's electrophysiology and ion channel screening expertise to global pharmaceutical and biotechnology clients. As part of the agreement, AMRI will be able to offer its customers access to Metrion's broad portfolio of assay tools and technologies for ion channel screening, cardiac safety profiling and neuroscience applications. | Metrion Biosciences Ltd | Collaboration | United Kingdom |
05-Sep-18 | Nemours / Alfred I. duPont Hospital for Children | $0 | The collaboration focuses on to initiate a clinical trial in children with Fragile X Syndrome. The planned protocol for the pilot open-label trial will dose Fragile X patients from 8 to less than 18 years of age, using a dosing regimen similar to that being tested in AD patients. | Neurotrope | Clinical Collaboration | United States |
05-Sep-18 | Secarna Pharmaceuticals | $0 | Secarna's proprietary antisense oligonucleotide platform LNAplusTM to be combined with Firebrand Therapeutics' scientifically leading research into mechanisms of cancer metastasis | Firebrand Therapeutics | Development Agreement | Germany |
05-Sep-18 | KK Women's and Children's Hospital | $0 | The partnership provides Blockchain-based healthcare services power improvements to training for hospital staff and care management for expecting and neonatal mothers | Everest | Partnership | Singapore |
05-Sep-18 | Nestlé Skin Health/ Galderma | $0 | The GALDERMA R&D site in Sophia-Antipolis which opened in 2006 is the world’s largest research and development center focused on medical and cosmetic solutions for the skin. The new capabilities will strengthen NUVISAN’S core service lines in Bioanalysis, Clinical Trial Supplies and Pharmaceutical Analytics as well as enhancing the portfolio by adding GMP-API synthesis and formulation capability for prescription drugs and cosmetics. | Nuvisan Pharma Services | Research Agreement | Switzerland |
05-Sep-18 | Suono Bio | $0 | Suono Bio leverages the technology developed by Institute Professor Robert Langer at the Massachusetts Institute of Technology to facilitate rapid, local administration of therapeutics to treat inflammatory-mediated diseases. | FUJIFILM Corporation | Financing | United States |
05-Sep-18 | CrystalGenomics | $0 | Apsen will secure exclusive rights for the Brazilian market to sell and market Acelex 2mg, a novel COX-2 inhibitor developed by CrystalGenomics for the treatment of osteoarthritis. CrystalGenomics will exclusively supply Apsen with the finished drug product at an agreed upon transfer price. | Apsen Farmacêutica | Export Agreement | South Korea |
05-Sep-18 | XoNovo | $0 | The partnership aims to generate crucial information concerning XoNovo’s lead compound, XN001, a patented new chemical entity (NCE); an autophagy modulator for the treatment of neurodegenerative diseases. According to the agreement, Inoviem will apply its expertise and cutting-edge technological solutions to isolate and identify XN001’s therapeutic targets and elucidate its mode of action. | Inoviem Scientific | Partnership | Israel |
06-Sep-18 | Moffitt Cancer Center | $0 | As part of the collaboration, Atara will gain access to novel CAR T targeting and co?stimulation domains designed to improve T cell proliferation and enhance persistence. This agreement furthers the Company’s strategy to develop next generation engineered CAR T immunotherapies across multiple therapeutic areas and leverage the Company’s off-the-shelf, allogeneic T-cell immunotherapy platform. | Atara Biotherapeutics | Collaboration | United States |
06-Sep-18 | Leukocare AG | $0 | LEUKOCARE will work closely with Xellia's team of product development experts and apply its proprietary SPS® (Stabilizing and Protecting Solutions) formulation technology platform. Xellia will have access to LEUKOCARE´s proprietary SPS® formulation technology platform to be used for its antibiotic and antifungal product portfolio. | Xellia Pharmaceuticals | Partnership | Germany |
06-Sep-18 | BeiGene | $0 | The aim of the global clinical collaboration agreement is to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene’s investigational RAF dimer inhibitor, lifirafenib (BGB-283) and SpringWorks Therapeutics’ investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors. | SpringWorks Therapeutics | Clinical Collaboration | China |
06-Sep-18 | Cedars-Sinai Medical Center | $0 | The collaboration is for the evaluation of the efficacy and safety of SYN-010- modified-release reformulation of lovastatin lactone, which is exclusively licensed to Synthetic Biology by Cedars-Sinai Medical Center. SYN-010 is designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). | Synthetic Biologics | Clinical Collaboration | United States |
06-Sep-18 | Pliant Therapeutics | $0 | The collaboration aims to accelerate the discovery of potential disease targets for gastrointestinal fibrosis. The collaborators will utilize primary human cells, tissues and organ culture systems as well as novel animal models of intestinal fibrosis to identify and validate new druggable targets for fibrosis of the gut that results from conditions such as Crohn’s disease. | Cleveland Clinic | Collaboration | United States |
06-Sep-18 | Managed Health Care Associates, Inc. (MHA) | $0 | Going forward, SoftWriters, which develops innovative pharmacy management software solutions for long-term care pharmacies, will be responsible for the support, delivery and further development of RxPertise, the acclaimed Medication Regimen Review (MRR) software application for consultant pharmacists specializing in long-term care. | SoftWriters | Partnership | United States |
06-Sep-18 | GNS Healthcare | $0 | The goal of the collaboration is to better understand the factors that drive and predict a patient's response to Amgen's metastatic CRC treatment, panitumumab. GNS will leverage its powerful causal AI platform to create causal models from the CALGB 80405 (Alliance) phase III clinical trial data in combination with Amgen's PEAK trial data. | Amgen | Partnership | United States |
06-Sep-18 | Medicines360 | $0 | Through this alliance, Medicines360, a nonprofit, and Afaxys will co-promote LILETTA to the 340B-participating public health sector, helping to expand access to the full range of FDA-approved contraception for women. LILETTA is a sterile, levonorgestrel-releasing intrauterine system indicated for prevention of pregnancy for up to 4 years. | Afaxys Pharma | Collaboration | United States |
06-Sep-18 | AG Mednet | $0 | GCTP works collaboratively with clients to determine an approach that best suits their unique needs and handles development of the endpoint process from start to finish. | Global Clinical Trial Partners | Partnership | United Kingdom |
06-Sep-18 | sanaplasma AG | $0 | The acquisition of sanaplasma AG is expected to increase Shire’s access to plasma in the longer term and add to its European plasma collection network, complementing existing core capabilities in plasma supply and manufacturing. | Shire PLC | Acquisition | Ireland |
06-Sep-18 | Walgreens | $0 | AUVI-Q is a prescription medicine approved by the FDA to treat emergency allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions. Through the AUVI-Q AffordAbility program provided by kaléo, eligible patients with commercial insurance, even those with high-deductible plans, can obtain AUVI-Q at no cost. | Kaléo | Partnership | United States |
06-Sep-18 | TGaS® Advisors | $0 | Trinity will add TGaS’s unique benchmarking products to its real-world evidence and primary market research capabilities to power its strategic advisory offerings in corporate and product strategy, launch readiness, pricing and market access, and health economics. | Trinity Partners | Acquisition | United States |
06-Sep-18 | GlaxoSmithKline | $0 | Ezogabine, also known as retigabine, is the only anti-epileptic drug previously approved by the FDA with a mechanism of action that potentiates Kv7-mediated potassium current. GlaxoSmithKline (GSK) marketed ezogabine in various jurisdictions – as Potiga® in the U.S. and Trobalt™ in Europe – but withdrew the drug from the market worldwide in June 2017 citing commercial reasons. | Xenon Pharmaceuticals | Expansion | United Kingdom |
06-Sep-18 | CYTOO | $0 | Initially, the aim of the research collaboration will be to modify CYTOO' s existing MyoScreenTM platform to enable its potential use as a Duchenne muscular dystrophy (DMD) target discovery platform. | Pfizer Inc. | Option Agreement | France |
06-Sep-18 | Evotec AG | $0 | Evotec and Celgene will leverage Evotec’s Panomics platform in order to identify drug targets which are traditionally difficult to track. Evotec’s Panomics platform applies in particular high-end proteomics and transcriptomics at industrial scale to profile and select promising drug candidates on the basis of comprehensive cell biological profiles. | Celgene Corporation | Partnership | Germany |
06-Sep-18 | Amedica Corporation | $0 | CTL Medical will acquire all of Amedica’s commercial spine business for total consideration of up to $10 million. The deal will make CTL Medical the world's exclusive provider of silicon nitride spine products and give it unique access to markets like Brazil and Australia, and widen its European footprint, further strengthening its position as a global leader serving the spine industry. | CTL Medical Corporation | Asset Acquisition | United States |
06-Sep-18 | Ieso Digital Health | $0 | The aim of this program is to demonstrate that those diabetes patients with mental health issues can be successfully identified and their depression or anxiety treated, through an integrated, holistic approach – ultimately leading to better and more effective management of their whole condition. | Roche | Collaboration | United Kingdom |
06-Sep-18 | Bloom Science | $0 | Under the agreement, Biose industrie will develop a manufacturing process at its industry leading development and manufacturing facility in France. Bloom Science is rapidly advancing the science of translating the ketogenic diet into a new class of neuroprotective medicines for patients with epilepsy and other challenging neurological conditions. | Biose industrie | Manufacturing Investment | United States |
07-Sep-18 | BDD Pharma | $0 | The agreement, which includes an upfront payment, milestones and future royalties, relates to the development of CTx-1301 and CTx-1302 for the treatment of ADHD. BDD's proprietary OralogiK™ technology provides unrivalled control of drug release in vivo - delivery at the right place and the right time. | Cingulate Therapeutics | Licensing Agreement | Scotland |
07-Sep-18 | PharmaMar | $0 | This was previously announced as one of the key elements of the strategy for the merger between Pharma Mar and Zeltia S.A. (regulatory announcement of 2 Dec 2014) and in other subsequent communications. | Undisclosed | IPO | Spain |
07-Sep-18 | Dyadic International | $0 | Sanofi will fund the collaborative research which will utilize the proprietary and patented C1 Gene Expression Platform Technology to express multiple genes for vaccine and drug applications. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosim | Sanofi | Collaboration | United States |
09-Sep-18 | A. Menarini Diagnostics S.r.l. (Menarini Group) | $0 | LabSat™ Frozen is an ultra-rapid automated tissue staining solution performing immunohistochemistry (IHC) assays in a few minutes. Thanks to this breakthrough technology, patients will be able to benefit from a faster, better and more personalized treatment starting in the operating room. | Lunaphore Technologies SA | Partnership | Italy |
10-Sep-18 | Centre for the Commercialization of Antibodies and Biologics (CCAB) | $0 | The agreement provides Triumvira with an exclusive license for antibodies discovered at the University of Toronto (U of T) on specified therapeutic targets. CCAB is the assigned agent for the U of T for the commercialization of a large portfolio of human antibodies. U of T will receive up-front fees, milestone payments and royalty payments on net sales of products on three therapeutic targets: BCMA, ROR1 and one undisclosed target. | Triumvira Immunologics | Licensing Agreement | Canada |
10-Sep-18 | AltiBio | $0 | AltiBio is developing two molecules for undisclosed rare diseases. The company has conducted successful proof of concept studies and has filed patent applications to support its therapeutic strategies for three projects: ATB223, ATB224, and ATB338. | BioMarin | Series A Financing | United States |
10-Sep-18 | Inhibrx | $0 | The agreement showcases the expansive biologics pipeline of Inhibrx and the world leading technical expertise and capabilities of WuXi Biologics. Inhibrx will exclusively use WuXi Biologics for GMP manufacturing of its human biologic therapeutics for all projects to be initiated within next 3 years which Inhibrx plans to first initiate clinical trials outside of China. | WuXi AppTec | Partnership | United States |
10-Sep-18 | Mundipharma | $0 | The companies have signed an agreement for the marketing, sales and distribution of well-known pain medicine brands Voltaren® (diclofenac sodium) and Cataflam® (diclofenac potassium) in Malaysia, Thailand, and the Philippines. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain, swelling (inflammation), and joint stiffness caused by arthritis. | Novartis | Partnership | Singapore |
10-Sep-18 | Haplogen Bioscience | $0 | The project exploits Cyclenium’s proprietary CMRT™ (“smart”) drug discovery technology together with Haplogen’s exquisite expertise in flaviviral biology to identify new agents for therapeutic and prophylactic use against all major pathogenic organisms from this family, including dengue, Zika, West Nile, Japanese encephalitis and yellow fever viruses. Haplogen Bioscience will continue to thoroughly characterize the therapeutic molecules. The partners intend to jointly develop and commercialize t | National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) | Grants & Awards | Austria |
10-Sep-18 | ATP Science Pty Ltd | $0 | Both ATP Science and Griffith University (GU) will work together to develop a novel plant extraction process and analyte detection methodology. ATP Science believes that the research collaboration with Griffith University will specifically yield new knowledge in novel plant extracts that can be incorporated into new and existing ATP Science supplement products to enhance the nutritional value delivered to clients and end-users of the products. | Griffith Institute | Collaboration | Australia |
10-Sep-18 | Sherpa Clinical Packaging | $0 | The acquisition of Sherpa, a provider of clinical trial supply services, further strengthens PCI’s position as a leader in outsourced clinical trial support services. Sherpa’s core services include primary and secondary packaging and labeling for Phase I-IV studies, distribution, storage and returns. | PCI Pharma Services | Acquisition | United States |
11-Sep-18 | Foundation Medicine, Inc. | $0 | The agreement is for the development, regulatory support and commercialization of companion diagnostics (CDx), with an initial focus on CDx development for pemigatinib (INCB54828), Incyte’s selective FGFR1/2/3 inhibitor, in patients with cholangiocarcinoma. The initial CDx is expected to be included in the detection of activating FGFR2 translocations. | Incyte | Commercialization Agreement | United States |
12-Sep-18 | Glenmark Pharmaceuticals | $0 | Glenmark's immuno-oncology pipeline currently includes three bispecific monoclonal antibody (bsAb) candidates being studied in a wide range of tumor types. GBR 1302, a HER2xCD3 bsAb and GBR 1342, a CD38XCD3 bsAb are currently in Phase 1; and GBR 1372, an EGFRxCD3 bsAb, is in preclinical development. | Mitra Biotech | Partnership | Switzerland |
12-Sep-18 | Amygdala Neurosciences | $0 | NIAAA will fund and conduct a Phase 2, human laboratory study of ANS-6637 for the treatment of alcohol use disorder. ANS-6637 is a selective ALDH2 Inhibitor that prevents pathophysiologic dopamine surge and associated craving without changes to basal dopamine. | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Clinical Collaboration | United States |
12-Sep-18 | Systech | $0 | This partnership provides a revolutionary blockchain-enabled solution for the pharmaceutical industry that leverages FarmaTrust's blockchain and AI technologies. The Systech platform will now provide a solution that goes beyond today's current compliance, traceability, anti-counterfeit and product safety solutions, enabling clients to ensure product authenticity from the manufacturing floor to a patient's hands. | FarmaTrust | Partnership | United States |
12-Sep-18 | Entitled Health on the Map | $0 | The creation of the platform is the result of Abbott's research "Patient Empowerment - Importance and Challenges", made with 960 people from all regions of Brazil, diagnosed with diabetes and hypertension. | Abbott | Launch & Partnerships | Brazil |
12-Sep-18 | Samsung Bioepis | $0 | Immunomedics' Chief Technology Officer said " The partnership will ensure that we have sufficient long-term supply of our lead antibody-drug conjugate, sacituzumab govitecan, as we advance it into additional patient segments and earlier lines of breast and urothelial cancers, as well as broadening into other cancer indications and expanding the company’s ex-US geographic footprint. | Immunomedics | Manufacturing Investment | South Korea |
12-Sep-18 | Drug Substance Manufacturing Facility | $0 | Two Russian-Chinese joint ventures will be established with the main purpose of development, manufacturing, authorization, and marketing of at least six BIOCAD products used in advanced therapy of cancer and autoimmune diseases (chronic lymphpatic leukemia, colorectal cancer, lung cancer, breast cancer, psoriasis, ankylosing spondylitis, etc.). | BIOCAD, Shanghai Pharmaceuticals Holding | Joint Venture | China |
12-Sep-18 | One Nucleus | $0 | This exclusive partnership will give One Nucleus members immediate access to thousands of CROs, CMOs, academic institutes, core labs and a global community of scientists from the world’s top R&D organizations. | Science Exchange | Collaboration | United Kingdom |
12-Sep-18 | Spotlyte Digital Hub | $0 | Beyond the editorial, Spotlyte will provide access to a team of trained specialists ready to offer real-time support and chat directly with anyone considering medical aesthetic treatments, as well as help connect readers to local licensed providers. | Allergan plc | Launch & Partnerships | Ireland |
13-Sep-18 | RadiaDyne | $0 | This transaction expands AngioDynamics’ growing Oncology business by adding RadiaDyne’s early-stage, proprietary OARtrac® real-time radiation dose monitoring platform and other market-leading oncology solutions, including the IsoLoc®/ImmobiLoc® and Alatus® balloon stabilizing technologies. | AngioDynamics | Acquisition | United States |
13-Sep-18 | Ron Keizer, PhD | $0 | Pirana is a flexible, extendible pharmacometrics workbench that provides modelers with structure, tools and a graphical user interface to facilitate the iterative processes used to create pharmacometric models and perform simulations. | Certara | Asset Acquisition | United States |
13-Sep-18 | Novacyt (Primerdesign) | $0 | Primerdesign and AMI can provide a full suite of assay development services from probe designs, through to assay optimisation, regulatory and manufacturing of SNP microarrays. The microarray based molecular diagnostic tests developed under this partnership will play a crucial role in the early diagnosis, and improve patient management. | Applied Microarrays | Partnership | France |
13-Sep-18 | Primary Care Global Business Unit; China & Emerging Markets | $0 | The company will create a new Primary Care GBU that combines the product portfolios of Sanofi's existing Diabetes and Cardiovascular (DCV) GBU with Established Products. Sanofi is creating a second new global business unit called China & Emerging Markets to be led by Olivier Charmeil, currently head of the GEM GBU. This newly-formed business will focus on growth opportunities in China which is Sanofi's second largest market after the United States. | Sanofi | Launch & Partnerships | France |
13-Sep-18 | Brain Biomarker Solutions Gothenburg AB | $0 | The objective of the research collaboration is to develop new and improved diagnostic methods for Alzheimer's disease by identifying and measuring new biomarkers in cerebrospinal fluid (CSF) and blood. Support for this hypothesis is that BioArctic's drug candidate BAN2401, which is directed towards amyloid beta protofibrils, recently in a large Phase 2b study showed significant clinical efficacy. | BioArctic AB | Research Agreement | Sweden |
13-Sep-18 | Nashville Facility | $0 | PMI Bio's protein sciences express and purify proteins and develop assays around protein targets using NMR, SPR, crystallography, ITC, (TR)FRET, and DSF to name a few. | PMI BioPharma Solutions | Manufacturing Investment | United States |
13-Sep-18 | Relief Therapeutics Holding SA | $0 | The Agreement will follow a four-year development plan including pre-clinical and clinical milestones with the goal of reducing allergenicity or even preventing food (particularly milk) allergy in humans. | Health and Happiness (H&H) Hong Kong Limited | Licensing Agreement | Switzerland |
13-Sep-18 | Jackson Laboratory, Azitra | $0 | The goal of the program is to identify bioactive compounds produced by Staphylococcus epidermidis (S. epidermidis) that can inhibit Staphylococcus aureus (S. aureus) and ultimately treat skin infections. | Department of Defense | Grants & Awards | United States |
13-Sep-18 | J. David Gladstone Institutes | $0 | Fate Therapeutics has exclusively licensed intellectual property from the J. David Gladstone Institutes that covers the generation of induced pluripotent stem cells using CRISPR-mediated gene activation. This new approach for inducing pluripotency uses CRISPR to directly target a specific location of the genome and activate endogenous gene expression, and does not rely on established methods of cellular reprogramming that require the transduction of multiple transcription factors. | Fate Therapeutics | Licensing Agreement | United States |
14-Sep-18 | Horizon Discovery Group | $0 | AstraZeneca has been evaluating Horizon’s Edit-R human whole genome crRNA library for gene knockout since late 2017, and will soon add the Company’s platform of arrayed synthetic crRNA libraries for CRISPR-mediated transcriptional activation (CRISPRa). | AstraZeneca | Collaboration | United Kingdom |
15-Sep-18 | Genecast Biotechnology | $0 | Under the partnership, Genecast will develop a cancer diagnosis system and kit specifically targeting colorectal cancer. Genecast will also develop a cancer diagnosis system and kit aimed at lung cancer based on Illumina's NGS technology. | Illumina | Partnership | China |
17-Sep-18 | Evotec AG | $0 | Through the research collaboration, the companies will develop first-in-class therapeutics through a novel approach to disrupt cell signalling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis. The collaboration combines Evotec’s cutting-edge drug discovery and pre-clinical development platforms with Almirall’s leading expertise in dermatology diseases. | Almirall, S.A. | Collaboration | Germany |
17-Sep-18 | Agawam, MA facility | $0 | Avista Pharma is investing to upgrade its Agawam, MA facility, increasing its analytical chemistry footprint while expanding its compendial and raw material testing capabilities. | Avista Pharma Solutions | Manufacturing Investment | United States |
17-Sep-18 | CSP Technologies | $0 | Activ-BlisterTM solutions is among CSP’s latest innovations, designed to actively control the internal atmosphere/headspace of individual blister cavities without the use of purging, allowing for improved stability and enhanced shelf life. | PCI Pharma Services | Collaboration | United States |
17-Sep-18 | Fate Therapeutics | $0 | Using Fate Therapeutics’ proprietary induced pluripotent stem cell (iPSC) product platform, the two CAR T-cell collaboration candidates will each be derived from a clonal master iPSC line engineered to completely eliminate endogenous TCR expression, insert a chimeric antigen receptor (CAR) into the TRAC locus and incorporate other anti-tumor functionality. | Ono Pharmaceutical | Collaboration | United States |
17-Sep-18 | Houston Methodist Research Institute | $0 | The agreement will additionally enable VGXI’s parent company, GeneOne Life Science, to leverage the design capabilities provided by Houston Methodist and the research team led by John Cooke, MD, PhD for development of new RNA vaccines and therapies. | GeneOne Life Science | Licensing Agreement | United States |
17-Sep-18 | Datavant | $0 | “Partnering with Datavant will allow PAREXEL to optimize clinical studies and real-world evidence generation using techniques that represent a true inflection point in how information will be consolidated in our industry.” | PAREXEL International Corporation | Partnership | Switzerland |
18-Sep-18 | CSP Technologies | $0 | CSP Technologies, Inc. is a world leader in moisture protection and gas scavenging solutions, and has developed several gas scavenging solutions to protect sensitive products in a variety of industries, including pharmaceuticals, drug delivery systems/medical devices, and diagnostics. | PCI Pharma Services | Collaboration | United States |
18-Sep-18 | GE Healthcare | $0 | The KUBio will be located in Guangzhou, the capital city of Guangdong Province, China, where an increasing number of biotech firms are establishing operations. BeiGene is already using GE Healthcare’s FlexFactory, its existing manufacturing plant in Suzhou, China to manufacture mAbs for clinical trials. | BeiGene | Manufacturing Investment | United States |
18-Sep-18 | Valeo Pharma | $0 | Utrogestan is indicated for luteal phase support during in-vitro fertilization (IVF) cycles. "As Utrogestan® has already been granted marketing approval by Health Canada, we are on track for a 2019 product launch," added Marc Leger, Chief Commercial Officer. | Besins Healthcare | Commercialization Agreement | Canada |
18-Sep-18 | MorphoSys AG | $0 | The objective of the alliance is to identify novel, peptide-derived therapeutics for unmet medical needs that will be valuable additions to both companies’ pipelines. | Leo Pharma | Partnership | Germany |
18-Sep-18 | Pandion Therapeutics | $0 | Just will provide Pandion with a suite of services leveraging Just’s fully integrated technology platform, J.DESIGN™. The services include cell line development, process development, and Phase 1 cGMP clinical manufacturing of a selected drug candidate to expedite Pandion’s IND filing by the end of 2019. | Just Biotherapeutics | Manufacturing Investment | United States |
18-Sep-18 | Neurimmune | $0 | Neurimmune conducts research to generate and validate human-derived monoclonal antibodies using its proprietary Reverse Translational MedicineTM (RTMTM) technology platform. Ono will be responsible for worldwide development and marketing of products derived from this collaboration. Neurimmune is eligible to receive research fees, success-based milestones on the research and development progress, as well as royalties on product sales. | Ono Pharmaceutical | Milestone Payment | Switzerland |
19-Sep-18 | Emory University School of Medicine | $0 | Celltrion will share Celltrion’s accumulated biologics development expertise with Emory University School of Medicine and the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, and provide research costs and manufacturing materials of new drug candidates for atherosclerosis. Celltrion will have a preferential right to acquire a license for inventions resulting from the agreement. | Celltrion | Seed Financing | United States |
19-Sep-18 | Tmunity Therapeutics | $0 | Under the agreement Abzena will humanize monoclonal antibodies using its Composite Human Antibody™ technology. This technology combines humanization and deimmunisation technologies to generate fully-humanized therapeutic antibodies devoid of CD4+ T cell epitopes. | Abzena | Licensing Agreement | United Kingdom |
19-Sep-18 | University of Jaén | $0 | The goal for the program is to synthesize and develop a backup clinical compound to the Company's lead product candidate, PRP. The development of the backup compound will be used for treating patients with limited therapeutic options for the treatment of solid tumors, | Propanc Biopharma | Collaboration | Spain |
19-Sep-18 | APEIRON Biologics AG | $0 | The two companies will perform drug discovery activities to optimize and develop novel small molecules addressing immune checkpoints, important gatekeepers in cancer immunity. All molecules deriving from this collaboration are proprietary to APEIRON and will strengthen APEIRON’s development pipeline. | Lead Discovery Center GmbH | Collaboration | Austria |
19-Sep-18 | Servier's Hu-PreciMED project | $0 | The project was jointly launched by Oncodesign, Servier and Intersystems. With more than 45 innovative digital and medical companies already participating, Hu-PreciMED aims to bring together all public and private players working in the field of precision medicine and connect them efficiently to medical data from patients. | Medicen Paris Region | Partnership | France |
20-Sep-18 | Academic Health Science Network | $0 | The collaborative projects will address the new national priority areas of the AHSN Network. The Greater Manchester Pharmaceutical Industry Partnership has resulted in the progression of three substantial projects in Hepatitis C, COPD and mental health in its first year of operation. | Association of the British Pharmaceutical Industry | Partnership | United Kingdom |
20-Sep-18 | Oswaldo Cruz Foundation ‘Fiocruz’ | $0 | The MoU initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region. | Emergex Vaccines Holding | Memorandum of Understanding | Brazil |
20-Sep-18 | HealthCare Partners (DaVita) | $0 | Both organizations agreed to working on an integrated delivery system and offer seamless patient care management through open lines of communication and care coordination between HealthCare Partners physicians and the KPC Health system of hospitals where they practice. | KPC Health | Partnership | United States |
20-Sep-18 | Vaximm AG | $0 | VAXIMM will collaborate with CMS, which will have the full rights in China and other Asian countries (excluding Japan) to VAXIMM's existing programs, enabling the development and commercialization of VAXIMM's pipeline of oral cancer immunotherapy candidates in the region. In parallel with the agreement, CMS will make an equity investment in VAXIMM, as part of VAXIMM's current Series B financing. | China Medical System Holdings | Commercialization Agreement | Switzerland |
20-Sep-18 | Amprologix, University of Plymouth | $0 | Amprologix aims to develop and bring to market novel antimicrobials to tackle antibiotic resistance. Amprologix will develop and commercialise the work of Professor Mathew Upton, Chief Scientific Officer at Ingenza. Epidermicin can now be produced in a GMP compliant microbe, suitable for industrial scale-up using synthetic biology methods developed by Ingenza. | Ingenza | Spin off | United Kingdom |
20-Sep-18 | Oxford Genetics | $0 | The agreement, which previously allowed Oxford Genetics to supply CRISPR modified cell lines to the US and Europe, has been extended to include the Asia Pacific (APAC) region, to support the company’s international growth following demand for the service quadrupling in 2018. | ERS Genomics | Licensing Agreement | United Kingdom |
20-Sep-18 | Tencent Holdings | $0 | The collaboration will focus on heart disease and give patients access to Tencent’s health services, including reminders to take their medication, Bertrand Bodson, Novartis’s digital strategy leader since January, said Wednesday in an interview. Medicine-tracking systems will help patients avoid counterfeit products, according to Novartis. | Novartis | Partnership | China |
20-Sep-18 | Daiichi Sankyo | $0 | Under the terms of the agreement, Daiichi Sankyo will conduct a two-part phase 1b multicenter, open-label study to determine the safety, tolerability and dose of DS-8201 in combination with KEYTRUDA and evaluate efficacy of the combination in patients with HER2 expressing advanced/metastatic breast cancer and patients with HER2 expressing or HER2 mutant advanced/metastatic NSCLC. | Merck & Co. | Clinical Collaboration | Japan |
21-Sep-18 | Tessa Therapeutics | $0 | The goal of the partnership is to accelerate the preclinical development of CAR-expressing Virus-Specific T cells (VSTs) leading to clinical testing in the near future. | St. Jude Children’s Research Hospital | Collaboration | Singapore |
21-Sep-18 | Invicro (Konica Minolta Company) | $0 | Enigma will hold the various commercial and distribution licenses and be responsible for development and global tracer access whereas Invicro will focus on informatics solutions for better interpretation of this cutting-edge biomarker technology. Use of this biomarker platform is an additional approach to supporting development of disease-modifying therapies for neurodegenerative disorders. | Enigma Biomedical | Memorandum of Understanding | United States |
21-Sep-18 | CareNet, Inc., Medical Incubator Japan K.K, Vital KSK Holdings, Inc. and Astem Inc. | $0 | In the SB623 development program targeting chronic motor deficit from ischemic stroke in the US, phase 2b clinical trials are currently underway. SanBio is currently preparing for the development of SB623 with an aim of launching the product targeting chronic motor deficit from ischemic stroke in Japan ahead of anywhere else in the world. | SanBio Group | Joint Venture | Japan |
21-Sep-18 | SignalPath Research Consortium | $0 | The SignalPath Research Consortium is a rapidly growing network of sophisticated clinical trials sites connected via a technical foundation. New York Cancer and Blood Specialists is a leading example; this innovative community-based oncology practice is deploying SignalPath's novel operational, financial, oversight and study start-up software to support the conduct of research at their sites. | SignalPath | Partnership | United States |
24-Sep-18 | MEBIAS Discovery | $0 | MEBIAS Discovery will use the NIDA funds to complete preclinical pharmacological and pharmaceutical profiling. Once milestones outlined in the grant are met, MEBIAS is eligible for continued funding from NIDA to progress the lead compound into Phase 1 clinical studies. | National Institute of Drug Abuse (NIDA) | Grants & Awards | United States |
25-Sep-18 | NextWave Pharmaceuticals | $0 | The acquisition further expands Tris' portfolio of products for the treatment of patients with ADHD. The agreement includes the acquisition of Quillivant XR, the first and only marketed extended-release oral liquid methylphenidate, and QuilliChew ER, the first and only extended-release methylphenidate chewable tablet, both of which are central nervous system (CNS) stimulants approved for the treatment of ADHD. | Tris Pharma | Acquisition | United States |
25-Sep-18 | Santen Pharmaceutical | $0 | PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against multiple ophthalmic disease targets of interest selected by Santen, and to optimize hit peptides into therapeutic peptides products for such indications. | PeptiDream | Development Agreement | Japan |
25-Sep-18 | Enesi Pharma | $0 | Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, announces it has entered a Cooperative Research and Development Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR), a United States Department of Defense Laboratory, regarding Shigella vaccine development. | Walter Reed Army Institute of Research (WRAIR) | Research Agreement | United Kingdom |
25-Sep-18 | Astellas Pharma | $0 | The leading development product using i-DPS technology, APS001F, a recombinant Bifidobacterium to express Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is under a phase 1 clinical trial in the U.S. | Anaeropharma Science | Collaboration | Japan |
26-Sep-18 | I-Mab Biopharma | $0 | Through the extension of existing collaboration agreement, I-Mab Biopharma licensed proprietary WuXiBody™ Platform to develop three bispecific antibodies. WuXi Biologics will also be the exclusive partner to develop and manufacture these bispecifics. | WuXi AppTec | Licensing Agreement | China |
26-Sep-18 | Agilent Technologies | $0 | Under the terms of the agreement, Agilent will manufacture and supply Cancer Genetics with the custom probe for use in the Company’s FISH-based HPV-Associated Cancer Test (FHACT®). Additionally, Cancer Genetics’ plans to outlicense the probes through domestic and international distribution channels, with such licensors having the ability to purchase probes manufactured by Agilent. | Cancer Genetics | Supply Agreement | United States |
26-Sep-18 | Fullerton Healthcare Corporation Ltd. | $0 | The Partnership to fully integrate online and offline healthcare services in the region by combining the complementary strengths of the two partners. The new HMO platform will provide WeDoctor's approximately 160 million registered users in China with access to Fullerton Health's extensive network of over 500 healthcare facilities and over 8,000 network healthcare providers. | We Doctor Holdings Limited | Partnership | Hong Kong |
26-Sep-18 | Brill Pharma Laboratories | $0 | The formulation, marketed in the United States as Acuicyn™ Eyelid and Eyelash Hygiene solution, is a safe and efficacious method to keep areas around the eye and eyelids/eyelashes clean. The Spanish/Portuguese formulation, to be branded as Ocudox™, will be marketed as a pre-surgical antimicrobial for use in eye surgery, intraoculus injections and any eye manipulation that requires sterile conditions. | Sonoma Pharmaceuticals | Licensing Agreement | Spain |
26-Sep-18 | ACT Genomics | $0 | ACTG's flagship NGS panel, ACTOnco®+, investigates 440 cancer-related genes by incorporating a signaling pathway design. ACTOnco®+ provides optimal treatment suggestion to clinicians, including targeted therapies, hormonal therapies, chemotherapies, and immunotherapies, for all solid tumor types. | CLSA | Equity Investment | Japan |
26-Sep-18 | Urgo Medical North America | $0 | The newly formed entity created today, September 26th, takes the name Urgo Medical North America. Its headquarters will remain in Fort Worth, Texas, under the leadership of the former management team. With a yearly turnover of approximately $20M, Urgo Medical North America will operate in the USA and Canada with ambitions to become a global leading player in the world's largest advanced wound care market of North America. | URGO Medical, SteadMed Medical | Merger Agreement | United States |
27-Sep-18 | Global Antibiotic Research & Development Partnership | $0 | Agreement focuses on further enhancing generic antibiotics and increasing access for children in low- and middle-income countries (LMICs); Development will target heat-stable, pediatric formulations such as dispersible tablets against bacterial infections – a leading cause of death in under-fives; and Partnership will leverage knowledge and share expertise between Sandoz, the Novartis generics division, and GARDP. | Novartis | Partnership | Switzerland |
27-Sep-18 | Oricula Therapeutics | $0 | ORC-13361 is a new chemical entity (NCE) currently being investigated for the prevention of ototoxicity which results from treatment with aminoglycoside antibiotics. A Phase I clinical trial to evaluate safety, tolerability and pharmacokinetics of ORC-13361 is currently ongoing. | Decibel Therapeutics | Licensing Agreement | United States |
27-Sep-18 | Mikart | $0 | Mikart’s broad range of capabilities includes formulation development, clinical trial supplies, regulatory filing support, analytical services, clinical manufacturing, commercial manufacturing, and packaging while emphasizing a quality-first approach and best-in-class manufacturing and regulatory capabilities. . | Nautic Partners | Acquisition | United States |
27-Sep-18 | UPMC Health Plan | $0 | The goal of the contract is to align the incentives of the manufacturer, Boehringer Ingelheim, with the UPMC Health Plan, and will link reimbursement of the drug to costs associated with clinical outcomes in the real-world population. In a first-of-its-kind contract, reimbursement for the medication will be linked to total costs of care for all people with diabetes treated. | Boehringer Ingelheim | Contract Agreement | United States |
27-Sep-18 | Aetna's Medicare Part D business unit | $0 | Aetna announced an agreement to divest all of Aetna’s standalone Medicare Part D business to a subsidiary of WellCare Health Plans, Inc. (WellCare). The divestiture is subject to the completion of CVS Health’s proposed acquisition of Aetna, regulatory approvals and other customary closing conditions. | WellCare Health Plans | Divestment | United States |
27-Sep-18 | Pharmacia Corporation | $0 | This protease platform is a novel combination of enzymes first isolated and developed by Pharmacia Corporation in Sweden. It has been tested in over 551 patients and has demonstrated safety and efficacy for multiple indications including wound healing, thrombogenic disease and anti-viral applications. | Marizyme | Asset Acquisition | Sweden |
27-Sep-18 | Dova Pharmaceuticals | $0 | As part of the co-promotion arrangement, Salix intends to deploy approximately 100 sales specialists who will promote DOPTELET to gastroenterology healthcare professionals. DOPTELET is designed to mimic the effects of TPO, the primary regulator of normal platelet production. | Salix Pharmaceuticals | Development Agreement | United States |
28-Sep-18 | Luitpold Pharmaceuticals (Daiichi Sankyo Company) | $0 | LYNCH Biologics will market the GEM 21S product together with a suite of complementary regenerative biologic products direct to oral surgeons, periodontists and implant dentists through its cranio-maxillofacial division. | LYNCH Biologics | Marketing Agreement | Japan |
04-Oct-18 | Arrowhead Pharmaceuticals | $3,700 | Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three additional RNA interference (RNAi) therapeutics against new targets to be selected by Janssen. The transactions have a combined potential value of over $3.7 billion for Arrowhead. | Johnson & Johnson | Licensing Agreement | United States |
18-Oct-18 | Endocyte | $2,100 | Acquisition would add 177Lu-PSMA-617, a potential first-in-class radioligand therapy in Phase III development for metastatic castration-resistant prostate cancer, 177Lu-PSMA-617 targets the prostate-specific membrane antigen (PSMA), present in the majority of patients with mCRPC, and has shown promising Phase II data. | Novartis | Acquisition | United States |
31-Oct-18 | Tango Therapeutics | $1,700 | Tango Therapeutics will be responsible for target discovery and validation under the multi-year partnership. Gilead will hold the option to claim global rights for up to five targets resulting from Tango’s functional genomics-based discovery platform. | Gilead Sciences | Collaboration | United States |
05-Oct-18 | Publicis Media | $1,500 | GSK Consumer Healthcare VP and Global Head of Media Scott Grenz commented: “We ran a very thorough and competitive pitch process with strong presentations from all companies, but ultimately Publicis was the best fit for us. We’re excited about the new partnership and the potential of the platform GSK model as we continue to progress our marketing transformation program.” | GlaxoSmithKline | Contract Agreement | France |
15-Oct-18 | SQZ Biotechnologies | $1,000 | The expanded partnership furthers the synergistic combination of SQZ's expertise in cell therapy with Roche's cancer immunotherapy expertise. SQZ and Roche will jointly develop and commercialize certain products based on antigen presenting cells (APCs) created by the SQZ platform for the treatment of oncology indications. | Roche | Expansion | United States |
30-Oct-18 | AstraZeneca | $922 | Nexium, a proton pump inhibitor developed by AstraZeneca, helps to reduce the amount of acid produced by the stomach in patients with gastrointestinal reflux conditions and ulcers. | Grünenthal | Divestment | United Kingdom |
10-Oct-18 | Ionis Pharmaceuticals | $760 | This new agreement builds upon our productive relationship with Roche on IONIS-HTTRx (RG6042), an antisense drug for the treatment of people with Huntington's disease," said Brett P. Monia, chief operating officer at Ionis. "Our antisense technology is the first to demonstrate robust, dose-dependent and sustained reduction of FB in a clinical study. | Roche | Collaboration | United States |
01-Oct-18 | Dragonfly Therapeutics | $695 | The collaboration grants Merck the option to license exclusive worldwide intellectual property rights to products developed using Dragonfly's TriNKET™ technology platform for a number of solid-tumor programs, with the potential to earn Dragonfly up to $695 million in up front and milestone payments per program as well as royalties on sales of approved products. | Merck & Co. | Licensing Agreement | United States |
24-Oct-18 | Kraft Heinz Co. | $625 | “The sale of this niche business fits into our overall global growth strategy and our focus on investing in and growing brands within our core categories,” said Bernardo Hees, Chief Executive Officer of Kraft Heinz. | Zydus Cadila | Asset Acquisition | United States |
29-Oct-18 | Dicerna Pharmaceuticals | $550 | The companies will utilize Dicerna's proprietary GalXC™ RNAi technology platform to progress new drug targets, along with collaborating to move beyond the current technical paradigm in order to generate next-generation oligonucleotide therapeutic agents. | Eli Lilly and Company | Collaboration | United States |
23-Oct-18 | Zymeworks | $480 | LEO Pharma will have exclusive rights to further develop and commercialize two bispecific candidates in dermatology indications, while Zymeworks retains rights to develop antibodies in all other therapeutic areas. | Leo Pharma | Licensing Agreement | Canada |
01-Oct-18 | Forbion IV Fund | $410 | Forbion IV will target substantial initial stakes, looking to take lead positions and work alongside entrepreneurial management teams to deliver exceptional financial and societal returns. Forbion has already had considerable success with this strategy via its first three funds, with the EUR 183 million Forbion III already delivering 4 exits including the sale of Rigontec to MSD and the highly successful IPO of Replimune on NASDAQ in July 2018. | Undisclosed | Investment | The Netherlands |
23-Oct-18 | Cerevel Therapeutics | $350 | Pfizer is contributing a portfolio of pre-commercial neuroscience assets to Cerevel, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. | Pfizer Inc. | Launch & Partnerships | United States |
05-Oct-18 | GW Pharmaceuticals | $345 | GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase I and Phase II trials for epilepsy, glioblastoma, autism spectrum disorder and schizophrenia. | Goldman Sachs | IPO | United Kingdom |
10-Oct-18 | Allogene Therapeutics | $324 | Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T(AlloCAR T™) therapies for cancer, today announced the pricing of its initial public offering of 18,000,000 shares of its common stock at a price to the public of $18.00 per share. | Goldman Sachs | IPO | United States |
31-Oct-18 | Center for Multimodality Clinical Trial Materials, Center for Active Ingredient for Biopharmaceuticals | $257 | Astellas currently has multiple development programs utilizing these approaches at the clinical and pre-clinical stage. Therefore, with a view to the future progress of development and commercialization of these programs, Astellas has decided to construct R&D facilities in Japan and overseas for the manufacture of clinical trial materials and the initial commercial production of these products. | Astellas Pharma | Manufacturing Investment | Japan |
16-Oct-18 | Taiho Ventures | $250 | The increase in the investment pool illustrates Taiho Ventures' strong commitment to its continuous support of innovative biotech start-ups pursuing cutting-edge drug discovery activities based on state-of-the-art science. Taiho Pharmaceutical also aims to accelerate its open innovation through these investment efforts. | Taiho Pharmaceutical Co., Ltd. | Investment | Japan |
24-Oct-18 | Dicerna Pharmaceuticals | $247 | “This collaboration provides the opportunity to continue building on our more than two decades of complement expertise using Dicerna’s proprietary GalXC RNAi technology platform, which provides a potentially promising new way of inhibiting the uncontrolled complement activation that we know plays a significant role in many devastating diseases.” | Alexion Pharmaceuticals | Collaboration | United States |
23-Oct-18 | Innate Pharma | $245 | AZ will obtain full oncology rights to the first-in-class humanised anti-NKG2A antibody, monalizumab, expanding its partnership with Innate. AZ also gains option rights to IPH5201, an antibody targeting CD39, as well as four preclinical molecules from Innate’s pipeline. Innate is licensing the US and EU commercial rights to recently FDA-approved Lumoxiti (moxetumomab pasudotox) for hairy cell leukaemia. | AstraZeneca | Equity Stake | France |
24-Oct-18 | Galapagos NV | $200 | AbbVie's research program aims to develop a best-in-class, triple-combination therapy for patients living with cystic fibrosis. | AbbVie | Collaboration | Switzerland |
30-Oct-18 | Orchard Therapeutics | $200 | The biotech that specializes in ex vivo gene therapies sold 14.3 million shares to raise $200.2 million. | J.P. Morgan | IPO | United Kingdom |
02-Oct-18 | GO Therapeutics | $195 | "GO's glycoprotein targeting platform opens an exciting class of tumor-specific antigens that can help widen the therapeutic window for cancer therapies such as T-cell bispecific antibodies, CAR-T and ADCs (Antibody Drug Conjugates). Preclinical data show GO’s approach can provide superior specificity in targeting solid tumors over normal tissue, and demonstrate clean in-vivo toxicity profiles in the context of potent immunotherapies." | Roche | Licensing Agreement | United States |
29-Oct-18 | Rigel Pharmaceuticals | $180 | Kissei gains exclusive rights to fostamatinib in all current and potential indications in Japan and other Asian countries. Rigel to receive product transfer price payments in the mid to upper twenty percent range based on tiered net sales for exclusive supply of TAVALISSE | Kissei Pharmaceutical | Licensing Agreement | United States |
11-Oct-18 | Verastem Oncology | $145 | COPIKTRA also received accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. | Lazard Frères & Co. LLC | Registered Direct Offering | United States |
19-Oct-18 | SI-BONE | $140 | SI-BONE is a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System® | Undisclosed | IPO | United States |
30-Oct-18 | Axonics Modulation Technologies, Inc. | $138 | Axonics has developed an innovative rechargeable SNM system for the treatment of patients with OAB, FI, and UR. | BofA Merrill Lynch | IPO | United States |
15-Oct-18 | Lysogene | $128 | Lysogene intends to apply the funds raised for general corporate purposes including the further development of LYS-GM101 for GM1 gangliosidosis. | Sarepta Therapeutics | Licensing Agreement | France |
22-Oct-18 | China Everbright Limited | $115 | China Everbright Limited has held its first close for its Everbright Medical Healthcare Fund III at CNY 800 million ($115.2 million, €100.6 million). The fund will target investments in biotechnology and healthcare services in China. | Undisclosed | Financing | Hong Kong |
02-Oct-18 | Kala Pharmaceuticals | $110 | “We expect this financing to support Kala’s efforts to achieve significant milestones, including the NDA filing for KPI-121 0.25% for dry eye disease by the end of 2018, the launch of INVELTYS in early 2019, and topline results for the STRIDE-3 trial of KPI-121 0.25% expected in Q4 2019.” | Athyrium Capital Management, LP | Financing | United States |
23-Oct-18 | Synthego | $110 | The new funds further Synthego's mission to accelerate CRISPR capabilities for rapid and precise genome engineering in applications such as cell and gene therapies. | Founders Fund | Series C Financing | United States |
22-Oct-18 | Aclaris Therapeutics | $107 | Aclaris' focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses, common warts, alopecia areata, and vitiligo. | Leerink Partners | IPO | United States |
18-Oct-18 | Infection Research | $100 | The Infection Research Initiative is a comprehensive approach to improve outcomes associated with infections through enhanced detection, diagnosis, prevention, and treatment. | Cystic Fibrosis Foundation | Research Agreement | United States |
18-Oct-18 | Morphic Therapeutic | $100 | Both the companies have entered into a research and development collaboration designed to advance a number of Morphic's oral integrin therapeutics for fibrosis-related indications. | AbbVie | Collaboration | United States |
15-Oct-18 | Berkeley Lights, Inc. | $95 | Berkeley Lights’ Beacon® digital cell biology platform is becoming a proven asset for the world’s top biopharmaceutical companies working in large molecule drug discovery and development. | Sequoia China | Investment | United States |
03-Oct-18 | Genomatica | $90 | "Genomatica has delivered high-volume bio-based chemicals to market at costs competitive with petrochemical production, not just once but multiple times," said Jason Kelly, CEO of Ginkgo Bioworks. | Casdin Capital | Investment | United States |
23-Oct-18 | Stoke Therapeutics | $90 | Stoke has identified thousands of genes that could be addressed by its proprietary TANGO technology, which targets non-productive RNA splicing to increase gene expression and address the root cause of monogenic diseases caused by loss or reduction of gene function. | RTW Investments | Series B Financing | United States |
03-Oct-18 | Kodiak Sciences | $90 | Kodiak Sciences Inc. is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. | Morgan Stanley | IPO | United States |
25-Oct-18 | Vaccines Launch Facility | $82 | The new facility in Leiden, the Netherlands has been built by Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson. | Johnson & Johnson | Manufacturing Investment | The Netherlands |
23-Oct-18 | LogicBio Therapeutics | $81 | GeneRide™ enables the site-specific integration of a therapeutic transgene in a nuclease-free and promotorless approach by relying on the native process of homologous recombination to drive lifelong expression. | Arix Biosciences | IPO | United States |
19-Oct-18 | TP Therapeutics | $80 | TP Therapeutics will use the proceeds to advance its lead product candidate, Repotrectinib (TPX-0005), into a Phase 2 potential registration study in early 2019 for ROS1-positive non-small cell lung cancer (NSCLC) and NTRK-positive solid tumors. | Foresite Capital, venBio Partners | Financing | United States |
30-Oct-18 | Terns Pharmaceuticals | $80 | Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs to treat NASH and cancer, today announced the closing of an $80 million Series B financing. | Vivo Capital | Series B Financing | China |
25-Oct-18 | Milestone Pharmaceuticals | $80 | Etripamil is a new, potent, short-acting, investigational calcium channel blocker being developed as a rapid-onset nasal spray that can be self-administered by the patient to potentially terminate PSVT episodes whenever and wherever they may occur. | Venrock Healthcare Partners | Financing | Canada |
15-Oct-18 | NGM Biopharmaceuticals | $75 | Its lead drug, a once-daily injectable called NGM-282, is an engineered variant of the human hormone FGF19 and will enter a mid-stage trial in first-quarter 2019. | Undisclosed | IPO | United States |
23-Oct-18 | Proteostasis Therapeutics | $74 | Proteostasis intends to use the net proceeds from the proposed offering to fund critical path activities for PTI-428 as an add on to standard of care and continue the advancement of PTI-proprietary combination therapies, for drug substance (API) for Phase 3 for PTI-428, PTI-801 and PTI-808. | Leerink Partners | IPO | United States |
19-Oct-18 | Castle Creek Pharma | $72 | Castle Creek plans to use this additional funding to support the late-stage development of an investigational drug, diacerein ointment (CCP-020). | Fidelity Management | Investment | United States |
22-Oct-18 | Montrose Production Facility | $70 | Active pharmaceutical ingredients (APIs) for use in GSK’s Ellipta respiratory inhalers will be produced in the building which is the second multi-million investment in the Montrose site over the last two years. | GlaxoSmithKline | Manufacturing Investment | Scotland |
18-Oct-18 | Oxford Nanopore | $66 | The investment in Oxford Nanopore aligns with Amgen's strategic focus on using human genetics to deliver new medicines to patients. Nanopore technology is uniquely scalable. MinIONTM, the only pocket-sized sequencer, can be used to sequence in any location. In addition, Oxford Nanopore has developed benchtop, on-demand, high-throughput devices such as PromethIONTM. | Amgen | Equity Investment | United Kingdom |
12-Oct-18 | Equillium | $65 | Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. | Jefferies LLC | IPO | United States |
22-Oct-18 | University of North Carolina at Chapel Hill | $65 | Pinnacle Hill will focus on drug research projects that are approved and directed by a joint steering committee comprised of members from UNC-Chapel Hill and Deerfield leadership teams. Each selected project has the potential to receive funding to support investigational new drug enabling studies. | Deerfield Management | Partnership | United States |
15-Oct-18 | Allergan | $65 | The acquisition includes an exclusive license to certain intellectual property for RHOFADE, which is approved for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults. | Aclaris Therapeutics | Asset Acquisition | Ireland |
18-Oct-18 | Merck Group | $63 | Luminex will own the flow cytometry platforms Amnis® and Guava® and the associated reagents under those brands. Merck continues to actively manage its comprehensive portfolio by tapping into innovation and placing it in the best hands to continuously drive value for customers. | Luminex Corporation | Acquisition | Germany |
03-Oct-18 | Kala Pharmaceuticals | $62 | Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary MPP technology which the company has applied to a corticosteroid, LE, designed for ocular applications, resulting in recently approved INVELTYS for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease. | BofA Merrill Lynch | IPO | United States |
17-Oct-18 | Osmotica Pharmaceuticals | $61 | Osmotica has a late-stage development pipeline highlighted by two NDA candidates in Phase III clinical trials: Arbaclofen ER (extended?release) tablets for muscle spasticity in multiple sclerosis patients and RVL?1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for the treatment of blepharoptosis, or droopy eyelid. | Jefferies LLC | IPO | United States |
25-Oct-18 | 89Bio | $60 | The funding will be used to advance the company's pipeline of biologic and small molecule drug candidates acquired from Teva. 89Bio's lead candidate for the treatment of NASH is BIO89-100 (formerly TEV-47948). Currently in Phase 1, BIO89-100 is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue that was developed using a proprietary glycopegylation technology to prolong the half-life and optimize the biological activity of native FGF21. | OrbiMed | Series A Financing | Israel |
01-Oct-18 | VelosBio | $58 | Arix has built a diverse oncology portfolio that covers a range of different therapeutic modalities including CAR-T, DNA damage response / synthetic lethality, bi-specific antibodies, and targeted viruses. Arix's position in oncology is further strengthened by the investment into VelosBio, extending into ADCs which are meant to only target cancer cells so that healthy cells are less affected. | Arix Biosciences | Series A Financing | United States |
10-Oct-18 | Gotham Therapeutics | $54 | Versant created and seeded Gotham based upon the seminal discoveries of co-founder Samie Jaffrey, M.D. Ph.D. in a field within RNA metabolism called epitranscriptomics. The Series A proceeds will allow Gotham to establish clinical proof of concept and to invest broadly in a pipeline of preclinical candidates that have potential to treat diseases intractable to classical approaches. | Celgene Corporation | Series B Financing | United States |
04-Oct-18 | Accera (Cerecin) | $50 | "Rebranding as Cerecin marks the start of a new chapter and the Company's continued commitment to managing some of the world's most devastating brain diseases. The new name, is a combination of the words cerebrum, the Latin word for brain, and medicine, affirming the company's commitment to brain health," explains Charles Stacey, President and CEO of Cerecin. | Wilmar Ventures Pte. Ltd. (Wilmar International Limited) | Investment | Singapore |
01-Oct-18 | Owlstone Medical | $50 | The funds have been raised to expand commercial opportunities in precision medicine including through the launch of targeted Breath Biopsy kits, and to enable further investment in the technology platform to support the development of additional high value applications. | Horizons Ventures | Investment | United Kingdom |
01-Oct-18 | Pharmeasy | $50 | Pharmeasy provides a technology platform to offer various healthcare services like medicine delivery, medicine refills & reminders, along with teleconsultation. | Eight Roads Ventures India | Series C Financing | India |
22-Oct-18 | Therapix Biosciences Ltd. | $48 | The Transaction is structured at a fixed price of $48M USD ($62.4M CAD), representing approximately 130 million class B subordinate shares of FSD Pharma and nearly 10% of the Company today. | FSD Pharma | Acquisition | Israel |
24-Oct-18 | XtalPi Inc | $46 | Building on XtalPi’s current momentum and success, the new financing will fuel the development of AI applications for critical steps of drug research and development (R&D), with an immediate focus on algorithmic tools that expand the searchable chemical space in drug discovery. | China Life Healthcare Fund | Series B Financing | United States |
17-Oct-18 | PhaseBio Pharmaceuticals | $46 | PhaseBio's lead product candidate is PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and our second product candidate is PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension. PB1046 utilizes our proprietary elastin-like polypeptide (ELP) technology, which also serves as the engine for our preclinical pipeline. | Needham & Company | IPO | United States |
01-Oct-18 | Verastem Oncology | $45 | COPIKTRA also received accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. | CSPC Pharmaceutical Group Limited | Commercialization Agreement | United States |
15-Oct-18 | Zhejiang Huahai Pharmaceuticals | $43 | A wholly-owned domestic subsidiary that got some of the money is responsible for drug research and development, manufacturing and the import and export of materials and technologies. | Linhai Economic Development Zone | Grants & Awards | China |
26-Oct-18 | Gamida Cell | $40 | Gamida Cell is a clinical stage biopharmaceutical company leveraging its proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The company is leveraging its nicotinamide-, or NAM-, based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. | Undisclosed | IPO | United States |
22-Oct-18 | Qpex Biopharma | $33 | Qpex is focused on developing new antibiotics to combat the growing threat of global antimicrobial resistance. Qpex acquired the preclinical-stage anti-infective assets of The Medicines Company (MDCO), including proprietary broad spectrum beta-lactamase inhibitor technology. | New Enterprise Associates | Series A Financing | United States |
26-Oct-18 | Undisclosed | $32 | Halobetasol foam is a potent corticosteroid used to treat plaque psoriasis. This product received US Food and Drug Administration approval in May 2018 and Mayne Pharma is planning for the commercial launch of this product in early 2019. | Mayne Pharma | Asset Acquisition | |
01-Oct-18 | Modis Therapeutics | $30 | Modis is advancing its lead experimental therapy, MT1621, as a treatment for thymidine kinase 2 deficiency (TK2d), a rare, genetically defined mitochondrial DNA (mtDNA) depletion disorder. | F-Prime Capital Partners | Series A Financing | United States |
09-Oct-18 | Glympse Bio | $22 | Glympse’s activity sensors are precisely bioengineered to be transported to the site of disease in patients, directly interrogate the biological activity of the diseased tissue, and emit a signal which can be detected noninvasively from the recipient’s urine. | LS Polaris Innovation Fund | Series A Financing | United States |
25-Oct-18 | Xgene Pharma | $20 | Xgene Pharma develops small-molecule drugs for chronic pain, infectious diseases and tumors. Xgene's lead product, a combination of naproxen and pregabalin (Lyrica®) for chronic pain, is in Phase II trials in the US. | Ping An Ventures | Series B Financing | China |
10-Oct-18 | Cardialen | $17 | The Cardialen UPT therapy delivers a sequence of low-energy electrical pulses designed to restore abnormally rapid heart rates to a normal rhythm. | RiverVest Venture Partners | Series B Financing | United States |
31-Oct-18 | Chembio Diagnostics | $16 | Chembio intends to use the net proceeds from the offering to fund its proposed acquisition of opTricon GmbH announced on October 22nd, to support its business growth strategy, including broadening U.S. manufacturing automation and expanding and improving facilities. | Craig-Hallum Capital Group | IPO | United States |
16-Oct-18 | Acticor Biotech | $15 | ACT017 is a humanised Antibody Fragment (Fab) which inhibits the action of platelet glycoprotein VI, a novel target of major interest. Evidence of antithrombotic efficacy of ACT017 have been established both ex vivo and in vivo. | Newton BioCapital | Series B Financing | France |
16-Oct-18 | BioMarin Pharmaceutical | $15 | Medivation, acquired by Pfizer, is responsible for all research, development, regulatory and commercialization activities for all indications globally. In June of this year, the European Medicines Agency accepted the Marketing Application for talazoparib. | Pfizer Inc. | Milestone Payment | United States |
16-Oct-18 | Garnet Valley Facility | $15 | The Garnet Valley site will focus on developing small molecule oral drug products, supporting development programs from the preclinical stage through to clinical proof-of-concept. | Quotient Sciences | Manufacturing Investment | United States |
01-Oct-18 | Asterias Biotherapeutics | $15 | The site will support Novo Nordisk's increased commitment to develop stem-cell based therapies within type 1 diabetes and other serious chronic diseases. | Novo Nordisk | Licensing Agreement | United States |
10-Oct-18 | RWDC Industries | $13 | Series A2 funds will primarily be used to expand RWDC's PHA (polyhydroxyalkanoate) production capacity in Athens, Georgia (USA), to 2,000 tonnes per year, making it among the world's largest PHA producers by early 2019. | Vickers Venture Partners | Series A Financing | Singapore |
16-Oct-18 | Chembio Diagnostics | $11 | Chembio’s DPP® HIV 1/2 Assay detects antibodies to HIV-1 and HIV-2 in oral fluid, fingerstick whole blood, venous whole blood, serum or plasma samples, and it provides results in as little as 15 minutes. | Bio-Manguinhos | IPO | United States |
03-Oct-18 | Bayshore Pharmaceuticals | $10 | The acquisition of the majority stake in Bayshore by Ipca Labs’ wholly-owned subsidiary, will enable the company to commercialise its registered generics drug products in the US market through Bayshore. The Company will be able to utilise Bayshore's platform for commercialisation of its registered generics drug products in the United States of America. | Ipca Laboratories | Equity Stake | United States |
10-Oct-18 | NanoView Biosciences | $10 | The company’s proprietary product, the ExoView™ system, was designed to fully characterize exosomes and other extracellular vesicles for use in research and in the implementation of precision medicine | Sands Capital Ventures | Series B Financing | United States |
22-Oct-18 | Glycotest (NetScientific plc) | $10 | NetScientific’s controlling interest will be 51.5% of Glycotest Inc. calculated on a fully-diluted basis following the closing of the Series A Financing. The proceeds will be used to bring Glycotest Inc.’s diagnostic HCC Panel and advance pipeline assets in liver fibrosis and cholangiocarcinoma (bile duct cancer). | Shanghai Fosun Pharmaceutical Group | Series A Financing | United Kingdom |
19-Oct-18 | Princeton University | $10 | The agreement provides $10 million over the next five-years to support healthcare and drug discovery-related technology projects. | New Jersey Health Foundation | Investment | United States |
02-Oct-18 | HiFiBiO Therapeutics | $10 | Kite and HiFiBiO intend to adapt HiFiBiO’s proprietary single cell technology platform to create a high throughput approach that will potentially allow for the in-depth screening of TCR repertoires from patient samples to identify shared antigen and neoantigen TCRs for use in adoptive cellular therapies. | Gilead Sciences | Licensing Agreement | Hong Kong |
04-Oct-18 | Catalent RP Scherer Softgel | $7 | The first phase of investment, completed in August 2018, saw the expansion and upgrade of the facility’s integrated packaging capabilities, and the commissioning of the first of five new softgel encapsulation lines. It is expected that these four new lines will be fully operational by January 2019. | Catalent Pharma Solutions | Manufacturing Investment | Italy |
31-Oct-18 | Inception-4 | $6 | Through this acquisition, Ophthotech gains worldwide development and commercialization rights to Inception 4’s small molecule inhibitors of HtrA1 (high temperature requirement A serine peptidase 1 protein). | Ophthotech Corporation | Acquisition | United States |
18-Oct-18 | Weconnect | $6 | The WEconnect app supports patients in their first year of recovery after substance abuse treatment, a crucial time in the rehabilitation process. | ServiceNow, Buckingham Capital | Series A Financing | United States |
11-Oct-18 | Evotec AG | $6 | The collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging Evotec’s unique human induced pluripotent stem cell (“iPSC”) technology platform, which is one of the largest and most sophisticated platforms in the industry. | Celgene Corporation | Collaboration | Germany |
23-Oct-18 | opTricon GmbH | $6 | “The acquisition of opTricon will enable us to further advance our innovative technology development.” | Chembio Diagnostics | Acquisition | Germany |
24-Oct-18 | Wize Pharma | $4 | Wize Pharma is currently conducting a Phase II trial of LO2A for patients with CCH and a Phase IV study for LO2A for DES in patients with Sjögren's. LO2A is currently registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES and CCH and in the Netherlands for the treatment of DES and Sjögren's. | Fordham Financial Management | Private Placement | Israel |
23-Oct-18 | Cell Care Therapeutics | $4 | This round of funding will be used to develop Cell Care’s manufacturing platform and to advance its lead preclinical-stage drug candidate for major eye diseases, including diabetic retinopathy (DR) and neovascular age-related macular degeneration (wet AMD | Syndicate of Individual investors | Seed Financing | United States |
22-Oct-18 | Raremark | $4 | Raremark provides biopharmaceutical companies with access to anonymized and aggregated patient data, helping to reduce the time and cost of clinical development. | Oltre Venture | Investment | United Kingdom |
09-Oct-18 | Nash Pharmaceuticals | $4 | “Nash Pharma has an exciting story to tell about its technology and its value driven and risk reduced approach to drug development through drug re-purposing.” | Breathtec Biomedical | Acquisition | Canada |
03-Oct-18 | University College London | $4 | The investment in the UCL Biochemical Engineering's industrial research collaboration program with Pall Biotech is valued at £2.7M ($3.5M) and will engage in multi-level interactions to enable knowledge transfer and address critical industry challenges. | Pall Biotech | Partnership | United States |
11-Oct-18 | OmniComm Systems | $4 | The agreement will yield multiple benefits for both companies and provide the clinical research center with the opportunity to further enhance the efficiency of its clinical trials. OmniComm was selected for the partnership based on its EDC solutions, which offer inherent flexibility and broad capabilities to support clinical studies across all phases of clinical development. | Major Cancer Research Center | Partnership | United States |
09-Oct-18 | Astrotech Corporation | $3 | Astrotech (NASDAQ: ASTC) is a science and technology development and commercialization company that launches, manages, and builds scalable companies based on innovative technology | Thomas B. Pickens III | Private Placement | United States |
29-Oct-18 | Argonaut Therapeutics | $3 | The Korean drug maker will acquire 25 percent stake in the company to become the second-largest shareholder and will have management rights in the Oxford-based firm, Argonaut Therapeutics is a startup biotech founded at the University of Oxford in 2016. Oxford Sciences Innovationis its largest shareholder. | JW Pharmaceutical | Equity Stake | United Kingdom |
29-Oct-18 | Ionis Pharmaceuticals | $3 | QR-1123 is a first-in-class investigational oligonucleotide (gapmer) that was developed by Ionis Pharmaceuticals using Ionis’ proprietary antisense technology for the treatment of adRP due to the P23H mutation in the RHO gene. | ProQR Therapeutics | Licensing Agreement | United States |
08-Oct-18 | Milan Facility | $2 | The 1,350 sq. m (approx. 14,500 sq. ft) facility manufactures intermediates and APIs under GMP conditions. Cambrex currently manufactures over 70 generic APIs which are produced to cGMP standards. The Milan site comprises seven production departments, supported by a pilot plant, kilo-scale plant and development and analytical laboratories. | Cambrex Corporation | Manufacturing Investment | Italy |
17-Oct-18 | Oligomerix | $2 | Given that the development of tau pathology correlates well with cognitive impairment, we believe that targeting pathological tau aggregates will be effective using preventive or therapeutic treatment approaches. Dr. Davies, a renowned leader in tau biology, will independently perform these blinded studies. | National Institutes of Health, National Institute on Aging | Grants & Awards | United States |
25-Oct-18 | Sitka Biopharma | $2 | This funding round will enable the company to complete critical GLP toxicology studies and GMP manufacture of clinical drug product. This in turn will allow Sitka and partner Cancer Research UK (CRUK) to complete initial Phase 1 clinical trials of STK-01, Sitka’s lead product for the treatment of bladder cancer. | Quark Venture Inc. | Financing | Canada |
02-Oct-18 | Arcus Biosciences, Inc. | $2 | Following its recent development successes in the isolation and preservation of microRNA (miRNA) and oncology biomarkers, Arcis is now looking to invest further in R&D, product development, and to drive international business expansion. | Capital Cell | Investment | United Kingdom |
13-Oct-18 | Palashbari Manufacturing Facility | $2 | Notably, Sun Pharma, the number one pharmaceutical company in India and the 5th largest generic drug manufacturing company worldwide, has invested Rs 120 crore to set up this product line which will boost the company's capacity to manufacture liquid vials, injectables, eye drops, tablets. | Sun Pharmaceutical Industries Ltd. | Manufacturing Investment | India |
10-Oct-18 | RoslinCT, ReproCell | $2 | The Gov of UK made the investment to collaborate with REPROCELL Europe Ltd (REPROCELL), a UK-based stem cell company, on a project which will develop a faster, more cost-effective method of producing clinical-grade induced pluripotent stem cells (iPSCs). | Innovate UK | Investment | United Kingdom |
10-Oct-18 | Linus Pauling Institute, Helfgott Research Institute | $1 | The NCCIH four-year R01 research project aims to understand how a compound called xanthohumol, from the flowers of the hop plant (Humulus lupulus), may reduce the severity of inflammation in IBD. | National Center for Complementary and Integrative Health (NCCIH) | Grants & Awards | United States |
29-Oct-18 | Rthm Technologies | $1 | Rthm has developed a complete suite of proprietary technology including advanced heart rate tracking and analysis algorithms and comprehensive circadian rhythm mapping techniques. | Australis Capital | Acquisition | Canada |
22-Oct-18 | NCL Foundation | $0.1 | The NCL Foundation announced today that it is jointly supporting a three-year PhD program in the field of child dementia research with the biotechnology company Evotec AG (Frankfurt Stock Exchange: EVT, MDAX, TecDAX, ISIN: DE0005664809). Under the scientific direction of Dr. med. Guido Hermey (University of Hamburg), the PhD program will take place in the premises and laboratories of Evotec AG. | Evotec AG | Grants & Awards | Germany |
05-Oct-18 | Alligator Bioscience AB, SARomics Biostructures | $0.1 | ATOR-1017 is an immunostimulatory antibody in development for the treatment of metastatic cancer. It binds to the receptor 4-1BB on tumor-specific T cells and NK cells. The aim is to achieve effective tumor-targeted immune stimulation with minimum side effects. ATOR-1017 is planned to enter clinical studies in cancer patients 2019. | Vinnova | Grants & Awards | Sweden |
04-Oct-18 | Paracelsus Neuroscience | $0.1 | HealthStartNJ funds health-related research, projects or programs of researchers associated with Kessler Foundation, New Jersey Institute of Technology, Princeton University, Rowan University, Rutgers University and Stevens Institute of Technology. | HealthStartNJ (New Jersey Health Foundation) | Investment | United States |
01-Oct-18 | Amgros | $0 | Effective from today, this first-of-its-kind contract includes current and future CFTR modulator medicines, and means eligible Danish cystic fibrosis (CF) patients will have access to all current medicines as well as future medicines after regulatory approval. | Vertex Pharmaceuticals | Contract Agreement | Denmark |
01-Oct-18 | Hitachi Chemical Advanced Therapeutics Solutions | $0 | NY-ESO is expressed across a variety of tumors including sarcomas, melanoma, multiple myeloma, bladder cancer, non-small cell lung cancer, ovarian cancer and gastro-intestinal cancers. Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS, formerly PCT Cell Therapy Services, LLC) leverages nearly two decades of experience exclusively focused on the cell therapy industry. | GlaxoSmithKline | Manufacturing Investment | United States |
01-Oct-18 | Enesi Pharma | $0 | The collaboration is focused on the development and evaluation of a novel solid-dose formulation of a number of PHE’s proprietary vaccine candidates including Anthrax recombinant Protective Antigen (rPA) and Crimean-Congo Haemorrhagic Fever (CCHF) for delivery via Enesi Pharma’s ImplaVax® needle-free technology. | Public Health England | Collaboration | United Kingdom |
01-Oct-18 | Dr. Reddy's Laboratories | $0 | The plant and associated facilities focus on manufacturing or packaging amoxicillin-based products, which include a semi-synthetic penicillin. | Neopharma | Divestment | United States |
01-Oct-18 | Lupin Limited | $0 | The partnership between the two companies was initiated in 2011 to expand the promotion and distribution of Lilly's diabetes portfolio in India where Lupin has a large network | Eli Lilly and Company | Partnership | India |
01-Oct-18 | Roche | $0 | Global Head of Roche Diabetes Care Marcel Gmuender added that, "synching Novo Nordisk insulin data with our digital diabetes management solutions like mySugr and Accu-Chek Smart Pix will allow us to enhance quality of care and help create more sustainable healthcare systems." | Novo Nordisk | Partnership | United States |
01-Oct-18 | Janssen Pharmaceuticals | $0 | Symtuza is a once-daily darunavir-based single-tablet regimen (STR). It is a fixed-dose combination of four active substances – darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF). The funding will enable clinicians across England to routinely prescribe D/C/F/TAF to eligible patients. | NHS England | Financing | United Kingdom |
01-Oct-18 | Lunatus | $0 | INSYS will supply SUBSYS to Lunatus, and Lunatus will obtain the regulatory approvals and commercialize SUBSYS in the territory. | INSYS Therapeutics | Licensing Agreement | Turkey |
02-Oct-18 | Mayo Clinic | $0 | Baxter International, a global innovator in renal care, and Mayo Clinic today announced a new collaboration to develop a renal care center of excellence in the U.S. The center will serve patients across the continuum of renal care — from chronic kidney disease (CKD) management through transplant — and drive better patient outcomes. | Baxter | Collaboration | United States |
02-Oct-18 | Promius Pharma (Dr. Reddy’s Laboratories) | $0 | Ron Owens, President of EPI Health, said, “We are very pleased to have completed this agreement with Dr. Reddy’s to acquire Cloderm® Cream in the United States. Cloderm® Cream, and its authorized generic, are widely recognized and time-tested among the dermatology community." | EPI Health | Divestment | United States |
03-Oct-18 | Boston Pharmaceuticals | $0 | Boston Pharmaceuticals acquired worldwide rights to two complementary candidates targeting carbapenem-resistant enterobacteriaceae (CRE) and one candidate targeting Pseudomonas. | Novartis | Licensing Agreement | United States |
03-Oct-18 | Boston Pharmaceuticals | $0 | The portfolio includes two Phase 2-ready development candidates, one Phase 1-ready development candidate and two undisclosed preclinical programs with identified lead candidates. | GlaxoSmithKline | Licensing Agreement | United States |
03-Oct-18 | AXA Hong Kong | $0 | The newly set up AXA Signature Network will be available in selected plans that will enable its customers to enjoy high-quality medical services, simplified procedures and a revolutionary medical services experience. It may also help to relieve the burden on the public medical system and the pressure on hospital beds. | HKSH Medical Group | Collaboration | Hong Kong |
03-Oct-18 | Medherant | $0 | The grant will enable the Company to buy equipment and move forward with its plans to extend its pilot scale manufacture of patches formulated with its unique TEPI Patch® technology to GMP manufacture for clinical trials. | Innovate UK | Grants & Awards | United Kingdom |
04-Oct-18 | Evotec AG | $0 | Evotec will apply its industry-leading discovery technologies to these projects to facilitate rapid and efficient drug discovery and development. For each project, Sanofi has the option to assume development responsibility upon the achievement of pre-agreed milestone criteria. | Sanofi | Collaboration | Germany |
04-Oct-18 | Clarus | $0 | This acquisition launches Blackstone Life Sciences, an industry-leading private investment platform with capabilities to invest across the life-cycle of companies and products within the key life sciences sectors. | Blackstone Group | Acquisition | United States |
04-Oct-18 | ERS Genomics | $0 | ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, co-inventor of the breakthrough gene editing technology. Axcelead has all the functions related to non-clinical drug discovery research and is also able to draw on the scientific powerhouse of our personnel with expertise, deep knowledge and experience in a range of therapeutic areas through their previous work at Takeda. | Axcelead | Licensing Agreement | Japan |
04-Oct-18 | Vital Access | $0 | Vwing™ is an implantable device designed to facilitate safe and reliable access to arteriovenous fistulas (AVF) in obese patients suffering from end stage renal disease undergoing hemodialysis. | Advent Access | IPR Agreement | United States |
04-Oct-18 | Ypsomed Group | $0 | The two companies agree to jointly develop and deploy new digital self-medication adherence monitoring services based on Ypsomed’s connected devices and Philips’ cloud-based HealthSuite digital platform. | Royal Philips | Collaboration | United Kingdom |
04-Oct-18 | Orgenesis | $0 | HekaBio and Orgenesis will collaborate in the clinical development and commercialization of regeneration and cell and gene therapeutic products in Japan. | HekaBio K.K. | Licensing Agreement | Israel |
04-Oct-18 | Polaris Pharmacy Services | $0 | Polaris will outfit its new pharmacies in Michigan, Minnesota and Florida with MedBank Mini and Tower devices allowing them to reduce labor costs, while improving medication security, availability and delivery for their customers in different states, according to Polaris' Chief Operating Officer Steve Baker. | CUBEX® LLC MedBank™ Solutions | Partnership | United States |
05-Oct-18 | Gilead Sciences | $0 | The CAR-T therapy – Axicabtagene ciloleucel, also known as Yescarta – offers new hope for adult patients whose large cell lymphoma has returned or has stopped responding to previous treatment. | NHS England | Commercialization Agreement | United States |
08-Oct-18 | Novartis | $0 | The Novartis Biome connects with external innovators in multiple ways, including issuing challenges through an initiative called the HealthX World Series, proactively scouting for technology, and tapping a large network for referrals. | Novartis | Launch & Partnerships | United Kingdom |
08-Oct-18 | Sarepta Therapeutics | $0 | The partnership will provide Sarepta access to additional commercial manufacturing capacity for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as a manufacturing platform for future gene therapy programs, such as Limb-girdle muscular dystrophy (LGMD). | Paragon Bioservices | Manufacturing Investment | United States |
08-Oct-18 | Clinical Trials Laboratory Services (CTLS) | $0 | CTLS provides dedicated high-quality serum, plasma and blood collection services. It also offers full-service cell processing capabilities on site. | BioIVT | Acquisition | United States |
09-Oct-18 | GLyPharma Therapeutic Inc. | $0 | This transformational deal marks Therachon's evolution to a multi-asset rare disease company by adding apraglutide (FE 203799), a next-generation synthetic GLP-2 analog targeting short bowel syndrome (SBS) and other devastating rare G.I. diseases. | Therachon AG | Acquisition | Canada |
09-Oct-18 | ERS Genomics | $0 | “Through our agreement with ERS Genomics, we are pleased to be able to enhance the success of our customers' research programs by offering original state-of-the-art CRISPR/Cas9 genome editing services with significantly high knock-in (KI) efficiency,” commented Tsukasa Sugo, CEO of GenAhead. GenAhead Bio is a new spinout biotechnology company focused on genome editing and nucleic acid delivery. | GenAhead Bio Incorporated | Licensing Agreement | Japan |
09-Oct-18 | Jnana Therapeutics | $0 | The collaboration will leverage Jnana's proprietary drug discovery platform across the solute carrier (SLC) family of transporters and Neurocrine's research and development expertise in CNS disorders to advance new medicines. | Neurocrine Biosciences | Collaboration | United States |
09-Oct-18 | Iris Pharma | $0 | Keen Eye is building decision-support and GLP-compliant image analysis solutions to accelerate the development of new therapies with better, faster and accurate analytics. "Through this partnership, we are expecting to contribute to the most challenging image-based assays to better fight eye diseases." -Sylvain Berlemont, Founder & CEO of Keen Eye | Keen Eye | Partnership | France |
09-Oct-18 | Netsmart | $0 | Cornerstone will leverage the powerful, easy-to-use myUnity Netsmart platform, built specifically for post-acute providers, coupled with its innovative solutions and services that go beyond the traditional EHR. | Cornerstone Hospice and Palliative Care | Partnership | United States |
09-Oct-18 | Canalis Pharmaceuticals | $0 | Canalis is a drug discovery and development company that is using cannabinoids and their NCEs (New Chemical Entities) as small molecule libraries for identifying compounds with human therapeutic activity. | Teewinot Life Sciences Corporation | Launch & Partnerships | United States |
09-Oct-18 | DiaSorin S.p.A. | $0 | Meridian and DiaSorin will begin collaborating on sales and marketing efforts to hospitals and reference laboratories in the U.S. Moreover, Meridian will receive royalties on sales of the LIAISON H. pylori stool antigen test in the U.S. and now also in the UK, in addition to the royalties received under the previous agreement. | Meridian Bioscience, Inc | Collaboration | Italy |
09-Oct-18 | Vector Neurosciences | $0 | MeiraGTx has expanded its portfolio of clinical stage product candidates to include adeno-associated virus encoding glutamic acid decarboxylase (AAV-GAD), a gene therapy product candidate ready for continued Phase 2 clinical development for Parkinson’s disease. | MeiraGTx Holdings Plc | Acquisition | United States |
10-Oct-18 | Children’s Hospital of Philadelphia, University of Pennsylvania | $0 | The study demonstrated that by reducing levels of a key protein called Foxp3 in immune cells using FANA antisense oligonucleotides (FANA ASOs), a next-generation gene silencing technology, lung cancer survival could be improved. Without Foxp3, Treg cells are unable to perform their immune suppressing function. | AUM LifeTech | Partnership | United States |
10-Oct-18 | Cinfa Biotech | $0 | Pelmeg® (originator Neulasta®3) is a pegylated version of granulocyte-colony stimulating factor (G-CSF) for the treatment of chemotherapy-induced neutropenia that works by stimulating the bone marrow to produce more neutrophils, thereby reducing the incidence of infection. | Mundipharma | Acquisition | Spain |
10-Oct-18 | Sensei Labs | $0 | As an internal communications, collaboration, work orchestration, and learning platform, WE connect provides WE team members with the company information they need to collaborate at scale and thrive in WE’s fast-paced work environment. The platform’s integrated social app, with its dynamic news feed, lets team members share content and interact and connect with peers around the world. | WE connect (WE) | Partnership | Canada |
10-Oct-18 | Digi-Trax Corporation | $0 | As partners, WellSky and Digi-Trax are combining efforts to seamlessly integrate cellular therapy compliance labeling and cellular therapy management for clinical laboratory, stem cell transplant, and regenerative medicine. WellSky Biotherapies Lab technology is the preferred cellular laboratory system for Digi-Trax’s HemaTrax®-CT system that offers end-to-end services to safely and efficiently manage donor, clinician, product, and recipient data all in one place with ISBT 128-compliant labeling | WellSky | Partnership | Australia |
10-Oct-18 | Urgent Care Group | $0 | Urgent Care Group will use DocuTAP companywide and has implemented DocuTAP’s EMR and PM software solutions in their seven MEDcare Urgent Care centers across South Carolina in Anderson, Spartanburg, Columbia, and Charleston. | DocuTAP | Partnership | United States |
10-Oct-18 | RaySearch Laboratories AB | $0 | The collaboration, that will generate products that will initially be launched in the US market, is expected to enable a more efficient workflow in the process of virtual simulation. | Canon Medical Systems Corporation | Collaboration | Sweden |
10-Oct-18 | Myriad Genetics | $0 | Myriad will provide BRACAnalysis CDx® testing in a Phase 2 study evaluating talazoparib, Pfizer’s investigational polymerase (PARP) inhibitor, for neo-adjuvant treatment of germline BRCA-mutated triple negative breast cancer. | Pfizer Inc. | Services Agreement | United States |
11-Oct-18 | BTG plc | $0 | CT900 is a targeted therapy that combines targeting folate receptor ? (FR?) and inhibiting thymidylate synthase. The small molecule compound selectively enters cancer cells that over express folate receptor ? (FR?) versus normal tissues and inhibits thymidylate synthase, leading to cell death. | Carrick Therapeutics | Licensing Agreement | United Kingdom |
12-Oct-18 | Adynxx | $0 | Adynxx’s lead product candidate, brivoligide for the reduction of postoperative pain, is intended to provide long-term pain relief and reduced opioid usage with a single administration during surgery. | Alliqua BioMedical | Merger Agreement | United States |
15-Oct-18 | Dr. Reddy's Laboratories | $0 | Therapiva is a joint venture between Omnicare Drugs India, a wholly-owned subsidiary of Abu Dhabi based Neopharma LLC, and Laxai Life Sciences. This divestiture is being done by way of slump sale (as a going concern) and includes all related fixed assets (land and building), current assets, current liabilities, and its employees. | Therapiva Private Limited | Divestment | India |
15-Oct-18 | Eagle Genomics | $0 | Eagle Genomics’ knowledge discovery platform, the e[automateddatascientist], utilizes machine learning and Azure cloud technology to transform data into actionable insights that drive scientific decision making. | Microsoft Genomics | Partnership | United Kingdom |
15-Oct-18 | H-Immune Therapeutics | $0 | The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop diverse antibody therapeutics. | HiFiBiO Therapeutics | Acquisition | China |
15-Oct-18 | Hemogenyx Pharmaceuticals (Immugenyx) | $0 | Immugenyx will use its advanced hematopoietic chimeras, a new type of humanised mouse with a functional human immune system, to develop a model of lupus. | Johnson & Johnson | Collaboration | United Kingdom |
15-Oct-18 | Allele Biotechnology | $0 | Allele has engineered novel multi-valent and multi-specific nAbs, originally identified from an immunized llama, to combat cytokine storms. These nAbs have superior therapeutic efficacy over conventional antibody drugs in animal models of sepsis because of their unique structural and functional properties. | National Institute of General Medical Sciences of NIH | Grants & Awards | United States |
16-Oct-18 | Acturum Biovation | $0 | The phase II ready molecule (mGluR5 antagonist) could enhance recovery of brain functions after stroke. It was first developed by AstraZeneca and has previously been studied in clinical phase II patients with neuropathic pain. | Sinntaxis AB | Option Agreement | Sweden |
16-Oct-18 | Verastem Oncology | $0 | COPIKTRA is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies. | Catalent Pharma Solutions | Partnership | United States |
16-Oct-18 | ERS Genomics | $0 | This non-exclusive license agreement which provides Syngulon with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in combination with Syngulon Patent Rights. | Syngulon | Licensing Agreement | Japan |
16-Oct-18 | IQVIA | $0 | This strategic collaboration with a leading innovator in life sciences utilizes IQVIA’s open technology designs and innovative biopharma solutions to enable easy deployment across the globe. | Roche | Collaboration | United States |
16-Oct-18 | MeiraGTx Holdings | $0 | MeiraGTx will use their proprietary riboswitch technology to engineer regulatable gene therapy constructs encoding proprietary gene sequences from Janssen. | Johnson & Johnson | Collaboration | United States |
16-Oct-18 | Orion Corporation | $0 | Novan plans to transfer the technology for the manufacture of SB204, currently in Phase 3 development for the treatment of acne, and intends for Orion to be able to manufacture the drug product, or the finished dosage form of the gel, in accordance with Novan’s established manufacturing processes, in compliance with applicable regulatory guidelines, as appropriate for clinical trials and alongside Novan’s current manufacturing capabilities. | Novan | Manufacturing Investment | Finland |
16-Oct-18 | Teleflex | $0 | Teleflex will harness Arcis’ advanced nucleic acid sample preparation chemistry in the development of a novel technology, which it believes will be disruptive, and is intended to empower clinicians and drive better patient outcomes. | Arcis Biotechnology | Licensing Agreement | United States |
16-Oct-18 | Eisai Co | $0 | Eisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for development and sales in each country. | Eurofarma Laboratorios | Licensing Agreement | Japan |
16-Oct-18 | Warp Drive Bio | $0 | “The merged R&D portfolio represents a rich pipeline of near- and long-term development opportunities for our R&D team to advance in support of our continuing commitment to translate frontier oncology targets on behalf of cancer patients,” said Mark A. Goldsmith, M.D., Ph.D., president and chief executive officer of REVOLUTION Medicines. | REVOLUTION Medicines | Acquisition | United States |
16-Oct-18 | Discovery Life Sciences | $0 | The new company will leverage deep scientific expertise and consultative services, combined with the largest repository of more than 10 million research-quality biospecimens—all available and processed for analysis—to accelerate the discovery, research, and development of novel biomarkers, drug candidates, and diagnostics. | Conversant Bio, Folio Bio and Phylogeny | Merger Agreement | United States |
16-Oct-18 | Regenerative Medical Technologies | $0 | The acquisition includes an allogeneic stem cell product design, intellectual property, access to data and medical records from patients in 13 clinics, and clinical trial methodology for degenerative disc disease (DDD). | Predictive Technology Group | Acquisition | China |
17-Oct-18 | Evotec AG | $0 | Evotec will apply its drug discovery platform to design novel and efficacious treatments in partnership with Ferring. The multi-target, multi-year collaboration aims to deliver small molecule pre-clinical development (PDC) and investigational new drug (IND) ready candidates. As part of the alliance, Evotec is eligible for undisclosed research funding and milestones. | Ferring Pharmaceuticals | Research Agreement | Germany |
17-Oct-18 | OmniComm Systems | $0 | The CRO selected TrialOne, apart from its status as the market-leading eSource and site automation system for Phase I clinics, because TrialOne enables research organizations to greatly improve the productivity and efficiency of their Phase I clinics. | Global CRO | Partnership | United States |
17-Oct-18 | Clinical Network Services | $0 | As part of the deal, clients can access leading services from both groups including the CNS BioDesk, that provides early stage product development advice including toxicology, CMC and FDA/EMA regulatory consulting and interactions; and Novotech’s advanced regional IT infrastructure, to support their clinical research programs. | Novotech (Australia) Pty Limited | Acquisition | Australia |
17-Oct-18 | ZappRx | $0 | ZappRx and CureDuchenne’s partnership will drive a more streamlined delivery of life-changing drugs developed from specialty pharmaceuticals emerging to Duchenne patients. | CureDuchenne | Investment | United States |
18-Oct-18 | Herbolea S.r.l. | $0 | AGMEDICA and HERBOLEA plan to leverage the licensing agreement to deliver distinct and true full-spectrum extracts derived from fresh cannabis and hemp as well as traditional extracts from dried cannabis and hemp, to service the Canadian and German markets. | AgMedica Bioscience | Licensing Agreement | Italy |
18-Oct-18 | LabCorp | $0 | The collaboration, between Definiens and LabCorp’s Covance drug development business, will enable seamless integration of digital pathology with clinical-trial design and tissue-based testing solutions, resulting in a faster and more rigorous approach to biomarker validation and companion diagnostic co-development. | Covance | Collaboration | United States |
18-Oct-18 | MaSTherCell S.A. | $0 | MaSTherCell will manufacture TIL for Iovance’s European late-stage clinical trials in its commercial-ready cGMP manufacturing suites. | Iovance Biotherapeutics | Manufacturing Investment | Belgium |
18-Oct-18 | Berkeley Lights, Inc. | $0 | The collaboration is for the acquisition of Beacon® optofluidic platform through which the companies will leverage the technology to accelerate cell line development with the Selexis SUREtechnology Platform™. | Selexis SA | Asset Acquisition | United States |
18-Oct-18 | Genecast Biotechnology | $0 | Tissue of Origin® (TOO) Test is a microarray-based gene expression test that analyzes a tumor’s genomic information to help identify its origin, which is valuable in classifying metastatic, poorly differentiated, or undifferentiated cancers. | Cancer Genetics | Commercialization Agreement | China |
18-Oct-18 | Microbiome Insights | $0 | Rebiotix (part of the Ferring Pharmaceuticals Group) and Microbiome Insights, are collaborating to validate one such tool: a proprietary analysis to determine how closely a patient's microbiome resembles that of someone with IBD. | Rebiotix (Ferring Pharmaceuticals) | Collaboration | United States |
18-Oct-18 | National Center for Tumor Diseases (NCT) | $0 | Through this collaboration, Protagen and the NCT Heidelberg will utilize Protagen's Cancer Immunotherapy Array to address challenges such as patients' response to treatment, and checkpoint inhibitors triggered (often severe) immune-related Adverse Events. | Protagen AG | Collaboration | Germany |
18-Oct-18 | gA (Grupo Assa) | $0 | gA was the perfect partner with the right qualifications, and was recommended to LifeScan by Oracle. gA was also LifeScan’s implementation partner for the upgrade to 9.2 release, a pre-requisite for moving to the Cloud, and had in-depth knowledge of LifeScan’s product offering. | LifeScan | Partnership | Argentina |
18-Oct-18 | Genomenon | $0 | Fabric Genomics speeds and scales genomic interpretation by combining the most advanced AI algorithms with automated workflows, while Genomenon’s literature search engine facilitates comprehensive literature review, which is advantageous for accurate interpretation. | Fabric Genomics | Partnership | United States |
18-Oct-18 | Conversa | $0 | Formativ, which works with physician practices, hospitals and health systems to manage all facets of their patients’ experiences, is using Conversa to enable its clients to communicate easier, faster and in a more significant way with patients. | Formativ Health | Partnership | United States |
18-Oct-18 | Baptist Health | $0 | The new agreement builds upon and deepens an established relationship of more than five years. LabCorp has provided reference testing services as the primary laboratory for Baptist Health’s hospitals and Baptist Health Medical Group physician network. | LabCorp Diagnostics | Collaboration | United States |
18-Oct-18 | AELIX Therapeutics | $0 | The collaboration will enable the conduct of a clinical study, entitled AELIX-003, to investigate the safety, tolerability, immunogenicity and efficacy of a regimen containing AELIX Therapeutics’ HTI T-cell vaccine and Gilead´s Toll-Like Receptor 7 (TLR7) agonist vesatolimod in HIV-infected individuals on antiretroviral therapy. | Gilead Sciences | Clinical Collaboration | Spain |
19-Oct-18 | GlycoBac (University of Wyoming) | $0 | GlycoBac’s development of a proven rhabdovirus-negative (RVN) cell line enables MilliporeSigma to offer the first Sf-9 platform combining a rhabdovirus-free insect cell line with a corresponding, chemically defined cell culture medium. | Merck Group | Licensing Agreement | United Kingdom |
19-Oct-18 | Inolife R&D | $0 | Inolife developed its Inojex 30 and Nanojex devices to be easy-to-use, safe, pain-free, and more efficient in delivering treatment to patients than is possible with traditional needle-based injections. | Empower Clinics | Distribution Agreement | Canada |
19-Oct-18 | Biomatrica | $0 | Biomatrica will continue to deploy its capabilities in Exact Sciences’ early cancer screening pipeline as well as with its expanding client base in diagnostics and consumer genomics. | Exact Sciences | Acquisition | United States |
21-Oct-18 | Gammaray Private Health Services | $0 | At the beginning of 2018, Gammaray decided to enter the diagnostics market with liquid biopsy/tissue biopsy/gene signature brands. Gammaray Private Health Services welcomes OncoDNA test brands which are best in class diagnostics to its portfolio as a healthcare provider. | OncoDNA | Distribution Agreement | Turkey |
22-Oct-18 | Medicines Discovery Catapult | $0 | For the first time UK small and medium-sized enterprises (SMEs) will have access to this state-of-the-art bioanalytical technology through research partnerships with the Catapult. The collaboration will also enable AstraZeneca to further unlock the potential of AMI-MS by accessing Medicines Discovery Catapult’s technical expertise. | AstraZeneca | Collaboration | United Kingdom |
22-Oct-18 | Anaeropharma Science | $0 | The leading product developed using i-DPS technology, APS001F, a recombinant Bifidobacterium to express Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is under a phase 1 clinical trial in the U.S. | Roche | Collaboration | Japan |
22-Oct-18 | SpineThera | $0 | The companies believe there is a substantial clinical need for an FDA-approved epidural steroid that demonstrates a long duration of pain relief with a favorable safety profile. | Purdue Pharma | Acquisition | United States |
23-Oct-18 | Laurus Labs Limited | $0 | Dr. Satyanarayana Chava, Founder and CEO, Laurus Labs, commented, "The transfer of TDF ANDA for its use in China enhances our strategic focus to leverage our development and manufacturing capabilities in the markets where we have little presence. Partnering with CASI, in particular, would enable Laurus Labs to monetize its asset in China while building a robust pipeline and commercialize quality drugs in other markets. | CASI Pharmaceuticals | Transfer Agreement | India |
23-Oct-18 | WuXi Biologics | $0 | CANbridge expects to file the first Investigational New Drug (IND) application in a rare disease in China with the lead candidate from this program in 2019. This partnership leverages WuXi Biologics’ drug discovery, development and manufacturing capabilities and CANbridge’s clinical, regulatory and commercial leadership. | CANbridge Pharmaceuticals | Licensing Agreement | China |
23-Oct-18 | Ablexis | $0 | The non-exclusive license grants Voyager rights to use the AlivaMab Mouse for antibody drug discovery. The AlivaMab Mouse is designed to enable and optimize antibody discovery and development. | Voyager Therapeutics | Licensing Agreement | United States |
23-Oct-18 | Pennside Partners Ltd. | $0 | Two Labs is a leading pharmaceutical services company that provides a portfolio of product commercialization and lifecycle services to pharmaceutical manufacturers. | Two Labs | Acquisition | United States |
23-Oct-18 | NeuRx Pharmaceuticals | $0 | NT0501 will be developed to address the significant unmet medical needs for the treatment of chronic sialorrhea in adult and pediatric patients with neurological conditions including cerebral palsy, Parkinson’s disease, mental retardation, and amyotrophic lateral sclerosis (ALS). | Neos Therapeutics | Asset Acquisition | United States |
23-Oct-18 | Genoptix | $0 | “The acquisition of Genoptix enhances NeoGenomics’ leadership in the oncology test market, significantly expanding our coverage of oncology practices, increasing our customer reach and leaving us better positioned for growth.” said Douglas M. VanOort, NeoGenomics’ Chairman and CEO. | NeoGenomics | Acquisition | United States |
23-Oct-18 | Flex | $0 | After rigorous evaluation, Novo Nordisk selected the medical-grade BrightInsight™ platform from Flex Digital Health to build and operate these solutions and securely manage millions of its smart medical devices and the corresponding data within a regulatory-compliant environment. | Novo Nordisk | Partnership | United States |
24-Oct-18 | Bazelet | $0 | Bazelet will manufacture the products in its recently completed, state of the art, fully GMP compliant manufacturing facility, and expects to begin marketing the products in the first half of 2019. | Alvit LCS Pharma | Licensing Agreement | Israel |
24-Oct-18 | TP Therapeutics | $0 | Almac will develop the NGS diagnostic based on the ArcherDx’s Anchored Multiplex PCR (AMP™) chemistry, with the intent of submitting it for regulatory approval in the United States. | Almac Diagnostic Services | Collaboration | United States |
24-Oct-18 | Novartis | $0 | FLAREX® (fluorometholone acetate ophthalmic suspension) 0.1% is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye. | Eyevance Pharmaceuticals | Asset Acquisition | Switzerland |
24-Oct-18 | DelSiTech Ltd | $0 | DelSiTech[TM]Silica Matrix is an advanced, sustained and controlled release delivery technology for administration of injectable, implant and topical eye drop dosage forms. | Bill & Melinda Gates Foundation | Grants & Awards | Finland |
25-Oct-18 | Merck Group | $0 | The collaboration aims to evaluate the combination of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC), in combination with the checkpoint inhibitor avelumab and/or an investigational Merck KGaA, Darmstadt, Germany DNA damage response (DDR) inhibitor, in patients with HER2 expressing or mutated solid tumors. | Daiichi Sankyo | Clinical Collaboration | Germany |
25-Oct-18 | Brigham and Women's Hospital | $0 | To better understand how oncolytic viruses work in human GBM patients, Dr. Lawler is leveraging Mitra's CANscript platform to study their biological mechanisms of action, with the goal of identifying key features involved in response to oncolytic virus therapy. | Mitra Biotech | Collaboration | United States |
25-Oct-18 | KYAN Therapeutics | $0 | Under the agreement both companies will evaluate the solid tumor responses to various novel combination therapies and dosing seen with Trethera's compound TRE-515. | Trethera Corporation | Collaboration | Singapore |
25-Oct-18 | Medicines Development for Global Health | $0 | Moxidectin is a macrocyclic lactone anthelmintic medicine that selectively binds to a disease-causing parasite's glutamate-gated chloride ion channels, vital to the function of its nerve and muscle cells. | Alcami Corporation | Collaboration | Australia |
25-Oct-18 | Compact Imaging | $0 | Novartis will fund Compact Imaging’s development of a low-cost home-based monitor to detect disease progression in advanced cases of age-related macular degeneration (AMD) and diabetic retinopathy (DR). | Novartis | Collaboration | United States |
25-Oct-18 | Charles River | $0 | A combination of Distributed Bio’s antibody libraries and Charles River’s extensive drug development expertise will create a unique end-to-end platform for therapeutic antibody discovery and development. | Distributed Bio | Partnership | United States |
25-Oct-18 | Autism Speaks® Autism Treatment Network (ATN) | $0 | When Quadrant CEO Richard Uhlig learned of the exciting work being conducted by the ATN group, he immediately saw synergies. “Dr. Wink and her colleagues are doing exceptional work on the positive effects of minocycline on children with autism." | Quadrant Biosciences | Collaboration | United States |
26-Oct-18 | Karius | $0 | The Karius Test is commercially available in the United States, and the partnership with Brazil represents the first expansion into the international market. Specimen samples from local reference laboratories in Brazil will be processed and reported at the CLIA-certified, CAP-accredited Karius laboratory in Redwood City, California. Results will typically be available within 48 hours after receipt of the samples. | Dasa | Partnership | United States |
26-Oct-18 | Idifarma | $0 | Idifarma will handle the full pharmaceutical development of Palobiofarma’s new development candidate, the compound PBF-2897, including drug formulation, development of analytical methods and GMP manufacturing for clinical trials from its EU GMP facility in Pamplona, Spain. | Palobiofarma | Partnership | Spain |
28-Oct-18 | Chitose Group | $0 | In order to commercialize Mitsui Chemicals’ plant cell culture technology and Chitose Group’s microbiota-activated cultivation technology*, Chitose Group has established “PHYTO Renaissance, Inc.” and “Tierraponica, Inc.” respectively. Chitose Group accepts Mitsui Chemicals employees as a representative of each company and aims to put the businesses of both companies on growth track. | Mitsui Chemicals | Joint Venture | Japan |
29-Oct-18 | Novartis | $0 | The companies will conduct both non-clinical and Phase 1 clinical studies of Pfizer’s investigational therapies, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, currently in Phase 2), a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, Phase 1) and a Ketohexokinase (KHK) Inhibitor (PF-06835919, Phase 2), together with Novartis’s tropifexor, a non-bile acid, Farnesoid X receptor (FXR) agonist. | Pfizer Inc. | Clinical Collaboration | United States |
29-Oct-18 | Symphogen | $0 | The new collaboration will develop protein analysis workflows to accelerate drug development for biopharmaceutical innovators, biosimilar manufacturers, contract research organizations, and contract development and manufacturing organizations. | Thermo Fisher Scientific | Collaboration | United States |
29-Oct-18 | Centre For Genetic Health Care (CGHC) | $0 | MedGenome-CGHC will now have cross functional team comprising of experienced medical geneticists, scientists and bioinformatics etc, who can leverage knowledge and depth on patient scenarios with large amount of curated content for enhanced reporting. | MedGenome | Acquisition | India |
29-Oct-18 | Pharmacy Network Services | $0 | "We are always looking to enhance medication safety and drive operational efficiencies so that we can provide our customers with the best possible service," said Jason Guinn, Pharmacy Network Services Chief Financial Officer. "MedBank is our preferred partner because of its secured, CUBIE Exchange Replenishment Process which allows us to improve our total cost of ownership while at the same time providing the highest accountability for medication management. | CUBEX® LLC MedBank™ Solutions | Partnership | United States |
29-Oct-18 | SeraCare Life Sciences | $0 | SeraCare is the leading provider of reference materials for clinical genomics applications through their Seraseq brand of highly-multiplexed DNA and RNA reference standards that are helping assay developers and clinical laboratories develop, validate and implement next-generation sequencing (NGS)-based assays more quickly and with higher confidence. | AccuRef Diagnostics | Partnership | United States |
29-Oct-18 | ViewRay | $0 | The agreement will allow GenesisCare to advance its vision of precision radiation medicine by contributing to the evidence base for, and delivering, high quality image-guided, adaptive radiotherapy. | GenesisCare | Collaboration | United States |
29-Oct-18 | Alnylam Pharmaceuticals Inc | $0 | The Alnylam Act® program was developed to reduce barriers to genetic testing and counseling in order to help people make informed decisions about their health. As part of the Alnylam Act® program, patients in the U.S. and Canada with a suspected diagnosis or a confirmed family history of primary hyperoxaluria may be eligible to receive Invitae genetic testing at no charge. Invitae will provide results to participating clinicians and their patients in as little as two weeks. Alnylam provides fund | Invitae Corporation | Partnership | United States |
29-Oct-18 | Babo Botanicals | $0 | The strategic acquisition of Babo Botanicals will allow Expanscience to strengthen its presence in the baby and family category, with the addition of a business and brand that are complementary to its own Mustela brand, in terms of product lines, customers and expertise, particularly in the natural skin care and mineral-based sun care categories. | Laboratoires Expanscience | Acquisition | United States |
29-Oct-18 | Octane Biotech | $0 | Following an intensive joint-development program, the CocoonTM system now incorporates the majority of unit operations needed for scalable end-to-end manufacturing of cell therapies including Mesenchymal stem cells (MSC) and Chimeric Antigen Receptor T cells (CAR-T cells). | Lonza CDMO | Equity Stake | Canada |
30-Oct-18 | Transgene | $0 | NEC and Transgene will co-invest in the first stage of development of an individualized immunotherapy, which includes clinical trials focusing on ovarian cancer and HPV-negative head and neck cancer. | NEC Corporation | Memorandum of Understanding | France |
30-Oct-18 | Caresyntax | $0 | MC Healthcare, providing an integrated healthcare supply chain platform for hospitals, is serving about 250+ facilities in Japan. | MC Healthcare | Partnership | Germany |
31-Oct-18 | MeiraGTx Holdings | $0 | MeiraGTx will receive worldwide rights to adeno-associated virus vector mediated gene delivery of aquaporin-1, designated AAV-AQP1, for Sjögren’s syndrome patients with associated xerostomia (dry mouth) or xerophthalmia (dry eyes). | National Institute of Dental and Craniofacial Research (NIDCR) | Licensing Agreement | United States |
31-Oct-18 | University of Pennsylvania | $0 | Best vitelliform macular dystrophy affects individuals in both eyes and is an orphan inherited degenerative retinal disease caused by mutations in the BEST1 gene. Ophthotech will sponsor research at Penn, facilitated by the Penn Center for Innovation (PCI), and the University of Florida to conduct preclinical and natural history studies of Best disease. | Ophthotech Corporation | Option Agreement | United States |
20-Nov-18 | BTG plc | $4,200 | BTG has three key businesses, the largest of which is its Interventional Medicine portfolio which encompasses several peripheral interventional product lines. The interventional oncology franchise includes the TheraSphere® Y-90 radiotherapy microspheres and the GALIL™ cryoablation system, used to treat patients with liver, kidney and other cancers. | Boston Scientific | Acquisition | United Kingdom |
13-Nov-18 | AstraZeneca | $1,500 | AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus. Sobi will also have the right to participate in AstraZeneca’s share of US profits and losses related to potential new medicine MEDI8897. AstraZeneca will continue to develop MEDI8897 in collaboration with Sanofi Pasteur, the vaccines division of Sanofi S.A. | Swedish Orphan Biovitrum AB | Divestment | United Kingdom |
15-Nov-18 | Pacific Biosciences | $1,200 | While Illumina’s accurate and economic short-read sequencing platforms address the majority of sequencing applications optimally, select applications, such as de novo sequencing and sequencing of highly homologous regions of genomes, are better addressed with accurate long-reads. | Illumina | Acquisition | United States |
01-Nov-18 | Arena Pharmaceuticals, Inc. | $800 | This transaction represents a significant milestone in the development of ralinepag and will strategically position Arena to aggressively advance our best-in-class pipeline, anchored by etrasimod and olorinab, with the focus and resources essential for long-term success." | United Therapeutics | Licensing Agreement | United States |
05-Nov-18 | MatrixCare | $750 | MatrixCare will continue to operate as a standalone business within ResMed’s SaaS portfolio, with targeted commercial, technical and operating links to ResMed and Brightree. There will be no immediate changes to management, locations or business processes. MatrixCare CEO John Damgaard will continue in his current role, reporting to Raj Sodhi. | ResMed | Acquisition | United States |
05-Nov-18 | Perceptive Credit Opportunities Fund II (Perceptive Advisors) | $675 | Fund II exceeded its target and was oversubscribed, reaching its hard cap. With the closing of Fund II, Perceptive manages approximately $1 billion of capital dedicated to private credit. Perceptive Credit Opportunities will continue its focused investment strategy in Fund II, which centers on providing customized, minimally-dilutive debt financing solutions to innovative healthcare companies. | Undisclosed | Investment | United States |
19-Nov-18 | iNtRON Biotechnology | $668 | Roivant has created a dedicated subsidiary to pursue the global development and commercialization of endolysin products from iNtRON Bio. Roivant plans to initiate a Phase 2 trial for SAL200 in 2019. | Roivant Sciences | Licensing Agreement | South Korea |
08-Nov-18 | Sarepta Therapeutics | $500 | Sarepta intends to use the net proceeds from the offering principally for the continuation and initiation of further clinical trials, commercialization, manufacturing, business development activities including the potential licensing or acquisition of complementary products and technologies and other general corporate purposes. | Undisclosed | IPO | United States |
06-Nov-18 | AstraZeneca | $350 | The rights cover markets outside the US and the US royalties for the medicines. Covis Pharma currently commercialises Alvesco, Omnaris and Zetonna in the US and will become the owner of the medicines upon closing. | Covis Pharma B.V. | Divestment | United Kingdom |
08-Nov-18 | Biomatics Capital Partners | $300 | The announcement comes after Biomatics successfully completed its first fund, which invested $200 million into more than a dozen companies including GRAIL, Denali Therapeutics, Verana Health, Aledade, eGenesis, BlackThorn Therapeutics and Omniome. | Undisclosed | Investment | United States |
27-Nov-18 | Genomics Medicine Ireland (GMI) | $295 | The GMI acquisition forms part of a $400 million investment programme in precision medicine unveiled in Dublin today by WuXi NextCODE and a consortium of Irish and international sovereign and technology investors, and which positions Ireland to play a leading role in the global innovation of genome-driven drug discovery and diagnostics. | WuXi AppTec | Acquisition | Ireland |
13-Nov-18 | Leerink Holdings | $280 | The new entity, SVB Leerink, will operate as a wholly-owned subsidiary of SVB Financial Group. With the acquisition, SVB will complement its commercial banking and lending products with a full range of investment banking services focused on healthcare and life science companies. | SVB Financial Group | Acquisition | United States |
27-Nov-18 | ACADIA Pharmaceuticals | $275 | ACADIA has developed and is commercializing the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA has ongoing clinical development efforts in dementia-related psychosis, schizophrenia inadequate response, schizophrenia-negative symptoms, major depressive disorder, and Rett syndrome. | Undisclosed | IPO | United States |
20-Nov-18 | Avista Pharma Solutions | $252 | Cambrex will enter the large and growing market for early stage small molecule development and testing services. Avista offers a broad suite of scientifically differentiated services ranging from API and drug product development and cGMP manufacturing to stand-alone analytical, microbiology testing and solid state sciences. | Cambrex Corporation | Acquisition | United States |
19-Nov-18 | Huadong Medicine Company Limited (HMC) | $222 | Huadong Medicine Co Ltd. Gains Access to Sinclair Pharma’s Highly Differentiated Aesthetics Products to Expand Business Beyond China into United States and Other Markets | Sinclair Pharma plc | Acquisition | China |
27-Nov-18 | WuXi NextCODE | $200 | WuXi NextCODE is focusing the proceeds from this round on rapidly expanding operations at GMI, and to accelerate the program to enroll and sequence the entire genome of some 400,000 people from across Ireland. | Ireland Strategic Investment Fund (ISIF) | Series C Financing | Ireland |
01-Nov-18 | Strongbridge Biopharma plc | $145 | Novo Nordisk to acquire the rights to MACRILEN™ (macimorelin) in the United States (U.S.) and Canada. MACRILEN is the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency (AGHD). | Novo Nordisk | Divestment | United States |
09-Nov-18 | Suzhou Hybiome Biomedical Engineering | $130 | Hybiome is specialized in automated immunoassay tests. Hybiome markets two automated, mid-throughput immunoassay systems (AE-180 and AE-240) using the latest generation CLIA1 technology and featuring a menu of nearly 80 parameters. Hybiome also recently received CFDA clearance for the AE-120 system, to further increase access to its menu of assays. | bioMérieux | Equity Stake | China |
01-Nov-18 | Denali Therapeutics | $125 | The two lead molecules (DNL747 and DNL758) target a critical signaling protein known as the receptor-interacting serine/threonine-protein kinase 1 (RIPK1) in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body. The companies plan to study DNL747 in multiple sclerosis (MS), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS), and DNL758 in systemic inflammatory diseases such as rheumatoid arthritis and psoriasis. | Sanofi | Collaboration | United States |
07-Nov-18 | Mirum Pharmaceuticals | $120 | Maralixibat Phase 2b study interim analysis suggests proof of concept in Alagille syndromeCombined leadership from former Lumena and Tobira teams to pursue registration in Alagille syndrome, progressive familial intrahepatic cholestasis and other liver diseases | New Enterprise Associates | Series A Financing | United States |
16-Nov-18 | Alphamab Oncology | $100 | Alphamab Oncology plans to use the proceeds to advance global clinical development of its innovative pipeline, especially its second-generation immuno-oncology medicine, to expand its global clinical and commercial teams, as well as to complete the ongoing construction of its state-of-the-art biologics manufacturing facilities. | Advantech Capital | Series A Financing | China |
19-Nov-18 | Immunocore Limited | $100 | Immunocore will lead the first-in-human clinical trial to establish safety and preliminary efficacy of IMC-C103C as both monotherapy and in combination with atezolizumab (Tecentriq®). The clinical trial, which is scheduled to commence in early 2019, will enrol patients across a number of solid tumour types. | Roche | Partnership | United Kingdom |
28-Nov-18 | Aimmune Therapeutics | $98 | Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age. Aimmune plans to submit regulatory filings for marketing approval of AR101 in the United States and Europe based on data from the pivotal Phase 3 PALISADE clinical trial of AR101. | Nestlé Health Science | Equity Investment | United States |
13-Nov-18 | NextCure | $93 | The proceeds will be primarily used to support clinical development for the company’s two lead drug candidates, including NC318, preclinical development of additional novel immunomedicine drug candidates, and the Company’s activities under its previously announced collaboration with Eli Lilly and Company to discover and develop novel cancer targets with the Company’s proprietary FIND-IO™ platform. | Hillhouse Capital | Series B Financing | United States |
13-Nov-18 | Center for Protein Degradation at Dana-Farber | $80 | The goal of the Center for Protein Degradation is to interrogate and advance a large portfolio of advanced targeted protein degrader targets while creating a next-generation protein degrader platform. | Deerfield Management | Collaboration | United States |
12-Nov-18 | Greenville Site | $80 | As part of the Greenville site expansion, packaging capacity has more than doubled. One bottling line is dedicated for clinical packaging, and two commercial bottling lines have been qualified for serialization. | Metrics Contract Services (Mayne Pharma Group Limited) | Manufacturing Investment | United States |
01-Nov-18 | SIGA Technologies | $80 | SIGA was awarded the PRV in July 2018 upon approval by the U.S. Food and Drug Administration (FDA) of oral TPOXX® for the treatment of smallpox. | Eli Lilly and Company | Sales Agreement | United States |
29-Nov-18 | ViaCyte | $80 | ViaCyte currently has two stem cell-derived islet replacement therapy candidates at the clinical stage: PEC-Direct and PEC-Encap. The PEC-Direct product candidate is being developed as a transformative therapy for high-risk type 1 diabetes patients and is currently being evaluated in the second stage of a Phase 1/2 trial, with initial proof-of-efficacy data expected as early as mid-2019. | TPG | Series D Financing | United States |
05-Nov-18 | Centrexion Therapeutics | $75 | CNTX is developing CNTX-4975 currently in Phase 3 trials, a drug designed to selectively and locally target and disrupt the signaling of pain-sensing nerve fibers in patients with moderate to severe pain due to knee OA. | Undisclosed | IPO | United States |
20-Nov-18 | PellePharm | $70 | The agreement establishes a joint development committee with PellePharm maintaining responsibility for global development and LEO Pharma supporting in an advising role. | Leo Pharma | Collaboration | United States |
11-Nov-18 | Harpoon Therapeutics | $70 | Harpoon’s TriTAC platform was designed to advance the therapeutic potential of T cell engagers, with a long half-life extended format. Harpoon is developing a pipeline of four wholly owned TriTAC product candidates. Harpoon’s lead product candidate, HPN424, is currently in a Phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer, or mCRPC. | Eli Lilly and Company | Series C Financing | United States |
13-Nov-18 | Kymera Therapeutics | $65 | The financing will support the advancement of its lead asset into clinical development, and to progress its therapeutic pipeline in oncology and immunology. Kymera also entered into a two-year discovery collaboration agreement with GSK, leveraging innovations in small molecule-based targeted protein degradation and encoded library technologies. | 6 Dimensions Capital | Series B Financing | United States |
28-Nov-18 | Aprea Therapeutics | $57 | Proceeds from the financing will be used to advance the clinical development of APR-246, a first-in-class anticancer agent that reactivates mutated p53 tumor suppressor protein. Aprea is planning to begin a Phase 3 clinical study in myelodysplastic syndromes (MDS) and is nearing completion of a Phase Ib/II clinical trial in p53 mutated high-risk myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML) with APR-246 and azacitidine. | Redmile Group | Series C Financing | United States |
05-Nov-18 | Yuhan Corporation | $50 | The collaboration's aim is to develop Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer (NSCLC). | Johnson & Johnson | Collaboration | South Korea |
28-Nov-18 | Prometic Life Sciences | $50 | With R&D costs expected to fall by $30 million in 2019, one side of the equation looks to be in place. However, Prometic is yet to land the deal it needs to deliver a hit of non-dilutive financing and secure the future of Ryplazim and its other pipeline prospect PBI-4050. | Canaccord Genuity | Private Placement | Canada |
01-Nov-18 | BioArctic AB | $50 | BAN0805 is the most advanced of the BioArctic alpha-synuclein antibodies, that are being developed as a disease modifying treatment of Parkinson's disease with a goal to potentially impact disease progression. Preparation of an IND-application is ongoing in order to start the first clinical study with BAN0805 in the US 2019. | AbbVie | Option Agreement | Sweden |
14-Nov-18 | Dragonfly Therapeutics | $50 | The new agreement builds upon Celgene's existing four-target collaboration with Dragonfly, agreed upon in 2017, and increases the number of TriNKET™ immunotherapy drug candidates available for in licensing by Celgene to a total of eight. | Celgene Corporation | Collaboration | United States |
19-Nov-18 | Inflazome | $46 | Inflazome is developing potent and selective small-molecule inhibitors of the NLRP3 inflammasome, to stop the cycle of chronic inflammation that drives such diseases. The Series B proceeds will be used to advance the Company’s first-in-class NLRP3 inflammasome inhibitors into multiple clinical trials in 2019, with next-generation compounds following thereafter. | Forbion | Series B Financing | Ireland |
15-Nov-18 | Camel-IDS | $42 | Camel-IDS is developing new radiopharmaceuticals based on linking single domain antibody fragments with radioisotopes to treat cancer. Funding will be used for a phase Ib/II trial of the lead program CAM-H2, while further developing preclinical programs and broadening the pipeline. | HealthCap | Series A Financing | Belgium |
27-Nov-18 | Zymeworks | $40 | Zymeworks has granted BeiGene exclusive rights to develop and commercialize Zymeworks’ clinical-stage bispecific antibody candidate ZW25 and its preclinical-stage bispecific antibody drug conjugate (ADC) ZW49 in Asia (excluding Japan), Australia, and New Zealand. | BeiGene | Collaboration | Canada |
05-Nov-18 | RegenXBio | $40 | REGENXBIO grants Abeona new licenses to NAV AAV9 for the development and commercialization of treatments for MPS IIIA, MPS IIIB, CLN1 and CLN3 Batten Disease | Abeona Therapeutics | Licensing Agreement | United States |
05-Nov-18 | NextCure | $40 | The multi-year collaboration focused on the discovery and development of immuno-oncology therapies. The collaboration seeks to discover novel cancer targets utilizing NextCure's proprietary FIND-IO™ platform. | Eli Lilly and Company | Collaboration | United States |
15-Nov-18 | Cadent Therapeutics | $40 | Cadent Therapeutics is developing novel allosteric modulators of ion channels to improve neuronal firing regularity. This first-of-its-kind approach has the potential to restore neuronal control and benefit patients with movement and cognitive disorders. | Cowen Healthcare Investments | Series B Financing | United States |
08-Nov-18 | VISEN Pharmaceuticals | $40 | Ascendis has granted Visen exclusive rights to develop and commercialize TransCon hGH, TransCon PTH and TransCon CNP in Greater China, and has received 50 percent ownership of Visen. | Ascendis Pharma A/S Vivo Capital, | Joint Venture | China |
09-Nov-18 | AcelRx Pharmaceuticals, Inc. | $40 | AcelRx intends to use the net proceeds from the offering, in addition to its existing cash resources, to fund the commercial launch of DSUVIA and for general corporate purposes. | Undisclosed | IPO | United States |
08-Nov-18 | Cabaletta Bio | $38 | The Company’s lead product is designed to selectively eradicate B cells that produce autoantibodies to desmoglein 3 (DSG3), which are necessary to cause mPV. The engineered T cell technology utilizes chimeric autoantibody receptors (CAARs) to bind and destroy only disease-causing B cells, while sparing the normal B cells which are essential for human health. | University of Pennsylvania | Licensing Agreement | United States |
13-Nov-18 | Avenue Therapeutics | $35 | The novel intravenous drug delivery method of Tramadol addresses extremely crucial and hitherto unmet needs in pain management. This investment is in keeping with our stated intention to build a specialty pipeline in the U.S. market, and reinforces Cipla’s innovation-led approach and commitment to caring for the life of patients. | Cipla | Equity Stake | United States |
13-Nov-18 | Ribometrix | $30 | Ribometrix’s discovery pipeline focuses on targeting RNA molecules that fold into complex 3D structures yielding pockets amenable to small molecules with high selectivity and favorable drug-like characteristics. | Amgen | Series A Financing | United States |
22-Nov-18 | F2G Biotech GmbH | $27 | F2G will be spending most of its resources on R&D, in particular on the clinical trials of its lead compound “Olorofim”. | European Investment Bank (EIB) | Investment | Austria |
26-Nov-18 | Adrenomed AG | $27 | The new funds will be used to execute a proof-of-concept clinical program of lead product candidate Adrecizumab in early septic shock - Adrecizumab provides a highly novel approach to treat life-threatening conditions by focusing on the preservation of vascular integrity. | Wellington Partners | Investment | Germany |
27-Nov-18 | Antios Therapeutics | $25 | The proceeds from this financing will be used to develop ATI-2173, Antios' lead oral drug candidate for treating patients infected with Hepatitis B virus (HBV) and potentially Hepatitis D virus (HDV). | Lumira Ventures | Series A Financing | United States |
26-Nov-18 | Rheostat Therapeutics | $23 | Proceeds will be used to advance its programs towards clinical trials, build its internal team and expand studies evaluating biomarkers. | AbbVie | Series A Financing | United States |
20-Nov-18 | Santhera Pharmaceuticals | $20 | Initial clinical data suggest that vamorolone has the anti-inflammatory efficacy of steroids with reduced steroid-associated safety concerns, which would represent a significant improvement over current standard of care glucocorticoid therapy in patients with Duchenne muscular dystrophy (DMD), vamorolone's lead indication. | Idorsia | Option Agreement | Switzerland |
06-Nov-18 | ADC Biotechnology | $20 | Abzena’s antibody Drug Substance manufacturing solution will be built in two new suites housed in the facility recently opened by Abzena in San Diego. These will contain new Sartorius 500 L and 2000 L single use bioreactors supported by a comprehensive range of scale up and process development equipment. The service will be further complemented by additional cell line development and chemistry capacity. | Abzena | Manufacturing Investment | United States |
02-Nov-18 | OMEICOS Therapeutics GmbH | $20 | The proceeds from this round will finance PROMISE-AF, a placebo controlled, double-blinded, randomized, dose finding Phase II study on OMT-28 in maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fibrillation. | Forbion | Series C Financing | Germany |
21-Nov-18 | OMass Therapeutics | $18 | The Oxford University spinout plans to use the investment to fuel its structural mass spectrometry to identify new medicines. | Syncona | Series A Financing | United Kingdom |
15-Nov-18 | Epizyme | $15 | The global collaboration focused on the research, development and commercialization of novel small molecule inhibitors directed toward two previously unaddressed epigenetic targets as potential therapies for people with cancer. | Boehringer Ingelheim | Collaboration | United States |
08-Nov-18 | Vectura Group plc | $15 | Vectura and Hikma believe the Open-Inhale-Close dry powder inhaler device has the potential to be developed as an AB-rated substitutable drug-device combination for generic versions of the GSK Ellipta® portfolio. Hikma and Vectura have agreed to develop and commercialise at least three of the portfolio products. | Hikma Pharmaceuticals | Commercialization Agreement | United Kingdom |
12-Nov-18 | Advent Pharmaceuticals Pty Ltd. | $13 | Acquisition of certain R & D assets from Advent Pharmaceuticals pty Ltd., Australia, which is into the business of R & D in complex specialty generics. Acquisition provides an opportunity to acquire assets that would be used for specialty generics business. | Aurobindo Pharma | Asset Acquisition | Australia |
28-Nov-18 | Vedanta Biosciences | $12 | The initiation of a Phase 1 clinical study of VE202, the Company’s orally-administered, live biotherapeutic product (LBP) candidate for inflammatory bowel disease (IBD) that was licensed to Janssen Biotech, Inc. in 2015. Vedanta Biosciences will receive $12 million from Janssen in milestone payments as part of the ongoing collaboration. Vedanta Biosciences advanced VE202, a drug candidate consisting of a rationally-defined consortium of regulatory T cell – inducing bacteria. | Johnson & Johnson | Milestone Payment | United States |
05-Nov-18 | BioTime | $11 | “AgeX was created by BioTime to develop a pipeline of aging and age-related disease programs and this strategic sale of half of our ownership to Juvenescence for $43 million while distributing most of the remaining shares to BioTime shareholders is an excellent example of our two-pronged approach of unlocking value from our platform while investing in our core programs." | Juvenescence Limited | Partnership | United States |
05-Nov-18 | Mapi Pharma Ltd. | $10 | Mapi Pharma is engaged in the development of high barrier-to-entry, high added-value lifecycle management pharmaceuticals and complex active pharmaceutical ingredients (“APIs”) and formulations. The funds raised will support Mapi’s future development and enable the expansion of the company’s pipeline to additional 505(b)(2) and Depot innovative and QQ products beyond the lead product, Glatiramer Acetate (Copaxone®) Depot, or GA Depot, for the treatment of multiple sclerosis (MS) which is in fina | Zhejiang Jingxin Pharmaceutical Co. | Investment | Israel |
06-Nov-18 | Regulus Therapeutics Inc. | $7 | Regulus has granted Sanofi a worldwide exclusive license to develop and commercialize its investigational drug, targeting miR-21 for all indications, including Alport syndrome. | Sanofi | Licensing Agreement | United States |
02-Nov-18 | Intensity Therapeutics | $7 | Intensity plans to use the proceeds of the financing to advance the clinical development of lead product candidate INT230-6, a direct intratumoral injection that is currently being evaluated in a Phase 1/2 clinical study in patients with various advanced solid tumors | Undisclosed | Series B Financing | United States |
22-Nov-18 | Arc Trinova, Autolus Ltd | $5 | The £4.3 million funding aims to create more efficient and innovative methods for manufacturing medicines. The challenge works to set the UK apart as a leader with greater capacity for manufacture of safe, affordable and effective therapies. | Innovate UK | Government Funding | United Kingdom |
15-Nov-18 | I-Mab Biopharma | $4 | MOR210 is MorphoSys's proprietary, preclinical-stage antibody directed against C5aR. I-Mab will exercise its exclusive license rights for development and commercialization of MOR210 in its territories. With support from MorphoSys, I-Mab will perform and fund all global development activities for MOR210, including clinical trials in China and the U.S., towards clinical proof-of-concept (PoC) in oncology. | MorphoSys AG | Partnership | China |
14-Nov-18 | ADC Biotechnology | $3 | Charlie Johnson, CEO of ADC Bio commented: “We are delighted to have obtained this additional injection of funds that will be used to support the company’s strategic aspirations, including conceptual design of a downstream formulation and filling operation to complement our existing bioconjugation operations at the Deeside facility. We are also looking to fully exploit our core Lock-Release technology to create a transformative manufacturing paradigm that will significantly streamline ADC manufa | Maven Capital Partners | Manufacturing Investment | United Kingdom |
15-Nov-18 | Aspect Biosystems | $3 | Aspect Biosystems is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary Lab-on-a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. | Government of Canada | Government Funding | Canada |
23-Nov-18 | Oxford BioMedica | $3 | OXB is committed to investing in the UK and has recently announced the expansion of its manufacturing capacity to create an additional 82,398 sqft facility near its headquarters in Oxford. This new facility secures Oxford as a bioprocessing centre for OXB and will create up to 100 new, highly skilled positions at the Group over the next two years. | Innovate UK | Government Funding | United Kingdom |
13-Nov-18 | Clinical Supply Facility | $3 | The new 30,000 square-feet facility in Tangzhen, a district of Shanghai, will have three controlled temperature rooms operating at 2-8°C, 15-25°C, and -20°C, and will also offer returns and destruction services. Its location, outside of the Free Trade Zone (FTZ), will provide clinical trial sponsors with increased speed and efficiency when running trials in China, and its proximity to Catalent’s existing FTZ facility in Waigaoqiao, within China’s Zhangjiang Pharma Valley, will allow the company | Catalent Pharma Solutions | Manufacturing Investment | China |
26-Nov-18 | Synbal | $2 | The company will leverage their proprietary next-generation gene-editing platform, Active Genetics, to develop a preclinical model that expresses human drug metabolizing enzymes collectively termed P450. | National Cancer Institute | Government Funding | United States |
05-Nov-18 | EyePoint Pharmaceuticals | $2 | The License agreement is for the development and commercialization of EyePoint’s three-year micro insert using the Durasert™ technology for chronic, non-infectious posterior segment uveitis in the greater China territory, which is comprised of China, Hong Kong, Macau and Taiwan. | Ocumension Therapeutics | Licensing Agreement | United States |
08-Nov-18 | Recursion Pharmaceuticals | $2 | For the Phase 1 grant, Recursion set out to develop a morphological profile for senescent cells in a variety of human cell types, independent of existing biomarkers. For Phase 2, the company will leverage its platform to discover novel senolytic agents, molecules that preferentially destroy senescent cells while leaving healthy tissue intact. | National Institutes of Health (NIH) | Government Funding | United States |
26-Nov-18 | Pola Pharma Inc. | $1 | The portfolio of Pola Pharma primarily comprises dermatology products. Pola Pharma is a leading dermatology company and it will help [Sun] to launch its speciality and generic dermatology products in the Japanese market in future. Sun Pharma "also gets access to local manufacturing capability enabling us to serve the Japanese pharmaceutical market more effectively.” | Sun Pharmaceutical Industries Ltd. | Acquisition | Japan |
28-Nov-18 | Olaregen Therapeutix | $0.4 | Olaregen’s pipeline will focus on developing Excellasome® for the regeneration of bones, joints and cartilage. R&D efforts will address the use of Excellasome® in the treatment Osteo and Rheumatoid Arthritis, cartilage repair and plantar fasciitis. | Generex Biotechnology Corporation | Equity Stake | United States |
15-Nov-18 | NeuroVive Pharmaceutical AB | $0.2 | The development program that Vinnova is supporting involves formal preclinical development, including toxicology studies and process development for large-scale manufacture of NV354. | Vinnova | Investment | Sweden |
02-Nov-18 | University of Pennsylvania | $0 | Penn will be responsible for a dedicated preclinical research program from discovery through to the completion of IND-enabling studies in up to ten infectious disease indications. The goal of the exclusive, multi-year partnership is to develop novel nucleoside-modified mRNA vaccine candidates for the prevention and treatment of various infectious diseases. | BioNTech AG | Collaboration | United States |
05-Nov-18 | Infinity Pharmaceuticals | $0 | Infinity will operationalize MARIO-275: MAcrophage Reprogramming in Immuno-Oncology, a global, randomized Phase 2 study to evaluate the effect of adding IPI-549 to Opdivo in checkpoint-naïve advanced urothelial cancer patients who have progressed or recurred following treatment with platinum-based chemotherapy. | Bristol-Myers Squibb | Clinical Collaboration | United States |
05-Nov-18 | Crescendo Biologics | $0 | Takeda has taken an exclusive licence to Humabodies directed to one of its oncology targets. This licence option exercise comes substantially earlier than planned and marks the highly successful delivery and further pre-clinical evaluation by Takeda of Humabody® leads meeting its stringent criteria. | Takeda Pharmaceutical Company | Licensing Agreement | United Kingdom |
05-Nov-18 | Enesi Pharma | $0 | The collaboration is focused on the development and evaluation of solid dose versions of Sementis' lead peanut hypoallergy vaccine and their single vectored chikungunya/Zika vaccine candidates for administration via Enesi Pharma's ImplaVax® technology. Enesi Pharma will formulate solid dose implants based on SCV vaccine provided by Sementis, and Sementis will undertake safety and immunogenicity testing, and preclinical development. Pending positive outcomes, this agreement would set the founda | Sementis | Collaboration | United Kingdom |
05-Nov-18 | BioContinuum™ Platform for Next Generation Bioprocessing | $0 | Merck launched its new BioContinuum™ Platform to advance biotherapeutic drug manufacturing through improved efficiency, simplified plant operations and greater quality and consistency. The Life Science business sector of Merck also introduced its expanded Pellicon® Single-Pass Tangential Flow Filtration system to intensify operations in the purification of therapeutic proteins. | Merck Group | Manufacturing Investment | Germany |
05-Nov-18 | Nano Creaciones S.A. P.I. de D.V. Research LLC | $0 | The Nano Gauze is made from pure silver nanoparticles, which are carefully dispersed in cotton fibers that are subjected to a meticulous sterilization process with the most advanced technology for contact with wounds and human tissues without compromising the action of the silver nanostructures. Apotheca Biosciences believes that using Nano’s products to deliver CBD as a palliative will bring the utmost quality and precise dosing to the consumer market. | Apotheca Biosciences | Letter of Intent | Brazil |
06-Nov-18 | Red Star Contract Manufacturing | $0 | WishBone Medical is committed to providing anatomically appropriate innovative implants and instruments in sterile packed, single use, disposable kits for their surgeons, hospitals, and customers worldwide. Red Star Contract Manufacturing is a leader in injection molded disposable instruments for the medical device industry as well as having a fully functional sterile packaging clean room and fulfillment center. | WishBone Medical | Acquisition | United States |
06-Nov-18 | G&W Laboratories | $0 | G&W Dermatology has a market-leading and diversified portfolio of approximately 35 self-labeled generic topical dermatology products that are currently marketed and sold in the U.S. | Avista Capital Partners | Acquisition | United States |
06-Nov-18 | HuiyiHuiying | $0 | HY is collaborating with more than 800 medical institutions in China in clinical applications and scientific research projects, including the Chinese PLA General Hospital, Peking Union Medical College Hospital, Beijing Friendship Hospital and several medical associations. | Intel Capital | Investment | China |
07-Nov-18 | Medlac Pharma Italy Co. Ltd. | $0 | The acquisition includes a high-quality injectable facility, adjacent vacant land, Medlac’s product portfolio of 23 injectable products, its pipeline and all employees. Medlac operates an injectables facility in Hanoi, Vietnam. Since it commenced operations in 2012, it has built a strong reputation as a high-quality manufacturer in the areas of anti-infectives and cardiovascular. | Hikma Pharmaceuticals | Acquisition | Vietnam |
07-Nov-18 | IRX Therapeutics | $0 | Brooklyn's advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications. | Brooklyn ImmunoTherapeutics | Acquisition | United States |
07-Nov-18 | Asterias Biotherapeutics | $0 | “Our vision is to build BioTime into a premier cell therapy company and this acquisition can support that transformation as it not only diversifies our pipeline with two additional clinical-stage assets addressing high unmet medical needs, but also adds partnerships with notable institutions such as the California Institute for Regenerative Medicine and Cancer Research UK,” stated Brian M. Culley, Chief Executive Officer of BioTime. | BioTime | Merger Agreement | United States |
08-Nov-18 | Prenetics Limited | $0 | The joint venture will work on a direct-to-consumer model, allowing consumers the ability to purchase its suite of genetics enabled health services directly online. The joint venture will also seek collaborations with insurers, governments and other key stakeholders to ensure local market needs are met. The services will launch in the first quarter of next year. | Berry Genomics | Joint Venture | China |
08-Nov-18 | Cincinnati Children's Hospital Medical Center | $0 | This partnership will combine BridgeBio's strengths in therapeutic development for diseases of high unmet need with Cincinnati Children's world-class researchers and clinicians toward the mutual goal of discovering new therapies targeting genetic diseases at the source. | BridgeBio Pharma | Collaboration | United States |
12-Nov-18 | BioArctic AB | $0 | BioArctic has obtained financial support for a postgraduate studentship linked to Uppsala University in Sweden to contribute to the education of young researchers. The company may get access to a technology that can lead to even better diagnostic tools and biomarkers as well as PET ligands for the protein alpha-synuclein. The research initiative contributes to the development of new treatments for Parkinson's disease. | EU's Horizon 2020 | Government Funding | Sweden |
12-Nov-18 | Medicines Patent Pool | $0 | The licence will enable quality-assured manufacturers to develop and sell generic medicines containing G/P in 99 low- and middle-income countries (LMICs) and territories at affordable prices, enabling access to and treatment scale-up with the most effective pan-genotypic regimens. | AbbVie | Licensing Agreement | United States |
12-Nov-18 | Kadimastem, Defymed | $0 | Kadimastem is developing an innovative cell therapy for diabetes by producing functional cells capable of producing and releasing insulin according to blood sugar levels. Defymed has developed MailPan®, a Bio-Artificial Pancreas device designed, using suitable cells such as Kadimastem's cells, to treat diabetes in patients without the use of immunosuppressants. | EUREKA's Eurostars Programme | Government Funding | Israel |
12-Nov-18 | Linde AG | $0 | The N-Tidal devices are unique breath monitors capable of unprecedentedly precise measurement of the tidal breathing CO2 waveform shape, which is an established but under-used respiratory biomarker. | Cambridge Respiratory Innovations Limited (CRiL) | Collaboration | Germany |
13-Nov-18 | Liquidity Services | $0 | The partnership can provide immediate capital infusions by disposing of biopharma assets via online auctions, consignment sales or direct negotiations with global buyers. It also has the capital resources to purchase such assets outright in principal deals. | Tiger Liquidity Services Biopharma Partners | Partnership | United States |
13-Nov-18 | INVO Bioscience Inc. | $0 | The INVOcell IVC device uses a woman’s own body as a natural incubator during fertilization and early embryo development. | Ferring Pharmaceuticals | Commercialization Agreement | United States |
13-Nov-18 | GenomOncology | $0 | The partnership between GO and IU is a part of Indiana University's Grand Challenge Precision Health Initiative (IUPHI) which is conducting clinical trials in triple negative breast cancer, multiple myeloma and pediatric sarcomas. | Indiana University School of Medicine | Partnership | United States |
13-Nov-18 | Rockford Site | $0 | PCI is pleased to announce the expansion of our Clinical site at Rockford, IL. Construction of the expanded Clinical Services facility began on November 12, 2018. The site is one of two US-based PCI locations supporting investigational medicinal products, complementing facilities in the UK, Europe and Australia. | PCI Pharma Services | Expansion | United States |
14-Nov-18 | Averitas Pharma | $0 | Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the remaining global rights, including the US rights, for the product from Acorda Therapeutics. | Grünenthal | Acquisition | United States |
14-Nov-18 | Cellesce | $0 | The new partnership will expand the number of Repositive's partners on Cancer Models to 12. Repositive's integrated web-based solution, enables researchers to find cancer models derived from human tumours with many from commercial sources now searchable in one place. | Repositive | Partnership | United Kingdom |
15-Nov-18 | Kinetic Discovery | $0 | The acquisition builds up Exscientia's capabilities for tackling novel drug targets to create first-in-class drug candidates by seeding its algorithms with data generated through the use of fragment screening and structural biology. | Exscientia | Acquisition | United Kingdom |
15-Nov-18 | CLIA-Certified Lab | $0 | The company’s 8,000-square-foot facility at 2252 Welsch Industrial Court in Maryland Heights is twice the size of its previous lab and provides a foundation for future growth. | Mogene | Expansion | United States |
15-Nov-18 | KinderPharm | $0 | Pennsylvania-based KinderPharm is recognized for the only complete pediatrics clinical trial solution bolstered with advanced pharmacometric capabilities, including pharmacokinetic data analysis, PK/PD modeling, physiologically-based PK modeling, and population PK analysis, to facilitate efficient pediatric trial design and minimize patient numbers. | Synteract | Acquisition | United States |
15-Nov-18 | Mission Therapeutics | $0 | Alzheimer’s and Parkinson’s diseases are associated with the accumulation of misfolded, toxic proteins, which are believed to cause impaired function and death of nerve cells in the brain. DUBs play an important role in keeping a cell healthy by regulating the degradation of these proteins. AbbVie and Mission are aiming to develop potential therapeutics that enable the degradation of these toxic proteins and prevent their accumulation. | AbbVie | Collaboration | United Kingdom |
15-Nov-18 | Sinopharm Nutraceuticals Industrial (Sinopharm Group) | $0 | The partnership is the exploration and execution of investment opportunities in the pharmaceutical, healthcare and biotechnology industries by leveraging each other's strengths and resources. | Cedrus Investments | Cooperation Agreement | China |
16-Nov-18 | Luxcel Biosciences, Little Island, Cork facility | $0 | The addition of Luxcel expands Agilent's cell analysis portfolio and brings new capabilities through technology and research which will drive advancements in this fast-evolving field for Agilent globally. | Agilent Technologies | Expansion | Ireland |
16-Nov-18 | Rentschler Aseptic Fill & Finish Facility | $0 | The new facility of Rentschler Fill Solutions – fully equipped with the latest technical infrastructure – was completed in the record time of two years. Rentschler Fill Solutions expects approval from the US Food and Drug Administration (FDA) in 2019. Through the strategic partnership of Rentschler Fill Solutions, Rentschler Biopharma and Leukocare, clients also benefit from one-stop solutions from gene to vial and clinic to market. | Rentschler Fill Solutions GmbH | Manufacturing Investment | Austria |
19-Nov-18 | Pacific Biomarkers, NEOMED-LABS | $0 | This merger brings together two leading bioanalytical CROs with unrivaled credentials in immunology and particular expertise in assay development, custom biomarker validation, and high-throughput clinical sample testing. | Ampersand Capital Partners | Merger Agreement | United States |
19-Nov-18 | Enlivex Therapeutics Ltd. | $0 | Enlivex is developing a novel immunotherapy with a unique mechanism of action that targets clinical indications that are defined as “life-threatening with an unmet medical need,” such as preventing or treating complications associated with bone-marrow transplantations and sepsis, (the third-leading cause of mortality in the U.S. after cardiovascular and cancer diseases) and as a treatment for solid tumors via immune checkpoint reprogramming, which could increase the efficacy of CAR-T, TCR and ot | Bioblast Pharma Ltd. | Merger Agreement | Israel |
19-Nov-18 | Syntropy (Palantir Technologies) | $0 | Syntropy is expected to empower scientists and research centers with a collaborative technology platform to advance cancer research, help drive scientific discovery, and improve human lives. Syntropy aims to unlock the value of this untapped data, enabling the world's leading experts to collaborate in the fight against cancer and many other diseases. | Merck Group | Joint Venture | United States |
19-Nov-18 | Ascletis Pharma Inc | $0 | Following the first successful partnership and promising launch for Ganovo (Danoprevir), Ascletis and Roche have decided to embark on a Pegasys partnership. Roche will grant Ascletis an exclusive sales & marketing promotion right in Mainland China for Pegasys, a leading pegylated interferon treatment for Hepatitis B and C. | Roche | Partnership | China |
20-Nov-18 | Ennore API site | $0 | Ennore is a key API site in the PPS integrated site network, with capabilities from early development through commercial manufacturing, with an available capacity of over 300kL. The site supplies Key Starting Materials, Registered Starting Materials, Advanced Intermediates and APIs for both large pharma and biotech firms, in North America, Europe, and RoW markets. | Piramal Pharma Solutions | Manufacturing Investment | India |
20-Nov-18 | Eurofins Genomics | $0 | Eurofins Genomics and Synthego are ideal business partners given their unmatched flexibility for any kind of genomic research and applications of CRISPR. A combined understanding of their customers' challenges with CRISPR was the basis for the cooperation between the two life sciences leaders, and aligned interests and values in offering best in class solutions make the Eurofins-Synthego partnership all the more powerful. | Synthego | Partnership | Germany |
20-Nov-18 | HitGen | $0 | This collaboration further emphasizes the role of HitGen in the rapidly developing field of DNA-encoded chemistry. In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads which will be licensed exclusively to Biogen. | Biogen | Collaboration | China |
21-Nov-18 | Nutrino Health | $0 | The companies recognized an opportunity to improve clinical outcomes for people with diabetes by integrating Nutrino's extensive food analysis infrastructure, nutrition science expertise and artificial intelligence (AI)-driven personalized insights with Medtronic's technology and future innovations. | Medtronic PLC | Acquisition | United States |
21-Nov-18 | Ligand Pharmaceuticals | $0 | iMBP gains access to the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ in their drug discovery efforts. As part of the agreement, Ligand will fund and facilitate selected early antibody discovery activities and will in return receive an ownership position in iMBP. | iMetabolic Biopharma Corporation | Partnership | United States |
21-Nov-18 | Immuneering Corporation | $0 | The research collaboration brings together Evotec’s leading induced pluripotent stem cell (“iPSC”) platform and broad drug discovery capabilities with Immuneering’s unique Artificial Intelligence-driven drug discovery platform to accelerate ligand identification for novel targets. | Evotec AG | Collaboration | United States |
21-Nov-18 | Tessa Therapeutics | $0 | The goal of the partnership is to scale Tessa’s therapies world-wide in a safe and efficient manner, supporting both late clinical stage therapies approaching commercialization and early-phase therapies progressing through various clinical stages. Tessa’s Virus-Specific T cell (VST) technology is showing compelling results and an excellent safety profile in the treatment of cancer. | Vineti | Partnership | Singapore |
22-Nov-18 | Dalton Pharma Services | $0 | Dalton will be responsible for the formulation and fill/finish of UM171, a constituent of ExCellThera`s lead technology, ECT-001, to support phase II clinical trials in Canada & the United States. | ExCellThera Inc. | Manufacturing Investment | Canada |
22-Nov-18 | Biologics Innovation Center | $0 | The new state-of-the-art biologics center will integrate biologics discovery, development, clinical and commercial manufacturing which will be built to meet global cGMP standards while implementing modular and flexible design. This will be one of the largest facilities of its kind with 1.6 million sq. ft. and will accommodate more than 3000 scientists. | WuXi AppTec | Manufacturing Investment | China |
22-Nov-18 | Phoenix Group | $0 | The first projects to commence under the strategic partnership are being rolled out in certain Central & Eastern European (CEE) markets. "In PHOENIX we are confident that we have found the right partner for distribution and commercial activities. We are looking forward to expanding our collaboration to benefit even more markets in the future," says Robert Storch, Head of Trade & Revenue, Zentiva Group. | Zentiva | Partnership | Germany |
23-Nov-18 | Lucence Diagnostics | $0 | iGenetic will be distributing Lucence’s flagship liquid biopsy test – LiquidHALLMARK - a blood test to span multiple cancer-causing mutations and viruses. The blood test analyzes the cancer-driving mutations from the DNA shed by the tumor into the bloodstream to determine the best available treatment, which include targeted therapy and immunotherapy. | iGenetic Diagnostics | Distribution Agreement | Singapore |
23-Nov-18 | Seracare Life Sciences | $0 | The acquisition of SeraCare strengthens LGC's position across the spectrum of clinical quality control tools market and builds upon its existing calibration verification materials and proficiency testing offerings including those of LGC Maine Standards, acquired in 2015. | LGC Group | Acquisition | United Kingdom |
26-Nov-18 | Edge Therapeutics | $0 | PDS Biotechnology is developing PDS0101 for the treatment of multiple human papilloma virus (HPV)-induced cancers, including cervical, anal and head and neck cancers. PDS Biotechnology plans to initiate multiple Phase 2/3 clinical trials for PDS0101 in HPV-associated cancers. | PDS Biotechnology Corporation | Merger Agreement | United States |
26-Nov-18 | Fusion Antibodies | $0 | This collaboration will boost Fusion Antibodies’ continual efforts to improve its algorithms to understand the structure/function relationship of its target antibodies. Fusion Antibodies’ CDRx™ humanization platform makes it possible to perform multiple virtual experiments with panels of selected antibodies to discover properties that meet desired functionality and developability requirements with the long-term goal of reducing development costs and accelerating timelines so that novel antibody | Analytics Engines | Collaboration | Ireland |
26-Nov-18 | Jecure Therapeutics | $0 | Genentech will obtain full rights to Jecure’s entire preclinical portfolio of NLRP3 inhibitors. | Roche | Acquisition | United States |
27-Nov-18 | Shefield & Sons | $0 | Abattis' vaporizers provide therapeutic benefits in the delivery of cannabidiol and tetrahydrocannabinol extracts, utilizing a system of rapid absorption for the quick delivery of cannabinoids. With the Distribution Agreement in place, the Company is anticipating increased sales growth of its entire vaporizer line for 2019. | Abattis Bioceuticals Corp | Distribution Agreement | Canada |
27-Nov-18 | University of Nottingham, BC Platforms | $0 | The collaboration will see BC Platforms opening up its connector technology across the biobanking platform in order to develop an open standard that can be utilised and reimplemented by any accredited party. The biobanking platform - directory.biobankinguk.org - is hosted by the University of Nottingham's UKCRC Tissue Directory and Coordination Centre (UKCRC TDCC) and run under the national registry for biobanks holding over 150 biobanks. | UKCRC Tissue Directory and Coordination Centre | Collaboration | Switzerland |
27-Nov-18 | Daiichi Sankyo | $0 | Roche will seek to develop, manufacture and commercialize worldwide an immunohistochemistry (IHC) companion diagnostic test with the goal of identifying patients with HER2 low expressing metastatic breast cancer to be enrolled into a pivotal phase 3 study evaluating the safety and efficacy of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC). | Roche | Collaboration | Japan |
27-Nov-18 | Accinov GMP manufacturing site | $0 | The new Lyon site will focus on providing ABL’s clients with increased options and capacities in response to the rapid growth in demand for the production of viral vectors observed in the immuno-oncolytic and gene therapy space. | Advanced BioScience Laboratories (ABL) | Acquisition | France |
27-Nov-18 | Generex Biotechnology Corporation | $0 | The clinical trial, sponsored by Generex and conducted in conjunction with Merck, is currently being reviewed by the FDA, and clinical operations including site qualification, drug shipment and packaging, and IRB review and approval are underway, with plans to enroll patients in the first quarter of 2019. | NSABP Foundation | Clinical Collaboration | United States |
27-Nov-18 | X4 Pharmaceuticals | $0 | The merger would result in a combined company operating under the X4 Pharmaceuticals name that will focus on the development and commercialization of X4’s lead product candidate, X4P-001, and the advancement of X4’s pipeline of treatments for rare diseases of the immune system and rare cancers. | Arsanis | Merger Agreement | United States |
27-Nov-18 | Aileron Therapeutics | $0 | ALRN-6924 is a first-in-class, stabilized cell-permeating peptide that mimics the p53 tumor suppressor protein to disrupt the interaction with both its endogenous inhibitors, MDMX and MDM2. Palbociclib is an oral inhibitor of cell cycle check-point regulators CDK4/6. Aileron expects this Phase 1B trial to start enrolling patients with solid tumors in the first quarter of 2019. Pfizer will provide drug supply in support of the trial. | Pfizer Inc. | Clinical Collaboration | United States |
27-Nov-18 | Stevenage Bioscience Catalyst (SBC) Open Innovation Campus | $0 | In the first half of 2019, the center will start producing a fiber-based purification platform, which has the potential to significantly improve efficiency in the purification steps of manufacturing biopharmaceuticals, gene therapies and viral vectors. “The fiber-based chromatography technology developed and manufactured in Stevenage will extend GE Healthcare’s start-to-finish bioprocess purification portfolio.” | GE Healthcare Life Sciences | Manufacturing Investment | United Kingdom |
27-Nov-18 | Elto Pharma Subs Amarantus Biosciences Holdings | $0 | Elto Phama is developing eltoprazine, a serotonergic agonist in Phase 2b development for the treatment of Parkinson's disease levodopa-induced dyskinesias (Parkinson's LID). | Coeptis Pharmaceuticals | Acquisition | United States |
28-Nov-18 | ABL Bio | $0 | The agreement showcases the expansive biologics pipeline of ABL Bio and the world leading technical expertise and capabilities of WuXi Biologics in developing bispecific programs.WuXi Biologics has enabled several preclinical and clinical manufacturing programs for ABL Bio as well as collaboration with I-Mab," said Dr. Sang Hoon Lee, Chief Executive Officer of ABL Bio. | WuXi AppTec | Manufacturing Investment | South Korea |
28-Nov-18 | Neuro Motor Innovations Corporation (NMI) | $0 | MindMaze will further develop and commercialize NMI's technology that targets treatment of a wide range of neurological diseases and injuries from the acute through chronic stages. Additionally, the immersive cognitive-motor experiences can be used for healthy aging and wellness, as it has become apparent that complex movements are essential for maintaining executive cognitive function. | MindMaze | Acquisition | United States |
28-Nov-18 | GE Healthcare | $0 | The agreement gives Q BioMed ownership of the brand, trademarks and market authorizations in 22 countries. | Q BioMed | Asset Acquisition | United States |
28-Nov-18 | Wellthy Therapeutics | $0 | Roche announced its partnership with the digital therapeutic company Wellthy Therapeutics to offer users of the Accu-Chek Active system, a clinically validated artificial intelligence-based digital diabetes coaching solution. The bundle is being launched in the South and West Zones of India. | Roche | Partnership | India |
28-Nov-18 | I-Mab Biopharma | $0 | TRACON and I-Mab entered into a cost-sharing product development collaboration whereby TRACON will be responsible for the regulatory and clinical development of TJD5 and up to five of the BsAbs in North America, with the majority of the development effort expected to occur in the U.S. | TRACON Pharmaceuticals | Partnership | China |
29-Nov-18 | Jianke Pharmaceutical | $0 | jianke.com, the first B2C Internet drug company to be approved and be in full compliance with all medical requirements for operation in Guangdong province. jianke.com announced the new brand image for Jianke Doctor to the public for the first time, and entered into a strategic collaboration with Pfizer. | Pfizer Inc. | Collaboration | China |
29-Nov-18 | Autolus Limited | $0 | AbCellera is applying its microfluidic single-cell screening platform to find novel antibodies which can be used for the development of new Chimeric Antigen Receptor (CAR) T cell therapies. | AbCellera Biologics | Collaboration | United Kingdom |
29-Nov-18 | Hutchison MediPharma Limited | $0 | Innovent and Hutchison MediPharma will jointly explore potential application of this combination in solid tumors with global unmet medical needs through development efforts both in the US and in China. | Innovent Biologics | Clinical Collaboration | China |
30-Nov-18 | Bioquell PLC | $0 | Bioquell’s innovative bio-decontamination and isolator technologies and services help ensure residue-free surface decontamination in cleanrooms and research and development labs at biotech start-ups, pharmaceutical manufacturers and Fortune 500 companies, and in patient rooms at hospitals in more than 50 countries. | Ecolab Inc. | Acquisition | United Kingdom |
30-Nov-18 | GlaxoSmithKline | $0 | Crown Laboratories has acquired North American distribution rights of five (5) OTC consumer brands from GlaxoSmithKline | Crown Laboratories | Distribution Agreement | United Kingdom |
30-Nov-18 | Pfizer Inc. | $0 | AbbVie grants Pfizer a non-exclusive patent license for the use and sale of Pfizer’s proposed adalimumab biosimilar for many countries around the world. Pfizer may launch its adalimumab biosimilar upon approval by the European Medicines Agency in Europe. In the United States, the license period will begin on November 20, 2023. | AbbVie | IPR Agreement | United States |
03-Dec-18 | Tesaro | $5,100 | TESARO is a commercial-stage biopharmaceutical company, with a major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer. Clinical trials to assess the use of Zejula in “all-comers” patient populations, as a monotherapy and in combinations, for the significantly larger opportunity of first line maintenance treatment of ovarian cancer are also underway. | GlaxoSmithKline | Acquisition | United States |
17-Dec-18 | Johnson & Johnson | $5,000 | Johnson & Johnson today announced that the Board of Directors has authorized the repurchase of up to $5 billion of the company's common stock. | Undisclosed | Purchase Agreement | United States |
14-Dec-18 | Antelliq Group | $2,400 | Merck Animal Health is a leader in the animal health business and has delivered consistent above-market growth driven by a broad portfolio of innovative pharmaceuticals, vaccines and other value-added technologies and services. Antelliq’s people and products complement this portfolio by adding market-leading digital products, extending the range of solutions we can provide our customers and further driving the growth of our business. | Merck & Co. | Acquisition | France |
12-Dec-18 | Zoetis Inc | $2,000 | Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets medicines, vaccines, and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. | Undisclosed | Purchase Agreement | United States |
19-Dec-18 | UPSA | $1,600 | Taisho entered the OTC market in certain Asian countries through the purchase of PT Squibb Indonesia from Bristol-Myers Squibb. Taisho is the largest over-the-counter (OTC) drug company in Japan, with over a century of experience in this field. Taisho holds a leading presence in anti-inflammatory analgesic, cold and flu and hair growth segments in Japan and Southeast Asia. | Taisho Pharmaceutical Holdings Co., Ltd. | Divestment | France |
13-Dec-18 | WuXi AppTec | $1,010 | The Hong Kong IPO will be used to enhance the Company’s capability and capacity worldwide. This could include acquiring CROs and CDMO/CMOs, developing cutting-edge technologies, fostering a healthcare ecosystem, boosting working capital | Undisclosed | IPO | China |
20-Dec-18 | Boehringer Ingelheim | $800 | BI 860585 is a potent and selective ATP-competitive mTOR serine/threonine kinase inhibitor. Xynomic plans to initiate 2 clinical trials in the next 6-9 months, among which, one is a potentially pivotal phase 2 trial combining BI 860585 with a standard-of-care treatment against breast cancer and the other is a phase 1b trial combining BI 860585 with Xynomic's XP-102 (formerly known as BI 882370) against colorectal cancer. | Xynomic Pharmaceuticals | Licensing Agreement | Germany |
06-Dec-18 | Moderna Therapeutics | $604 | Moderna pioneers the discovery and development of messenger RNA (mRNA) therapeutics and vaccines to direct the body’s cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals. | Undisclosed | IPO | United States |
17-Dec-18 | Versant Ventures | $600 | Both funds exceeded their initial targets and were supported by existing investors and a select number of new top-tier limited partners. Fund VII will be allocated across 20 or more biotechnology companies in the U.S., Canada and Europe focused on translating breakthrough innovation into the next generation of therapeutics targeting the most important unmet medical needs. | Versant Ventures | Financing | United States |
03-Dec-18 | argenx | $500 | Cusatuzumab is currently in development in a Phase 1/2 combination study with Vidaza® for newly diagnosed, elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) who are unfit for chemotherapy. | Johnson & Johnson | Licensing Agreement | Belgium |
17-Dec-18 | Staten Biotechnology | $491 | Staten Biotechnology has developed STT-5058, a new promising concept validated by human genetics, for the treatment of hypertriglyceridemia. Novo Nordisk will provide research and development (R&D) funding and support for Staten to develop its lead asset STT-5058 for treatment of dyslipidaemia. | Novo Nordisk | Collaboration | The Netherlands |
05-Dec-18 | WuXi Biologics | $450 | The deal brings together Oxford Biotherapeutics’ target discovery and development expertise with WuXi Biologics’ extensive expertise in developing world-class bispecific antibodies, to build value for both companies as OBT works to develop and commercialize this exciting portfolio of potential next-generation antibody-based cancer drugs. | Oxford BioTherapeutics | Collaboration | China |
13-Dec-18 | Zymergen | $400 | By leveraging advances in artificial intelligence, robotic lab automation, and cutting-edge genomics, Zymergen has unlocked previously inaccessible sources of molecular diversity for critical industries around the world. With its proprietary technology platform, the company makes novel and improved molecules to meet the greatest needs of global leaders in manufacturing, specialty chemicals, food and agriculture, electronics, and pharmaceuticals. Zymergen delivers its customers material diversity | SoftBank Vision Fund | Series C Financing | United States |
20-Dec-18 | Relay Therapeutics | $400 | Relay Therapeutics’ initial discovery programs in cancer have led to the development of highly selective inhibitors of disease-causing proteins in genomically defined patient populations. | SoftBank Vision Fund, Foresite Capital | Series C Financing | United States |
17-Dec-18 | Shanghai Junshi Biosciences Co., Ltd. | $394 | The company is developing JS001, an anti-progressive disease (PD)-1 monoclonal antibody that is in Phase I and II clinical trials for various tumors; UBP1211, a biosimilar of Humira for the treatment of autoimmune diseases, including rheumatoid arthritis; and JS002, an anti-proprotein convertase subtilisin/kexin type 9 monoclonal antibody that is in Phase I clinical trial to treat hypercholesterolemia and mixed dyslipidemia. It is also involved in the development of UBP1213, an anti-B lymphocyte | Undisclosed | IPO | China |
05-Dec-18 | Icagen | $274 | The program incorporates Icagen's platform for ion channels and is directed at a specific novel ion channel target expressed in neurons. This collaboration is a great example of combining Icagen's depth and expertise in ion channel drug discovery with the therapeutic area and developmental expertise of a company like Roche to enhance the likelihood of identifying meaningful new therapies. | Roche | Licensing Agreement | United States |
11-Dec-18 | Entera Bio Ltd. | $270 | Entera will use its proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected. Amgen also has an option to select up to two additional programs to include in the collaboration. | Amgen | Collaboration | Israel |
24-Dec-18 | Gossamer Bio | $265 | The company said it plans to use the IPO proceeds to fund research and development for its three clinical-stage drug programs, and to continue developing the three preclinical programs in its pipeline. Gossamer’s lead product candidate, known as GB001, is a treatment for eosinophilic asthma, a hard-to-manage form of the chronic lung condition. | Undisclosed | IPO | United States |
03-Dec-18 | Theravance Biopharma | $250 | The Company intends to use the net proceeds from this transaction to support continued execution of its key strategic programs. The first potential medicine to emerge from our research focus on immunology and localized treatments is an oral, gut-selective pan-Janus kinase (JAK) inhibitor, currently in development to treat a range of inflammatory intestinal diseases. In addition, we have an economic interest in future payments that may be made by Glaxo Group or one of its affiliates (GSK) pursuan | Triple Royalty Sub | Private Placement | Ireland |
03-Dec-18 | Propeller Health | $225 | Propeller Health is a digital therapeutics company providing connected health solutions for people living with chronic obstructive pulmonary disease (COPD) and asthma. Propeller helps people and their doctors better manage their COPD and asthma. Propeller’s digital medicine platform consists of small sensors that easily attach to consumers’ inhalers and pair with a mobile app to automatically track medication use and provide personal feedback and insights. | ResMed | Acquisition | United States |
12-Dec-18 | Synergy Pharmaceuticals | $200 | Synergy filed a voluntary petition for reorganization under Chapter 11 of the U.S. Code (the "Bankruptcy Code") with the U.S. Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court") earlier today. Under the terms of the agreement, and subject to Bankruptcy Court approval, Bausch Health will serve as the "stalking horse" bidder in a court-supervised auction and sale process, which Synergy will conduct pursuant to Section 363 of the Bankruptcy Code. | Valeant Pharmaceuticals | Stalking Horse" Agreement | Canada |
20-Dec-18 | Intrexon Corp. | $175 | Intrexon has assumed its agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company for the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, which are genetically engineered t-cells with synthetic receptors that recognize a specific antigen expressed on tumor cells. The agreement will enable Precigen's complete autonomy of its CAR-T program and allow Merck KGaA, Darmstadt, Germany, to maintain an investment in the future potential of next generatio | Merck Group | Development Agreement | United States |
14-Dec-18 | Kurma Partners | $170 | Kurma Biofund III will invest in private companies, addressing high unmet medical and patient needs. | Undisclosed | Financing | France |
14-Dec-18 | Potenza Therapeutics | $165 | The clinical IO therapies developed through this collaboration may also provide a platform for IO combinations with Astellas' existing non-IO programs for life cycle management and future novel IO combinations. | Astellas Pharma | Acquisition | United States |
06-Dec-18 | Global Blood Therapeutics | $150 | GBT intends to use the net proceeds from the offering to fund its clinical development of voxelotor for the treatment of sickle cell disease, including its ongoing clinical studies, as well as preparation for the potential commercial launch of voxelotor, if approved by the U.S. Food and Drug Administration, future clinical trials of voxelotor and other product candidates that GBT may elect to pursue, including inclacumab, its other research and development activities | Cantor Fitzgerald | IPO | United States |
20-Dec-18 | Agenus | $150 | The immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies. | Gilead Sciences | Collaboration | United States |
04-Dec-18 | Changzhou Qianhong Bio-pharma Co., Ltd. | $145 | Changzhou Qianhong Bio-pharma, a leading biochemical maker of polysaccharides and enzymes drugs is a major manufacturer of pancreatic kininogenase, heparin sodium and low molecular weight heparin, as well as compound digestive enzyme preparations and asparaginase, all of which had, prior to the roll out of the phase one facility, never been produced in China. | Changzhou Qianhong Bio-pharma Co., Ltd. | Manufacturing Investment | China |
14-Dec-18 | The Medicines Company | $145 | The Company expects to use the net proceeds of the offering (including from any exercise by the initial purchaser of its option to purchase additional notes) to fund its development of inclisiran. | Undisclosed | IPO | United States |
20-Dec-18 | Rakuten Aspyrian | $134 | The proceeds from this financing will support continued development of our lead program, ASP-1929, which we recently announced has entered into a global, pivotal Phase 3 clinical trial for head and neck cancer. We thank our generous investors for their belief and support of Rakuten Aspyrian as we continue executing on our mission. | SBI Group | Series C Financing | United States |
06-Dec-18 | Synthorx | $131 | Synthorx’s proprietary, first-of-its-kind Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, referred to as Synthorins. The company’s lead product candidate, THOR-707, a variant of IL-2, is in development in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. | Undisclosed | IPO | United States |
12-Dec-18 | AC Immune | $131 | The collaboration will focus primarily on AC Immune's lead molecule, ACI-3024, which has demonstrated tau aggregation inhibition in preclinical models. AC Immune will conduct the initial Phase 1 development of the Morphomer tau aggregation inhibitors, while Lilly will fund and conduct further clinical development. Lilly will receive worldwide commercialization rights for the tau aggregation inhibitors in the area of Alzheimer's disease. | Eli Lilly and Company | Licensing Agreement | Switzerland |
13-Dec-18 | Biohaven Pharmaceutical Holding Company | $125 | Biohaven Pharmaceutical Holding Company, a clinical?stage biopharmaceutical company has a portfolio of innovative, late?stage product candidates targeting migraine and neurological diseases, including rare disorders, announced the pricing of its underwritten public offering. | Undisclosed | IPO | United States |
06-Dec-18 | European Joint Programme on Rare Diseases (EJP RD) | $114 | The European Joint Programme on Rare Diseases (EJP RD) will establish a virtual platform to coordinate access to rare disease information, research data and services to optimise exchange of information and knowledge between research and clinical practice. | European Commission | Research Agreement | Germany |
17-Dec-18 | Proteostasis Therapeutics | $100 | The proteostasis network consists of more than 1,000 proteins organized into pathways that can be regulated or targeted by drugs. Genetic mutations, environmental factors, and aging can cause the proteome to become imbalanced, w | Roche | Licensing Agreement | United States |
18-Dec-18 | Harpoon Therapeutics | $86 | Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases using its proprietary Tri-specific T cell Activating Construct™ (“TriTAC”), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. | Undisclosed | IPO | United States |
19-Dec-18 | Scholar Rock Holding | $80 | Gilead has exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGF? programs: inhibitors that target activation of latent TGF?1 with high affinity and specificity, inhibitors that selectively target activation of latent TGF?1 localized to extracellular matrix, and a third TGF? discovery program. Scholar Rock is responsible for antibody discovery and preclinical research through product candidate nomination, after which, upon exercising the opti | Gilead Sciences | Licensing Agreement | United States |
06-Dec-18 | Impel NeuroPharma | $68 | Crossover Financing to Advance Clinical Development of Central Nervous System Assets in Migraine, Parkinson’s Disease and Acute Agitation. This financing will enable Impel to accelerate its existing clinical development portfolio in CNS disorders. Impel is currently investigating three programs leveraging its novel Precision Olfactory Delivery, or POD®, device technology: INP104 in a Phase 3 trial for the treatment of acute migraine headache, INP103 in a Phase 2 trial for the reversal of OFF epi | Norwest Venture Partners | Series D Financing | United States |
21-Dec-18 | Alkermes | $65 | Meloxicam is a long-acting, preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory and antipyretic activities. IV meloxicam was designed using the NanoCrystal® platform, a technology that enables enhanced bioavailability of poorly water-soluble drug compounds. | Recro Pharma | Licensing Agreement | Ireland |
20-Dec-18 | Hutchison MediPharma Limited | $60 | The 2018 Amendment covers adjustments in the respective roles and responsibilities of Chi-Med and Lilly, in China, for the development and commercialization of fruquintinib in the areas of future life cycle planning and development, collaborations for co-development of fruquintinib with other third-party anti-cancer agents as well as promotion and distribution rights of fruquintinib. | Eli Lilly and Company | Licensing Agreement | China |
18-Dec-18 | Entrada Therapeutics | $59 | The first application of Entrada's platform is focused on treating a rare and fatal mitochondrial disease with no approved treatments that is caused by mutations in a gene that codes for an intracellular enzyme. The Series A financing will allow Entrada to advance its lead program into human clinical trials. | Roche | Series A Financing | United States |
05-Dec-18 | Mereo | $57 | Potential partnership with OncoMed’s navicixizumab program which is currently in a Phase 1b clinical study and has shown encouraging data in heavily pre-treated ovarian cancer patients. Ongoing collaboration with Celgene Corporation with an option to license OncoMed’s etigilimab (anti-TIGIT) program. | OncoMed | Merger Agreement | United Kingdom |
13-Dec-18 | Perosphere Pharmaceuticals | $50 | Through this acquisition, AMAG will acquire global rights to ciraparantag, a next generation anticoagulant reversal agent, further enhancing its development pipeline and leveraging AMAG’s expertise in hematology. Ciraparantag is being investigated for patients treated with novel oral anticoagulants (NOACs) or low molecular weight heparin (LMWH) when reversal of the anticoagulant effect of these products is needed for emergency surgery, urgent procedures or due to life-threatening or uncontrolled | AMAG Pharmaceuticals | Acquisition | United States |
19-Dec-18 | Molecular Partners AG | $50 | The companies will jointly develop MP0310, a Pre-clinical FAP x 4-1BB Multi-Specific DARPin® Molecule, in Combination with Amgen’s Oncology Assets, Including BiTE® Molecules. Molecular Partners Retains Rights to Develop MP0310 in Combination With its Pipeline Products | Amgen | Licensing Agreement | Switzerland |
17-Dec-18 | Alvotech | $50 | Fuji´s investment into Alvotech further strengthens the partnership between the companies and reflects long-term commitment from both companies. Alvotech‘s current pipeline consists of six biosimilar monoclonal antibodies aimed at treating cancer, autoimmune, inflammatory and other diseases, with first products expected to be brought to market by 2020. | Fuji Pharma Co., Ltd. | Equity Stake | Iceland |
14-Dec-18 | BioArctic AB | $50 | BAN0805 is the most advanced alpha-synuclein targeting antibody within the BioArctic portfolio and is being developed as a disease modifying treatment for Parkinson's disease. AbbVie will progress BAN0805, now known as ABBV-0805, into clinical development with the first clinical study planned for 2019. | AbbVie | Option Agreement | Sweden |
14-Dec-18 | Pulse Biosciences | $45 | Pulse Biosciences is a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform. The Company’s CellFX NPS platform provides a novel, precise, non-thermal treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing acellular tissue. | Undisclosed | IPO | United States |
18-Dec-18 | Erasca | $42 | Erasca has multiple discovery programs underway for undisclosed targets that are biological drivers of cancer. The company anticipates it will disclose more about these programs as it moves into human clinical studies. Erasca is also pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations. | City Hill Ventures | Series A Financing | United States |
16-Dec-18 | Innovent Biologics | $40 | Fibroblast growth factor receptors (FGFRs) play an important role in tumor cell proliferation and survival, migration and angiogenesis (the formation of new blood vessels). FIGHT-202 in patients with metastatic or surgically unresectable cholangiocarcinoma who have failed previous therapy, including with activating FGFR2 translocations; and FIGHT-203 in patients with myeloproliferative neoplasms with activating FGFR1 translocations. | Incyte | Licensing Agreement | China |
18-Dec-18 | Bridge Biotherapeutics | $40 | BBT-401, discovered by SKKU (Sungkyunkwan University) and KRICT (Korea Research Institute of Chemical Technology) is a GI-tract restricted small molecule inhibitor of Pellino-1. From the Phase I study, the drug candidate was proved to be well tolerated and safe in humans. | Daewoong Pharmaceutical | Licensing Agreement | South Korea |
18-Dec-18 | Tetra Discovery Partners | $40 | Tetra is developing BPN14770 for the treatment of brain disorders marked by cognitive and memory deficits, including Fragile X Syndrome, Alzheimer’s disease and other dementias, learning/developmental disabilities, major depression, and schizophrenia. | Shionogi & Co., Ltd. | Collaboration | United States |
16-Dec-18 | Seer Bio | $36 | Seer’s core technology, the Proteograph™ platform, is designed to provide rapid, cost-effective, and broad-scale proteomic profiling with high accuracy. Seer is using the proceeds to advance its Proteograph platform, expand its industry-leading proteomic database, advance its multiple discovery programs, and develop first-in-class liquid biopsy products for early disease detection, with an initial focus on oncology and neurology. | Maverick Ventures | Series A Financing | United States |
04-Dec-18 | Revance Therapeutics | $30 | Revance’s proprietary DaxibotulinumtoxinA for Injection (RT002) is a novel, long-lasting neuromodulator in development for the treatment of aesthetic conditions, including glabellar and upper facial lines, and neuroscience conditions including cervical dystonia, plantar fasciitis, adult upper limb spasticity and chronic migraine. | Shanghai Fosun Pharmaceutical Group | Licensing Agreement | China |
24-Dec-18 | Lupin Limited | $30 | Under the partnership, AbbVie gains exclusive global rights to develop and commercialize Lupin's MALT1 inhibitors. Lupin's MALT1 or Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 inhibitor program (MALT-1) is a protein involved in T-cell and B-cell lymphocyte activation and AbbVie intends to pursue development across a range of hematological cancers, many with limited current treatment options. | AbbVie | Licensing Agreement | India |
14-Dec-18 | Zentiva Bucharest (formerly Sicomed) | $26 | Czech pharmaceutical group Zentiva announced the launch of a public offer for the residual stake of 6.7% in Romanian drug producer Zentiva Bucharest (formerly Sicomed). | Zentiva | Equity Stake | Romania |
12-Dec-18 | Instituto Butantan | $26 | Merck and Instituto Butantan have agreed to collaborate to share clinical data and other learnings from their respective dengue vaccine development programs, both derived from licensed materials from the NIAID. The agreement builds upon a productive long-term collaboration between MSD Brazil and Instituto Butantan, initiated in 2012, for human papillomavirus (HPV) and Hepatitis-A vaccine products. | Merck & Co. | Collaboration | Brazil |
12-Dec-18 | Synthace Limited | $26 | Synthace is a leader in Computer Aided Biology, a new paradigm that comprises two domains: the Digital and the Physical. The Digital, powered by artificial intelligence, includes software for designing and simulating biological systems, as well as methods of collating, structuring and analysing experimental data. | Horizons Ventures | Series B Financing | United Kingdom |
13-Dec-18 | Dragonfly Therapeutics | $24 | "These licenses provide Celgene exclusive worldwide intellectual property rights to the first two products developed for Celgene using Dragonfly's TriNKET technology" said Rupert Vessey, FRCP DPhil, President of Research and Early Development for Celgene Corporation. | Celgene Corporation | Licensing Agreement | United States |
18-Dec-18 | Morphogen-IX | $23 | This investment will support formal preclinical development of its lead candidate, MGX292, and initiation of clinical trials by 2021. MGX292 is a protein-engineered variant of BMP9 that has proven highly efficacious and safe in extensive preclinical studies. MGX292 is the first agent with the potential to be truly disease-modifying and to transform the lives of patients with PAH. | Medicxi Ventures | Series B Financing | United Kingdom |
12-Dec-18 | Checkmate Pharmaceuticals | $22 | Proceeds from the financing will support ongoing clinical development of Checkmate’s lead product CMP-001 in advanced melanoma and non-small cell lung cancer (NSCLC) refractory to prior anti-PD-1 therapy, along with expansion into additional solid tumor types. | Sofinnova Partners | Financing | United States |
05-Dec-18 | Diabetes Finished Products (DFP) manufacturing facility | $22 | Novo Nordisk’s Diabetes Finished Products (DFP) manufacturing facility in Clayton is responsible for the formulation, filling, inspection, assembly and packaging of diabetes and obesity medicines. | Novo Nordisk | Manufacturing Investment | United States |
11-Dec-18 | Black Diamond Therapeutics | $20 | During its stealth stage, Black Diamond built and established proof of concept for its MAP (mutation, allostery and pharmacology) platform to uncover, discover and target allosteric mutant oncogenes. The application of the MAP platform has generated a pipeline of five programs, including three that have progressed compounds through lead optimization or into IND-enabling studies. | Versant Ventures | Series A Financing | Switzerland |
06-Dec-18 | XyloCor Therapeutics | $17 | An Investigational New Drug (IND) application for XC001 is open with the FDA and XyloCor intends to commence clinical trials in 2019. XyloCor also has a secondary product, XC002, in discovery stage being investigated for the regeneration of cardiac tissue in patients with cardiac damage from heart attacks. | Sofinnova Partners | Series A Financing | United States |
07-Dec-18 | DiaMedica Therapeutics | $16 | DiaMedica expects to use the net proceeds from the offering to fund clinical development of DiaMedica’s lead drug candidate, DM199, to conduct research activities and for working capital | Craig-Hallum Capital Group | IPO | United States |
07-Dec-18 | Tonix Pharmaceuticals | $15 | The Company expects to use the net proceeds from this offering to help fund a new Phase 3 study using a modified trial design for its lead product candidate, TNX-102 SL | Alliance Global Partners | IPO | United States |
18-Dec-18 | Aristea Therapeutics | $15 | The Aristea team has deep experience in the development and commercialization of novel medicines, highlighted by eight previous drug product approvals in a broad range of therapeutic categories including neuroscience, diabetes/metabolic diseases, inflammation, oncology and infectious diseases. Aristea has also obtained exclusive global rights to its lead program RIST4721, from AstraZeneca. Aristea plans to initiate a Phase 2 clinical study in early 2019. | Novo Holdings | Series A Financing | United States |
17-Dec-18 | Kineta Immuno-Oncology | $15 | The research collaboration and license agreement grants to Pfizer the exclusive rights to KIO's RIG-I screening platform and related compounds and technologies. | Pfizer Inc. | Licensing Agreement | United States |
20-Dec-18 | PLx Pharma | $15 | The Company intends to use the proceeds from the issuance of the Preferred Stock to advance Vazalore to market readiness. If approved, Vazalore will be the first-ever FDA-approved liquid-filled aspirin capsule with the potential to become the new standard of care aspirin for physicians treating patients at risk of having a cardiovascular or cerebrovascular event. | Park West Asset Management LLC | Financing | United States |
03-Dec-18 | Biologics Manufacturing Facility | $14 | Construction of the 15,000-square-foot facility infrastructure, which will include five new packaging suites and a new quality control laboratory, is due to be completed in February 2019, with installation and commissioning of new equipment to be phased throughout the year. | Catalent Pharma Solutions | Manufacturing Investment | United States |
17-Dec-18 | Mobidiag Ltd. | $14 | Mobidiag and Autobio will jointly invest €12.3m to establish a joint venture company in China. Mobidiag will grant to the JV an exclusive license for human infectious disease assays (except for sepsis) for China. Initial activities of the JV will include the registration of the Novodiag® platform and three assays for the rapid detection of respiratory and gastroenteric infections and meningitis with the National Medical Products Administration. | Autobio Diagnostics | Joint Venture | Finland |
11-Dec-18 | Aro Biotherapeutics | $13 | Aro holds an exclusive worldwide license for Centyrin protein therapeutics, which were discovered by Dr. O’Neil and her team at Janssen. Centyrins are designed to achieve improved efficacy and safety profiles for patients diagnosed with cancer and other serious diseases. Aro was established through an initial start-up investment from Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and BioMotiv, LLC. | Undisclosed | Financing | United States |
18-Dec-18 | Aptorum Group Limited | $12 | Aptorum Group Limited is a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs. The company is pursuing therapeutic and diagnostic projects (including projects seeking to use extracts or derivatives from natural substances to treat diseases) in neurology, infectious diseases, gastroenterology, oncology and other disease areas. | Undisclosed | IPO | Hong Kong |
18-Dec-18 | Aduro Biotech | $12 | As part of the agreement, Lilly will gain access to novel molecules from Aduro that are designed to inhibit the cGAS-STING pathway. The companies will collaborate to advance these molecules, as well as others from Lilly, into clinical development. | Eli Lilly and Company | Licensing Agreement | United States |
06-Dec-18 | VBI Vaccines | $11 | VBI Vaccines & Brii Biosciences entered into a license and collaboration agreement for the development of a functional cure for the treatment of chronic hepatitis B infection, using VBI’s recombinant, protein-based immuno-therapeutic, VBI-2601. VBI and Brii Bio will collaborate in the development of the product through to completion of a proof-of-concept clinical trial in China, following which, Brii Bio will be responsible for funding all development in the licensed territory. | Brii Biosciences | Collaboration | United States |
12-Dec-18 | CarThera | $10 | The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. | Panakès Partners | Series B Financing | France |
07-Dec-18 | Tenax Therapeutics | $10 | The Company owns the North American rights to develop and commercialize levosimendan and is currently initiating a Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). | Ladenburg Thalmann & Co. Inc | Series A Financing | United States |
20-Dec-18 | Ayala Pharmaceuticals | $10 | AL102 is an oral small-molecule that inhibits gamma secretase, an enzyme which may be targeted to increase levels of BCMA, which is expressed in most multiple myeloma patients. | Novartis | Licensing Agreement | Israel |
17-Dec-18 | Palvella Therapeutics | $10 | Palvella has a lead product candidate - PTX-022 (QTORIN™ rapamycin formulation) for the treatment of pachyonychia congenita (PC). Palvella is entering a Phase 2/3 clinical study of PTX-022 for the treatment of PC, a rare, chronically debilitating and lifelong monogenic disease in which mutations of genes responsible for keratin production lead to dysregulated keratinocyte proliferation, increased skin fragility and impaired skin barrier function on the plantar aspects of the feet. | Ligand Pharmaceuticals Incorporated | Licensing Agreement | United States |
11-Dec-18 | GenEdit | $9 | This round will help the company continue to build and advance its proprietary polymer nanoparticle system. GenEdit's technology will address one of the biggest challenges in gene therapy and gene editing which is safe and efficient delivery to the target tissues. GenEdit's technology platform solves current delivery challenges by systematically screening its proprietary nanoparticle library and providing safer and efficient delivery to target tissues. | Data Collective Bio (DCVC Bio) | Seed Financing | United States |
06-Dec-18 | Diamyd Medical AB | $6 | Diamyd Medical develops the diabetes vaccine Diamyd®, for antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. | Undisclosed | Financing | Sweden |
13-Dec-18 | Adynxx | $6 | The grant award received by Adynxx will provide Adynxx with $5.7 million over the two-year UG3 phase to complete a Phase 2 study of brivoligide in patients undergoing mastectomy with immediate tissue expander or implant placement that score high on the Pain Catastrophizing Scale (PCS). The funding is a UG3/UH3 Phase Innovation Awards Cooperative Agreement involving two phases. | National Institute on Drug Abuse (NIDA) | Grants & Awards | United States |
03-Dec-18 | ABL Bio | $5 | TRIGR to lead clinical development of TR009, a dual VEGF/DLL4 BsAb showing early single agent activity in heavily pretreated, Avastin® and immunotherapy refractory patients with solid tumors. TR009 (formerly known as ABL001 or NOV1501), an ABL developed bispecific antibody candidate targeting two important angiogenic factors, VEGF and DLL4. | TRIGR Therapeutics | Licensing Agreement | South Korea |
17-Dec-18 | HedgePath Pharmaceuticals | $5 | Mayne Pharma will assume control of the regulatory and clinical development program for SUBA®-Itraconazole for the treatment of basal cell carcinoma nevus syndrome (SUBA-Itraconazole BCCNS) in anticipation of conducting a global Phase 3 pivotal clinical trial based on results achieved in the Phase 2(b) trial conducted by HPPI in the U.S. | Mayne Pharma | Collaboration | United States |
28-Dec-18 | Medi Futures | $5 | MEDI FUTURES has commercialized ultrasonic endoscopic disk surgical instruments and enzyme-free ultrasound stem cell separators based on ultrasonic platform technology. | Samho Green Investment | Financing | South Korea |
04-Dec-18 | Aridis Pharmaceuticals | $5 | CF Foundation expands research agreement for AR-501 (for cystic fibrosis) to include additional award amount of up to $4.6 million, FDA grants Fast-Track and QIDP Designations for AR-501, enabling future Priority Review status and the FDA cleared AR-501's Investigational New Drug Application (IND) and the Company intends to initiate the Phase 1/2a clinical trial next month. | Cystic Fibrosis Foundation | Financing | United States |
17-Dec-18 | Nicox SA | $4 | Ocumension will receive exclusive rights to develop and commercialize NCX 470, at its own cost, in the agreed territory. Ocumension is expected to have to conduct additional clinical studies for the regulatory approval of NCX 470 in the Chinese market. All development activities will be overseen by a Joint Development Committee comprising representatives of both companies, with Ocumension responsible for undertaking all the activities at its own cost. | Ocumension Therapeutics | Licensing Agreement | France |
12-Dec-18 | VLP Therapeutics | $4 | VLP Therapeutics has developed a novel dengue VLP vaccine using its proprietary technology. VLP Therapeutics' previously funded GHIT project demonstrated the dengue VLP vaccine's efficacy and safety in preclinical studies including non-human primates. | Global Health Innovative Technology Fund (GHIT) | Grants & Awards | United States |
18-Dec-18 | Spiral Therapeutics | $4 | Spiral Therapeutics initiated its Phase 1 clinical trial of LPT99, the company's lead investigational drug candidate targeting prevention and treatment of hearing loss. | Camden Partners | Series A Financing | United States |
04-Dec-18 | KDA Group, Pharmapar | $3 | Strides has agreed to acquire 80% all the issued and outstanding common shares of Pharmapar, the generic distribution arm of KDA, in consideration of four million Canadian dollars existing cash on hand, on the terms and conditions agreed substantially in accordance with the LOI. | Strides Pharma Global Pte Ltd. | Divestment | Canada |
17-Dec-18 | OncoImmunity AS | $3 | The company’s flagship product, the ImmuneProfiler™, is a unique machine learning solution that has made inroads into solving the neoantigen prediction challenge. The funding will advance further its capability to tailor the ImmuneProfiler™ for specific vaccine platforms, facilitating the design of safer and more efficacious personalized cancer vaccines. | Undisclosed | Financing | Norway |
19-Dec-18 | AVEO Pharmaceuticals | $2 | AVEO intends to use the $2.3 million payment to cover the milestone obligation due in January 2019 to St. Vincent’s Hospital Sydney Ltd. (“St. Vincent’s”) under AVEO’s Amended and Restated License Agreement with St. Vincent’s dated August 13, 2015, pursuant to which AVEO in-licensed certain of the intellectual property underlying the AV380 Program. | Novartis | Milestone Payment | United States |
07-Dec-18 | Revive Therapeutics | $2 | The Company’s novel cannabinoid delivery technology is being advanced to fill the unmet medical needs for diseases and disorders such as pain, inflammation, and wound care. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory and liver diseases, which the FDA granted to the Company orphan drug designation for CBD in the treatment of autoimmune hepatitis and in the prevention of ischemia and reperfusion injury resulting from solid organ transplantation, such as liver, kidney | Herman Holdings Limited | Private Placement | Canada |
07-Dec-18 | Arcinova | $2 | The award will be used to develop a digital manufacturing platform to accelerate the production time of patient-specific medicines. The Fill-Inova Project aims to create a more responsive and economical method for producing complex formulations in smaller volumes. | UK Research and Innovation (UKRI) | Grants & Awards | United Kingdom |
18-Dec-18 | Novartis | $2 | Pradigastat is a well-characterized molecule which has progressed to Phase 3 clinical testing. Anji has secured rights to pursue new indications for pradigastat, with an initial focus on regulatory approval in China. | Anji Pharmaceuticals | Licensing Agreement | Switzerland |
17-Dec-18 | CSPC Pharmaceutical Group Co., Ltd. | $2 | I-Mab's will grant an exclusive license to CSPC to develop I-Mab's long-acting GLP-1 Fc program (TG103) in China. TG103 is an innovative, long-acting recombinant glucagon-like peptide-1 (GLP-1) for which I-Mab has achieved IND approval as a Fc-fusion with extended half-life. | I-Mab Biopharma | Partnership | China |
04-Dec-18 | Integral Molecular | $1 | With this Phase 2 SBIR grant, Integral Molecular builds on its successful Phase 1 SBIR program isolating antibodies with high specificity and high affinity for CB1. The goal of the Phase 2 project is to develop antibodies for initiating preclinical studies. | National Institutes of Health | Grants & Awards | United States |
10-Dec-18 | Pharmacy Operation | $1 | Premier Health Group is pleased to announce that as a part of its growth strategy to cover the major verticals associated with primary care, it has signed a binding Letter of Intent ("LOI") to acquire a Vancouver, British Columbia based pharmacy. | Premier | Letter of Intent | Canada |
11-Dec-18 | High Point, NC site | $1 | At the facility, Cambrex produces complex APIs and intermediates requiring multi-step synthetic processes in batch sizes from milligrams to 100kg to support clinical trials from Phase I to Phase III. The expansion and fit out, which will include the installation of an additional 10 ultra-performance liquid chromatography (UPLC) instruments, is set to be completed by year-end 2018. | Cambrex Corporation | Expansion | United States |
15-Dec-18 | Arizona Bioindustry Association (AZBio) | $0.3 | The Arizona Bioscience Cluster Sustainable Seed Fund Project has been designed to help close the funding gap for early-stage life science and healthcare technology companies in the region’s bioscience cluster by creating a new and sustained flow of equity-based funding in a state that has lacked available capital from local institutional investors since 2006. | US Economic Development Administration’s (EDA) | Grants & Awards | United States |
13-Dec-18 | PredictImmune | $0.13 | PredictImmune’s first product, PredictSURE IBD™, which will launch in January 2019, will enable the stratification of inflammatory bowel disease (IBD) patients at the point of diagnosis, based on their risk of relapse. The test will allow the use of more aggressive treatments to be focussed on those patients at the greatest risk of aggressive disease; focussing on the optimal use of existing treatments to improve patient outcomes. | Innovate UK | Grants & Awards | United Kingdom |
03-Dec-18 | Arrayit Corporation | $0 | Arrayit offers simple non-invasive testing services that measure reactivity of immunoglobulin E (IgE) antibodies to an extensive panel of food, environmental and specialty allergens as a precision healthcare solution to assist physicians in the diagnosis and treatment of allergy and asthma. | Undisclosed | Services Agreement | United States |
03-Dec-18 | Schrödinger | $0 | The companies aim to accelerate the discovery of novel CNS therapeutics by leveraging Schrödinger’s advanced computational platform and SPARC’s extensive drug development expertise and insights in neurodegeneration. | Sun Pharma Advanced Research Company Ltd | Collaboration | United States |
03-Dec-18 | NeuCyte Inc. | $0 | The hospital intends to use this technology for internal research, teaching and educational purposes, and to perform services to other academic institutions. "NeuCyte has the exclusive rights to Stanford's original neuronal induction technology and has further developed it to incorporate into our proprietary in vitro drug discovery platforms," said Jonathan Davila, PhD, Co-founder and CEO of NeuCyte. | Boston Children's Hospital | Licensing Agreement | United States |
03-Dec-18 | Parata Systems | $0 | Together, TCGRx and Parata currently have more than 4,500 medication adherence packagers, inspection systems and vial-filling robots installed in retail, long term care, hospital, government and mail order pharmacies throughout North America. In addition to these pharmacy automation technologies, the company will expand on their existing growth initiatives with central fill, inventory control and automated blister card packaging technologies. | TCGRx (Frazier Healthcare Partners) | Merger Agreement | United States |
04-Dec-18 | Domain Therapeutics | $0 | The collaboration combines the expertise of Domain Therapeutics, a French and Canadian biopharmaceutical company, in the discovery of GPCR targeting drugs in CNS, oncology and immuno-oncology, with Boehringer Ingelheim’s expertise in the discovery and clinical development of therapeutics on multiple indications. | Boehringer Ingelheim | Licensing Agreement | France |
04-Dec-18 | Carnot BioSciences | $0 | Following the spin-off, SmartZyme will focus on advancing its core asset, a next-generation glucose-sensing enzyme designed to make continuous glucose monitors significantly more affordable and easier to manufacture for use by people living with Type 1 and insulin-requiring Type 2 diabetes. | HemoShear Therapeutics | Spin off | United States |
04-Dec-18 | Sanofi | $0 | Sanofi is embarking on a unique five-year study of asthma patients that will merge traditional lab techniques with an array of digital tools, enabling scientists to gain a far deeper understanding of the workings of one of the most widespread chronic diseases. | Mount Sinai Innovation Partners | Collaboration | France |
04-Dec-18 | LEO Pharma | $0 | The collaboration leverages Evotec’s industry-leading hit identification platform including the extensive screening, structural biology and fragment-based drug design capabilities and expertise together with LEO Pharma’s 110-year track record of drug development and advancing science in dermatology. Evotec’s integrated discovery scientists will work in a joint team with scientists from LEO Pharma. The alliance will receive further support with high-value drug development and discovery ADME-Tox s | Evotec AG | Collaboration | Denmark |
04-Dec-18 | Protagen AG | $0 | Through the present new collaboration, Protagen and the EORTC Brain Tumor Group will utilize Protagen’s Cancer Immunotherapy Array to understand the immunological profile of such patients to learn how to predict such long-term survival and potentially define novel pathways for therapeutic intervention. | European Organization for Research and Treatment of Cancer (EORTC) Brain Tumor Group | Collaboration | Germany |
05-Dec-18 | WuXi Biologics | $0 | Being the company’s first site outside of China which is supported by the Irish Government through IDA Ireland, this state-of-the-art “facility of the future” is designed to run both traditional fed-batch or perfusion process and continuous bioprocessing, a next generation manufacturing technology to be first implemented globally in this 26-hectare campus. When completed, a total capacity of 48,000L fed-batch and 6,000L perfusion will be installed, representing one of the world’s largest facilit | IDA Ireland (Irish Government) | Manufacturing Investment | China |
05-Dec-18 | The University of Pittsburgh | $0 | The partnership enables medical companies to access the latest translational research tools and technologies. The University offers an array of services to industry through Scientist.com, including computational modeling for pharmacology, drug target discovery services and translational technology development. | Scientist.com | Partnership | United States |
05-Dec-18 | PAREXEL International Corporation | $0 | Parexel and Eli Lilly collaboration is on a clinical research learning and development program in China. The program will bring high-value training opportunities to China’s clinical trial sites and investigators, enhancing the execution of local clinical trials and driving innovation in China’s biopharmaceutical industry. | Eli Lilly and Company | Collaboration | United States |
05-Dec-18 | Preformulation and Formulation Capability | $0 | Abzena’s existing expertise in analytical assessment of biologics and ADCs is strengthened with the addition of miniaturized and high throughput preformulation equipment requiring low material quantities, as well as advanced lyophilization capability. | Abzena | Expansion | United Kingdom |
05-Dec-18 | Vast Therapeutics | $0 | Partnership with Shionogi Ltd Includes Collaboration for Development of Proprietary Nitric Oxide Powder Technology for Antimicrobial Resistant Bacteria in Respiratory Applications | Shionogi & Co., Ltd. | Series A Financing | United States |
06-Dec-18 | Client Outlook | $0 | The use of medical imaging data as an endpoint in clinical trials is becoming increasingly important due to its critical role in determining disease state and progression, especially in therapeutic areas like oncology where nearly all trials rely on imaging. Medidata selected eUnity™ to help manage medical images based on its HTML5-based zero-footprint architecture which demonstrated superior ability to tightly integrate with the Medidata Cloud. | Medidata | Partnership | Canada |
06-Dec-18 | Vir Biotechnology, WuXi Biologics | $0 | These collaborations include two clinical development programs focused on hepatitis B virus (HBV) infection and China-based exclusive research agreements to develop novel immunotherapeutics to treat infectious diseases and other immune dysfunctions. In addition, the company has formally established its research and development headquarters in Beijing and has forged a public-private partnership to promote public health and develop translational research capabilities. | Brii Biosciences | IPO | United States |
06-Dec-18 | PPD Laboratories Athlone | $0 | The enhancements in PPD® Laboratories’ Athlone location complement the ongoing capacity and capability expansions at its flagship GMP lab in Middleton, Wisconsin, enabling the company to expand the global reach of its industry-leading biologics testing services. PPD Laboratories’ GMP lab is a leading provider of chemistry, manufacturing and controls (CMC) laboratory services for all phases of drug development. | Pharmaceutical Product Development, LLC | Expansion | Ireland |
06-Dec-18 | Cyclica | $0 | This year-long agreement will enable Merck to quickly and efficiently elucidate mechanisms of action, evaluate safety profiles and explore additional applications for a number of its investigational small molecules, including those identified in highly disease-relevant phenotypic screens. | Merck Group | Licensing Agreement | Canada |
06-Dec-18 | QIAGEN N.V. | $0 | QIAGEN’s companion diagnostic for PIK3CA mutations will provide a complete Sample to Insight workflow, from DNA extraction to detection of the clinically relevant mutations and final reporting. The test will be clinically validated for analysis of both FFPE tissue and liquid biopsy samples using plasma. | Novartis | Clinical Collaboration | Germany |
06-Dec-18 | Casey Eye Institute, Oregon National Primate Research Center | $0 | The collaboration will combine the complementary expertise of 4D Molecular Therapeutics with the Casey Eye Institute and the Oregon National Primate Research Center to identify and develop gene therapies for degenerative retinal diseases. 4DMT will provide research access to its proprietary vector and gene therapy product technology, development expertise and manufacturing capabilities. CEI and ONPRC will provide access to its researchers and resources for the inception, design and conduct of jo | 4D Molecular Therapeutics | Collaboration | United States |
06-Dec-18 | BlueRock Therapeutics | $0 | Core to BlueRock's distinctive technology is the ability to create cell therapies with high purity, potency, and specificity. The partnership encompasses an operations and infrastructure expansion. BlueRock will be moving into an additional 14,000 square feet within UHN in Toronto's MaRS Discovery District, co-located with the McEwen Institute. The new lab will be in close proximity to the already established 7,000 square foot faculty housing BlueRock process development and manufacturing tea | McEwen Stem Cell Institute | Collaboration | Canada |
06-Dec-18 | Trianni | $0 | "With the Trianni Mouse in our discovery toolbox, MacroGenics now has the ability to incorporate fully human antibody sequences into molecules that are based on our Fc optimization and multi-specific DART® and TRIDENT™ platforms, further accelerating our discovery and candidate development processes," said Ezio Bonvini, M.D., Chief Scientific Officer of MacroGenics. | MacroGenics | Licensing Agreement | United States |
06-Dec-18 | Ra Pharmaceuticals | $0 | Initiated in 2013, this collaboration leverages Ra Pharma’s Extreme Diversity™ platform aimed at producing macrocyclic peptides that have the diversity and specificity of antibodies, while retaining the pharmacologic attributes of small molecules. | Merck & Co. | Milestone Payment | United States |
06-Dec-18 | Ablexis | $0 | The license grants Allogene rights to research, develop and commercialize certain AlivaMab antibodies against several targets. | Allogene Therapeutics | Licensing Agreement | United States |
06-Dec-18 | The University of Texas Southwestern Medical Center | $0 | The license includes commercial rights to a patent application covering small molecules, and to screening assay technologies to aid discovery of small molecules that can disrupt the interaction between the BECN1 protein and a negative regulator, BCL2. | Casma Therapeutics | Licensing Agreement | United States |
06-Dec-18 | New Specialty Generics Company | $0 | Mallinckrodt plc, a leading global specialty pharmaceutical company, announced plans to spin off a new company consisting of Mallinckrodt's Specialty Generics/Active Pharmaceutical Ingredients (Specialty Generics) business and AMITIZA® (lubiprostone) to Mallinckrodt shareholders, subject to final Board approval. The separation is expected to create two independent, appropriately capitalized, publicly traded companies – one focused on innovative specialty pharmaceutical brands, the other concent | Mallinckrodt | Spin off | United Kingdom |
07-Dec-18 | Abbott | $0 | Abbott will promote and distribute Dapagliflozin under the brand name GLEDEPA. Abbott will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name GLEDEPA MET. | AstraZeneca | Distribution Agreement | India |
05-Dec-18 | WuXi Biologics | $0 | This collaboration will further integrate the advantages of the two companies and expedite the development of Brii Bio's pipeline. Brii Bio has the access to WuXi Biologics' entire antibody platform capabilities including the WuXiBody™ technology to discover novel bispecific antibodies. WuXi Biologics will also be the exclusive development and manufacturing partner of any novel bispecific antibodies discovered from the WuXiBody™ Platform. | Brii Biosciences | Collaboration | China |
10-Dec-18 | genOway | $0 | Through an exclusive worldwide license of Merck’s foundational CRISPR integration patents, genOway will develop new models and solutions allowing non-profit and for-profit scientists to use CRISPR/Cas9 technology. | Merck Group | Partnership | France |
10-Dec-18 | Applied DNA Sciences | $0 | Under the Agreement the parties will develop and market a combined physical and digital supply chain traceability and certification solution utilizing the Company’s CertainT molecular tagging and authentication systems together with Everledger’s blockchain-based platform. | Everledger | Joint Venture | United States |
10-Dec-18 | Vedanta Biosciences | $0 | The clinical trial collaboration to evaluate Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo in combination with Vedanta Biosciences’ VE800, a rationally-defined human bacterial consortium, in patients with advanced or metastatic cancers. | Bristol-Myers Squibb | Clinical Collaboration | United States |
10-Dec-18 | San Diego R&D Site | $0 | WuXi AppTec's newly expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including phase I GMP manufacturing. The expansion will provide key elements of WuXi's small molecule capability and technology platform under one roof, further enhancing services to North American pharmaceutical and biotech industries. | WuXi AppTec | Expansion | United States |
10-Dec-18 | AstraZeneca | $0 | AstraZeneca's collaboration with Cancer Research UK to launch a centre of excellence in genetic screening, cancer modelling and big data processing is aimed at accelerating the discovery of new cancer medicines. The Functional Genomics Centre will further develop CRISPR technology to better understand the biology of cancer, creating biological models that may be more reflective of human disease, and advancing computational approaches to better analyse big datasets. | Cancer Research UK | Collaboration | United Kingdom |
11-Dec-18 | Vect-Horus | $0 | The goal of this collaboration is to use Vect-Horus' proprietary technology to transport various Janssen monoclonal antibodies to the brain for the treatment of neurodegenerative diseases. Vect-Horus will oversee the design of the conjugates and the conduct of the in vivo proof-of-concept brain uptake studies. Janssen will lead further preclinical and clinical development. | Johnson & Johnson | Collaboration | France |
12-Dec-18 | Paul Turner Lab | $0 | APT is committed to leveraging the exquisite specificity and potency of phage in the fight against the global rise of MDR infections. Under the terms of the agreement, APT will manufacture therapeutic phage in their state-of-the-art facilities under the Food and Drug Administration (FDA) Good Manufacturing Practice conditions. | Adaptive Phage Therapeutics | Collaboration | United States |
12-Dec-18 | X-Chem | $0 | X-Chem will utilize its industry-leading DNA-encoded library (DEX™) screening platform and proprietary informatics tools to search for novel hits for Almirall targets. X-Chem’s DEX libraries enable the screening of vast areas of drug-like chemical space, and support Almirall’s goal of identifying drug-like leads with shorter development timelines. | Almirall, S.A. | Collaboration | Spain |
13-Dec-18 | ERS Genomics | $0 | The license agreement to provide Lonza with access to ERS Genomics’ CRISPR/Cas9 genome editing technology patents. Lonza will have the ability to utilize CRISPR/Cas9 in its bioproduction products and services and also for use in induced pluripotent stem cells (iPSC) for research applications. | Lonza Pharma | Licensing Agreement | Ireland |
13-Dec-18 | SC Liver Research Consortium | $0 | SCLRC is a site management organization consisting of over 85 clinical sites based in the United States with specialized expertise in hepatology. SCLRC has successfully executed phase 1-3 trials in hepatitis C, hepatitis B, NASH, cirrhosis and HCC. Perspectum are imaging experts in Magnetic Resonance Imaging (MRI) and provide specialized imaging clinical research services in NASH, cholestatic liver disease and HCC. | Perspectum Diagnostics | Collaboration | United States |
14-Dec-18 | SupplementHunt.com | $0 | Innovus Pharmaceuticals believes that the relatively immediate benefits to Innovus Pharma from the acquisition includes an important proprietary sales platform and marketing technology that can expand to many of Innovus Pharma’s current products. | Innovus Pharmaceuticals | Acquisition | United States |
13-Dec-18 | Vast Therapeutics | $0 | BIOC51 is a novel polyglucosamine biopolymer covalently modified with N?diazeniumdiolate nitric oxide (NO) donors to facilitate spontaneous (without the need of enzymes) and controlled NO release. The level of NO release from BIOC51 has proved sufficient for eradicating planktonic and biofilm-based bacteria and can be delivered to the lungs as a dry powder or solution (e.g., nebulization). | Cystic Fibrosis Foundation | Financing | United States |
04-Dec-18 | OPEN Health, Peloton Advantage | $0 | OPEN Health is a multi-disciplinary health communications and market access group. | Amulet Capital Partners | Merger Agreement | United Kingdom |
04-Dec-18 | Sema4, Mount Sinai Health System | $0 | The study will generate real-world data about patients through innovative molecular profiling of biological samples and digital monitoring of the environment. Clinical research teams from all three organizations will deploy advanced analytics on this information to better understand how the disease functions, what triggers asthma attacks, which patient segments are most likely to respond to certain therapies, why the disease affects people differently, and more. | Sanofi | Clinical Collaboration | United States |
04-Dec-18 | Predictimmune | $0 | The Crohn's & Colitis Foundation is a non-profit organisation dedicated to finding cures for Crohn’s disease and ulcerative colitis and to improving the quality of life of those affected by these diseases. | US Crohn’s & Colitis Foundation | Clinical Collaboration | United Kingdom |
03-Dec-18 | HitGen | $0 | HitGen has established an industry-leading platform for early-stage drug discovery research centred on DNA encoded chemical libraries (DELs). HitGen’s DELs include encoded syntheses for more than 300 billion novel, diverse, drug-like small molecule and macrocycle compounds. In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads. | Roche | Collaboration | China |
03-Dec-18 | MedShorts | $0 | MedShorts, a Vizient supplier, is an online marketplace that connects hospital pharmacies with short-dated drugs (medications with less than 12 months dating). Vizient has been the only GPO on the MedShorts platform since its inception. | Vizient | Collaboration | United States |
03-Dec-18 | Sartorius Stedim Biotech | $0 | Immunochina will gain preferred access to SSB’s bioprocess technology platform for development, scale-up and production, new cellular immunotherapy production equipment and related commercial-scale manufacturing expertise, while Immunochina will provide technical feedback to SSB. Beijing-based Immunochina is a clinical stage biotechnology company developing best-in-class chimeric antigen receptor T-cell (CAR-T) therapies and a lentiviral vector manufacturing platform. | Immunochina Pharmaceuticals | Partnership | Germany |
21-Dec-18 | Exemplar Genetics (Intrexon Corp.) | $0 | The new company, Cytotheryx, headquartered in Rochester, Minnesota, will leverage the expertise and experience of Exemplar Genetics with the capabilities of Mayo Clinic's researchers to deliver this much-needed resource. | Mayo Clinic | Joint Venture | United States |
20-Dec-18 | Kuraray Europe | $0 | PVA polymers form the backbone of several of Merck’s high value, state-of-the-art products for formulation and drug delivery, such as Parteck® MXP excipient for hot melt extrusion. Merck’s design know-how, in combination with Kuraray’s manufacturing expertise, will make a wide variety of PVA polymer grades for pharmaceutical applications available. The developments from this collaboration will include injectable grades with low levels of specific impurities. | Merck Group | Collaboration | Germany |
20-Dec-18 | HitGen | $0 | HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for Bayer research endeavours. | Bayer | Collaboration | China |
11-Dec-18 | HitGen | $0 | The collaboration will use HitGen’s libraries containing more than 300 billion individually DNA-encoded compounds. The DNA encoding of molecules enables screening and analysis of vast chemical space, supporting MTPC’s aim to increase success rates for the generation of target leads for new drugs and to drastically shorten screening timelines for expanding MTPC’s pipeline. | Mitsubishi Tanabe Pharma Corporation | Collaboration | China |
06-Dec-18 | University College London | $0 | E2814 is an anti-tau monoclonal antibody which is designed to slow the progression of Alzheimer’s disease and other tauopathies*. The collaboration was established as part of Eisai’s Open Innovation strategy to collaborate with leading researchers in order to translate new research findings into innovative treatments for patients with neurodegenerative diseases. E2814 is one outcome out of a portfolio of projects established during the first phase of the collaboration with UCL. | Eisai Co., Ltd. | Collaboration | United Kingdom |
07-Dec-18 | Veeda Clinical Research Private Limited | $0 | Veeda offers a diverse range of clinical studies including healthy volunteers and patient trials for Generics, NCE and Biopharmaceuticals. Veeda is a partner of choice for many global pharmaceutical companies and is reputed for its knowledge, quality and ethics. | CX Partners Fund 2 Limited | Equity Stake | India |
11-Dec-18 | Shandong Luoxin Pharmaceutical Group | $0 | Aurobindo's wholly owned subsidiary, Helix Healthcare B.V, Netherlands, has entered into an agreement with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd, China (Luoxin) to establish a Joint Venture Company in China with manufacturing facilities to manufacture nebuliser inhaler and other products for China, US and EU markets. | Aurobindo Pharma | Joint Venture | China |
10-Dec-18 | Spatial Transcriptomics | $0 | The Spatial Transcriptomics workflow bridges microscopy and RNA sequencing to generate complete transcriptome data from a single intact tissue sample, and utilizes standard instrumentation for sequencing already present in most labs, allowing for barrier-free adoption. | 10x Genomics | Acquisition | Sweden |
17-Dec-18 | Daiichi Sankyo | $0 | DS-6051 is an oral, selective small molecule ROS1/NTRK inhibitor currently being evaluated in two phase 1 clinical studies in patients with solid tumors harboring either a ROS1 or NTRK fusion gene and neuroendocrine tumors in the U.S. and Japan. | AnHeart Therapeutics | Licensing Agreement | Japan |
13-Dec-18 | Fremont CGMP manufacturing Facility | $0 | Orchard Therapeutics has signed a long-term lease agreement to build-out a gene therapy manufacturing facility in Fremont, California. The new 150,000-square-foot facility significantly increases Orchard’s California footprint and adds to the Foster City and Menlo Park, California sites, which oversee the ongoing development and validation of the manufacture of Orchard’s ex vivo gene therapy product candidates. In addition to this expanded capacity, Orchard also plans to continue its close colla | Orchard Therapeutics | Manufacturing Investment | United States |
14-Dec-18 | Evidation Health | $0 | Lilly will leverage Evidation's Andromeda data platform to analyze large scale data aimed at uncovering novel digital measures of health | Eli Lilly and Company | Collaboration | United States |
14-Dec-18 | SIRION Biotech GmbH | $0 | Orchard has licensed SIRION’s LentiBOOST™ technology to enhance manufacturing efficiency for certain of Orchard’s ex vivo autologous hematopoietic stem cell gene therapy drug candidates. | Orchard Therapeutics | Licensing Agreement | Germany |
13-Dec-18 | Guardant Health | $0 | Guardant Health will develop and pursue FDA approval for a Guardant360® CDx test for Tagrisso® (osimertinib), AstraZeneca’s best-in-class, third-generation EGFR inhibitor in advanced non small cell lung cancer (NSCLC). Use of this assay will help identify patients that may respond to Tagrisso via a minimally-invasive blood test. | AstraZeneca | Collaboration | United States |
17-Dec-18 | H3 Biomedicine | $0 | H3 and Bristol-Myers Squibb will jointly conduct the research focused on developing immune therapies using H3’s RNA splicing platform. Bristol-Myers Squibb will be responsible for development and commercialization of selected compounds. | Bristol-Myers Squibb | Collaboration | Japan |
14-Dec-18 | Hydra Biosciences | $0 | Eli Lilly announced an agreement with Hydra Biosciences to acquire all assets related to Hydra's pre-clinical program of TRPA1 antagonists, part of the Transient Receptor Potential (TRP) family of ion channels, that is currently being studied for the potential treatment of chronic pain syndromes. | Eli Lilly and Company | Partnership | United States |
03-Dec-18 | TARGET PharmaSolutions | $0 | TARGET-IBD is a longitudinal observational study that evaluates patients with Inflammatory Bowel Disease, including adult and pediatric patients with ulcerative colitis, Crohn’s disease and indeterminate Colitis. TARGET-IBD has enrolled over 1,850 patients to date at 30 investigative sites. TARGET-IBD is led by an academic steering committee co-chaired by Bruce Sands, MD (Mount Sinai), David Rubin, MD (University of Chicago), and Millie Long, MD (University of North Carolina). | Bristol-Myers Squibb | Clinical Collaboration | United States |
13-Dec-18 | Duke Clinical Research Institute (DCRI) | $0 | The research program, COORDINATE-Diabetes (COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs), will be funded by Boehringer Ingelheim and Eli Lilly. | Boehringer Ingelheim | Partnership | United States |
12-Dec-18 | Crest Cellulose | $0 | The addition of Crest Cellulose’s know-how and production capabilities to Roquette’s strong expertise and track-record in the pharmaceutical excipients market will create new opportunities for both Roquette’s and Crest Cellulose’s customers and employees as the companies both share a commitment towards innovation, quality and excellence. | Roquette | Equity Stake | India |
17-Dec-18 | Shire PLC | $0 | The development and manufacturing site will be leveraged as a CDMO by Rentschler Biopharma. Under the terms of the agreement, Rentschler Biopharma will continue to manufacture product for Shire at the site. | Rentschler Biopharma SE | Acquisition | United States |
19-Dec-18 | Gan & Lee Pharmaceutical | $0 | The commercialization and supply agreement with Gan & Lee aims at bringing to market biosimilar versions of glargine, lispro and aspart, the three top insulin medicines by sales. Gan & Lee is a leading insulin supplier headquartered in China with more than 20 years' experience in insulins and production capacity with attractive cost of goods sold (COGS) structures. | Novartis | Commercialization Agreement | China |
18-Dec-18 | DelSiTech Ltd | $0 | The difficulties faced in the past to formulate this peptide, using other technologies even for shorter release times than the one achieved, proves the robustness of DelSiTech's Technology which can be applied to any type of molecule. Innovare will use DelSiTech's technology on its peptide membrane fusion inhibitor, targeting the envelope protein of human immunodeficiency virus-1 (HIV-1). | Innovare R&D | Licensing Agreement | Finland |
20-Dec-18 | CellforCure (LFB S.A.) | $0 | Novartis would acquire the share capital of CellforCure from LFB including the cell and gene manufacturing facility located in Les Ulis and the related adjacent land. CellforCure is a French CDMO producing cell and gene therapies in Europe. Novartis and CellforCure have successfully completed technology transfer and Kymriah clinical supply production is expected to begin by mid-2019. | Novartis | Acquisition | France |
19-Dec-18 | Tear Film Innovations | $0 | Tear Film Innovations is a privately-held company and manufacturer of the iLux® Device, an innovative therapeutic device used to treat Meibomian Gland Dysfunction, a leading cause of dry eye. | Alcon | Acquisition | United States |
19-Dec-18 | Imperial College London | $0 | Researchers at Imperial are partnering with Bayer Pharmaceuticals to explore how AI can accelerate new drug discovery for heart conditions. As part of the new collaboration, researchers will draw on data from UK Biobank, a national health resource containing a wealth of information on 500,000 people in the UK. The data available will enable researchers to discover pathways involved in heart disease that could provide new targets for treatment. | Bayer | Partnership | United Kingdom |
19-Dec-18 | Akaal Pharma Pty Limited | $0 | Akaal Pharma has demonstrated the clinical activity of AKP-11 in multiple Phase-1 clinical studies. Boston Pharmaceuticals is responsible for the further clinical development and commercialisation of AKP-11 for the Americas and Europe. Akaal Pharma has the rights for the rest of the world. | Boston Pharmaceuticals | Licensing Agreement | Australia |
17-Dec-18 | Boston Medical Center | $0 | BMS and Boston Medical Center will conduct a multi-year joint research study to identify and analyze potential sensitivity and resistance markers in patients treated with standard-of-care checkpoint inhibitors. | Bristol-Myers Squibb | Collaboration | United States |
19-Dec-18 | Fuji Pharma | $0 | Alvotech will be responsible for development and supply of multiple high value biosimilar assets from its current product pipeline, while Fuji Pharma will be responsible for registration and commercialization of these assets in Japan. | Alvogen | Partnership | Japan |
19-Dec-18 | WuXi Biologics | $0 | AC Immune and WuXi Biologics have entered into a memorandum of understanding governing the terms of a preferred partnership allowing AC Immune to leverage WuXi Biologics’ capacities and capabilities in the manufacturing and supply of traditional and innovative New Biological Entities (NBE) against disorders of the central nervous system (CNS). | AC Immune SA | Manufacturing Investment | China |
12-Dec-18 | AstraZeneca | $0 | Aveo will team up with AstraZeneca to evaluate the safety and efficacy of AstraZeneca's IMFINZI® (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in combination with FOTIVDA® (tivozanib), AVEO’s oral, once-daily, potent and highly-selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) in first-line hepatocellular carcinoma (HCC), or liver cancer, in a Phase 1/2 study. | AVEO Oncology | Clinical Collaboration | United Kingdom |
18-Dec-18 | XL-protein GmbH | $0 | Ajinomoto will apply its proprietary Corynex® expression system together with XL-protein’s proprietary PASylation® technology for plasma half-life extension to develop a series of therapeutic compounds. | Ajinomoto Bio-Pharma Services (Ajinomoto Co. Inc.) | Partnership | Germany |
04-Dec-18 | CCA Clinical Research | $0 | ARG is an industry leader in rare disease, immunology, and oncology clinical trials management. CCA, founded in 1988 and recognized for its network of clinical research experts across Europe, has been an ARG strategic partner since 2007. The combination of the two companies creates a comprehensive, global, clinical trial management solution for small to mid-sized biotech companies. | Atlantic Research Group | Acquisition | United Kingdom |
20-Dec-18 | Columbia University Irving Medical Center | $0 | APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. | Apexigen, Inc. | Clinical Collaboration | United States |
19-Dec-18 | IncellDx | $0 | The investigational assay will incorporate biomarkers from Zomedica's canine cancer research programs with IncellDx's core BioINK reagents and novel cell cycle capabilities on CTCs. | Zomedica | Development Agreement | United States |
18-Dec-18 | Mawdsley-Brooks & Co. Ltd. | $0 | The storage and distribution agreement allows Mawdsley-Brooks & Co. to distribute various strengths of capecitabine and temololomide on WPEL's behalf to hospitals in the United Kingdom (UK) under binding contracts that WPEL has secured with the UK National Health Service. | Waverley Pharma Europe Limited | Distribution Agreement | United Kingdom |
14-Dec-18 | Xiamen Encheng Group Co., Ltd. | $0 | Specifically, the Encheng Group will exclusively license the New York State Department of Health CLIA-certified DarwinOncoTarget and DarwinOncoTreat tests as part of a multi-year agreement that will grant Encheng the rights to deploy, evaluate, and market them in the Greater China region, including Hong Kong, Macao, and Taiwan. | DarwinHealth | Partnership | China |
18-Dec-18 | TrakCel | $0 | Marken has chosen TrakCel to deepen capabilities in the cell and gene therapy supply chain. TrakCel has developed leading integrated technology to effectively and easily orchestrate the cell therapy supply chain for autologous and allogeneic therapies. | Marken (UPS) | Collaboration | United States |
14-Dec-18 | OnDosis | $0 | The agreement with Grünenthal, a leading pain specialist, is the first partnering deal for life science startup OnDosis on their innovative technology. While this agreement covers the indication area pain; other focus areas of OnDosis, like ADHD and immunosuppression, remain available for further cooperation with third parties. | Grünenthal | Collaboration | Sweden |
13-Dec-18 | Ridgeback Biotherapeutics LP | $0 | mAb114 has completed a Phase 1 safety study and is currently being administered to some Ebola patients in the Democratic Republic of Congo under two separate protocols. The experimental treatments are being evaluated for efficacy and safety for the treatment of Ebola patients. This trial is coordinated by WHO, and led and sponsored by the DRC's National Institute for Biomedical Research (INRB) in partnership with the DRC Ministry of Health, NIAID, The Alliance for International Medical Action | National Institute of Allergy and Infectious Diseases (NIAID) | Licensing Agreement | United States |
17-Dec-18 | AstraZeneca | $0 | Pyramid Biosciences seeks to develop the TRK modulator for a range of dermatological and inflammatory diseases, including psoriasis and atopic dermatitis. PBI-100 is a clinically-validated TRK modulator which displays anti-itch and anti-inflammatory effects. Pyramid Biosciences will conduct further clinical testing of PBI-100 for use in selected dermatological indications beginning in 2019. | Pyramid Biosciences, Inc. | Licensing Agreement | United States |
13-Dec-18 | Oklahoma Health Care Authority | $0 | Under this arrangement focused on enabling the use of INVEGA SUSTENNA® (paliperidone palmitate) and INVEGA TRINZA® (paliperidone palmitate) earlier in treatment of adults with schizophrenia, OHCA aims to improve care among patients with schizophrenia and reduce expenses for medical services. The agreement enables potential cost savings for OHCA for these medicines. | Johnson & Johnson | Contract Agreement | United States |
13-Dec-18 | QuVa Pharma | $0 | QuVa has an extensive array of sterile compounded I.V. products, sourced from both FDA approved pharmaceutical products and active pharmaceutical ingredients as starting material, gives us unrivalled capability to service customers including in times of drug shortage. | Premier | Services Agreement | United States |
04-Dec-18 | Boehringer Ingelheim | $0 | MPC has vast experience manufacturing cGMP (*3)-compliant commercialized synthetic pharmaceuticals as well as compounds in clinical development on a range of scales. Leveraging AGC's fluorination technologies and extensive experience in in-house drug discovery and the CDMO business built up in Japan, AGC, with the addition of MPC, will be able to offer its CDMO services. | AGC Group | Acquisition | Spain |
12-Dec-18 | SRI International | $0 | SRI has broad expertise in solving formulation, drug delivery, and characterization challenges of small molecule drugs and biologics. The formulation team is experienced in the development of novel formulations for clinical trials. | Q BioMed | Collaboration | United States |
13-Dec-18 | MIREA-Russian Technological University | $0 | The drug, together with a photosensitizer, spreads throughout the body after being introduced into the body, but doctors can`t know for sure when its concentration will reach the desired maximum in a particular area or organ to immediate begin surgery. | NUST MISiS | Collaboration | Russia |
18-Dec-18 | Genetic Immunity | $0 | Under terms of the agreement, Pharmadis received rights to market Genetic Immunity's HIV technology in Russia and the Commonwealth of Independent States. DermaVir is the next generation of plasmid DNA-based vaccine for the treatment of chronic diseases | JSC Pharmadis | Licensing Agreement | Russia |
18-Dec-18 | cGMP microBiomanufacturing™ Center | $0 | LakePharma collaborates on projects at all stages of biologics development from discovery, preclinical to cGMP manufacturing for Phase I/II clinical trials. With its microBiomanufacturing Center operational, the company provides fully integrated solutions from vector design to manufacturing of non-GMP and fully compliant GMP-grade plasmid DNA. | LakePharma | Manufacturing Investment | United States |
18-Dec-18 | Prognos | $0 | Under the agreement, Biocept will supply de-identified data from its liquid biopsy testing to Prognos, which will leverage its AI capabilities to help its pharmaceutical clients ensure that the right patients receive the right therapies. | Biocept | Supply Agreement | United States |
18-Dec-18 | MangoGen Pharma, Orgenesis | $0 | Baculoviral systems have a number of advantages over other vectors due to the fact that they do not integrate into the hosts DNA and are therefore unlikely to cause problems with mutation or immunogenicity. By using MangoGen’s baculovirus, it could potentially enhance manufacturing processes and reduce the cost of goods for Orgenesis’ IPCs and other cell therapies. | Canada-Israel Industrial R&D Foundation | Grants & Awards | United States |
19-Dec-18 | Daiichi Sankyo | $0 | Daiichi Sankyo has a wide range of compounds in development. Medicines that Roivant opts to license will be developed by new subsidiary companies of Roivant. | Roivant Sciences | Collaboration | Japan |
18-Dec-18 | Thermo Fisher Scientific | $0 | The full portfolio of Roquette pharmaceutical ingredients will be included in the distribution agreement, including the newly launched KLEPTOSE® BioPharma HPB/HP grades hydroxypropyl ?- cyclodextrins, recently acquired Microcrystalline Cellulose products and other market-leading excipients. | Roquette | Distribution Agreement | France |
28-Dec-18 | GE Healthcare | $0 | General Electric Co. has filed confidentially for an initial public offering of its health-care unit. The industrial conglomerate is working with Goldman Sachs Group Inc., Bank of America Corp., Citigroup Inc., JPMorgan Chase & Co. and Morgan Stanley on the planned listing. | Goldman Sachs | Spin off | United States |
19-Dec-18 | Verily Life Sciences | $0 | Initially, the companies are developing a medication adherence pilot project that will deploy devices and other approaches designed to improve adherence. Walgreens together with Onduo, Verily’s joint venture with Sanofi, will also launch a virtual diabetes solution to Walgreens employees and family members with Type 2 diabetes through the Walgreens employee health plan. | Walgreens Boots Alliance | Partnership | United States |
18-Dec-18 | Ares Genetics GmbH (Curetis N.V.) | $0 | he agreement with Ares Genetics, a wholly owned subsidiary of Curetis N.V. and Curetis GmbH, will allow Sandoz to leverage the Ares Genetics database on genetics of antibiotic resistance, ARESdb, and the ARES Technology Platform for development of the Sandoz Anti-Infectives portfolio. | Novartis | Collaboration | Austria |
26-Dec-18 | Johnson Matthey | $0 | Immunomedics and Johnson Matthey announced a supply agreement under which Johnson Matthey will continue to scale the manufacturing of CL2A-SN-38, the drug-linker that is a key component of sacituzumab govitecan, Immunomedics’ lead antibody-drug conjugate currently under priority review by the FDA for accelerated approval as a treatment for patients with metastatic triple-negative breast cancer. | Immunomedics | Partnership | United Kingdom |